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1  Introduction   
 Introduction 
 Signal transduction - Overview 
In physics, the term “signal transduction” means the conversion of energy or information from one 
form into another and was already used long before it was introduced in biology. The biochemist 
Martin Rodbell was the first who coined the term “signal transduction” 1980 in a biological sense. He 
described the principles how cells can regulate their metabolism with GTP and GTP-binding proteins1. 
Signal transduction in biological systems involves a vast number of different molecules and 
structures. It is therefore helpful to subdivide the signaling complex into larger groups. Hormones are 
prominent examples of first messenger molecules that are characterized by early occurrence in the 
stream of biological information. In the course of evolution, some species adopted differently to the 
environment than others, leading to huge biological diversity that might explain interspecies 
variances in structure, expression levels, constitution and function of signal transduction proteins. 
The more the need for complex regulation, the more complex the interplay between information and 
signals, the more diverse is the capacity to generate and process signals differently. One way to fine-
tune biological response is the presence of various receptors for the same ligand. Interestingly, 
although it seems a general rule that the receptors evolved later in the evolution than their ligands 
(e.g. first messenger), some invertebrates do express thyroid and vitamin D receptors, which 
seemingly undertake highly specialized tasks, but do not express sex or adrenalin receptors, both 
processing ancient biological stimuli2,3. 
 First and second messenger 
First messenger are (mostly extracellular) ligands, such as hormones, neurotransmitters, cytokines, 
lymphokines, growth factors or chemoattractants. Notably, there is considerable functional overlap 
within types of first messenger, demonstrating the evolutionary evolved versatility of organisms and 
the interdependency within their signaling network structures to code and decode one signal with 
different informational content4. Most of the first messenger act from the aqueous extracellular 
milieu on surface receptors, which process and modulate the signal at this level because 
biomembranes are semipermeable barriers that interdict the crossing of many first messenger due to 
their hydrophilic structure. But there are also hormones or other first messenger that act from 
intracellular compartments (at receptors or other interaction partners), mainly because they are 
lipophilic enough to pass the cell membrane such as progesterone and other steroid hormones5. 
However, it is becoming increasingly clear that active transportation of ligands provides an 
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opportunity to bring even hydrophilic compounds across lipophilic membranes6. Thus, considerations 
about membrane permeability solely based on physicochemical compound parameter fall short. 
Transduction of one point to another (be it temporally or spatially in nature) involves a transducer. A 
possibility that is widely used in biological systems is the concept of receptors. Those signaling 
proteins process one form of signal (first messenger) into other forms of signals (second messenger). 
Second messenger in turn are signal transduction molecules, which carry on the information to 
further signaling partners, triggering distinct signaling pathways that finally elicit a cellular 
phenotype7. Main devices by which the binding of ligands is converted into a cellular consequence 
are clusters of phosphorylation/dephosphorylation proteins8,9. Prominent second messenger are the 
cyclic nucleotides of adenosine monophosphate and guanosine monophosphate, cAMP and cGMP, 
respectively, but also inostitolphosphates (e.g. IP3), calcium ions, nitric monoxide or G proteins, such 
as Ras. These examples make clear that second messenger do not share a common structural or 
physical feature. Furthermore, as the nature of the first messenger does not determine the nature of 
the second messenger, the stream of information is rather complexly regulated and subject to 
extensive modulation.  
Among the second messenger, the cyclic nucleotides will be described in more detail because 
members of the family of cyclic nucleotides and G proteins are the key signaling components studied 
in chapter 6 and chapter 7 of this thesis.  
Cyclic adenosine monophosphate (cAMP) acts as a mediator in all pro- and eukaryotic cells10. The cell 
can respond rapidly to a first messenger stimulus with changes of intracellular levels of cAMP, which 
requires the presence of a balanced system of synthesis and breakdown11. Prerequisites of second 
messenger function are therefore their specific generation and signal termination but most 
importantly their biological function. cAMP is generated by membrane-associated (mAC) or soluble 
forms (sAC) of the enzyme adenylyl cyclase that  converts ATP into cyclic AMP. In turn, it is 
continuously degraded by phosphodiesterases (PDEs), where there are eight isoforms in mammals, 
which are all regulated by G proteins or calcium ions12. In mammals 21 genes encode for PDEs13, 
which are expressed throughout the human body with different tissue distribution and different 
specificity for certain cyclic nucleotides. The balanced process of generation and termination is fine-
tuned by other input signals that change the cellular activation state.  
The second messenger cAMP mediates a variety of cell responses, such as thyroid hormone 
synthesis, cortisol synthesis, progesterone secretion, glycogen breakdown, bone resorption, increase 
in heart rate and force of heart contraction, water resorption and triglyceride breakdown14. These 
functions illustrate the variability of signal transduction through the same stimulus that is differently 
interpreted depending on the cellular setting, such as tissue expression, cellular equipment, 
metabolic state, temporal rhythm, etc. Most biological effects of cAMP are mediated by the protein 
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kinase A (PKA), a multienzyme complex consisting of two regulatory and two catalytic subunits. Upon 
cAMP binding to the regulatory subunits the catalytic subunits dissociate and activate, i.e. 
phosphorylate, specific target proteins15. Interestingly, PKA also phosphorylates and thereby 
activates adjacent phosphodiesterases, which in turn lead to a rapid decrease of cAMP levels14. This 
provide a means to tightly control cAMP effects in the greater context of signal generation and 
termination.  
Cyclic guanosine monophosphate (cGMP) is a likewise physiologically relevant second messenger. It is 
involved in the process of vision in the retina of vertebrates, the vasodilatation of blood vessels and 
bronchodilation. cGMP levels are regulated by modules similar to cAMP, such as phosphodiesterases 
and specific nucleotidyl cyclases, in this case guanylyl cyclases16. The pharmacological targeting of 
signaling units that modulate cAMP and cGMP levels is already clinically exploited. Inhibitors of 
phosphodiesterase type V are used as drugs against pulmonary arterial hypertension (PAH) and 
erectile dysfunction, while PDE-IV inhibitors are integrated in the treatment of chronic obstructive 
pulmonary disease (COPD), whereas stimulators of the soluble guanylyl cyclase (sGC) are used to 
treat chronic thromboembolic pulmonary hypertension (CTEPH) as well as pulmonary arterial 
hypertension (PAH). Chapter 6 of this thesis focusses on the exploration of non-canonical cyclic 
nucleotides, such as cyclic cytidine monophosphate (cCMP) and cyclic uridine monophosphate 
(cUMP). These molecules are far less studied than cAMP and cGMP but nevertheless fulfill all criteria 
of second messenger and can be considered to undertake a significant job in the regulation of the 
cellular state17. 
 G proteins 
Upstream of the second messenger are other cellular signaling proteins. Surface receptors were 
already mentioned but in between we often find so called G proteins that function as molecular 
switches to control and distribute signaling input not only further downstream but also upstream of 
the G protein level thus establishing a bidirectional flow of information. G proteins are guanosine 
triphosphate (GTP)-binding proteins and exist in two states: the active GTP-bound state and the 
inactive guanosine diphosphate (GDP)-bound state18–20. GTPase activity of the G protein degrades 
GTP to GDP and thus turns the G protein in its inactive state again. Because of this inherent enzyme 
activity, G proteins also belong to the class of GTPases. Two groups of G proteins can be 
distinguished: the large or heterotrimeric G proteins, which play a crucial role in the signal 
transduction triggered by G protein coupled receptors (GPCRs), and the small monomeric G proteins, 
related to the protein products of the Ras proto-oncogenes. Small G proteins function as regulators 
of cell motility and cell division and process multiple signaling inputs3,14.  
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 Heterotrimeric G proteins 
Heterotrimeric G proteins consist of three subunits: α, β and γ. The β subunit is tightly associated 
with the γ subunits so that the βγ subunit behave as a single functional entity18–22. The nucleotide 
binding pocket is located within the α subunits that contacts the β subunit, involving two highly 
conserved regions, switch I and switch II, as well as its N-terminal helix18,19. The whole heterotrimeric 
protein is anchored to the plasma membrane via lipid modifications at the G protein, one at the N-
terminal end of the α subunit and one at the C-terminal end of the γ subunit20,23 (Figure 1).  
 
Figure 1 Schematic of a heterotrimeric G protein consisting of the α- (orange) and the βγ-subunit (blue) and anchored to the 
plasma membrane by lipid modifications. Key interaction epitopes between α and βγ-subunit are labelled as switch I and II in 
the Ras-like domain of the α subunit. Depicted is the inactive, GDP-bound, conformation. The nucleotide binding site is 
located between the Ras-like and the helical domain within the α-subunit. Modified after 24. 
The cycle of G protein activation/deactivation starts and ends in the GDP-bound state. After 
interaction with a guanine nucleotide-exchange factor (GEF), which can be a GPCR, GDP is released 
and GTP binds to the α subunit, mainly due to the intracellular excess of GTP compared to GDP19. The 
GDP/GTP exchange is driven by a conformational change within the α subunit25. In the GTP-bound, 
active conformation, the G protein has lower affinity for the interaction with and dissociates from 
the GEF. It is commonly acknowledged, that upon activation, the α subunit and the βγ subunit 
dissociate and each are capable to subsequently induce signaling events26. GTP is then hydrolyzed to 
GDP, turning the G protein into the inactive state again, allowing the re-association of α and βγ 
subunit to the heterotrimeric G protein. The deactivation step is accelerated by GTPase-activating 
proteins (GAPs) like regulators of G protein signaling (RGS)27 (Figure 2). 
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G proteins are monostable switches, that means their activation is kinetically regulated, positively by 
the rate of GDP dissociation and negatively by the rate of GTP hydrolysis. The activation state can 
thus be approximated by the ratio of the rate constant for GDP dissociation (kdiss) and the rate 
constant for GTP hydrolysis (Kcat). Both Kdiss and Kcat can be modulated by proteins that interact with 
the α subunit3. These modulations are allosteric in nature and are already described as the 
interaction with GEFs, GAPs or RGS proteins27. 
 
Figure 2 The G protein activation cycle. In the ‘off’ state, the G protein rests in the GDP-bound form. Upon activation, e.g. by 
the interaction with a guanine nucleotide exchange factor (GEF), a conformational change within the G protein induces the 
release of GDP and the binding of GTP to the α-subunit. This triggers the dissociation of α- and βγ-subunit, both of which in 
turn can interact with signaling effectors. GTPase-activating proteins (GAPs) enhance the intrinsic GTPase activity of the α-
subunit and thus allow the βγ-subunit to re-associate with the GDP-bound α-subunit to form an inactive heterotrimeric G 
protein again. 
Heterotrimeric G proteins are classified by their α subunits28. There are 16 genes encoding for α 
subunits. Some of them are only found in a specific cell type, such as αt, αolf, αgut in sensory cells but 
most are ubiquitously expressed, although αo shows high levels in neuronal tissue. There are four 
main classes of Gα subunits: αs, αi, αq and α12/1329. Gαs proteins stimulate membrane-bound adenylyl 
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cyclases and thereby increase intracellular cAMP levels. In contrast, Gαi proteins inhibit the adenylyl 
cyclase leading to a reduction of cAMP level. Gαq subunits activate the phospholipase-Cβ 
pathway28,30. However, not all Gα subunits regulate second messenger levels in a narrow sense. 
Gα12/13 for example activate a RhoGEF protein that modulates the Ras-related GTPase Rho and thus 
regulate cell morphology30. 
Five subtypes of β subunits and 12 subtypes of γ subunits expand the variability of possible 
heterotrimeric G protein assemblies, although not all possible combinations exist in nature21,31. It 
could be shown that the identity of the βγ dimer contributes to the G protein coupling of individual 
receptors32–35. An important modification within the βγ dimer is the attachment of geranylgeranyl or 
farnesyl groups to the C-terminus of the γ subunit. This extension tethers the γ subunits (and with 
them the associated β subunits) to the membrane36. Furthermore, beside Gα subunits, also the βγ 
subunits can induce signaling. The effect of Acetylcholine on cardiac output, for example, relies of 
the opening of K+ channels by interaction with βγ dimers. Activation of phospholipase A237 and some 
β-isoforms of phospholipase C38 were also reported to be mediated by an interaction with βγ 
subunits. In addition, βγ subunits play roles in the localization, coupling and deactivation of α 
subunits, the regulation of the affinity of the receptors for their activating ligands and are required 
for certain α subunits to undergo covalent modification by PTX21,39. βγ subunits also reduce the 
tendency of GDP to dissociate from α subunits and thereby stabilize the inactive state21,39. Table 1 
summarizes key aspects of heterotrimeric G proteins. 
Table 1 Overview of mammalian heterotrimeric G proteins 
Subunit Expression Effects 
αs αs ubiquitous adenylate cyclase ↑ 
αolf olfactory neurons 
αi/o αi1-i3 ubiquitous adenylate cyclase ↓ 
αo1/2 neurons 
αt1/2 photoreceptors cGMP-PDE ↑ 
αz neurons, platelets K+-channel ↓ 
αgust taste buds  
αq/11 αq/11 ubiquitous PLC-β ↑ 
α14/15/16 hematopoietic cells 
α12/13 α12/13 ubiquitous RhoGEF ↕ 
β/γ β1-5 most cells PLC-β↑,GIRK-channels↑, Scr↑, 
Ca2+-channels↑, … γ1-12 most cells 
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 Structural considerations on G proteins 
The N-terminal sequence of Gα proteins is the site of interaction with the βγ subunits and also 
subject of myristic acid attachment in the Gαi/o protein family40,41. The α subunit consists of two 
independent domains. Because of close similarity to the monomeric GTPase Ras, one is named Ras-
like domain, wherein the GDP/GTP exchange takes place. It provides a binding surface for interaction 
with various interacting proteins, such as the βγ subunit, RGS proteins, receptors and effectors. The 
second domain is a six-helix bundle and can only be found in heterotrimeric G proteins but not in 
monomeric G proteins3.  
In contrast to the conserved Ras-like domain, the helical domain is more variable across the α 
subunits. It covers the GTP-binding pocket and is involved in the nucleotide binding as well as in GTP 
hydrolysis20. Three flexible loops (switch I, II and III) within the Ras-like domain can be found that 
undergo significant conformational changes upon switching from the GDP-bound to the GTP-bound 
state25,42–44. It is currently not clear, which structural changes within the G protein dictate GDP 
release but two models are discussed20 and both imply a significant role of the Gβγ subunit in the 
process of G protein activation (Figure 3). In the first (lever arm model), the receptor uses the N-
terminal helix of Gα as a lever arm to pull Gβγ away from Gα, enabling GDP release. In the second 
(gear shift model), the receptor uses the N-terminal helix of Gα to force Gβγ into Gα, thereby 
allowing the N-terminus of Gγ to engage the helical domain of Gα, causing a gap between helical and 
Ras-like domain and subsequently the GPD exit. After GDP release, a high-affinity state between the 
empty-pocket conformation of Gα and an active GEF (e.g. receptor) conformation occurs. This state 
is only intermediate in intact cells since high amounts of guanine nucleotides allow for quick 
entrance of GTP into the empty pocket and thus induce a conformational change that leads to 
dissociation of the α subunit from the receptor protein as well as from the βγ subunit45,46. 
 
Figure 3 Proposed model of G protein activation. a) In the lever-arm model, the βγ-subunit (green/yellow) is pulled away 
from the α-subunit (blue), prying switch II (orange) apart from the nucleotide-binding pocket, leading to GDP release. b) In 
the gear-shift model, the receptor pushes the βγ-subunit closer to the α helical domain (purple), resulting in a reorientation 
of the Ras-like and helical domain, which causes the GDP exit. Modified after 20. 
a b
 
Introduction  8 
The C-terminal end of Gα subunits dictates the specificity of interaction with the receptor. This is also 
the site of two important Gα subunit modifications: a) PTX, a toxin from the bacterium Bordetella 
pertussis, ADP-ribosylates a cysteine four residues from the C-terminal end. This modification 
uncouples the G protein from the receptor, thus freezing the G protein it its GDP-bound state47,48. 
PTX selectively targets the Gαi/o protein subfamily with the exception of Gαz. PTX emerged as an 
invaluable tool to dissect G protein signaling. b) Another ADP-ribosylating toxin is produced by the 
bacterium Vibrio cholerae (Cholera toxin, CTX), which targets an arginine residues (R201) situated in 
close proximity to the γ-phosphate of the bound GTP. As a result of this modification, the G protein 
turns GTPase deficient and thus remains in an active conformation. Despite the selectivity for Gαs 
proteins, the use of CTX is limited because it activates rather than inhibits the respective G proteins. 
Nevertheless, it is used to overstimulate Gαs mediated pathways with the result that no further 
activation can be detected. Thus, CTX silences Gαs signaling indirectly. 
 Monomeric G proteins 
Monomeric G proteins are also named small GTPases since they bind and hydrolyze GTP like the α 
subunits of heterotrimeric G proteins. The most well-known members are the Ras proteins, which 
were discovered as oncogene products. Mutations in the genes encoding Ras proteins frequently 
lead to the phenotype of cancer. Thus, Ras proteins are products of proto-oncogenes. This also 
underlines the importance of monomeric G proteins in the regulation of cell proliferation and 
differentiation49–52. Subgroups of the Ras superfamily are Rho, Rab, Ran, Arf and Kir/Rem/Rad. Like in 
heterotrimeric G proteins also in monomeric GTPases, two switch regions change their conformation 
in the process of GDP/GTP exchange and are moreover involved in the interaction with effector or 
regulator molecules3. 
 Receptors 
Receptors function as mediators between two forms of signals and act like microprocessors decoding 
and encoding information. The manifestation as a receptor can be multifaceted (see Table 1). They 
can form an integral part of the cellular membrane, such as the group of G protein coupled receptors 
(GPCRs) (e.g. β-adrenergic receptors) or ligand activated ion channels (e.g. nicotinic acetylcholine 
receptors). Receptors can be endowed with an intrinsic tyrosine kinase activity (e.g. epidermal 
growth factor receptors) or with intrinsic serine/threonine kinase activity (e.g. transforming growth 
factor receptors) and finally those that interact with cytosolic tyrosine kinases or those who are 
linked to tyrosine kinases (e.g. cytokine receptors). Among the cytokine receptors there are also 
soluble receptors but they do not constitute the only receptor family that can be found apart from 
membranes. Nuclear receptors are localized in the cytosol as well and comprise a superfamily of 
9  Introduction   
receptors that are targets of steroid hormones, thyroid hormones, retinoids, vitamin D and other 
lipids. From the aforementioned receptor types, G protein-coupled receptors constitute by far the 
largest class of drug targets53. They can be found throughout the body of most living forms on earth 
and play, directly or indirectly, vital roles in nearly every biological process. Therefore, this receptor 
class will now be described in more detail. 
Table 2 Overview of different receptor classes 
Class Examples 
G protein-couples receptors β-adrenergic receptors, muscarinic Acetylcholine receptors, Free 
fatty acid receptors, … 
Ionotropic receptors nicotinic Acetylcholine receptors, GABAA receptor, NMDA 
receptors, P2X receptors, … 
Kinase-linked receptors EGFR, Insulin receptors, VEGF receptors, … 
Nuclear receptors PPARγ receptors, Thyroid hormone receptor, Vitamin D receptor, 
Retinoid X receptor, … 
 
 G protein-coupled receptors 
G protein-coupled receptors can be divided into five main classes54,55. i) the Rhodopsin family (class 
A), ii) the Secretin family (class B), iii) the Glutamate and GABA family (class C), iv) the frizzled class 
and v) the adhesion family receptors. They all share a common structural feature, i.e. a single peptide 
chain that traverses the cell membrane seven times, with the N-terminus projected to the outside 
and the C-terminus to the cytosolic side56,57. That is why G protein-coupled receptors are also named 
7TM (7 transmembrane) receptors58. Three extracellular (ECLs) and three intracellular loops (ICLs) 
connect the seven α helices that span the membrane. Most but not all GPCRs activate intracellular G 
proteins. Common structural and functional features of 7TM receptors in all domains of life suggest a 
common ancestor, i.e. all 7TM receptors are structurally homologous59. With regard to substantial 
functional and structural differences between each GPCR family, the similarity might arise from 
convergent rather than divergent evolution. In the human genome there are approximately 800 
genes encoding for GPCRs, making up 2 % of the whole human genome and representing the largest 
group of transmembrane proteins54,55. The Rhodopsin family is the largest subfamily with 701 
members, of which 460 are olfactory and 241 are non-olfactory54. 
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 Structural elements of GPCRs 
GPCRs can be divided into an extracellular part, consisting of the N-terminus and the three 
extracellular loops (ECL1-ECL3), a transmembrane (TM) region, consisting of seven α helices (TM1-
TM7) and an intracellular part, consisting of three intracellular loops (ICL1-ICL3), an amphipathic helix 
(H8) and the C-terminus56,57 (Figure 4). 
 
Figure 4 Structural features common to all class A GPCRs. Seven α helices (TM1-7) spanning the cell membrane constitute 
the transmembrane region, in which most orthosteric ligands are assumed to bind. The N-terminus of the protein and three 
extracellular loops (ECL1-3) connecting the transmembrane helices build the outer surface of the receptor, in which many 
allosteric ligands are expected to bind. The C-terminal tail and three intracellular loops (ICL1-3) form the inner surface and 
potential binding sites for intracellular signaling molecules, such as G proteins or receptor kinases.  
From crystal structures it is known, that there are two types of extracellular regions. Those who 
occlude the ligand-binding pocket (like in Rhodopsin60 or in the sphingosine-1-phosphate receptor61) 
and those who leave the ligand-binding pocket water-accessible. Strikingly, both receptors that show 
occluded ligand binding-pockets are targeted by hydrophobic ligands that enter the receptor from a 
transmembrane region of the receptors61–63, which was also shown for a hydrophobic ligand at the 
free fatty acid receptor FFA1 by crystallization and subsequent X-ray analysis64 and discussed for 
further lipid GPCRs65–68. Mainly ECL2 dictates the ligand entry for class A GPCRs and can function as a 
“lid” obstructing the ligand entry path into the core region of the receptor protein. ECL2 can differ 
structurally between receptors and might account for different ligand binding selectivity and binding 
kinetics. Indeed, ECL2 was shown to be involved in the ligand recognition and selectivity of 
β-adrenergic receptors69,70 and the binding kinetics at a muscarinic acetylcholine receptor71. In 
chapter 2 of this thesis, the function of ECL2 in the free fatty acid receptor FFA2 and its impact on 
extracellular loops: ECL1-ECL3
intracellular loops: ICL1-ICL3
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N-terminal tail
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receptor activation upon ligand binding is discussed. Another common feature of most GPCRs is a 
disulphide bridge between TM3 and ECL2 that stabilizes the receptor and limits the extent of 
conformational changes in this part during activation57. 
The seven α helices in the transmembrane region are stabilized by non-covalent interactions, 
wherein most ligands are expected to bind. It is this core region where a consensus network of six 
topographically equivalent amino acids has been identified that directly contribute to ligand 
recognition57. Although the shape and structure of the ligands that target GPCRs vary greatly, four 
conserved residues in the transmembrane region were found57, even though binding can occur at 
different depth within the transmembrane core. TM1 does not seem to be involved in ligand binding. 
TM1 and TM2, which are within the first parts that are synthesized at the ribosome, are rather 
thought to be important for correct membrane insertion and protein folding than for more 
specialized tasks such as ligand recognition72. Interestingly, beside the consensus scaffold in class A 
GPCRs in TM3, TM6 and TM7, water molecules were shown to be indirectly involved in mediating 
receptor-ligand contact73–76. There are three amino acid sequences within the TM segments that are 
highly conserved and are found across all GPCRs, which points to a common evolutionary origin and a 
fundamental role in the functioning of the receptor. The P-I-F-motif forms an interface between TM3, 
TM5 and TM6 and was shown to be involved in the formation of active-state conformations of the 5-
HT1B receptor77. The D(E)RY motif at the bottom TM3 is also thought to affect the adaption of active 
conformations and the regulation of constitutive activity78. Finally, the NPxxY-motif in TM7 was 
discovered to be required in the tyrosine toggle switch, a microswitch initially studied for Rhodopsin 
but likely common to most GPCRs79,80. 
The intracellular parts of a GPCR are responsible for binding of downstream effectors such as 
G proteins, GPCR kinases (GRKs) and arrestins24,81. Mutations or phosphorylation of ICL2 has been 
linked to decreased structural stability and a conformational shift towards the active state82,83. The 
amphipathic helix (H8) was thought to be involved in G protein contact, but crystal structures so far 
could not corroborate this idea24. Among the intracellular parts of a GPCR, ICL3 and the C-terminal 
tail are rather variable and disordered regions, which typically expose linear peptide motifs that 
recognize specific binding partners84,85. According to the “barcode hypothesis” certain residues in the 
C-terminal tail are post-translationally modified and serve as a recognition pattern for effector and 
regulator molecules to modulate receptor activity and internalization from the membrane86.  
 Conformational changes during receptor activation 
Typically, a GPCR that binds a ligand in the extracellular or upper part of the transmembrane region 
undergoes a conformational shift from an inactive to an active state, if the binding ligand is an 
 
Introduction  12 
agonist. The small conformational changes in the direct neighborhood of the ligand binding site 
translates into a larger structural change deeper within the TM region and finally at the interface of 
the receptor and the cytosol with several possible signaling transducers present. While X-ray 
structures - although with unreached precision and fidelity - only allow a snapshot of one possible 
conformation, several other experimental techniques, such as atomistic molecular dynamics 
simulations or quantitative mass spectrometry gave insight into intermediate events taking place 
during receptor activation. For instance, it could be shown for the β2-adrenergic receptor that the 
receptor undergoes discrete conformational intermediates56,86,87. In general, agonists induce more 
flexibility in the receptor protein whereas inverse agonists stabilize the receptor88,89, although the 
conformation that is finally adopted largely depends on the energy landscape of a specific 
receptor90,91. Furthermore, computational studies showed that ligands with different efficacies 
induced conformational changes according to their physiological response, which indicates that 
ligands induce distinct shapes that correspond to the biological effect triggered by the binding 
event92. 
It is remarkable, that despite the structural diversity of GPCRs and their ligands several 
conformational changes during the process of receptor activation might be common to all GPCRs. In 
this context, only three main mechanisms shall be described briefly. The first was already 
hypothesized by Schwartz et al. in 2006 named “global toggle switch model”93. Newer data from 
crystal structures confirm the key idea of a toggle movement of TM6 and TM5 at the inner part of 
the receptor opening a binding cleft for a G protein57,94. Beside this global conformational change, 
microswitches within the transmembrane segments were identified, from which two are described 
here. Salt bridges within the TM region (in particular with the D(E)RY motif at the bottom of TM3) 
break up upon agonist binding and induce of a rotamer change if a G protein is present24,73,75,95,96. 
This underlines the importance of allosteric events that affect the adaption of certain conformations 
of GPCRs. The second microswitch, the “ionic lock”, consists of a salt bridge between certain amino 
acids in TM3 and TM697,98. Although this has only been found for rhodopsin, alternative 
microswitches based on hydrogen bonds were found in other GPCRs99,100. 
 GPCR signaling repertoire 
Receptors were long recognized as simple on-off switches but it became increasingly evident that 
receptors and especially GPCRs can occur in multiple conformations101,102. The concept of only one 
active conformation, which is linked to a single pattern of pathway activation also falls short. Instead, 
GPCRs can engage various pathways associated to different active conformational states103,104, whose 
adaption depends on an wide range of factors, such as the nature of the ligand(s), the nature of the 
coupling G protein(s) or other interacting proteins, the cellular state and environment or the cellular 
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and subcellular localization of the receptor to name only a few. Therefore, it is not surprising that 
signaling via one receptor is multifaceted. The phenomenon of functional selectivity (ligand bias or 
agonist trafficking) describes the behavior of a receptor to signal via different pathways with 
different efficacy (multidimensional efficacy)105. In this regard, the terms agonist, partial agonist and 
inverse agonist need to be redefined and understood in its actual context. While being an inverse 
agonist or partial agonist for one pathway does not exclude the possibility to display full agonism on 
another pathway106. 
Signaling of GPCRs is canonically linked to the activation of G proteins. As already described above, 
G proteins are molecular switches that control receptor-dependent but also receptor-independent 
signaling pathways and occur in several subtypes29. Gαs proteins stimulate the adenylyl cyclase, 
thereby increasing intracellular cAMP levels, whereas Gαi proteins inhibit this enzyme and 
subsequently lead to a decrease of intracellular cAMP levels. Activation of G proteins of the αq family 
activate the phospholipase-Cβ, which in turn hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) 
into inositoltriphosphate (IP3) and diacylgylcerol (DAG). IP3 can bind to its receptor at the 
endoplasmic reticulum resulting in an intracellular rise of calcium ions. Together with these, DAG can 
activate the membranous form of the protein kinase C (PKC). On the other hand, effects of the 
Gα12/13 family are largely unknown. They are involved in the rearrangement of the cytoskeletal 
architecture by activating small GTPases, such as members of the Rho family (see above)30. But not 
only the α subunits induce signaling events, also the βγ subunit was shown to elicit certain biological 
effects, such as the opening of GIRK channels107.  
To protect the cell from overstimulation, several mechanisms evolved. After prolonged receptor 
activation, a GPCR is phosphorylated at the inner surface of the protein by G protein receptor kinases 
(GRKs)108. Subsequently, β-arrestin is recruited to the phosphorylated sites and thus blocks 
interaction with the G protein binding sites by steric hindrance109,110. After this first phase of receptor 
desensitization, β-arrestin leads to receptor internalization via clathrin coated pits111,112. Although 
internalization is long thought to stop signaling via GPCRs, it is now known that this is not true in all 
cases113. Several examples could show that internalized GPCRs continue to signaling to cAMP from 
endosomes114–116 (Figure 5). β-arrestins seem to play a part (together with Gβγ subunits) in this 
process as well, thereby linking the ability to target and internalize receptors with the event of signal 
generation117.  
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Figure 5 Classical versus endosomal signaling of a Gαs-coupled model GPCR. Agonist activation leads to cell membrane-
originated cAMP signaling (1). After phosphorylation by G protein-coupled receptor kinases (GRKs) (2) β-arrestin can 
mediate receptor internalization to endosomes (3). Phosphates and ligand are enzymatically removed (4) and endosomal 
receptors are either recycled to the plasma membrane (5) or degraded by lysosomes (6). In a new model, cAMP signaling 
can continue after internalization of ligand-GPCR complexes in endosomes (3’). Modified after 118. 
Indeed, there is ample evidence that β-arrestin is capable to signal alongside G protein signaling, 
such as the activation of the MAPK-pathway109,119–121. However, it is also posited that β-arrestins 
might mediate signaling in a G protein-independent manner. In fact, β-arrestins play a pivotal role as 
scaffold and might be crucially relevant for some signaling events, but their G protein-independent 
nature has not been evidenced to date and can be questioned122. Since there are no inhibitors for all 
G proteins available, it is difficult to answer this question satisfactorily. Until specific inhibitors for all 
subclasses of G proteins are available, the discussion about G protein-independent signaling of 
GPCRs will go on. These considerations make clear that often made distinctions between G protein-
dependent (or canonical) versus G protein-independent (or non-canonical) signaling are artificial and 
may not have distinct corresponding entities in nature. Pan-G protein inhibitors might serve as a 
highly desired molecular tool to distinguish between G protein-dependent and G protein-
independent signaling of GPCRs. Therefore, the compound BIM-46174 previously reported to act as 
such inhibitor attracted our interest. Chapter 7 explains our findings that the compound acts as a G 
protein inhibitor with an unfound molecular mode of action. However, it does not behave as a Pan-G 
protein inhibitor as proclaimed, which disqualifies its use as a discriminator between G protein-
dependent and independent signaling. 
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 Allosterism 
Allosterism is a common phenomenon in biochemistry123. By binding to an enzyme, the effector 
often changes the conformation of the enzyme and thus transduces the information into a structural 
change that might affect binding or response of another effector at another site124. Hence, the 
allosteric effector can enhance or reduce the binding or activity of other effectors at the enzyme, 
leading to the term of positive and negative cooperativity, respectively. GPCRs function as allosteric 
modules with several binding sites. Endogenous ligands usually approach the binding site of class 
GPCRs from the extracellular space and bind within the transmembrane region of the receptor. This 
binding epitope is designated the “orthosteric” binding site, whereas the “allosteric” binding pocket 
is spatially distinct and is expected to be situated on top of the orthosteric binding pocket in class A 
GPCRs. Obviously, this nomenclature is arbitrary and a matter of definition. Thus, the 
aforementioned cooperativity effects are not unidirectional but reciprocal125, i.e. the orthosteric 
ligand allosterically modulates the allosteric ligand to the same degree as the allosteric ligand 
modulates the orthosteric ligand. An allosteric ligand that enhances the binding and/or efficacy of an 
orthosteric ligand is called allosteric activator or positive allosteric modulator (PAM), but this effect is 
also measurable for the opposite direction, i.e. the orthosteric ligand enhances binding and/or 
efficacy of the allosteric ligand. Concordantly, an allosteric ligand that reduces the binding and/or 
efficacy of the orthosteric ligand (and vice versa) is designated allosteric inhibitor or negative 
allosteric modulator (NAM). Allosteric ligands that do not change the pharmacological properties of 
the orthosteric ligand are named neutral allosteric ligands (NALs) or silent allosteric modulator 
(SAMs)126–128. Notably, GPCRs do not only encompass one allosteric site but usually multiple binding 
sites. The intracellular binding of G proteins to the receptor is also a type of allosterism and affects 
structure and function of the GPCR with substantial consequences for ligand binding128. Meanwhile, 
other intracellular GPCR ligands were discovered that act as allosteric modulators: G proteins, GPCR-
interacting proteins, peptides, lipids and ions129–131. Pepducins use this approach on purpose. These 
lipidated peptides anchor in the plasma membrane and target the receptor intracellularly to 
modulate the signaling132. 
Allosteric modulation is characterized by four key features. i) Probe dependency: modulatory effects 
of an allosteric ligand might apply to one orthosteric ligand but not another. The allosteric modulator 
at the M4 Acetylcholine receptor LY2033298 enhances the binding affinity of the endogenous ligand 
Acetylcholine but displays neutral cooperativity against N-methylscopolamin133. Probe dependency 
was also reported for two positive allosteric modulators at the GLP-1 (glucagon-like peptide) 
receptor. While having only little effect on GLP-1, they greatly potentiated the affinity for the 
endogenous ligand Oxyntomodulin134,135. Moreover, these two allosteric ligands displayed ii) biased 
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signaling which constitutes another possible characteristic of allosteric ligands. They preferred 
signaling via cAMP production, β-arrestin recruitment and insulin secretion, but were inactive in 
terms of intracellular calcium mobilization and ERK phosphorylation134,135. iii) Allosteric ligands can 
have differential effects on efficacy and affinity of an orthosteric ligand. Naphmethonium potentiates 
the affinity of Pilocarpin but negatively modulates the efficacy of this orthosteric ligand136. iv) Finally, 
allosteric modulation is generally saturable, i.e. the modulatory effect of an allosteric ligand on 
affinity and/or efficacy of an orthosteric ligand reaches a maximum at complete occupancy of the 
allosteric binding site. This has beneficial implication for potential allosteric drugs, since these ligands 
display a “ceiling effect”, i.e. the correlation between allosteric drug and side-effects are not linear 
but are limited by the natural ceiling effect that is reached at saturating concentrations. This lowers 
the risk of over-dosing129,137. 
Since the allosteric binding site is far less conserved in comparison to the orthosteric binding site, 
allosteric ligands represent a possibility to design subtype-selective drugs for receptors that are 
difficult to target with orthosteric ligands. These advantages of allosteric ligands have attracted much 
attention and efforts to discover and develop allosteric ligands for GPCRs. Despite the benefits of 
allosteric ligands compared to orthosteric ligands, only a handful of allosteric drugs for class A GPCRs 
has been approved. This rather low number denotes less the insignificance of allosteric modulation 
of GPCRs but rather the difficulties that are linked to the drug discovery process of allosteric 
ligands138.  
 Free fatty acid receptor family – Overview 
Fatty acids are essential components in biological structures such as membranes but also serve as 
energy carriers and thus regulate host metabolism as metabolic substrates. Furthermore, they are 
precursors of several lipid signaling mediators. Fatty acids have long been recognized for their 
regulatory function in host metabolism but these effects were primarily attributed to their direct 
function as dietary nutrients or indirectly by their metabolic intermediates139–141. They can be 
classified by their chain length into short-chain fatty acids (SCFA) (C1-C6), medium-chain fatty acids 
(MCFA) (C7-C12) and long-chain fatty acids (LCFA) (>C12). In 2003, three working groups identified a 
cell surface receptor that responds to medium- to long-chain fatty acids, and that was subsequently 
named FFA1 (free fatty acid receptor 1), because the free carboxylic acid group is necessary to 
activate the receptor142–144. The genes for a group of related fatty acids receptors are tandemly 
located on the chromosomal locus 19q13.1145 and were formerly named GPR40-43. A study by 
Vassilatis et al. reported on a close phylogenetic relation between this receptor family and the 
cluster of nucleotide, eicosanoid, protease-activated and lipid class A GPCRs146. Formerly identified 
GPR43 and GPR41 were dubbed FFA2 and FFA3, respectively, recognizing SCFAs as their endogenous 
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ligands147–149. GPR42 was shown to be a gene duplicate of FFA3 (GPR41) with no distinct 
functionality147. Rodents only express one orthologue of the GPR42/GPR41 pair, suggesting that 
GPR42 indeed represents a gene duplication that occurred since divergence of primate and human 
lineages150. In 2005, GPR120 (FFA4) was reported to respond to unsaturated long-chain fatty acids 
and its gene was located on the long arm of chromosome 10151. Although likewise fatty acid 
receptors in a wider sense but more distantly encoded and with only minor similarity, there are the 
hydroxyl carboxylic acid (HCA) receptors GPR81 (HCA1), GPR109A (HCA2) and GPR109B (HCA3) as 
well as GPR84, which is activated by medium-chain fatty acids and GPR119, activated by the fatty 
acid derivative oleolylethanolamide. The affinity of FFA receptors for their cognate ligands is overall 
low (in the micro- to millimolar range), rendering the pharmacological characterization of these 
receptors difficult. With respect to the low affinity, the physiological relevance of the FFA receptors 
rely on the local concentrations of the respective ligands. LCFAs can reach blood levels from 0.01 to 
10 µM, depending on dietary intake, adipose recycling and hepatic turnover of neutral fats, 
cholesterol esters and phospholipids152. Main source of SCFA is bacterial fermentation of fibers, so 
that SCFA reach blood levels in the micromolar range (80-180 µM), depending on diet (fiber-rich or 
fiber-depleted) and microbial composition of the gut153,154. Intestinal concentrations of SCFA can 
even reach millimolar concentration155. Hence, ligand concentrations are high enough to be 
pharmacologically active at FFA receptors. 
For the reason of clarity, only the FFA1-3 receptors will be detailed in the following.  
 Free fatty acid receptor 1 (FFA1) 
Saturated and unsaturated long-chain fatty acids are endogenous ligands of the FFA1 but also the 
FFA4 receptor142–144,151. The beneficial effects of polyunsaturated fatty acids such as ω-3 fatty acids 
have been linked to the presence of FFA receptors, especially to the activation of FFA4156.  
The investigation of the physiological function of FFA1 was primarily guided by high expression levels 
of FFA1 on pancreatic β-cells142,144. FFA1 was further detected in a variety of different cell types, such 
as osteocytes157, enteroendocrine cells158,159, immune cells160, taste bud cells161 and brain tissue of 
primates162. The widespread expression pattern needs further validation, since antibody-dependent 
detection methods of the FFA1 receptor are not faultless (see chapter 4).  
LCFA are known to increase glucose-stimulated insulin secretion (GSIS)163 and were subsequently 
linked to activation of the FFA1 receptor on β-cells by many studies144,164–167. The beneficial effects of 
LCFA on the metabolic state occur under short-term exposure to LCFA but turn into detrimental 
effects if LCFA are applied for prolonged periods. Chronically elevated LCFA lead to β-cell death, 
which coined the term (gluco)lipotoxicity168. Although early reports indicated a link between the 
activation of FFA1 and the adverse LCFA effects169, further studies disagreed and pointed into a 
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protective role of the FFA1 receptor against LCFA-mediated lipotoxic effects165,166,170,171, which is 
supported by our own studies (172 and see chapter 4). After discussions about whether FFA1 agonists 
or antagonists should be developed, evidence for a beneficial role of FFA1 in both acutely and 
chronically elevated states of fatty acid level entailed the discovery of several small molecule 
agonists with higher potency and efficacy compared to endogenous agonists as possible drug 
candidates in the treatment of diabetes type 2 (see chapter 5). 
Beside the direct enhancement of GSIS via activation of the FFA1 receptor on β-cells, the indirect 
FFA1-mediated effects by promoting GLP-1 and GIP (glucose-dependent insulinotropic peptide or 
gastric inhibitory peptide) production in enteroendocrine cells might contribute to the overall effects 
of FFA1 stimulation173. However, further studies need to show whether this is beneficial or 
detrimental. 
FFA1 is reported to couple to Gαq proteins144. The potentiation of GSIS is mediated via direct 
elevation of intracellular calcium level via the Gαq-PLCβ-IP3-calcium pathway, but also via activation 
of the DAG-sensitive kinase PKD1 that in turn entails actin depolymerization, a prerequisite for 
insulin secretion174. Although it seems essential for potentiating GSIS, the FFA1 receptor is not 
restricted to signal via the Gαq pathway. In fact, it was previously demonstrated that FFA1 is also able 
to promote signaling via Gαi proteins144,175,176. However, the significance of this pathway for FFA1-
related biological effects is unknown and needs further attention.  
 Free fatty acid receptor 2 and 3 (FFA2 and FFA3) 
FFA2 and FFA3 are often portrayed together because of their overlapping ligand structure and 
partially overlapping expression pattern. Both receptors are activated by SCFA, making it difficult to 
distinguish FFA2 from FFA3 mediated effects in vivo177, wherefore chapter 3 is dedicated to this issue. 
Despite overall low affinity of the endogenous ligands, acetate (C2) has higher prevalence for the 
human FFA2 than the human FFA3 receptor, whereas valeric (C5) and caproic (C6) acid have higher 
affinity to FFA3147–149,178. There are enormous interspecies differences between ligand recognition for 
FFA2 and FFA3. While being active at both receptor types in human, propionic acid (C3) selectively 
activates the mouse FFA3 over the mouse FFA2179. The bovine FFA2 receptor shows increased 
responsiveness to longer chain length compared to the human FFA2, which points to a general 
difference between these species that may have resulted during evolution from specific adaptations 
to differences in nutrition and metabolism177,180. The FFA2 receptor shows promiscuous G protein 
coupling via Gαi and Gαq proteins, whereas FFA3 only couples to Gαi proteins147–149,181. 
FFA2 and FFA3 are both expressed on pancreatic islets182,183 and in adipose tissue147,148,181,184,185. 
While the expression of FFA2 in white adipose tissue seems well evidenced, the expression of FFA3 in 
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adipose tissue is controversial181,186,187. Intestinal L cells (containing GLP-1 and peptide YY) and 
intestinal I cells (producing cholecystokinin) express FFA2 and FFA3 receptors, thereby linking these 
receptors with potential roles in the regulation of host metabolism188–193. FFA2, but not FFA3, is 
highly expressed on immune cells such as neutrophils, eosinophils, monocytes and regulatory T 
cells147,148,178,184,194,195. FFA3 on the other hand is expressed on enteric neurons and the sympathetic 
neuron system187,196. 
The physiological functions of FFA2 and FFA3 are controversial. Since FFA2 and FFA3 are expressed in 
tissues and cells that are involved in the regulation of metabolic homeostasis, a modulatory effect on 
host metabolism is plausible. It was shown that a fiber-rich diet is associated with an ameliorated 
phenotype of obesity and diabetes type 2197 as well as inflammatory bowel disease198,199. The vast 
majority of physiologically occurring SCFA derive from bacterial fermentation in the digestive system 
and there is strong evidence for a causal link between the gut microbiome and effects on the 
metabolic and immune system. Hence, FFA2 and FFA3 emerged as potential mediators of the 
observed SCFA effects. Indeed, FFA2-/- mice showed exacerbated immune response in inflammatory 
models of colitis, asthma and arthritis178, however, others reported that FFA2-/- mice were protected 
from inflammatory response in a chronic colitis model200. Recently, FFA2 was revealed to also play a 
role in the progression of gout201. Amelioration of colitis was entailed to FFA2 effects on regulatory T 
cells by enhancing their suppressive function, thereby lowering the inflammatory response195, and on 
the activation of the macrophage inflammasome complex199, thereby controlling the inflammatory 
response. 
Under normal chow diet, a positive effect of FFA2 on glucose tolerance was shown by Tolhurst et 
al.202, whereas Bjursell et al. demonstrated under these conditions similar glucose tolerance level for 
FFA2 wild-type mice compared to FFA2-/- mice203. The beneficial effects of FFA2 on the metabolic 
homeostasis are mainly linked to the increased ability to secrete GLP-1 from enteroendocrine L 
cells202,204. But also a modulatory effect on immunocompetent cells is discussed because in the 
current understanding of atherogenesis and the pathophysiology of diabetes modulation of 
immunocompetent cells is involved such as adipose and intimal infiltration with activated monocytes 
and their differentiation to macrophages.  
FFA3 activation on enteroendocrine cells induces the production of peptide YY that reduces transit 
time and higher energy uptake. Thus FFA3-/- mice under high-fat diet revealed reduced weight gain 
compared to the wild-type mice190. In contrast, Bellahcene et al. reported that male, but not female 
FFA3-/- mice show increased fat mass upon normal and high-fat diet205. In conclusion, a role of FFA2 
and FFA3 in the regulation of immunological or metabolic disorders is without doubt, however, the 
direction and the actual extent of their effect is still under debate.
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 Thesis Outline 
The purpose of this work is to present main concepts in the exploration of cellular signaling with a 
special focus on signal transduction related to G protein-coupled receptors. Herein, I will explain the 
research question entailing context-relevant issues that requires our attentiveness, introduce the 
tools that are intended to provide the data basis to answer the question, describe the evidence from 
an experimental approach and highlight implications and consequences of the presented studies. 
This thesis is subdivided into four sections.  
Section I encompasses a detailed portray of a technology that is key for - or at least an integral part 
of - all following studies (chapter 1). Dynamic mass redistribution (DMR) represents a recently 
introduced method to obtain an integrative whole cell readout. The strengths and weaknesses of this 
novel technique are explained and its possible impact on the process of drug research is delineated. 
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Mol. Biol. 1272, 199–213 
Section II elucidates the biology of the free fatty acid receptor 2 (FFA2). In the first publication we 
report on the disclosure of a new mechanism for modulating receptors using FFA2 as a model GPCR 
(chapter 2), whereas the second publication describes the pharmacosynthetic approach to generate 
and characterize a designer receptor of FFA2 to probe FFA2 signaling and physiology (chapter 3). 
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Section III reports on the physiological and pathological function of the free fatty acid receptor 1 
(FFA1) and methodological concerns about commonly used FFA1 detection techniques (chapter 4). 
Chapter 5 summarizes the discovery and characterization of potent and selective small molecule 
FFA1 agonists. 
Wagner, R., Kaiser, G., Gerst, F., Christiansen, E., Due-Hansen, M. E., Grundmann, M., Machicao, F., 
Peter, A., Kostenis, E., Ulven, T., Fritsche, A., Häring, H.-U., and Ullrich, S. (2013) Reevaluation of 
fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 
62, 2106–2111 
Teutsch, C.-A., Panse, M., Grundmann, M., Kaiser, G., Kostenis, E., Häring, H.-U., and Ullrich, S. 
(2014) Detection of free fatty acid receptor 1 expression: the critical role of negative and positive 
controls. Diabetologia 57, 776–780 
 
Thesis outline  32 
Christiansen, E., Due-Hansen, M. E., Urban, C., Grundmann, M., Schmidt, J., Hansen, S. V. F., 
Hudson, B. D., Zaibi, M., Markussen, S. B., Hagesaether, E., Milligan, G., Cawthorne, M. A., Kostenis, 
E., Kassack, M. U., and Ulven, T. (2013) Discovery of a potent and selective free fatty acid receptor 
1 agonist with low lipophilicity and high oral bioavailability. J. Med. Chem. 56, 982–992 
Christiansen, E., Hansen, S. V. F., Urban, C., Hudson, B. D., Wargent, E. T., Grundmann, M., Jenkins, 
L., Zaibi, M., Stocker, C. J., Ullrich, S., Kostenis, E., Kassack, M. U., Milligan, G., Cawthorne, M. A., 
and Ulven, T. (2013) Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 
(FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett 4, 441–445 
Christiansen, E., Due-Hansen, M. E., Urban, C., Grundmann, M., Schröder, R., Hudson, B. D., 
Milligan, G., Cawthorne, M. A., Kostenis, E., Kassack, M. U., and Ulven, T. (2012) Free fatty acid 
receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves 
ADME properties. J. Med. Chem. 55, 6624–6628 
Section IV exemplifies the analysis of signal transduction at a post-receptor level. The first publication 
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 Prologue 
The current or recent-past state in industrial drug research is built on the concept of target-based 
drug discovery1,2. This entails the processing of high-capacity, homogenous assays of cellular signaling 
endpoints using reconstituted cellular systems overexpressing a receptor (= target) of interest3. As a 
result, huge compound libraries can be screened in a high-throughput manner for prospected effects 
at the target protein providing reliable and easy to interpret results – representing an important 
means in the process of decision-making. Much effort has been made to miniaturize and speed up 
this process resulting in large yet highly cost-efficient screening campaigns. A major drawback of 
such powerful approaches is the unsatisfactory transferability of the assay results to the pathological 
situation that should ultimately been addressed. High attrition rates of drug candidates especially in 
later stages of the drug discovery process have been associated with a lack of knowledge about 
biological compound behavior derived from early stage data that are generated using artificially 
engineered cell systems4. Introduction of model systems for certain disease states already in early 
stages of drug discovery represents a diametrically oriented venture to tackle this problem5–7. While 
holding the promise of better predictability, this translational approach imposes high demands on 
data interpretation because of the multifactorial nature with greater inter- and intra-individual 
variation in natural biological systems. Provocatively, tissue or organ-based assays were methods of 
choice before the times of target-based drug discovery and, at the time, enabled the development of 
several groundbreaking medicines. 
These considerations raise the question about the relevance of data from single endpoint assays, 
especially under the impression of a phenomenon that is increasingly recognized as functional 
selectivity8–10. Functionally selective compounds (= biased ligands) are fueling hopes for fine-tuned 
pharmacological intervention that specifically enable those signaling events that are beneficial but 
obviate those that are detrimental11,12. However, this requires in-depth insight into the complexity of 
physiological versus pathological signal transduction and their amalgamation in certain phenotypes, 
which is difficult to achieve but inextricably linked with basic biomedical research.  
Label-free techniques are increasingly engaged in the field of life sciences13. The term label-free 
refers to the absence of any label or marker that is traditionally used to allow the detection of 
changes in intracellular second messenger level, the spatial approximation of certain signaling 
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partners  or  the  relocation  of  distinct  signaling  molecules  within  cells  to  name  only  a  few 
applications1. Unfortunately,  label‐based assays bear the risk of perturbing the outcome by altering 
the physiological behavior due to the introduced label9.  
One example of a label‐free assay is a technology based on dynamic mass redistribution (DMR). Every 
cell  reacts  to  a  stimulus  generally  with  a  change  in  its  cellular  structure,  mostly  involving  a 
cytoskeleton  rearrangement.  This  activation  is  captured  as  DMR  by  an  optical  biosensor14,15.  In 
addition to the label‐free aspect, the DMR method provides a holistic view on the signal processes in 
living  cells. Because  this assay does not  restrict  the  researcher’s attention  to a  single  intracellular 
event (such as the production of a specific second messenger), but  instead allows the perception of 
the  cellular  reaction  as  a whole,  it  is  ideally  suited  to  explore widely  ramified  signal  transduction 
networks9,13,15.  Hence,  DMR  holds  the  promise  to  overcome  the  above mentioned  obstacles  by 
displaying whole cell responses non‐invasively and in an unbiased fashion.  
Because of deficient understanding about the events underlying the phenomenon of dynamic mass 
redistribution, this method is often referred to as a “black‐box assay” that causes skepticism among 
decision‐makers. Therefore,  the DMR  technique  is  rather underexploited and has not  found broad 
application to date16. 
The publication  in this chapter gives a comprehensive portray of the  label‐free DMR technique and 
provides a step‐by‐step protocol how to implement this method into laboratory routine experiments. 
Herein,  the prevention of common mistakes and pitfalls  that otherwise hamper good quality DMR 
readouts  was  emphasized  in  particular  with  the  aim  to  reduce  skepticism  towards  a  wider 
deployment of this technology. 
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 Label-Free Biosensor Assays in GPCR Screening 
 Manuel  Grundmann and  Evi  Kostenis 
 Abstract 
 About one third of currently marketed drugs target G protein-coupled receptors (GPCRs), which form 
the largest group of transmembrane proteins in the human proteome. GPCRs are ubiquitously expressed 
throughout the human body and play a pivotal role in a vast number of physiological and pathophysiologi-
cal processes. Because of their intriguing complexity, their relevance, and yet unexploited potential in the 
treatment of diseases, GPCRs are studied intensively by both academic and industrial research labs. 
 Classical biochemical and molecular biology techniques, including traditional second messenger 
assays, took biomedical research to the next level and represent the fascinating power of in vitro pharma-
cology. While extremely effi cient in capturing one clearly defi ned cellular readout, those methods do not 
authentically portray the events taking place in living cells as a whole; hence the process of drug discovery 
runs the risk to lose sight of a wider context already in early stages. Label-free cell-based assays hold the 
promise to overcome these shortcomings by considering cellular processes holistically. If combined with 
diligent assay adjustments, dynamic mass redistribution (DMR) technology is an excellent tool to investi-
gate GPCR signaling. In this article we aim to provide guidance for scientists seeking for information on 
how to set up and optimize DMR assays with the objective to establish a knowledge base on deciphering 
integrated cellular readouts. For this reason we focus on a basic DMR protocol for the investigation of the 
long-chain fatty acid FFA1 receptor as a model family A GPCR and complement it with information that 
allow a sophisticated approach to more specialized scientifi c questions with the use of this comparatively 
novel method. 
 Key words  Dynamic mass redistribution ,  DMR ,  Resonant waveguide grating ,  RWG ,  G protein- 
coupled receptor ,  Optical biosensor ,  Label-free ,  FFA1 ,  Holistic readout ,  Integrated cell response , 
 Real-time assay ,  Ligand bias 
1  Introduction 
 Optical label-free biosensors based on resonant waveguide grating 
(RWG), also known as guided-mode grated resonance, arose in the 
1990s and were primarily used to detect binding of target mole-
cules to immobilized receptors or, more generally, to determine 
interaction between molecular partners [ 1 ,  2 ]. The phenomenon 
underlying the technique can be described as electromagnetic res-
onance and explained by a simplifi ed design of the biosensor that 
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contains an optical grating interlocked with a layer of special glass 
(Fig.  1 ). More recently, it was recognized that the capabilities of 
this technology go far beyond analyzing binding events toward a 
more in-depth understanding of cellular signaling [ 3 – 6 ]. 
 Eukaryotic cells constantly exchange information with their 
environment. Transmembrane proteins such as G protein-coupled 
receptors (GPCRs), confi gured in a unique assembly of signaling 
pathway components, behave as molecular microprocessors that 
transduce signals from outside the cell into the cell’s interior. For a 
proper communication, both internally and externally cellular sys-
tems need an orchestrated behavior which emerges as morphologi-
cal transformation. This is often realized by a cytoskeleton-guided 
transport of molecules. The cellular architecture is controlled by a 
variety of effector molecules such as calmodulin or protein kinase 
A, activated by the classical second messenger calcium and cAMP, 
respectively. Hence, alpha-subunits of heterotrimeric G proteins 
like Gα s , Gα q , or Gα i but also Gα 12/13 modulate actin fi lament 
 Fig. 1  The structural connection between a planar waveguide and a dielectric diffraction grating allows polar-
ized light to couple in and out when illuminating the sensor under a defi ned angle. The high effi cient coupling 
wavelength is designated resonance wavelength, whose propagation along the biosensor induces evanescent 
waves that extend into a zone approximately 150 nm above the sensor. Depending on the optical density of the 
system (biosensor and adjacent areas above the sensor), a shift of the refl ected wavelength (Δpm) can be 
detected and recorded. In the case of a cell layer above the sensor, changes in optical density can occur by the 
redistribution of intracellular mass toward or away from the sensor, summarized as dynamic mass redistribu-
tion (DMR). Mass movements toward the sensor induce positive wavelength shifts ( p -DMR), whereas move-
ments away from the surface cause negative shifts of the refl ected wavelength ( n -DMR) at the bottom of the 
biosensor 
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structure within eukaryotic cells. Likewise, small GTPases such as 
Rho, Rac, or CDC42 and also Gβγ subunits interacting with PH 
domains (pleckstrin homology domains) are competent to regulate 
the cytoskeleton [ 7 ,  8 ]. In the fi eld of GPCRs, cell-based assays 
capturing morphological rearrangement demonstrate the potential 
of the technology to aid the understanding of receptor biology and 
compound behavior [ 9 ]. 
 The increasing mechanization and automation in drug discov-
ery programs in the past with the aim to accelerate the process 
from target identifi cation to lead identifi cation raised high hopes 
for an advent of novel drugs. As a result of an intensifi ed effort to 
understand the underlying pathophysiology of a given disease, the 
process of target validation has received much more attention. 
However, the reductionistic approach of taking a target out of a 
dysfunctioning context and confi ning it to a specifi c readout, often 
forced by genetic manipulation in an artifi cial biological environ-
ment, enabled researchers to run big screening campaigns testing 
millions of compounds with hitherto unprecedented effi ciency. 
Despite diligent and rigorous preselection of possible drug candi-
dates in this procedure, high dropout rates in preclinical and  clinical 
stages cannot obscure the fact that these hopes were disappointed. 
There are various well-argued approaches to that problem [ 10 ,  11 ] 
and growing consensus about the necessity to investigate com-
pound behavior in a more holistic manner, e.g., refl ected in a mul-
tiple signaling pathway readout. This becomes even more important 
when considering the impact of cellular background and altered 
physiology in disease states on the compound pharmacology and 
receptor biology [ 12 ]. To address the demand for extensive profi l-
ing of receptor-modulating ligands, a new approach based on 
innovative assay designs or combinations of existing assay formats 
is needed. 
 The process of drug discovery in particular could benefi t from 
the capabilities of the DMR technique. The label-free and holistic 
nature of the assay provides more pharmacologically relevant data, 
thus allows eliminating false-positive results from label-based 
assays, and improves signifi cance in selectivity screenings. Cellular 
rearrangement plays a pivotal role as a common cellular phenotype 
in various diseases such as infl ammatory disease, cancer, neurologi-
cal diseases, and cardiovascular diseases (e.g., cardiac hypertrophy), 
since many signaling pathways converge at the level of cytoskeleton 
architecture [ 13 ]. Hence, the assay has the potential to detect all 
cellular events that translate into mass movement, such as (intra)
cellular rearrangement or changes in cell morphology, as an inte-
grated cellular response to various inputs. One major advantage of 
this assay format is the option to investigate test compounds in a 
native or primary cell setting that is closer to in vivo conditions. 
Especially the possibility to integrate tissues from patients, refl ect-
ing disease relevant conditions holds the promise to stimulate the 
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fi eld of in vitro translational medicine and thereby addresses the 
issue of wasting time and money on the production of rather irrel-
evant data [ 14 ]. 
 Furthermore, DMR assays can be automated for HTS pur-
poses or other primary screens [ 15 ]. However, the main fi elds of 
application most likely are further pharmacological evaluation as an 
orthogonal assay platform, for example, in hit confi rmation or in 
structure-activity relationship (SAR) studies. By combining the 
HTS compatibility with the unbiased perspective of dynamic mass 
redistribution on cell response, the DMR assay facilitates uncover-
ing biased ligands, i.e., functionally selective ligands, more effi -
ciently. A key advantage of this assay is the sensitivity to investigate 
biased signaling of GPCRs and functional selectivity of their 
ligands, features that are proposed to deliver more precise thera-
peutic benefi t with reduced amount of side effects [ 16 ]. A study 
including a selection of molecular tool compounds extending the 
label-free assay allowed the dissection and characterization of all 
four G protein-mediated pathways and compared them with results 
from traditional endpoint assays [ 6 ]. 
 An interesting possibility opens up by monitoring cellular 
response in real time. It is becoming increasingly evident that con-
ceiving the spatiotemporal aspect of GPCR signaling solely as one 
isolated and linear event proves insuffi cient; in fact, recent data 
support the idea that signaling via GPCRs rather emerges as mul-
tiple signaling waves [ 17 ]. Research projects approaching kinetic 
questions could therefore benefi t from this method. 
 Downside aspects of the technology go along with the unique 
features of an integrated, holistic view on cellular events. Sometimes 
referred to as “black box assay,” the molecular mechanisms that 
account for the phenomenon of dynamic mass redistribution 
remain to be elucidated. As an integrated cell response, unper-
turbed DMR traces can be composed of on- and off-target effects. 
It is also possible that positive and negative DMR neutralize each 
other, and a net null signal would result that can lead to the misin-
terpretation as an indication of no biological effect. Without the 
appropriate molecular tools and the effort of different approaches 
like combining the label-free assay with other biological readouts, 
it can thus be challenging to decode DMR signatures. Also, high 
costs of biosensor plates might limit the widespread usability of this 
technology. Nevertheless, DMR is a powerful, highly versatile, and 
user-friendly technology platform that is applicable to a vast array 
of different cell types, ranging from overexpression to native cell 
systems, and that offers the great advantage of studying target pro-
tein behavior in the absence of any labels that may confound pro-
tein function. In this protocol, we exemplify the applicability of 
label-free DMR for analyzing real-time signaling of the long-chain 
fatty acid FFA1 receptor in different biological contexts. 
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2  Materials 
  1.  Centrifuge with rotor for microplates. 
  2.  12-channel pipettor for washing 384-well plates. 
  3.  8-channel manifold to aspirate liquids from 384-well plates. 
  4.  75 cm 2 sterile cell culture fl asks. 
  5.  Cell line: Flp-In™ T-REx™ 293 cells, stably transfected with 
the human FFA1 receptor (for more detailed information 
regarding this cell system, please refer to the manufacturer’s 
manual ( http://www.lifetechnologies.com )). 
  6.  Agonists: conjugated linolenic acids (CLA) as long fatty acids 
and the small molecule TUG-424. 
  7.  FFA1-HEK cell medium: DMEM (Dulbecco’s Modifi ed 
Eagle’s Medium), containing 10 % heat-inactivated fetal bovine 
serum (FBS), 1 % penicillin/streptomycin, 100 μg/mL hygro-
mycin B, and 15 μg/mL blasticidin S. 
  8.  Phosphate buffered saline (PBS): NaCl 8.01 g/L, KCl 
0.20 g/L, Na 2 HPO 4 × 2H 2 O 1.78 g/L, KH 2 PO 4 0.27 g/L, 
adjusted to pH 7.4 and sterilized. 
  9.  Trypsin/EDTA: 0.05/0.02 % in PBS, sterile fi ltered. 
  10.  Hank’s balanced salt solution (HBSS): CaCl 2 1.4 g/L, 
MgCl 2 × 6H 2 O 1 g/L, MgSO 4 x7H 2 O 1 g/L, KCl 4 g/L, 
KH 2 PO 4 0.6 g/l, NaCl 80 g/L, Na 2 HPO 4 x7H 2 O 0.9 g/L, 
 D -glucose 10 g/L. 
  11.  HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid). 
  1.  Corning ® Epic ® biosensor (Corning). 
  2.  PerkinElmer EnSpire ® label-free multimode reader 
(PerkinElmer). 
  3.  384-well liquid handling station for compound transfer 
or for carrying out washing steps. 
  4.  384-well tips for use with a liquid handling robot. 
  5.  Corning ® Epic ® biosensor (384-well, fi bronectin-coated) 
microplates (Corning). 
  6.  EnSpire ® -LFC (384-well, fi bronectin-coated) plate 
(PerkinElmer). 
  7.  384-well polypropylene microplate for compound dilutions. 
2.1  Microplates and 
Biosensor instruments
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3  Methods 
 Here, we present our standard protocol for basic investigation of 
the G protein-coupled receptor FFA1 (free fatty acid receptor 1), 
formerly described as GPR40 [ 18 ,  19 ], with the help of an optical 
label-free biosensor platform based on the phenomenon of dynamic 
mass redistribution (DMR). To this end, we use a HEK293 cell 
line inducibly expressing the receptor and both conjugated linole-
nic acids (CLA) as long-chain fatty acids and the selective small 
molecule TUG-424 as FFA1 agonists [ 20 ,  21 ]. For details about 
how to apply the DMR technology to decipher GPCR signaling 
using selective pathway inhibitors, refer to  Note 1 . To study cell 
lines endogenously expressing the receptor,  see  Note 2. In the fol-
lowing steps, all cell culture liquids and the biosensor plate are 
pre-warmed to 37 °C. 
  1.  Culture the cells in 75 cm 2 cell culture fl asks in 15 mL growth 
medium. When cells have reached approximately 80 % confl u-
ency, aspirate the medium, rinse with 5 mL PBS to remove any 
residues of growth medium, and aspirate the buffer. 
  2.  Subsequently, detach cells with 1 mL trypsin/EDTA 
(0.05 %/0.02 %) and count after addition of growth medium 
to stop trypsin-induced cell detachment. 
  3.  Resuspend in the appropriate amount of growth medium con-
taining 1 μg/mL doxycycline for receptor expression to achieve 
a cell density of 18,000 cells/30 μL, and seed 30 μL of this 
suspension into each well of a fi bronectin-coated ( see  Note 3 ) 
384-well biosensor plate. 
  4.  Spin down the plate for 10 s at 150 ×  g to assure cells settle 
onto the bottom of each well. 
  5.  Let cells adhere for approximately 18 h at 37 °C, 5 % CO 2 . 
Doxycycline will induce receptor expression during that time 
(for suspension mode  see  Note 4 ). 
  6.  Make sure that cells have reached confl uency ( see  Note 5 ) in 
the biosensor plate before removing the medium. 
  7.  Wash cells twice with 30 μL HBSS ( see  Note 6 ) supplemented 
with 20 mM HEPES and the appropriate amount of DMSO if 
needed ( see below) using a manifold or a liquid handling sta-
tion. Make sure to adjust the total volume to 30 μL buffer in 
each well after the last washing step. Caution: When aspirating 
the washing buffer, avoid detachment of cells by either direct 
contact or mechanical disintegration of the cellular monolayer. 
  8.  Keep the plate for at least 1 h at measurement temperature for 
equilibration purpose before starting the assay, preferably in a 
temperature-controlled DMR reader ( see  Note 7 ). Extend this 
time period in case of a starvation step ( see  Note 8 ). 
3.1  Preparation 
of Cells
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  1.  Prepare the compounds to be tested in HBSS buffer (+20 mM 
HEPES) ( see  Note 6 ) at fourfold concentration. If a com-
pound is solved in DMSO, make sure to adopt the correct 
DMSO amount in all concentration steps as well as in the 
washing buffer to avoid any solvent mismatch-induced DMR 
signals ( see  Note 9 ) when adding the compound solution to 
the cells during the assay. 
  2.  Transfer 30 μL of compound solution in each well of a 384-
well source plate, e.g., in triplicates. The exact amount depends 
on the geometry of the compound plate and the technical con-
ditions of the liquid handling system. 
  3.  Ensure to include negative controls (vehicle) as well as reliable 
positive controls to document cell viability, for example, by 
addressing endogenous receptors (ATP, PGE 1 ) or other targets 
(forskolin, FBS) and those to differentiate between on- and 
off- target effects ( see  Note 10 ). 
  4.  Equilibrate the compound plate at the same temperature as the 
biosensor plate to avoid temperature-caused shifts in DMR 
response ( see  Note 7 ). 
  1.  Start the measurement by recording a baseline read over 300 s. 
It might be necessary to record for a longer time period until 
the signal is stable, i.e., no or only weak shift in wavelength is 
detected ( see  Note 11 ). 
  2.  Add 10 μL of compound solution to the biosensor plate using 
a liquid handling station. 
  3.  Transfer the plate back to the reader and record DMR imme-
diately after addition to capture rapid cell responses. 
  4.  Monitor cellular response as long as needed—e.g., 1 h—then 
stop the measurement, save the run, and collect the data for 
further analysis. 
  1.  To illustrate cellular response, plot the wavelength shift in 
picometer ( y -axis) against the measurement time ( x -axis) (e.g., 
in GraphPad Prism ® ) with scatter for the respective replicates. 
Throughout this chapter, mean value + s.e.m. is shown. 
  2.  Subtract the buffer trace (i.e., cell response upon addition of 
vehicle) from compound-induced traces to obtain baseline- 
corrected DMR traces ( see  Note 11 ). 
  3.  Quantify the DMR response of agonist substances (for antago-
nist characterization, refer to  Note 12 ) by extracting an appro-
priate parameter, e.g., max Δpm values in a certain time frame 
( see  Note 13 ), and plot it against the concentration of com-
pound to generate concentration-response curves by nonlinear 
regression to determine agonist potency and effi cacy (Fig.  2 ). 
3.2  Preparation 
of Compounds
3.3  DMR 
Measurement
3.4  Data Analysis
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4  Notes 
  1.  Signal deconvolution: Since most GPCRs do not only signal via 
one pathway, the holistic readout of a DMR assay enables the 
researcher to uncover biased compounds, i.e., substances favor-
ing one signaling route over the other. The information- rich 
DMR trace refl ects a signaling fi ngerprint of the compound- cell 
interaction. Depending on the research question, it might be 
relevant to dissect these fi ngerprints with the help of pathway 
modulators such as PTX to inhibit Gα i and YM-254890 or 
FR900359 (= UBO-QIC) to inhibit Gα q proteins [ 22 – 24 ] 
( http://www.pharmbio.uni-bonn.de/signaltransduktion ). The 
FFA1 receptor is predominantly coupled to Gα q proteins as 
revealed by FFA1-HEK cells that were pretreated with 
YM-254890 for 1 h in the biosensor plate before the assay. 
However, the use of PTX, which is present in the medium dur-
ing 18–24 h before the assay, also uncovers a substantial contri-
bution of Gα i proteins to the overall cell response upon 
stimulation with the FFA1 agonist TUG-424 (Fig.  3 ). 
  2.  Impact of cellular background: As mentioned earlier, the DMR 
technology entails the advantage to investigate GPCRs in a 
variety of cell systems including primary, native, and recombi-
nant cell lines. Since the FFA1 receptor is abundantly expressed 
in pancreatic beta cells, it is possible to use dissociated islets 
isolated from mouse pancreas and the native rat beta cell line 
INS-1E endogenously expressing the FFA1 receptor (Fig.  4 ). 
  3.  Plate coating: Depending on the cellular background, it might 
be necessary to use extracellular matrix (ECM) or polymer- 
coated biosensor plates to establish a fi rm attachment in order 
to allow for uniform cellular behavior, such as cell movement. 
 Fig. 2  DMR traces of hFFA1-HEK cells challenged with increasing concentration of the 10t,12c CLA-isomer ( a ). 
In this case, the maximum Δpm value between 0 and 1,500 s was taken to generate the concentration effect 
curve (pEC 50 : 4.39) ( b ). Data from M. Grundmann, redrawn from ref.  20 
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Matrix coatings are likely to also infl uence growth, 
 differentiation, and overall cellular function. Preliminary tests 
and the experience with the particular cell culture will help to 
decide which coating material and cells will work in harness. 
Coating or even co-coating plates on your own with the mate-
rial of your choice is possible, but their suitability has to be 
determined in each case. 
  4.  Adherent vs. suspension mode: It is also possible to perform 
DMR experiments in suspension mode, e.g., for nonadherent 
cells or some primary cells. For this purpose, cells are prepared 
according to specifi c protocols for isolation and purifi cation. 
A higher cell number is required when running the assay in 
suspension mode (about threefold compared to adherent 
cells). The appropriate cell number is reconstituted in the assay 
buffer (e.g., HBSS + 20 mM HEPES), and 30 μL are seeded 
into each well of a 384-well biosensor plate. The plate is cen-
trifuged subsequently at 150 ×  g for 10 s to assure that cells are 
positioned in the bottom part of the well, i.e., in close  proximity 
to the biosensor surface. The subsequent steps correspond to 
the protocol for adherent cells. Depending on the cell system 
and the coating, interaction between the cells and the coating 
material might occur which can be displayed in a transient 
DMR response. This issue is encountered by an extended incu-
bation time. Note that the DMR traces obtained from suspen-
sion mode can differ signifi cantly from those in adherent mode 
 Fig. 3  Dissection of DMR response with pathway inhibitors in FFA1-HEK cells 
stimulated with 3 μM of FFA1 agonist TUG-424. The overall DMR signal is com-
posed of both Gα q and Gα i proteins as shown by pretreatment with Gα i inhibitor 
PTX (5 ng/mL) and/or the selective Gα q inhibitor YM-254890 (300 nM), each of 
which partially reduce the DMR response. The combination of the inhibitors, 
however, completely abolishes the signal. Redrawn from ref.  6 
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(and it might therefore be advisable to choose alternative 
parameters for data analysis) (Fig.  5 ). 
  5.  Confl uency: Critical steps in optimizing a DMR protocol 
include growth conditions and cell number in the biosensor 
plate, because intercellular interaction greatly infl uences the 
cell response. As a starting point for assay optimization, always 
 Fig. 4  Primary, native, and recombinant cell lines demonstrate the versatility of the assay platform. Rat islets 
were dissociated with trypsin and measured 6 days after seeding into the biosensor plate ( a ). INS-1E and 
FFA1-HEK cells were prepared according to the standard protocol with 30,000 cells/well (INS-1E) ( b ) and 
18,000 cells/well (FFA1-HEK) ( c ). The cells were then stimulated with the FFA1 agonist TUG-424 and DMR 
response was recorded. Different cellular backgrounds can have great impact on the behavior in the assay. 
Note the different  y -axis scaling! Data from M. Grundmann, University of Bonn, unpublished observations 
 Fig. 5  Rat beta cell line INS-1E endogenously expressing FFA1 and treated with FFA1 agonist TUG-424 shows 
positive DMR if growing adherent (30,000 cells/well) ( a ) and negative DMR when in suspension mode (90,000 
cells/well) ( b ). Data from M. Grundmann, University of Bonn, unpublished observations 
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aim for a confl uent cellular monolayer with nicely attached 
cells whose phenotype resembles their usual morphology. To 
achieve this, it might be necessary to vary growth medium 
additives, coating material, and especially the cell number. 
  6.  Buffer infl uence: Changing the assay buffer is possible, but 
should be made with caution. The system comprising biosen-
sor, cells and compounds might might react differently under 
modifi ed buffer conditions. Solubility of test compounds can 
be limited in one buffer and as a result, can greatly affect DMR 
response (Fig.  6c ). However, varying assay buffers is suggested 
as part of an assay optimization process. 
  7.  Temperature (Fig.  6a, b ): Optical density and accordingly the 
shift in wavelength as the readout of DMR assays are highly 
sensitive to changes in temperature. It is therefore recom-
mended to assure a uniform temperature throughout the mea-
surement, i.e., minimize temperature differences between test 
plate and compound plate to be transferred; keep the plates at 
the same temperature for a suffi cient time to ensure tempera-
ture equilibration. Otherwise, artifacts such as a wavelength 
 Fig. 6  Infl uence of temperature and buffer composition on the DMR assay. At higher assay temperatures, DMR 
signals appear accelerated and with greater amplitude (prostaglandin E1 activating EP2/4 receptors endoge-
nously expressed in HEK293 cells) ( a ). A small molecule CRTH2 agonist induces DMR in HEK cells stably 
transfected with the CRTH2 receptor at physiological temperature but not at 28°C ( b ). Changing the assay 
buffer can have great impact on DMR signals by either lowering the cellular responsiveness or limiting the 
solubility of test compound. Depicted are DMR responses of FFA1-HEK cells stimulated with 100 μM of the 
9c,11t CLA-isomer in standard HBSS buffer or Krebs-Ringer buffer ( c ). Data from M. Grundmann and 
R. Schröder, University of Bonn, unpublished observations 
 
DMR Assay in GPCR Research
210
shift or drift can occur, emerging under negative control 
 conditions such as vehicle addition. Since temperature can be 
distributed unevenly over the test plate (edge effects), it is rec-
ommended to position negative controls randomly over the 
plate. In addition to system-related effects, temperature has 
signifi cant impact on overall cellular function as well. Higher 
temperature generally leads to higher signal amplitude and 
accelerated kinetics of DMR signals. To some degree, this also 
implies an extended sensitivity to weak agonists to be detected 
in a threshold-based screening (Fig.  6b ). Note that under dif-
ferent temperature conditions, an expanded cellular repertoire 
can be displayed that might also complicate interpretation of 
DMR responses, for example, in signaling pathway decoding. 
  8.  Starvation: Keeping the cells under starvation conditions for 
varying time periods before the assay (e.g., serum starvation in 
serum-free medium or in the assay buffer) can also have an 
impact on cellular response in the DMR assay. Although not 
generally applicable, especially those experimental setups that 
suffer from a small assay amplitude may benefi t from starva-
tion techniques to gain signal enhancement. 
  9.  DMSO mismatch: DMSO artifacts generally recognized as 
sharp spikes (up to thousands of Δpm) occur if the DMSO 
amount in the compound solution is different from that in the 
assay buffer surrounding the cells. Adjust the DMSO concen-
tration in all assay solutions conscientiously, because the assay 
is very DMSO sensitive! Avoid DMSO concentrations way 
above 1.2 %! The DMR technology is less sensitive to other 
solvents such as ethanol. 
 10.  On- and off-target effects: The holistic nature of the method 
can make it challenging to differentiate between on- and off- 
target effects. To trace a given DMR response back to a spe-
cifi c molecular target, it is necessary to include negative 
controls in the setup. In the described protocol, we could use 
cells that were not induced with doxycycline and thus do not 
express our target protein on the cell surface. In the case of 
primary cells, knockout material would be an appropriate 
 negative control. Another possibility is the use of a target-spe-
cifi c antagonist that is capable of blocking the DMR response 
of an agonist ( see  Note 12 ). Furthermore—in the absence of 
suitable pharmacological inhibitors—cross-desensitization or 
gene silencing methods may be applied to help attribute a 
DMR signal to a certain cellular event. 
 11.  Buffer control: The course of the buffer signal can give insight 
into the overall cellular behavior such as detachment from the 
plate surface as well as temperature effects, which can result 
in a DMR drift over the time. Normally, these events can be 
prevented by optimizing cell culture conditions (e.g., cell 
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 density, plate-coating, media additives, etc.) or measurement 
options (e.g., temperature equilibration, time, and accuracy). 
 12.  Antagonist mode: The DMR technique is perfectly suited for 
characterizing antagonists as well. Besides standard determi-
nation of IC 50 -values or the mode of action (competitive, non-
competitive, uncompetitive, inverse agonist, partial agonist), it 
is also possible to describe the kinetic profi le of a test sub-
stance. Real-time DMR recordings after antagonist addition 
to agonist-induced cell responses allow the user to gain insight 
into kinetic features of test compounds or receptors (see , e.g., 
ref.  25 ) . A basic protocol to determine the mode of action of 
an antagonist involves a two-step addition. In the fi rst step, 
after washing the cells, increasing concentrations of antagonist 
are added, and DMR is recorded to detect any cellular response 
upon antagonist application. In the second step, after preincu-
bation with antagonist, the agonist is added. After DMR mea-
surement and basic data analysis, an inhibition curve or a 
Schild regression analysis can be performed to further describe 
antagonist parameters and mode of action (Fig.  7 ). 
 13.  Data quantifi cation: Parameters for data quantifi cation range 
from peak value at a certain time point or within a defi ned 
time frame, the area under curve (AUC) between certain time 
points or steepness of a tangent to the initial DMR trace to 
capture kinetic compound behavior. In certain cases, the real- 
time readout enables the researcher to distinguish between 
multiple phases in cell response. The number, the duration, or 
the time needed to pass one phase adds to the list of possible 
quantifi cation parameters. Since the content-rich DMR 
 readout can appear highly complex and multiphasic, we 
 recommend to address the issue of quantifi cation on a case-by-
case basis (Fig.  8 ). 
 Fig. 7  Analysis of the FFA1 antagonist  1 [ 26 ] competing with small molecule FFA1 agonist TUG-488 [ 27 ]. 
A pIC 50 of 6.45 can be determined for  1 by inhibition curve ( a ); Schild analysis reveals competitive/surmountable 
antagonism of  1 ( b ). Data from M. Grundmann, unpublished observations 
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 Epilogue 
In this chapter, we presented a comprehensive protocol to setup DMR experiments ranging from a 
basic  to  an  advanced  design.  Research  object was  the  FFA1  receptor  because  it  is well  suited  to 
demonstrate  the broad applicability of  the DMR method. FFA1  receptor signaling was studied  in a 
recombinant (HEK293) as well as in a native (INS‐1E) and a primary (pancreatic rat islets) cell system 
using both long‐chain fatty acids as endogenous ligands as well as synthetic small molecule agonists, 
thereby  reflecting  the  flexibility  of  the DMR  assay  technology.  Evidently,  taking  advantage  of  the 
unbiased  perspective  of  the  DMR  assay,  the  FFA1  receptor  could  be  classified  as  promiscuously 
coupling to both the Gαq and Gαi protein subfamilies. The combination of selective FFA1 agonists and 
pathway‐specific signal  transduction  inhibitors  (selective G protein  inhibitors: PTX and FR900359  (= 
UBO‐QIC)) revealed a shared, PTX‐ and FR900359‐sensitive signaling behavior.  
Hence, label‐free is applicable to a broad set of biological systems and it remains to be seen how this 
technology  integrates  into  the  recent  return  of  phenotypic  pharmacology1,2.  With  its  holistic 
approach  it  fulfills  all  requirements  to play  an  integral part  in  translational drug discovery  and  to 
shape the process from a reductionist to a holistic analysis of cellular readouts3. Since this technology 
is principally able to capture all facets of cell signaling differences, samples of cells or tissue specimen 
from patients might also be applicable and could thus stimulate the change of mindset from artificial 
in vitro conditions to a pathologically relevant level of investigation4,5. 
Label‐free  assays  offer  broad  pathway  coverage  and  delineate  an  integrated  cell  response.  As  a 
corollary,  texture‐rich  DMR  signatures  can  pose  a  challenge  to  analyze.  Auspiciously,  the  DMR 
technology can generally be hooked up with all kinds of cell manipulating methods such as genetic 
techniques:  Knock‐In,  Knock‐Out  or  Knock‐Down,  mutational  approaches  or  pharmacological 
perturbation,  whereby  the  entire  register  from  reversal,  irreversible,  competitive  or  allosteric 
inhibitors  might  be  employed.  Therefore,  it  is  tempting  to  envision  a  “developer’s  toolkit”  to 
interpret  label‐free  signatures  and  decipher  pathway  usage.  For  the  elucidation  of  GPCR‐related 
signal transduction a starting point could be the availability of compounds that selectively modulate 
the  activation  state  of  G  proteins6.  In  this  regard,  the  specific  inhibition  of  certain  G  protein 
subfamilies appears particularly attractive to further elucidate G protein‐mediated but also putative 
G protein‐independent GPCR‐mediated signaling. 
Further  advantages  of  label‐free  assays,  that  could  only  be  discussed  tangentially  in  the 
aforementioned publication, are the support of structure‐activity‐relationship (SAR) studies or mode‐
of‐action  (MoA) studies7,  the ability  to conduct  receptor panning studies  to  functionally determine 
which  receptors  are  expressed on  certain  cells or  the possibility  to  cross‐validate  a  compound of 
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interest at multiple receptor subtypes and, in particular, check for potential off-target effects. Since 
the optical biosensor is highly sensitive to changes of optical density directly above the growing 
surface, the DMR technology can also be used to detect changes in cell adherence and confluence 
and might therefore applicable for toxicity screens1,8.   
Finally, the capability of the DMR assay to monitor cell response in real time should be emphasized9. 
This label-free readout elegantly provides valuable insight into dynamic aspects of cell activation that 
would be otherwise arduous to acquire10,11. In the following chapter, we profoundly exploit this 
property to discover a new mechanism of GPCR activation by a small molecule GPCR modulator.    
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 Section II 
 Chapter 2: Sequentially activating ligands 
 Prologue 
GPCRs  belong  to  the most  successful  targets  in  the  history  of  pharmacological  intervention  and 
comprise the largest group of membrane proteins1–3. Until very recently, only three groups of ligands 
did exist for the modulation of GPCRs. These are i) orthosteric, ii) allosteric and iii) bitopic ligands4–7. 
In  this  chapter we  introduce  a  fourth  class  of  ligands:  iv)  Sequentially Activating  Ligands  (SEALs). 
These ligands are characterized by a stepwise activation mode of the receptor. By binding to multiple 
binding  sites,  SEALs  initiate  signaling  from  each  site  and  can  thus  direct  temporally  coordinated 
signaling. 
The  compound  4‐CMTB  was  discovered  among  several  phenylacetamides  in  a  high‐throughput‐
screening to  find selective FFA2  ligands and was subsequently characterized as an allosteric  ligand, 
i.e.  it modulates orthosterically‐mediated FFA2 activation while additionally activating  the  receptor 
on its own8 (ago‐PAM). Intriguingly, efforts to optimize the compound by structural variations and to 
determine the actual binding site at the FFA2 receptor were inconclusive9–11.  
Allosteric  ligands  are preferred  structures  to  target  closely  related GPCR  subtypes  that  cannot be 
selectively targeted with an orthosteric‐oriented drug discovery approach12. Several positive aspects 
of allosteric ligands have already been outlined in the introduction but there are also disadvantages 
of  allosteric  ligands,  of which  lack  of  efficacy  in  the  absence  of  the  orthosteric  ligand  is  a major 
concern.  However,  this  is  only  true  for  pure  allosteric  ligands  but  not  those who  show  intrinsic 
efficacy  on  their  own  (e.g.  allosteric  agonists  or  ago‐PAMs)13.  This  mode‐of‐action  is  especially 
interesting for diseases, in which endogenous agonist tone is low, such as Parkinson’s or Alzheimer’s 
disease14.  
Bitopic  ligands  are  ligands  that  span  two  spatially  separated binding  sites  at  a  receptor with one 
molecule that consists of two bridged pharmacophores6,7,15. This construction allows for targeting of 
two sites at the same time and takes advantage of different compound behavior at these two sites. 
For  example,  this  could  mean  a  subtype  selective  targeting  by  exploiting  the  structurally  less 
conserved  allosteric  binding  site  within  a  group  of  closely  related  receptors  and  simultaneously 
inducing receptor activation by binding to the orthosteric binding pocket. By  induction of a distinct 
set  of  receptor  conformations,  bitopic  ligands might  also  lead  to  biased  signaling  compared  to  a 
mono‐modal binding ligand6,16. 
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Sequentially activating ligands expand the spatially-centered understanding of receptor activation by 
another dimension, i.e. time. With SEALs it might be possible to induce distinct receptor 
conformations in a time-dependent manner by exploiting all features associated with either 
orthosteric or allosteric targeting. In this chapter, we describe the concept of SEALs in a proof-of-
concept study using the FFA2 receptor as a model class A GPCR. By that, we greatly benefit from the 
real time label-free DMR and impedance-based technology that are capable to monitor the cellular 
effects of ligands with this new mode-of-action. This information would have been missed by 
conducting only traditional equilibrium-state GPCR readouts17. However, only the direct comparison 
of classical endpoint assays and innovative label-free assays appropriately describes the process in its 
entirety and therefore exemplifies a complementation-based approach, which we used to disclose 
this mechanism. 
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Summary 
Ligands targeting seven-transmembrane receptors (7TMR) are currently classified as either 
orthosteric, allosteric or dualsteric/bitopic. Here, we define a new pharmacological concept for 7TMR 
functional modulation: sequentially activating ligands (SEALs). A hallmark feature of “SEALs” is the 
temporary activation of a first receptor site followed by sustained activation via a second 
topographically distinct site. We identify 4-CMTB, previously classified as a pure allosteric agonist of 
the free fatty acid receptor FFA2, as the first “SEAL” and corroborate its bifunctionality in living cells 
by tracking integrated responses with innovative optical- and impedance-based label-free biosensors 
capable of visualizing multiple signaling inputs in real-time. We validate this unique pharmacology with 
traditional cellular readouts along with mutational and pharmacological perturbations including 
molecular modelling, and propose a kinetic model applicable to analysis of SEAL action. Our proof-of-
concept study unveils 4-CMTB as prototype of a new class of ligands epitomizing a heretofore-
unobserved molecular mechanism of receptor activation.  
  
 
 
Introduction 
7TM receptors are involved in virtually every (patho)physiological process in mammals and therefore 
have been the most successful targets for drug development1,2. Most drugs act via binding to the 
orthosteric site, thereby competing with the endogenous ligands that naturally regulate receptor 
function. During the past years allosteric modulation of 7TM receptors has received considerable 
interest, and significantly allosteric ligands (that is ligands that bind to a distinct location) are emerging 
as promising alternatives for therapeutic intervention because they may obviate several of the 
inherent challenges of orthosteric target-centered approaches3–6. First, allosteric ligands may achieve 
greater receptor subtype selectivity because allosteric epitopes are less well conserved than 
orthosteric recognition sites, which have stringent evolutionary demands to retain conservation. 
Second, allosteric ligands may not stimulate the receptor directly but can act to enhance receptor 
function on a timescale governed by the endogenous agonist. A clear advantage of such “use-
dependence” may be the lower propensity for receptor desensitization7. If allosteric modulators 
enhance activity of the physiological agonist, either by altering its affinity or efficacy, they may provide 
a means to fine-tune cellular signaling by favoring selected signaling routes over others8. Third, 
allosteric modulators are characterized by their saturability of effect on the orthosteric recognition 
site. This in turn allows preservation of a low-level tone of the endogenous ligand and thus safeguards 
physiological function even under conditions of full occupancy of the allosteric site3,5. 
To date, allosteric ligands are classified as inhibitors (negative allosteric modulators, NAMs), 
potentiators (positive allosteric modulators, PAMs), agonists or ago-PAMs, as well as silent or neutral 
modulators (SAMs/NALs)3,9,10. Recently, a novel class of pharmacological agents has become available 
for modulation of 7TMR function: dualsteric or bitopic ligands11,12. These ligands harbor two 
pharmacophores connected by a linker to concomitantly engage both orthosteric and allosteric 
receptor binding pockets. Thus, dualsteric/bitopic ligands combine receptor subtype selectivity with 
the capacity to fine-tune the receptor’s natural signaling pattern13,14.  
 
 
The purpose of the present study is to introduce a novel mechanism of pharmacological intervention 
with 7TMR function: sequentially activating ligands (SEALs). This mechanism is posited to explain the 
differences observed in investigations into the molecular modes of action of two agonists for the free 
fatty acid receptor 2 (FFA2, formerly GPR43)15,16: the short chain fatty acid propionic acid C3 and the 
small molecule 4-CMTB (phenylacetamide, 2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide). 
Propionic acid is an endogenous agonist targeting the orthosteric pocket of FFA215,16. 4-CMTB, initially 
introduced as AMG7703, is a synthetic ligand that was identified in a high-throughput screening 
campaign in an effort to achieve selective activation of FFA2 over the closely related FFA3 receptor17. 
Interestingly, considerable optimization efforts have failed to provide ligands with significantly higher 
potency than the initial hit and attempts to map its binding site have been largely inconclusive18,19. 
Nevertheless, of the studies undertaken with 4-CMTB to date, all are indicative of a purely allosteric 
mode of action17–21.  
Herein, we do confirm allosteric receptor engagement of FFA2 by 4-CMTB but additionally reveal a 
hitherto unappreciated orthosteric component in its mechanism of action. Intriguingly, this orthosteric 
activation is only temporary in nature but is followed by sustained activation via the allosteric site. We 
validate this sequential mode of receptor engagement using a variety of functional assays under kinetic 
and equilibrium conditions in combination with pharmacological perturbations, receptor mutagenesis 
and molecular modeling. We also develop a kinetic model applicable to the analysis of SEAL action at 
7TMRs. 
With the identification of 4-CMTB as the prototype SEAL we not only expand the pharmacological 
toolbox of 7TM receptor modulators, but moreover present a mechanism of action heretofore 
unobserved with any other 7TM receptor agonist. We envision that SEALs may allow precise temporal 
control over receptor signaling dynamics to fine-tune cellular responses, thereby expanding the 
repertoire of cellular communication via 7TM receptors in space and time.   
 
 
Results 
Label-free techniques unveil different activation modes of C3 versus 4-CMTB 
Label-free assays based on the detection of dynamic mass redistribution (DMR) or bioimpedance 
capture integrated responses in living cells with high temporal resolution and broad signaling pathway 
coverage22–25. They have proven exquisitely suited to visualize cellular activation profiles of signaling-
competent proteins such as 7TM receptors26–28. We initially set out to compare the cellular reaction to 
either the endogenous, orthosteric agonist propionic acid (C3) or the synthetic allosteric agonist 
4-CMTB in HEK293 cells engineered to stably express the human FFA2 wild-type receptor (hFFA2, 
hFFA2-wt). Label-free impedance sensing unraveled a striking temporal difference in the signaling 
patterns triggered by the two receptor ligands. C3 provoked a sharp transient negative peak instantly 
after compound addition that reversed quickly toward baseline and that was followed by a second 
gradually descending phase. 4-CMTB largely lacked the first spike but preserved the second phase 
signal (Fig. 1a,b, for magnification of the early timescale see Supplementary Figure 1). Comparable 
results were obtained in optical biosensor-based DMR recordings. C3 generated a uniform signature 
with a maximal DMR peak at about 1,500 sec, after which it decayed slowly (Fig. 1c). 4-CMTB, in 
contrast, evoked a less pronounced initial increase with a delayed maximal response at approx. 3,000 
sec. Yet, overall DMR profiles at later time points were comparable  to those generated by C3 (Fig. 1d). 
To consider these temporal differences we quantified concentration-effect relationships for both 
ligands at early and late time points. This analysis revealed partial agonism of 4-CMTB for the first 
signaling impulse (Fig. 1e,f), but full agonism at later time points (Fig. 1g,h, and Supplementary Table 
1). Acetic acid (C2), another endogenous agonist of hFFA2, induced a phenotypic signaling profile 
reminiscent to that observed with C3 (Supplementary Figure 2). All cell responses in the label-free 
readouts were specifically mediated via the hFFA2 receptor, since untransfected cells did not react 
upon compound addition (Supplementary Figure 3). 
  
 
 
Structural integrity of the orthosteric site has impact on 4-CMTB signaling dynamics 
A key residue within the orthosteric binding pocket of hFFA2 is R2557.53 in helix 7 (Ballesteros-
Weinstein indexing system in superscript), which - if mutated to alanine (hFFA2-R255A) - renders 
hFFA2 unresponsive to short chain fatty acids despite appropriate surface expression (29, see methods). 
Consistent with these findings, C3 was completely inactive on the hFFA2-R255A mutant receptor in 
both impedance- and optical-based label-free whole cell recordings (Supplementary Figure 4a,b). As 
expected, 4-CMTB retained the capacity to trigger cell activation via the hFFA2-R255A receptor, 
corroborating its non-orthosteric mode of action. However, we noted that the kinetic profile of 
4-CMTB differed significantly from that obtained at the wild-type receptor. Both label-free assays 
yielded temporal fingerprints for 4-CMTB indicative of impaired early but enhanced late cell responses 
(Fig. 1i,j). Time-dependent quantification of label-free signatures at the hFFA2-R255A receptor 
revealed loss of function for the orthosteric agonist C3 at all points in time (Supplementary Figure 
4c,d) as opposed to selective abrogation of 4-CMTB activity for the first signaling impulse (Fig. 1k,l). 
Our mutagenic approach indicates that lack of orthosteric R255 impacts on signaling by 4-CMTB, either 
because allosteric site signaling requires the integrity of the orthosteric site and/or because 4-CMTB 
also interacts directly with the orthosteric receptor site. Notably, hFFA2-R255A transfected cells did 
not lose their ability to react rapidly per se. ATP, acting as an agonist at endogenously expressed P2Y 
receptors, induced a robust and immediate cell response whose phenotype resembled that of the 
hFFA2-wt and the untransfected host cell line (Supplementary Figure 5). A receptor-independent 
impairment causing a delay in the signaling kinetics is therefore unlikely. 
CATPB serves as a selective orthosteric probe  
To provide a complementary view on the biological role of the orthosteric binding site for 4-CMTB 
signaling, we chose to manipulate hFFA2 function using traditional pharmacological perturbation with 
CATPB, a small molecule previously reported to competitively antagonize hFFA2-wt receptor function20 
(Fig. 2a). We initially verified competitive antagonism of CATPB with C3 using Schild analysis of DMR 
 
 
recordings at the hFFA2-wt receptor (pA2: 7.61 ± 0.04, slope: 0.96 ± 0.01) (Fig. 2b,c). Competitive 
inhibition of C3 function by CATPB was further substantiated in ERK1/2 phosphorylation assays 
(Supplementary Figure 6a,b). Moreover, and consistent with previous reports30, CATPB - in its own 
right - showed intrinsic activity at hFFA2-wt receptor expressing cells in the DMR assay (Fig. 2d). 
Negative deflection of DMR traces relates to inverse agonism of CATPB at constitutively active hFFA2-
wt receptors because CATPB was inactive at the hFFA2-R255A mutant, which lacks constitutive activity 
(Fig. 2e,f, and Supplementary Figure 6c). Accordingly, CATPB also lowered basal levels of inositol 
phosphates (IP) and pERK1/2 in hFFA2-wt receptor expressing cells (Supplementary Figure 6d,e). 
Furthermore, at no time did CATPB affect non-orthosteric 4-CMTB-mediated activation of the hFFA2-
R255A mutant in label-free recordings in spite of its capacity to bind to this mutant receptor form (Fig. 
2g,h,i and Supplementary Figure 7). Thus, data from the current and previous studies suggest 
occupancy of non-overlapping binding sites by CATPB and 4-CMTB at equilibrium and unambiguously 
define CATPB as orthosteric probe, competing with C3 for a common site within the orthosteric hFFA2 
pocket. Therefore, CATPB can be applied rationally to interrogate the mechanism of 4-CMTB activation 
at the wild-type hFFA2 receptor. 
Attenuation of orthosteric signaling by CATPB remodels the dynamics of 4-CMTB-mediated FFA2 
activation 
In accordance with an orthosteric mode of action, high concentrations of CATPB completely blocked 
C3-induced DMR and changes in cellular impedance in hFFA2-wt receptor expressing cells (Fig. 3a,b). 
In contrast, saturating concentrations of CATPB exclusively blunted rapid cell activation, but preserved 
or even enhanced the second signaling wave mediated by 4-CMTB (Fig. 3c,d, for quantification of early 
and late responses in label-free DMR and impedance assays, respectively, see Fig. 3e,f). Of note, CATPB 
did not affect DMR or impedance responses triggered by endogenously expressed P2Y receptors, 
confirming the specific nature of hFFA2-wt receptor inhibition (Supplementary Figure 8). Thus, 
pharmacological perturbation of FFA2 signaling by CATPB in conjunction with the orthosteric loss-of-
 
 
function mutation (Fig. 1i,j) does indeed provide a complementary view on the role of the orthosteric 
site for 4-CMTB signaling. 
Time-specific endpoint assays untangle the kinetics of orthosteric site-driven signaling  
To elucidate whether the characteristic temporal inhibition pattern of CATPB on 4-CMTB-induced cell 
responses is echoed in traditional readouts for 7TM receptor signaling pathways, multiple parallel 
assays were employed that either capture rapid (mobilization of intracellular Ca2+), delayed 
(accumulation of IP as well as inhibition of forskolin-mediated cAMP production) or both cell responses 
(ERK1/2 phosphorylation assays). Indeed, the transient rise of Ca2+, which is detectable within seconds 
after addition of both C3 and 4-CMTB, is blunted by CATPB (Fig. 3g,h; see Supplementary Figure 9 for 
real time Ca2+ traces). For both ligands, inhibition was complete and entirely consistent with 
competitive antagonism (Fig. 3i, Supplementary Table 2). CATPB did not block Ca2+ influx upon 
stimulation with the calcium ionophore A23187, or carbachol, which activates endogenously 
expressed muscarinic acetylcholine receptors (Supplementary Figure 10a,b), confirming specificity of 
the inhibitory effect. Second messenger production in IP (Fig. 3j) and cAMP accumulation assays (Fig. 
3k) after 4-CMTB stimulation was fully insensitive to inhibition with CATPB. This is in contrast to 
complete inhibition that was apparent when C3 was employed as the activating stimulus (Fig. 3j,k). 
Inhibition of early, partial inhibition of intermediate, but lack of CATPB sensitivity at late signaling time 
points is also recapitulated in ERK1/2 phosphorylation assays examining the time-dependence of 
interaction between 4-CMTB and CATPB (Fig. 3l; see Supplementary Figure 11a for unperturbed 4-
CMTB pERK1/2 kinetics over time). Inhibition of pERK1/2 levels by CATPB was FFA2 receptor-
dependent, since serum-induced controls were unaffected by the antagonist (Supplementary Figure 
11b). Of note, untransfected cells were nonresponsive to both C3 and 4-CMTB, corroborating FFA2 
receptor-specific effects across all second messenger assays (Supplementary Figure 12). In summary, 
with real-time label-free data, second messenger assays provide strong support for the notion that 
4-CMTB mediates early cellular responses via transient activation of the orthosteric site.    
 
 
Mutational analysis unveils dual input control of 4-CMTB signaling at the wild-type receptor 
A corollary of orthosteric receptor engagement by 4-CMTB is selective abrogation of early, but not 
late, cell responses in mutant forms of hFFA2 lacking a functional orthosteric site. To test this 
prediction, we investigated the temporal signaling pattern of 4-CMTB at the hFFA2-R255A receptor in 
both Ca2+ and second messenger assays. Consistent with our prediction, rapid signaling of transient 
Ca2+ flux upon 4-CMTB stimulation was abolished (Fig. 3m) but delayed cell responses in second 
messenger (Fig. 3n,o) and ERK1/2 accumulation assays (Fig. 3p) were preserved. Thus, by combining 
complementary strategies consisting of pharmacological inhibition, receptor mutagenesis along with 
label-free real-time and canonical endpoint assays, we posit that 4-CMTB dually controls input at the 
wild-type receptor by sequentially activating the orthosteric followed by the allosteric site, 
respectively. 
An ECL2 swap mutant exaggerates the transient orthosteric action of 4-CMTB 
We next chose to investigate the mechanism of receptor activation by 4-CMTB using a chimeric hFFA2 
receptor, in which the extracellular loop 2 (ECL2) of hFFA2 was exchanged for the counterpart of the 
cognate hFFA3 receptor (hereafter hFFA2-ECL). This mutant was designed previously in an effort to 
understand transmission of allosteric effects by 4-CMTB18. Both C3 and 4-CMTB displayed temporal 
activation patterns in hFFA2-ECL expressing HEK293 cells that were comparable with those observed 
at the wild-type receptor (Fig. 4a-d, compare with Fig. 1c,d,f,h). Inhibition of C3 by CATPB remained 
competitive at the hFFA2-ECL receptor (pA2: 7.00 ± 0.10; slope: 1.01 ± 0.04; Supplementary Figure 
13a,b). According to this, saturating concentrations of CATPB completely inhibited C3-induced DMR 
responses at all times (Fig. 4e). Intriguingly, CATPB inhibition of 4-CMTB signaling differed significantly 
from the pattern observed for the wild-type receptor because both initial and delayed activation of 4-
CMTB was largely diminished (Fig. 4f, compare with Fig. 3c). When we compared CATPB modulation 
of C3 and 4-CMTB signaling at early time points at the hFFA2-ECL receptor, we observed complete 
inhibition indistinguishable from competitive antagonism (Fig. 4g,h) and reminiscent of the profile at 
 
 
the wild-type receptor (Fig. 4i,j). Quantitative analysis of CATPB IC50-shifts indicates competitive 
antagonism for both C3 and 4-CMTB and thus strengthens the conclusion of temporary orthosteric 
receptor activation by 4-CMTB (Fig. 4k,l, Supplementary Table 3). Moreover, CATPB remained able to 
partially inhibit delayed 4-CMTB-induced cell responses at the hFFA2-ECL mutant (Supplementary 
Figure 14a,b), whereas it gradually turned into enhancement over time at the wild-type receptor 
(Supplementary Figure 14c,d; compare a with c, and b with d; for snap-shot quantification of time-
dependent modulation by CATPB of 30 µM 4-CMTB see Fig. 4m). These data argue for a gatekeeper 
role of ECL2 in determining the duration of orthosteric first phase agonism by 4-CMTB. To challenge 
this hypothesis we introduced the Arg255Ala mutation into the hFFA2-ECL receptor resulting in the 
double mutant hFFA2-R255A-ECL. If 4-CMTB initially adopted an orthosteric pose and provided that 
adoption of this pose is temporally extended in the hFFA2-ECL construct, then it should be lost in the 
hFFA2-R255A-ECL mutant and be reflected as a significant impairment of the initial signaling impulse. 
Indeed, DMR recordings in hFFA2-R255A-ECL expressing cells mirror the traces obtained in hFFA2-ECL 
cells in the presence of CATPB: DMR signatures indicate loss of the orthosteric contribution (“the fast 
component”) to the overall response but maintenance of the capacity to evoke activation via the 
allosteric site (“the slow component”, Fig. 4n). Consistently, Ca2+-ionophore, A23187, but not C3 and 
4-CMTB, elicited a calcium transient in hFFA2-R255A-ECL cells (Fig. 4o). However, delayed activation 
via the allosteric site was still detectable for 4-CMTB as evidenced by robust accumulation of inositol 
phosphates (Fig. 4p). These results led us to conclude that concomitant perturbation of the orthosteric 
binding pocket by Arg255Ala and of the gatekeeper function of ECL2 is well suited to illustrate the 
sequence of events during receptor activation by 4-CMTB, thereby associating the initial signaling 
impulse with an orthosteric and the prolonged signaling impulse with an allosteric mechanism.   
A single amino acid replacement is sufficient to trap 4-CMTB in an orthosteric pose 
The capacity to enhance duration of orthosteric 4-CMTB action in the ECL2 swap mutant prompted us 
to hypothesize that a similar effect might be achievable by replacement of key residues lining the 
allosteric FFA2 site by the corresponding FFA3 counterparts. Guided by homology modeling based on 
 
 
the crystal structure of the related FFA1 receptor we replaced K652.60 by arginine (hFFA2-K65R), a 
residue which has not been probed previously as determinant of 4-CMTB action (Fig. 5a,b and 31). Both 
C3 and 4-CMTB robustly activated hFFA2-K65R in DMR assays consistent with the mutated residue 
being outside the orthosteric area (Fig. 5c-f). Most notably, however, and entirely consistent with our 
hypothesis, both C3 and 4-CMTB were now fully antagonized by CATPB (Fig. 5g-i). Similar observations 
were made in IP accumulation assays: C3 and 4-CMTB induced robust IP production (Fig. 5j) and this 
response was completely ablated by CATPB in a manner compatible with competitive antagonism for 
both ligands (Fig. 5k-m, Supplementary table 4). Thus, at hFFA2-K65R the only mode of interaction 
available to 4-CMTB is occupancy of epitopes within the orthosteric pocket which manifests as 
complete sensitivity towards inhibition by CATPB.  
Mutational analysis defines orthosteric 4-CMTB topography 
To further corroborate transient orthosteric first phase agonism of 4-CMTB, we examined its signaling 
pattern in mutant forms of hFFA2, in which activation by C3 is either severely impaired (R1805.39A) or 
ablated (R1805.39A/R2557.53A, H2426.55A)29. DMR analysis confirms that each mutant lacks key epitopes 
defining the orthosteric pocket of hFFA2 (Supplementary Figure 15). If we assume that these residues 
are similarly important for shaping 4-CMTB’s orthosteric signaling element, then 4-CMTB action should 
be restricted to exclusive transmission of its allosteric second phase impulse in these mutants. Indeed, 
in all cases DMR recordings were indicative of selective loss of rapid orthosteric but preservation of 
delayed allosteric signaling (Fig. 6a-c; for quantification of early and late responses see Supplementary 
Figure 16). Consistently, 4-CMTB was unable to induce rapid orthosteric Ca2+ flux across all mutants 
(Fig. 6d-f, left panels), yet retained activity in IP accumulation assays capturing the allosteric response 
(Fig. 6d-f, right panels and Supplementary Figure 17). C3 was inactive or severely compromised in both 
Ca2+ and IP assays in line with DMR and published data (Supplementary Figure 15, and 18,29,32). 
Moreover, we also confirmed orthosteric elements of activation for 4-CMTB utilizing an FFA2 mutant 
designed to mimick the orthosteric site of FFA3: hFFA2-S86G3.29-Y90F3.30-I145Y4.61-E166LECL2. Because 
4-CMTB is selective for FFA2 over FFA3, we predicted the quadruple mutant to specifically lose rapid 
 
 
orthosteric but preserve allosteric activation. C3, in contrast, should retain functionality in both assays 
because it is unable to discriminate between FFA2 and FFA3. Indeed, C3 but not 4-CMTB induced 
intracellular Ca2+ flux (Fig. 6g, left panel), however, both ligands produced substantial responses in IP 
accumulation assays (Fig. 6g, right panel and Supplementary Fig. 18). In agreement with compromised 
orthosteric but functional allosteric signaling of the quadruple mutant, DMR recordings revealed rapid 
cell activation exclusively for C3 but delayed signaling that is superimposable for both ligands (Fig. 6h). 
Based on these results, we predicted that combined substitution of a key orthosteric residue together 
with the allosteric K65R mutation should be sufficient to severely impact, if not ablate, 4-CMTB 
function. Indeed, complete lack of activation by 4-CMTB of hFFA2-K65R-R255A in DMR assays, despite 
appropriate surface expression, indicates experimental validation of our prediction (Fig. 6i and 
Supplementary Fig. 19). Thus, we demonstrate in a definitive and systematic manner that a single 
ligand may activate a 7TMR in tandem via two topographically distinct receptor sites (Fig. 6j-l), thereby 
introducing the novel pharmacological concept of sequentially activating ligands (SEALs). A model 
applicable to mechanisms that involve sequential receptor activation by a single ligand via distinct 
receptor sites is provided in an Online Appendix.  
 
 
Discussion 
It is common sense that allosteric ligands differ structurally from orthosteric ligands because they 
address spatially distinct receptor binding sites. In this regard, action of the small molecule 4-CMTB as 
both orthosteric and allosteric ligand is surprising. In fact, 4-CMTB, which was previously considered 
to exclusively display allosteric pharmacology17,18,20,21, may now be classified as a unique bifunctional 
molecule, competent to sequentially activate both orthosteric and allosteric sites of the FFA2 receptor. 
This behavior has been inferred from a multifaceted experimental approach based on functional assays 
under equilibrium and kinetic conditions, label-free DMR and bio-impedance whole cell sensing, 
pharmacological and mutagenic receptor perturbations along with molecular and mathematical 
modeling to illustrate and refine the concept, respectively.  
Pharmacological targeting of more than one receptor site has to date only been achieved with 
dualsteric/bitopic ligands11,12. This ligand class consists of hybrid molecules, in which orthosteric and 
allosteric building blocks are bridged by a molecular linker. Thus, dualsteric/bitopic ligands span and 
simultaneously bind to orthosteric and allosteric receptor sites33. Dualsteric pharmacology is a 
captivating concept that underlies receptor subtype selectivity and may even confer signaling bias13,14. 
4-CMTB also engages ortho- and allosteric sites, however, this small molecule is distinct from bitopic 
ligands in that it does not contain individual building blocks that are separated by a defined molecular 
linker. Rather it achieves activation via targeting of spatially distinct FFA2 receptor sites by altering its 
signaling competence in a time-dependent manner. 
Distinction of receptor responses in early and late phases is not unprecedented in the literature, as 
several ligand-receptor systems are known that change signaling modalities over time such as the 
control over extracellular signal-regulated kinases ERK1/234. Differential spatial and kinetic patterns of 
ERK activation have, for example, been observed for angiotensin AT1A receptors in HEK293 cells with 
G protein-activated ERK peaking after 2 minutes as opposed to β-arrestin-dependent ERK activation 
that peaks at later time points and is more protracted35. Similar mechanistic distinctions were made 
 
 
for 7TMR-dependent regulation of AKT, a kinase operating downstream of PI3K. AKT activation upon 
stimulation of protease-activated receptor 1 (PAR1) may be both rapid and sustained and controlled 
by separate G protein and β-arrestin dependent mechanisms, respectively36. While regulation of kinase 
families by β-arrestin versus G protein-dependent mechanisms are well documented with numerous 
examples37, and while engagement of these parallel mechanisms can differ depending on the ligand 
chosen to stimulate the receptor, a phenomenon referred to as ligand bias, no such study – to the best 
of our knowledge – has yet linked first and second phase responses to occupancy of topographically 
distinct sites, which is the key characteristic in the concept of SEALs. We speculate that SEALs may be 
more frequent than anticipated, yet may have gone unnoticed if ligands were exclusively analyzed in 
equilibrium assays. Thus it is likely that the SEAL concept described here for 4-CMTB could only be 
discovered by combining real-time and canonical assays under both non-equilibrium and equilibrium 
conditions38.  
An intriguing feature of orthosteric-allosteric targeting of FFA2 by 4-CMTB is the chronological order 
of these events. The structure of class A 7TMRs would suggest that SEALs initiate contact within the 
allosteric vestibule followed by passage into the transmembrane binding pocket to elicit an orthosteric 
response39,40. 4-CMTB, however, appears to navigate via a different route. We speculate that 4-CMTB 
achieves sequential orthosteric-allosteric targeting by entering via the lipid bilayer. Such an entry mode 
differs from the common entrance via the extracellular space but has previously been shown for 
several class A 7TMR ligands41–46, particularly for ligands at lipid mediator 7TMRs, such as the ago-
allosteric agonist TAK875 (fasiglifam) at the related hFFA1 receptor31. Clearly, further studies are 
needed to investigate the entry mode of 4-CMTB at FFA2 in more detail. Nevertheless, and irrespective 
of the precise entry mode, 4-CMTB is – to the best of our knowledge - the first 7TMR modulator that 
conveys sequential activation via two distinct receptor sites. 
Our complementary approach identifies 4-CMTB as a small molecule altering its activation mechanism 
over time. Although compelling experimental evidence is provided in favor of this unique mode of 
action, we chose to verify the novel concept with a kinetic model to rationalize the sequence of events 
 
 
on a molecular level (see Online Appendix). We propose that two molecules of 4-CMTB bind the 
receptor at distinct loci with different binding kinetics. Slower binding of one 4-CMTB molecule to the 
allosteric binding site subsequently results in negative allosteric modulation of the 4-CMTB effect at 
the orthosteric site. The apparent transient orthosteric signaling phase is therefore rationalized if 
4-CMTB functioned as a NAM on its own efficacy at a distinct binding site. The extracellular loop 2 
(ECL2) likely contributes to cessation of orthosteric signaling, since the ECL2-swap from the FFA2 
receptor to the cognate counterpart of FFA3 substantially enhanced orthosteric elements of activation. 
Within hFFA2-K65R, however, which lacks a key residue of the allosteric pocket, 4-CMTB was 
essentially restricted to an orthosteric mechanism, as evidenced by the enhanced sensitivity toward 
the orthosteric FFA2 antagonist CATPB. In line with these findings, partial agonism of 4-CMTB 
progressively increased with a rank order of hFFA2-wt < hFFA2-ECL < hFFA2-K65R implying a 
correlation between residence and efficacy at the orthosteric site. Thus, capacity to switch 4-CMTB 
pharmacology to orthosteric in mutants lacking key allosteric residues and vice versa, i.e. to achieve 
both orthosteric and allosteric trapping, can only be rationalized by occupancy of two distinct sites by 
the same molecule, the molecular basis for coining the term SEAL to acknowledge this complex yet 
unprecedented pharmacological phenotype.  
With the assignment of 4-CMTB, previously classified as an ago-allosteric modulator, as the first SEAL, 
we uncover a heretofore uncharacterized mechanism of 7TMR signaling control. Because SEALs 
comprise allosteric components of activation, they provide the same potential advantages that are 
credited to the phenomenon of allosterism, ranging from subtype selectivity and probe dependency 
to functional selectivity3,4. Although much additional work is needed to understand the utility of this 
novel concept, we anticipate that discovery of the first SEAL will catalyze both identification of 
additional SEALs among ligands for 7TMRs with defined pharmacology and development of this class 
of ligands beyond FFA2 to achieve stimulus-specific cell responses to control the multiplicity of 7TMR 
coupling in space and time. 
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Figure 1. Label-free biosensors disclose unappreciated differences between C3 and 4-CMTB 
(a-d) Label-free real-time traces of HEK293 cells stably transfected with the hFFA2-wt receptor stimulated with 
C3 (a,c) and 4-CMTB (b,d) recorded with the impedance- and optical-based biosensor, respectively. (e-h) 
Concentration-response-curves (CRC) of FFA2 agonists calculated at early (e,f) and late (g,h) time points from 
bioimpedance (negative peak within 0 – 600 sec (e) and impedance at 3,600 sec (g)) and DMR recordings (peak 
within 0 – 800 sec (f) and DMR at 6,000 sec (h)). (i,j) Real-time signatures of 4-CMTB at the hFFA2-R255A construct 
in the impedance (i) and the DMR assay (j), respectively. (k,l) CRC of 4-CMTB at the hFFA2-R255A receptor 
calculated from early or late cell responses in the impedance (k) and DMR assay (l), respectively. Label-free 
signatures are shown as representative traces (mean + s.e.m.), measured in triplicates. CRC are depicted as mean 
values ± s.e.m from three to six independent experiments. 
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Figure 2. CATPB is an orthosteric inverse agonist at the hFFA2-wt receptor 
(a) Chemical structure of CATPB. (b,c) Effect of increasing concentration of CATPB on DMR-derived CRC of C3 at 
the hFFA2-wt receptor (b) with corresponding Schild plot (c). (d,e) Intrinsic activity of CATPB at hFFA2-wt (d) but 
not hFFA2-R255A transfected HEK cells (e) captured in the DMR assay. (f) CRC of CATPB at the hFFA2-wt (pIC50: 
6.81 ± 0.14) and hFFA2-R255A receptor. (g,h) Effect of CATPB on 4-CMTB (30 µM) signaling at the hFFA2-R255A 
receptor in the DMR (g) and bioimpedance (h) assay. (i) Analysis of DMR data from panel (g) at different time 
points (500 sec vs. 6,000 sec.). Real-time recordings are shown as representative traces (mean + s.e.m.), 
measured in triplicates. Quantified data are shown as mean values ± s.e.m. of three to six independent 
experiments. Where not shown error bars lie within dimensions of the symbols. 
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Figure 3. 4-CMTB shows time-dependent sensitivity towards the orthosteric antagonist CATPB and 
the mutation of a key residue within the orthosteric site. 
(a-d) Effect of CATPB on 30 µM C3 (a,b) and 4-CMTB (c,d)-mediated hFFA2-wt receptor activation in the optical- 
and impedance-based label-free readout, respectively. (e,f) Quantification of FFA2 receptor inhibition by CATPB 
in the DMR (e) and bioimpedance (f) readout at early (500 sec) and late time points (6,000 sec for DMR; 3,600 
sec for impedance). (g,h) Effect of CATPB on hFFA2-wt Ca2+ flux evoked by varying concentrations of C3 (g) and 
4-CMTB (h). (i) Analysis of IC50-shifts according to Cheng-Prusoff (slope: C3: 1.040 ± 0.024, r2: 0.9946; 4-CMTB: 
1.011 ± 0.045, r2: 0.9805). (j) CATPB effect on C3 (pIC50: 6.22 ± 0.39) or 4-CMTB-induced IP accumulation at the 
hFFA2-wt receptor. Data were baseline-corrected to remove the contribution of constitutive activity to IP 
signaling and CATPB responsiveness. (k) Impact of CATPB on C3 or 4-CMTB-mediated inhibition of 0.3 µM 
Forskolin-induced cAMP production. (l) Time point-differentiated analysis of CATPB effect on 4-CMTB-mediated 
ERK1/2 phosphorylation. (m) Ca2+ flux in hFFA2-R255A expressing HEK293 cells upon stimulation with FFA2 
agonists. Calcium-ionophore A23187 shown as control. (n-p) Equilibrium CRC of C3 and 4-CMTB at the hFFA2-
R255A receptor in the IP- (pEC50: 4.70 ± 0.09) (n), the cAMP-(pEC50: 5.96 ± 0.22) (o) and the pERK1/2-assay (pEC50: 
5.15 ± 0.04) (p). Label-free signatures are shown as representative traces + s.e.m., measured in triplicates. Bar 
diagrams and CRC represent mean values ± s.e.m of at least three independent experiments. Statistical 
significance was analyzed by two-tailed, unpaired Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
           hFFA2-ECL
0
1,
80
0
3,
60
0
5,
40
0
7,
20
0
-100
0
100
200
300
400
500
600
C
3  (lo
g
 M
)
vehicle
-2
-3
-3,5
-4
-4,5
-5
-6
-7
-8
time (s)
D
M
R
 (p
m
)
          hFFA2-ECL
0
1,
80
0
3,
60
0
5,
40
0
7,
20
0
-100
0
100
200
300
400
500
600
4-C
M
T
B
 (lo
g
 M
)
vehicle
-4
-4.25
-4.5
-5
-5.5
-6
-7
-8
time (s)
D
M
R
 (p
m
)
initial response
hFFA2-ECL
-10 -8 -6 -4 -2 0
-50
0
50
100
150
C3
4-CMTB
compound (log M)
D
M
R
 (%
 o
f C
3)
late response
hFFA2-ECL
-10 -8 -6 -4 -2 0
-50
0
50
100
150
C3
4-CMTB
compound (log M)
D
M
R
 (%
 o
f C
3)
             hFFA2-ECL
            30µM C3
0
1,8
00
3,6
00
5,4
00
7,2
00
0
100
200
300
400
C
A
T
P
B
 (lo
g
 M
)
-5
-6
-7
-8
w/o
time (s)
D
M
R
 (p
m
)
        hFFA2-ECL
        30µM 4-CMTB
0
1,
80
0
3,
60
0
5,
40
0
7,
20
0
0
100
200
300
400
w/o
-9
-8
-7
-6
-5
C
A
T
P
B
 (lo
g
 M
)
time (s)
D
M
R
 (p
m
)
hFFA2-ECL
800 seconds
-11 -10 -9 -8 -7 -6 -5 -4
-50
0
50
100
150
-4
-4.5
-5
-6
C
3 (lo
g
 M
)
CATPB (log M)
D
M
R
 (%
 o
f C
3)
hFFA2-ECL
800 seconds
-11 -10 -9 -8 -7 -6 -5 -4
-50
0
50
100
150
-4
-4.5
-5
-5.5
4-C
M
T
B
 (lo
g
 M
)
CATPB (log M)
D
M
R
 (%
 o
f 4
-C
M
T
B
)
hFFA2-wt
800 seconds
-11 -10 -9 -8 -7 -6 -5 -4
-50
0
50
100
150
-3
-4
-4.5
-5
-6
C
3 (lo
g
 M
)
CATPB (log M)
D
M
R
 (%
 o
f C
3)
hFFA2-wt
800 seconds
-11 -10 -9 -8 -7 -6 -5 -4
-50
0
50
100
150
-4
-4.5
-5
-5.5
4-C
M
T
B
 (lo
g
 M
)
CATPB (log M)
D
M
R
 (%
 o
f 4
-C
M
T
B
)
hFFA2-ECL
0 2 4 6 8
0
2
4
6
8
C3
4-CMTB
log [agonist]/EC50
IC
50
/p
A
2
hFFA2-wt
0 20 40 60
0
20
40
60
C3
4-CMTB
log [agonist]/EC 50
IC
50
/p
A
2
500 s 3,600 s 7,200 s
     hFFA2-wt/ECL
wt
EC
L wt
EC
L wt
EC
L
0
50
100
150
200
w/o CATPB
CATPB (10µM)
re
la
tiv
e 
D
M
R
 (%
 o
f 3
0µ
M
4-
C
M
T
B
 w
/o
 C
A
T
P
B
              hFFA2-R255A-ECL
0
1,
80
0
3,
60
0
5,
40
0
7,
20
0
-100
0
100
200
300
400
4-C
M
T
B
 (lo
g
 M
)
vehicle
-4
-4.5
-5
-5.5
-6
-7
-8
fsk (-4.5)
time (s)
D
M
R
 (p
m
)
  hFFA2-R255A-ECL
-8 -7 -6 -5 -4 -3 -2
-50
0
50
100
150
4-CMTB
C3
compound (log M)
IP
1 
(%
 o
f 1
00
µ
M
 C
ar
b
ac
h
o
l)
a b c d
e f g h
i j k l
m n o p          hFFA2-R255A-ECL
bu
ffe
r
Ca
-Io
no
ph
or
e 
(5
µM
)
C3
 (-
2)
C3
 (-
3)
4-
CM
TB
 (-
3.
5)
4-
CM
TB
 (-
4)
0
100
200
300
400
500
C
a
2+
 (R
F
U
)
 
Figure 4. Structural changes within the extracellular receptor region intensify susceptibility of 
4-CMTB effect to interrogation at the orthosteric site level 
(a,b) DMR traces of HEK293 cells stably transfected with the hFFA2-ECL receptor stimulated with C3 (a) or 4-
CMTB (b). (c,d) CRC of FFA2 agonists calculated at early ((c), peak within 0 – 800 sec) and late ((d), DMR at 6,000 
sec) time points. (e,f) Effect of increasing concentrations of CATPB on DMR traces of 30 µM C3 (e) and 4-CMTB 
(f) activating the hFFA2-ECL receptor. (g,h) Comparison of CATPB inhibition at early time points (800 sec) on 
hFFA2-ECL activation by C3 (g) or 4-CMTB (h). (i,j) Comparison of CATPB inhibition at early time points (800 sec) 
on hFFA2-wt activation by C3 (i) or 4-CMTB (j). (k,l) Analysis of IC50-shifts according to Cheng-Prusoff at the hFFA2-
ECL (slope: C3: 0.992 ± 0.020, r2: 0.996; 4-CMTB: 0.976 ± 0.046, r2: 0.978) (k) and hFFA2-wt receptor (slope: C3: 
1.049 ± 0.010, r2: 0.999; 4-CMTB: 1.030 ± 0.029, r2: 0.992) (l). (m) Temporal quantification of CATPB-sensitivity at 
the hFFA2-wt and the hFFA2-ECL receptor for 30 µM of 4-CMTB. (n) 4-CMTB effect at the double mutant hFFA2-
R255A-ECL in the DMR assay, Forskolin (fsk) is shown as control. (o) Ca2+ flux of FFA2 agonists at the hFFA2-
R255A-ECL receptor, calcium-ionophore A23187 is shown as control. (p) Assessment of IP levels upon hFFA2-
R255A-ECL receptor stimulation with C3 or 4-CMTB (pEC50: 4.23 ± 0.03) under equilibrium conditions. 
Representative real-time traces are shown as mean + s.e.m., measured in triplicates. Quantified data are 
depicted as mean values ± s.e.m. of at least three independent experiments. 
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Figure 5. Identification of K65 as a key residue within the allosteric site that controls trapping of 
4-CMTB in an orthosteric pose. 
(a,b) Superimposition of the FFA2 homology models. K65 is pointed towards the binding cavity in the FFA1-based 
model (white) due to the proline kink at position 2.58 that unwinds helix 2. This proline kink is conserved in the 
free fatty acid receptor family but absent in the previously used β2-adrenergic receptor-based model (cyan). (c,d) 
DMR traces of HEK293 cells stably transfected with the hFFA2-K65R receptor stimulated with C3 (c) or 4-CMTB 
(d). (e,f) CRC of FFA2 agonists calculated at early ((e), peak within 0 – 800 sec) and late ((f), DMR at 6,000 sec) 
time points. (g,h) Effect of increasing concentrations of CATPB on DMR signatures of 30 µM C3 (g) and 4-CMTB 
(h) activating the hFFA2-K65R receptor. (i) CATPB inhibition of hFFA2-K65R receptor-mediated cell activation by 
C3 (pIC50: 6.82 ± 0.06) or 4-CMTB (pIC50: 6.97 ± 0.10). (j) CRC of FFA2 agonists activating the hFFA2-K65R receptor 
in the IP assay (pEC50(C3): 4.21 ± 0.05; pEC50(4-CMTB): 4.66 ± 0.12). (k,l) CATPB inhibition of C3 (k) or 4-CMTB (l)-
elevated IP levels. (m) Analysis of IC50-shifts according to Cheng-Prusoff (slope: C3: 1.007 ± 0.029, r2: 0.990; 
4-CMTB: 1.033 ± 0.050, r2: 0.972). Representative real-time traces are shown as mean + s.e.m., measured in 
triplicates. Quantified data are depicted as mean values ± s.e.m. of three independent experiments. 
 
 
0
1,
50
0
3,
00
0
4,
50
0
6,
00
0
-50
0
50
100
150
200
250
        hFFA2-R180A
-4
-4.25
-4.5
-4.75
-5
-5.5
-6
-7
Cch (-4)
vehicle
4-C
M
T
B
 (lo
g
 M
)
time (s)
D
M
R
 (p
m
)
0
1,
50
0
3,
00
0
4,
50
0
6,
00
0
-50
0
50
100
150
200
250
        hFFA2-R180A-R255A
-4
-4.25
-4.5
-4.75
-5
-5.5
-6
-7
vehicle
Cch (-4)
4-C
M
T
B
 (lo
g
 M
)
time (s)
D
M
R
 (p
m
)
0
1,
50
0
3,
00
0
4,
50
0
6,
00
0
-50
0
50
100
150
200
250
       hFFA2-H242A
-4
-4.25
-4.5
-4.75
-5
-5.5
-6
-7
vehicle
Cch (-4)
4-C
M
T
B
 (lo
g
 M
)
time (s)
D
M
R
 (p
m
)
ba
sa
l
A2
31
87
 (5
µM
)
C3
 (1
m
M
)
4-
CM
TB
 (1
00
µM
)
0
20
40
60
80
100
120
        Calcium
C
a
2+
 (%
 o
f 5
µ
M
 A
23
18
7)
ba
sa
l
A2
31
87
 (5
µM
)
C3
 (1
m
M
)
4-
CM
TB
 (1
00
µM
)
0
20
40
60
80
100
120
        Calcium
C
a
2+
 (%
 o
f 5
µ
M
 A
23
18
7)
ba
sa
l
A2
31
87
 (5
µM
)
C3
 (1
m
M
)
4-
CM
TB
 (1
00
µM
)
0
20
40
60
80
100
120
       Calcium
C
a
2+
 (%
 o
f 5
µ
M
 A
23
18
7)
         hFFA2-S86G-Y90F-I145Y-E166L
0
2,
00
0
4,
00
0
6,
00
0
8,
00
0
-100
0
100
200
300
400
4-CMTB (-4)
C3 (-2)
vehicle
time (s)
D
M
R
 (p
m
)
ba
sa
l
C3
 (1
0m
M
)
4-
CM
TB
 (1
00
µM
)
0
20
40
60
80
100
120
      Calcium
C
a
2+
 (%
 o
f 1
0m
M
 C
3)
0
2,
00
0
4,
00
0
6,
00
0
-100
0
100
200
300
400
          hFFA2-K65R-R255A
-4
-4.25
-4.5
-4.75
-5
-5.5
-6
-7
Cch (-4)
vehicle
4-C
M
T
B
 (lo
g
 M
)
time (s)
D
M
R
 (p
m
)
ba
sa
l
Ca
rb
ac
ho
l (
10
0µ
M
)
C3
 (1
m
M
)
4-
CM
TB
 (3
00
µM
)
0
20
40
60
80
100
120
               IP
IP
 (%
 o
f 1
00
µ
M
 C
ar
b
ac
h
o
l)
ba
sa
l
Ca
rb
ac
ho
l (
10
0µ
M
)
C3
 (1
m
M
)
4-
CM
TB
 (3
00
µM
)
0
20
40
60
80
100
120
           IP
IP
 (%
 o
f 1
00
µ
M
 C
ar
b
ac
h
o
l)
ba
sa
l
Ca
rb
ac
ho
l (
10
0µ
M
)
C3
 (1
m
M
)
4-
CM
TB
 (3
00
µM
)
0
20
40
60
80
100
120
                  IP
IP
 (%
 o
f 1
00
µ
M
 C
ar
b
ac
h
o
l)
ba
sa
l
C3
 (1
0m
M
)
4-
CM
TB
 (1
00
µM
)
0
20
40
60
80
100
  IP
IP
1 
(%
 o
f 1
00
m
M
 C
3)
hFFA2-R180A hFFA2-R180A-R255A hFFA2-H242A
hFFA2-S86G-Y90F-I145Y-E166L
a b c
d e f
g h i
R2557.35
H2426.55 Y2386.51
E166
Y903.33
Y943.37
I1454.61
S863.29
K652.60
R2557.35
R1805.39
H2426.55
Y2386.51
E166
Y903.33
Y943.37
I1454.61
S863.29
K652.60
R2557.35
R1805.39
K652.60
kj l
 
Figure 6. FFA2 receptor mutagenesis delineates two distinct receptor sites that convey 4-CMTB 
action. 
(a-c) DMR traces of 4-CMTB activating HEK293 cells transiently expressing either the hFFA2-R180A (a), the hFFA2-
R180A-R255A (b) or the hFFA2-H242A (c) receptor construct, Carbachol is shown as control. (d-f) Ca2+-flux and IP 
level measurements as traditional endpoint assays capturing early and late cell response to stimulation with FFA2 
agonists at the hFFA2-R180A (d), the hFFA2-R180A-R255A (e) and the hFFA2-H242A (f) receptor mutant. (g) Ca2+-
flux and IP response after activation with C3 or 4-CMTB at the FFA2 quadruple mutant. (h) DMR traces to C3 and 
4-CMTB stimulation of the FFA2 quadruple mutant transfected HEK293 cells. (i) DMR readout of HEK293 cells 
 
 
transiently expressing the hFFA2-K65R-R255A receptor mutant. Carbachol is shown as control. (j,k) 4-CMTB 
binding at the FFA2 orthosteric (j) and allosteric site (k). Hydrogen bonding, aromatic and van der Waals 
interactions are shown in black, cyan and yellow dotted lines, respectively. The binding modes of 4-CMTB were 
obtained via docking to the FFA1-based homology model of FFA2 and mutagenesis validation. (l) Surface 
representation of the receptor with coloured orthosteric and allosteric sites in yellow and cyan, respectively. 
Only anchoring residues, R1805.39, H2426.55 and R2557.35 for the orthosteric site and K652.60 for the allosteric site 
are visualized. Representative real-time traces are shown as mean values, measured in triplicates. Quantified 
data are depicted as mean values ± s.e.m. of three independent experiments. 
  
 
 
Methods 
Chemical compounds 
Propionic acid (C3) was purchased from Sigma-Aldrich. (S)-3-(2-(3-Chlorophenyl)acetamido)-4-(4-
(trifluoromethyl)phenyl)butanoic acid  (CATPB) and 2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-
yl)butanamide (4-CMTB) were synthesized as described previously in 30 and 18, respectively. 
Plasmids and mutagenesis 
Enhanced yellow fluorescent protein (eYFP) was C-terminally fused to FFA2 receptor cDNA and 
subcloned into pcDNA5/FRT/TO (Invitrogen) as previously reported29. C-terminal tagging with eYFP 
was without effect on receptor functionality as confirmed by holistic label-free readouts 
(Supplementary figure 20). All functional studies were performed with eYFP-fused wt and mutated 
hFFA2 receptors, either stably (hFFA2-wt, hFFA2-R255A, hFFA2-ECL, hFFA2-R255A-ECL, hFFA2-K65R, 
hFFA2-S86G-Y90F-I145Y-E166L) or transiently (hFFA2-R180A, hFFA2-R180A-R255A, hFFA2-H242A, 
hFFA2-K65R-R255A) expressed in HEK293 cells at comparable levels (Supplementary figure 19). 
Fluorescent microscopy images were obtained with cells either induced with 1 µg/mL doxycycline or 
transiently transfected with respective receptor mutant and subsequently visualized using a 20x 
objective (Leica DM IL LED Fluo, Leica Microsystems).  Site-directed mutagenesis in receptor cDNA in 
pcDNA5/FRT/TO was carried out following the QuikChange® protocol (Agilent Technologies). DpnI was 
used to digest template DNA and the mutated constructs were sequenced to confirm correct 
mutations. ECL2-swap mutant hFFA2-receptor (hFFA2-ECL) was generated as previously described 18.  
Cell culture and transfections 
To generate stable cell lines inducibly expressing the receptors, Flp-InTM T-RExTM 293 cells (Invitrogen) 
were cotransfected with pcDNA5/FRT/TO containing the receptor of interest and pOG44 (Invitrogen) 
in a ratio of 1:9 using a calcium phosphate DNA precipitation method according to manufacturer’s 
instructions. pOG44 drives expression of recombinase, which enables recombination of FRT sites in the 
 
 
receptor-cDNA carrying plasmid and the host genome of Flp-InTM T-RExTM 293 cells. In consequence, 
Hygromycin B resistance introduced by pcDNA5/FRT/TO can identify receptor-transfected cells. Stably 
transfected Flp-InTM T-RExTM 293 cells were cultured in Dulbecco’s modified Eagle‘s medium (DMEM) 
containing 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 µg/mL), 
Hygromycin B (100 µg/mL) and Blasticidin (15 µg/mL) at 37°C and 5% CO2. Untransfected Flp-InTM T-
RExTM 293 host cells were maintained in DMEM supplemented with 10% (v/v) FBS, penicillin (100 
U/mL), streptomycin (100 µg/mL), 100 µg/mL Zeocin and 15 µg/mL Blasticidin at 37°C and 5% CO2. All 
experiments were carried out after inducing receptor expression with 1 µg/mL doxycycline for 
approximately 18 hours. 
Dynamic mass redistribution (DMR) assay 
DMR measurements were performed using either the Epic® System (Corning) or the EnSpire® System 
(PerkinElmer) as previously described in detail26,27. Briefly, 20,000 cells per well were seeded into a 384 
well biosensor plate in culture medium and left to adhere for 4 – 6 hours at 37°C and 5% CO2. 
Subsequently, medium was replaced by doxycycline (1 µg/mL) containing culture medium and the 
plate was incubated at 37°C and 5% CO2 for approximately 18 hours to drive receptor expression. Cells 
were then washed at least twice with HBSS (supplemented with 20mM HEPES) and incubated for 1 
hour at 37°C on the DMR reader. Compounds were diluted in HBSS (+20 mM HEPES) and added to the 
biosensor plate after 3 minutes of baseline read with a liquid handling system (CyBi®-SELMA, CyBio). 
Immediately after compound addition, DMR response was recorded for at least 1.5 hours. Where 
necessary, cells were preincubated with antagonist for 30 minutes.   
Bioimpedance assay 
Bioimpedance measurements were performed using the CellKeyTM System (MolecularDevices). For this 
purpose, 15,000 cells were seeded into 384 well poly-D-lysine (PDL)-coated CellKeyTM system 
microplates in culture medium and centrifuged at 150 x g for 1 minute. The plate was then incubated 
for 4 – 6 hours at 37°C and 5% CO2 to allow cells to adhere to the biosensor plate. Thereafter, medium 
 
 
was replaced by doxycycline containing (1 µg/mL) culture medium and incubated for approximately 18 
hours at 37°C and 5% CO2. Cells were then washed with HBSS (supplemented with 20 mM HEPES and 
the appropriate amount of DMSO according to the compound dilutions) three times using a manifold, 
which leaves 5 µL left in each well. 15 µL of wash buffer was added and the plate was subsequently 
transferred to the impedance reader and incubated for 1 hour at 37°C. Compounds were diluted in 
HBSS (containing 20 mM HEPES) and DMSO amount was adjusted in all dilution steps. 25 µL of 
compound solution was dispensed into a 384 well compound plate and subsequently incubated in the 
CellKeyTM system. A baseline read was then recorded for 5 minutes and compound solutions were 
added directly onto the biosensor plate. Changes in cellular impedance (ohms) were measured as a 
result of extracellular current (dZiec) for 1 hour. If needed, cells were preincubated with antagonist for 
30 minutes. 
Calcium flux assay 
Intracellular calcium mobilization was measured using the FLIPR® Calcium 5 Assay Kit in conjunction 
with the FlexStation® 3 Multimode Benchtop Reader (Molecular Devices). Briefly, cells were seeded 
into poly-D-lysine coated 96 well microplates at a density of 60,000 cells per well. After 4 – 6 hours the 
medium was replaced by culture medium supplemented with 1 µg/mL doxycycline and incubated for 
18 hours at 37°C and 5% CO2. Thereafter, cells were loaded with the FLIPR® Calcium 5 dye for 30 
minutes at 37°C and subsequently processed according to manufacturer’s instructions. Where 
necessary, cells were preincubated with antagonist for 30 minutes. 
IP and cAMP assay 
Intracellular levels of the second messenger IP and cAMP were quantified with a Mithras LB 940 
multimode reader (Berthold Technologies) using the HTRF®-IP-One kit and the HTRF®-cAMP dynamic 
kit (CisBio International), respectively, according to the manufacturer’s instructions. Briefly, for the IP 
assay, 10,000 receptor-expressing cells were seeded into a 384 well microplate and incubated for 20 
minutes at 37°C. Cells were then stimulated with agonist for 30 minutes and IP levels were quantified 
 
 
using the HTRF®-IP1 kit. Fr the cAMP assay, 3,000 cells were seeded into a 384 well microplate and 
incubated for 20 minutes at 37°C. Cells were stimulated with a mixture of agonist and forskolin for 30 
minutes and intracellular levels of cAMP were subsequently analyzed using the HTRF®-cAMP dynamic 
kit. If needed, cells were preincubated with antagonist for 30 minutes. 
pERK1/2 assay 
Intracellular levels of phosphorylated ERK1/2 were quantified using the HTRF®-Cellul’erk kit (Cisbio 
International) and the Mithras LB 940 multimode reader (Berthold Technologies) following 
manufacturer’s instructions. Briefly, 80,000 cells were seeded onto poly-D-lysine coated 96 well 
microplates and incubated for 4 – 6 hours at 37°C. Receptor expression was initiated by adding 
doxycycline (final concentration 1 µg/mL) and the plate was incubated for 18 hours at 37°C and 5% 
CO2. Thereafter medium was replaced by starvation medium, lacking 10% FCS, and incubated for 
another 4 hours at 37°C and 5% CO2. Compounds were added and pERK1/2 levels were determined 
using the HTRF®-Cellul’erk kit at time points as indicated. Where necessary, cells were preincubated 
with antagonist for 30 minutes. 
Radioligand binding assay 
The affinity of CATPB at wild type and R255A FFA2 was assessed through equilibrium displacement 
binding experiments against a radiolabeled form [3H]AZ136821499 of a recently described FFA2 
antagonist47. Membranes prepared from Flp-InTM T-RExTM 293 cell line induced to express the desired 
receptor variant were co-incubated in binding buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 
mM EDTA, pH 7.4) with a fixed concentration of [3H]AZ136821499 and increasing concentrations of 
CATPB for 2 h at 25°C. Membranes were then filtered through glass fiber filter paper and washed with 
PBS  before membrane-bound [3H] was measured by liquid scintillation spectrometry. In order to 
calculate pKi values, specific [3H] binding data were fit to a one-site displacement binding equation for 
which the Kd of [3H]AZ136821499 was constrained to the value obtained for wild type (7.5 ± 0.4 nM) 
or R255A (13.0 ± 0.5 nM) in saturation binding assays. 
 
 
Molecular modeling 
The FFA1 crystal structure with PDB code 4PHU31 was used as a template to generate the FFA2 
homology model employing the Prime 3.0 program (Schrödinger, LLC, USA) with the default settings. 
The model was refined using a default energy minimization protocol implemented in Prime 3.0. 
Docking was conducted using Glide 6.5 (Schrödinger, LLC, USA) with the receptor grid defined by 
residues at positions 3.37, 4.57, 5.39, 6.51 and 7.53.  The standard precision scoring function was used 
for docking. Modelling figures were generated with Maestro 9.9 (Schrödinger, LLC, USA). Molecular 
surface was built with probe radius of 0.9 Å.   
Curve fitting and data analysis 
All calculations were carried out using GraphPad Prism® 5.04 software (GraphPad Software). All label-
free data from the DMR and bioimpedance assay were buffer-corrected and quantified as indicated. 
Calcium response was calculated using the maximal peak fluorescence within 80 seconds. 
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Appendix 
A Kinetic Model for Sequential Agonism at a 7TMR 
In vitro, biochemical receptor experiments provide snapshots of agonist activity; label-
free technology allows real time to be a variable thereby unveiling kinetic effects. It is useful 
to model agonist effects in real time assuming first order onset according to: 
(1)     
  tkAket e )( 211    
where ρt is fractional receptor occupancy at time t, k1 the rate of onset (in s-1 M-1), k2 
the rate of offset (in s-1) and ρe the receptor occupancy at equilbrium. From the Mass action 
relationship an equation for the concentration of agonist ([A]) divided by the equilibrium 
dissociation constant of the agonist receptor complex (KA) can be derived: 
(2)    
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Combining equations (1) and (2) yields: 
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Expressing response according to the Black/Leff operational modelblack1 and 
substituting for [A]/KA for time t (equation (3)) yields an expression for the emergence of 
response as a function of time: 
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Equation (4) can be used to simulate concentration-response curves to an agonist at 
various times for agonists of varying rates of onset and offset. Fig. 1 shows an agonist with 
relatively slow kinetics (k
1A
= 10
3
 M
-1
 s
-1
, k
2A
 = 10
-3
 s
-1
, K
A
= 1 µM, τ
A
= 0.1); it can be seen that a single 
phase sigmoidal curve is observed at all times. It can also be shown that a series and/or parallel 
array of fast and slow kinetic stimulus-response functions (seen as forcing functions in Fig. 1) 
that emanate from a single drug-receptor binding interaction will lead to a single-phase 
sigmoidal function as well. 
In contrast, a different pattern emerges for two forcing functions of varying rates when 
one of the functions modifies the output of the second. Such an array is operative when 
considering the allosteric nature of receptors and two agonist binding sites utilized in tandem 
by sequentially activating ligands (SEALs) vide infra. As a preface, it is useful to describe the 
allosteric nature of receptors within the context of molecular dynamics. Seven transmembrane 
receptors (7TMRs) are nature’s prototypic allosteric protein and respond to binding of 
molecules by changing conformation. All agonists for 7TMRs are allosteric in that they alter 
the interaction of the receptor with cellular signaling proteins. It is useful to delineate binding 
loci on 7TMRs as orthosteric, referring to the site utilized by the natural agonist, and allosteric 
denoting a site distinct from the natural agonist binding site. According to standard allosteric 
theory, it cannot be assumed that the binding of a molecule to an allosteric site does not alter 
the interaction of molecules interacting at the orthosteric site and vice versa. Sequentially 
activating ligands are defined as those that demonstrate two kinetically distinct phases of 
agonism through binding at a first site followed by sustained activation via a second 
topographically distinct site (herein, site 1 is orthosteric and site 2 is allosteric). This is in 
 
 
contrast to canonical bitopic ligands which are defined as those that concomitantly engage 
both receptor sites on 7TMRs2–4. Thus, for clarification, the model described here considers a 
molecule that binds rapidly to the orthosteric site and then more slowly to an allosteric site on 
the receptor. Such kinetics are consistent with known orthosteric and allosteric ligands when 
viewed in terms of molecular dynamic models. 
 Receptors as seen from a molecular dynamic standpoint exist as ensembles of different 
conformations of similar free energy5–8. Under these circumstances there is no reason to 
assume that an allosteric site will be available for binding at all times, i.e. the site may appear 
or disappear with dynamic changes in protein conformation. In contrast, the orthosteric site is 
thought be to be open nearly at all times in view of it’s physiological role, i.e. availablity for 
binding on demand with the natural  agonist. This idea has been suggested to account for the 
relatively rapid enzyme inhibition by orthosteric  inhibitors of some p38  mitogen-activated 
protein (MAP) kinase inhibitors where the rate of onset of allosteric inhibitors is 500 times 
slower than for orthosteric antagonists9. Similarly, allosteric inhibitors of HIV-1 entry have half-
times for dissociation from the CCR 5 receptor ranging from 80 to >300 h with correspondingly 
long times of onset in contrast to the interaction of peptide chemokines binding to the 
orthosteric site10. Thus, in general, it is reasonable to propose binding to the orthosteric site 
will be more rapid than to the allosteric site of a receptor protein. 
A model applicable to mechanisms that involve sequential receptor activation by a 
single ligand with variation over time is shown in Fig. 2. This model assumes that the molecule 
is an agonist at both sites with an efficacy of τA for the orthosteric site and τB for the allosteric 
site. It also alters the affinity for interaction at the orthosteric site by an allosteric factor α and 
its efficacy by a factor β; these factors reciprocate toward the allosteric site as well as required 
by standard allosteric models. To accommodate binding to a second allosteric site, a second 
 
 
kinetic equation for onset to that site is defined just as with the orthosteric onset (equation 
(3)): 
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The equation for the allosteric modification of an orthosteric binding effect is given by 
the standard functional allosteric model11–13: 
(6)
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where the concentration of the allosteric modulator is [B], KB the equilibrium 
dissociation constant of the modulator-receptor complex, α the effect of the modulator on 
agonist affinity, β the effect of the modulator on agonist efficacy, τA and τB the intrinsic 
efficacies of the orthosteric and allosteric agonist, respectively. Substituting the kinetic 
expressions for [A]/KA for the orthosteric site (equation (3)) and the allosteric site (equation 
(5)) yields a kinetic equation for response production for an allosteric system: 
(7)  
 
     1111
1



BA
BA
tresponse


 
The kinetic behavior of a tandem orthosteric-allosteric activation model with a fast rate 
of onset for the orthosteric site and a slower rate of onset for the allosteric site is shown in 
Fig. 3 (for a model with k1A= 10
5
 M
-1
s
-1
, k2A= 10
-1 s
-1
, k1B=10
3
 s
-1
 and k2B= 3x10
-3
 M
-1
s
-1
 when 
response is measured at various times). The sequentially activating ligand has an orthosteric 
 
 
efficacy of τA=0.1, an allosteric efficacy of τB=10, orthosteric KA= 1 µM, allosteric KB= 3 µM , α= 
0.01  and β= 3 for reciprocal interaction between the orthosteric and allosteric sites when the 
ligand is bound to both. 
 It can be seen that the SEAL model concentration-response curve pattern (Fig. 3) differs 
from the varying rate single binding site model (Fig. 1). A single site slow onset is reflected by 
a single sigmoid characteristic curve with varying location parameters along the concentration 
axis with time. In contrast a SEAL can produce two distinctly different sigmoid curves at various 
times reflecting the orthosteric and then orthosteric-allosteric combination with time. It 
should be noted that the relative locations of the two kinetically distinct curves along the 
concentration axis depend on a number of parameters including KA, KB, α, β, τA and τB and 
therefore have no intrinsic meaning to the model. 
  
 
 
 
Figure 1. Concentration-response curves to a slow onset orthosteric agonist at various times. 
  
 
 
 
Figure 2. Dual occupancy by a sequentially activating ligand (SEAL) of an orthosteric site with rate of 
onset k1A and offset k2A and an allosteric site with rate of onset k1B and offset k2B produce a response 
with an efficacy τA for the orthosteric site and τB for the allosteric site. According to the allosteric 
system in the kinetic SEAL model, targeted perturbation of the orthosteric or the allosteric receptor 
site results in the omission/amplification of initial effect A or delayed effect B, respectively. 
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Figure 3. Concentration-response curves to sequentially activating ligands calculated with 
equation 7 for various times from t=5 to 2000 s. 
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 Epilogue 
The idea of a ligand-receptor interaction is a long-standing one and was first described by Ehrlich, 
Langley and Clark1,2 and was refined ever since then, which is still an ongoing process. In the 
perception of receptor theory, GPCRs evolved from simple “on-off” switches to highly complex 
microprocessors for the transduction of cell signaling3,4. Indispensable requirements for ligand-
receptor interaction are structural determinants. A ligand only binds to a receptor if it “fits” to 
certain epitopes on the receptor protein. Although large amounts of data pillow the effort (and 
partial success) to a priori predict whether a compound binds to a receptor and how this interaction 
influences the conformations of the receptor and thus cell signaling, the hurdles seem too high and 
this yet remains an attempt.  
Nonetheless, it is getting clear that GPCR activation upon agonist binding is intrinsically linked with a 
multistep process5, which must initially be considered separately from the sequential activation 
mode introduced in this chapter. On the other hand, binding to several sites of the receptor might in 
fact induce a set of different conformations that in turn trigger certain signaling events. Several 
studies could demonstrate that different agonists for the same GPCR induce distinct conformational 
changes within the receptor protein4,6,7. Since active states of GPCRs can be achieved by destabilizing 
the normal structure of those proteins and increasing their flexibility8,9, triggering molecular 
microswitches within GPCRs by their ligands is a well-supported concept of receptor activation10. Two 
of these microswitches are already described in the introductory section and should only be 
mentioned briefly here. i) The Rotamer Toggle Switch in TM611–14 and ii) an Ionic Lock between TM3 
and TM615,16. An increase in the destabilization of the GPCR structure by engagement of these and 
other microswitches has been associated with graded efficacy of agonists17. Since variations in the 
set of induced conformational changes have been attributed to different signaling behaviors, it could 
further be envisaged that those microswitches play a substantial role in the generation of signaling 
bias. Studies on peptide-binding at the neurokinin receptor for example revealed that a rapid binding 
component was associated with a calcium response, whereas a slow binding event was linked to a 
cAMP response18. Hence, although multistep agonist binding as delineated above and the concept of 
sequentially activating ligands are distinct phenomena with regard to cell signaling, the underlying 
structural rearrangements may be overlapping. 
A distinctive feature of 4-CMTB is the order of signaling events. An initial orthosteric activation is 
followed by an allosteric site-mediated signaling impulse. Since the orthosteric binding site is 
assumed to be situated deeper in the transmembrane region of the receptor protein, whereas the 
allosteric epitope is expected to be located in the extracellular vestibule of the receptor10, we 
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proposed an entry mode for 4-CMTB from the lipid bilayer. This mode-of-action is not 
unprecedented in the literature and is especially discussed for other lipid-recognizing receptors19–23. 
As mentioned in the prologue, ligands that show intrinsic activity and allosteric modulating features 
at the same time are attractive compounds for certain diseases24. Moreover, ago-allosteric ligands 
are not only therapeutically interesting but also mechanistically, since their mode-of-action still 
remains largely elusive25. A bitopic binding mode for ago-allosteric ligands has been discussed and 
some reports indicate that several previously recognized “pure” allosteric ligands might actually bind 
in a bitopic manner26–30. Although bitopic binding or binding to overlapping binding sites is not 
intuitively compatible with allosteric modulation between the allosteric and the orthosteric 
compound, Schwartz et al. proposed three possible binding scenarios for ago-allosteric ligands at 
GPCRs that involve a bitopic binding mode in a broader sense28. i) The ago-allosteric ligand could 
interconvert between two binding poses. In the absence of an orthosteric ligand, the ago-allosteric 
ligand would bind to the orthosteric receptor site (maybe overlapping with an allosteric epitope), 
whereas it would bind to an allosteric site in the presence of an orthosteric probe, presumably in 
another orientation. This mechanism would explain both the intrinsic activity of the ago-allosteric 
ligand and the allosteric modulating character of the compound. Furthermore, in this model the ago-
allosteric ligand blocks the exit of the agonist, which is in line with the classic expectation of allosteric 
ligands inhibiting the dissociation of the orthosteric ligand. ii) “Time-resolved allostery”, where the 
ago-allosteric and the orthosteric ligand bind to partially the same binding site, i.e. the ago-allosteric 
ligand binds to a site, that shows considerable overlap with the orthosteric binding site. Orthosteric 
and ago-allosteric ligand bind to distinct active receptor conformations that slowly interconvert into 
each other. Thus binding of each ligand occurs at different points in time. This scenario, however, 
would not explain the inhibition of orthosteric agonist dissociation by the allosteric compound. 
Notably, this scenario also implies a “bitopic” binding mode of the ago-allosteric ligand to both the 
classical allosteric and the orthosteric binding site. iii) In a dimeric binding mode, the ago-allosteric 
ligand might bind to an “allosteric” protomer, maybe in a bitopic fashion, whereas the endogenous 
ligand binds to the orthosteric protomer. This mechanism has recently been confirmed for the 
dopamine D2 receptor31.  
However, none of these mechanistic proposals can fully explain the behavior of the ago-allosteric 
ligand 4-CMTB. Hence, in the here presented study, 4-CMTB emerged as the prototype of a hitherto 
unknown class of GPCR ligands, for which we coined the term “sequentially activating ligands”. The 
ago-allosteric nature of 4-CMTB is explained by a sequential binding mechanism, wherein each 
interaction step is associated with distinct signaling impulses.  
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 Prologue 
Discovery of potent agonists that selectively target one member of a closely related receptor family 
constitutes a great challenge. Traditionally, lead discovery focused on the disclosure of compounds 
that engage the site of the receptor that is used by the endogenous ligand, also referred to as the 
orthosteric binding pocket. However, this approach is not suited to selectively target receptors that 
show greater sequence homology within this receptor epitope such as subtypes in a receptor family 
that share the same endogenous agonist1,2. This applies also to the family of free fatty acid 
receptors3. 
In the case of the free fatty acid receptor FFA2 the endogenous ligands comprise the short-chain 
fatty acids (SCFAs), primarily C1 to C5 with a rank order of potency: C2=C3>C4>C5=C14. The overall 
potency of the endogenous ligands is in the mid micromolar range and thus relatively low. The most 
obvious problem, however, is the overlap in ligand recognition between FFA2 and the closely related 
FFA3 receptor3,4. This in turn explains why SCFAs as agonists cannot distinguish between these two 
receptors. Although there is a slight difference in the rank order of potency for SCFAs at FFA2 
compared to FFA3, this difference does not suffice to selectively activate FFA2 over FFA3. To 
circumvent the obstacle of closely related structural realities in the orthosteric binding pocket, 
targeting sites distinct from the endogenous ligand binding site attracted much interest in the past1. 
These allosteric receptor epitopes are evolutionary less conserved and thus represent a possibility to 
selectively target receptor subtypes. Recently a structurally diverse series of ligands has been studied 
and found to be selective for activation of FFA2 over FFA35. 4-CMTB as the most potent and studied 
agonist from this compound series was already subject of intense research as detailed in the 
aforementioned chapter and previous publications6–8. This compound acts as both agonist and 
allosteric modulator at the FFA2 receptor and selectively activates FFA2. However, due to the 
allosteric aspect in the mode of action, 4-CMTB might be subjected to agonist-trafficking, which 
means that it could engage functionally different cellular outcomes compared to endogenous ligand-
stimulated FFA2 signaling. Thus, 4-CMTB data under physiological conditions ought to be treated 
with caution.  
Recently, a series of ligands from the patent literature were identified as orthosteric FFA2-selective 
agonists9,10. However, the exact mechanism of receptor activation remains to be elucidated. These 
compounds for example lost allosteric cooperativity with 4-CMTB, which can only be explained by 
the phenomenon of probe dependency or overlapping binding modes between the synthetic 
orthosteric ligands and 4-CMTB. The latter explanation seems reasonable because the lead structure 
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TUG-800 shares both an acidic function responsible for orthosteric recognition but also the 
prominent thiazolyl residue, which is common in the phenylacetamides that are believed to address 
an allosteric receptor epitope. Hence, a bitopic orientation of TUG-800 and related structures from 
that series is well conceivable. The uncertainty about these mechanistic fundamentals of receptor 
activation restricts the significance of the conclusions drawn from experiments with these ligands. 
Receptors solely activated by synthetic ligands (RASSLs) represent another opportunity to investigate 
receptor behavior in the context of closely related and often co-expressed receptors11,12. The RASSL 
concept relies on the structural modification within the wild-type receptor that alters the ligand 
recognition capabilities of the receptor. While the endogenous ligands lose their activity at a RASSL, a 
synthetic ligand that has no affinity to the wild-type receptor now activates the modified receptor13. 
This phenomenon might be used to investigate the physiological function of FFA2 because FFA2-
mediated biological effects can be explored independently of the presence of SCFAs as endogenous 
lipid ligands that interfere not only with FFA2 but also with FFA3 and a variety of other targets, which 
impedes the correct assignment of a cell response to a specific receptor11,14,15.  
In this chapter, we introduce a RASSL form of FFA2, which does not recognize the endogenous 
agonists but the small molecule sorbic acid, which has no effect at the wild-type receptor. While 
most designer receptors are discovered by random screening, this approach is of limited use to 
rationally design receptors16–18. In the following publication, we introduce the first FFA2 RASSL, which 
was carefully considered and reasonably developed based on species orthologue variations of FFA2 
and thus followed a rational design path.   
The advantages of designer receptors are the elucidation of physiological receptor function by 
mimicking the endogenous receptor without the drawback of insufficient selectivity and off target 
effects11. This concept could ultimately be used to therapeutically treat diseases by introduction of 
designer receptors in the affected tissue or cells using genetic techniques19. Furthermore, RASSLs 
could be used to modulate previously non-druggable cellular populations19 and, finally, to generate 
synthetically encoded behavior in vivo to gain insight into the significance of a specific receptor 
signaling in a certain disease context.  
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ABSTRACT When it is difficult to develop selective
ligands within a family of related G-protein-coupled re-
ceptors (GPCRs), chemically engineered receptors acti-
vated solely by synthetic ligands (RASSLs) are useful
alternatives for probing receptor function. In the present
work, we explored whether a RASSL of the free fatty acid
receptor 2 (FFA2) could be developed on the basis of
pharmacological variation between species orthologs. For
this, bovine FFA2 was characterized, revealing distinct
ligand selectivity compared with human FFA2. Homology
modeling and mutational analysis demonstrated a single
mutation in human FFA2 of C4.57G resulted in a human
FFA2 receptor with ligand selectivity similar to the bovine
receptor. This was exploited to generate human FFA2-
RASSL by the addition of a second mutation at a known
orthosteric ligand interaction site, H6.55Q. The resulting
FFA2-RASSL displayed a >100-fold loss of activity to
endogenous ligands, while responding to the distinct
ligand sorbic acid with pEC50 values for inhibition of
cAMP, 5.83  0.11; Ca2 mobilization, 4.63  0.05; ERK
phosphorylation, 5.61  0.06; and dynamic mass redistri-
bution, 5.35  0.06. This FFA2-RASSL will be useful in
future studies on this receptor and demonstrates that
exploitation of pharmacological variation between species
orthologs is a powerful method to generate novel chemi-
cally engineered GPCRs.—Hudson, B. D., Christiansen,
E., Tikhonova, I. G., Grundmann, M., Kostenis, E., Ad-
ams, D. R., Ulven, T., Milligan, G. Chemically engineering
ligand selectivity at the free fatty acid receptor 2 based on
pharmacological variation between species orthologs.
FASEB J. 26, 4951–4965 (2012). www.fasebj.org
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In recent times, it has become apparent that a series
of molecules previously considered only as metabolic
intermediates are actually able to mediate at least a
number of their functions via activation of members of
the G-protein-coupled receptor (GPCR) superfamily.
These include intermediates of the tricarboxylic acid
cycle, such as succinate (1), and molecules such as
lactate (2) and -hydroxybutyrate (3), involved in glu-
cogenic and ketogenic control of metabolism. A further
group of such intermediates are the free fatty acids. It is
now known that three related GPCRs, free fatty acid
receptors 1–3 (FFA1, FFA2, and FFA3; previously des-
ignated GPR40, GPR43, and GPR41, respectively;
ref. 4), respond to either medium- and longer-chain
(FFA1) or short-chain, C1-C5, (FFA2 and FFA3) free
fatty acids. There is considerable interest in the physi-
ological roles of FFA2, in particular (5, 6), and whether
this receptor might be useful as a novel therapeutic
target in areas ranging from diabetes and adiposity to
satiety and inflammation (7, 8). In the absence of
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synthetic ligands that bind to the same region of the
receptor as the short-chain fatty acids (SCFAs) and that
have reasonable potency and substantial selectivity be-
tween FFA2 and FFA3, the marked overlap of potency
of C1–C5 fatty acids at FFA2 and FFA3 makes efforts to
interpret selective activation of FFA2 vs. FFA3 imprac-
tical without more detailed analyses involving knockout
or knockdown studies (9–11). It would, therefore, be of
considerable value to develop chemically engineered
forms of these receptors with unique ligand responsive-
ness.
Such modified GPCRs have been developed for
several other receptors and are often described as
either designer receptors exclusively activated by de-
signed drugs (DREADDs) or as receptors activated
solely by synthetic ligands (RASSLs) (12–15). To date,
two general approaches have been employed to gener-
ate these chemically engineered GPCRs (16). The first
involves site-directed mutagenesis of known ligand in-
teraction sites in the GPCR followed by screening
ligands for activity at the resulting mutant receptors
(17), while the second method takes the opposite
approach, generating thousands of randomly mutated
forms of the receptor and screening these against a
candidate synthetic ligand (13). Although each of these
approaches has found some success, both rely largely
on random screening. Considering this, in the present
work, we have explored whether a more direct ap-
proach could be taken to develop chemically engi-
neered forms of human FFA2 (hFFA2), based on the
variation between species orthologs of this receptor.
Mammalian species orthologs of GPCRs are antici-
pated to respond to the same endogenously produced
agonists. However, the potency and affinity of such
agonist ligands may vary depending on the physiology
of individual species, and where such receptors re-
spond to a number of related ligands (as in the case of
FFA2 and the SCFAs; refs. 4, 18), the rank order of
function may differ. Although such variation is likely to
be limited for GPCRs that coordinate the responses of
ancient hormone and transmitter systems, such as the
catecholamines, that underpin key physiological pro-
cesses, including heart rate and intraneural communi-
cation, such differences may be substantially greater for
GPCRs that play more modulatory roles, or in cases
where the receptor is likely to be exposed to vastly
different concentrations of ligand between different
species. Because SCFAs are primarily produced by the
fermentation of nondigestible carbohydrates by the
microflora in the gut (6), it could be hypothesized that
FFA2 will show significant ortholog variation between
species that have greatly different dietary levels of
nondigestible carbohydrates and, therefore, different
levels of endogenous SCFA ligands. Considering this, in
the present work, the bovine ortholog was chosen as the
basis for producing chemically engineered forms of
hFFA2, since ruminants, such as bovines, are well
known to rely heavily on nondigestible carbohydrates.
MATERIALS AND METHODS
Cell culture, transfection, and production of stably
expressing cell lines
HEK293 cells were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% FBS at 37°C
and 5% CO2. For experiments utilizing transiently transfected
HEK293 cells, transfections were carried out using polyethyl-
enimine, and experiments were conducted 48 h post-trans-
fection. For experiments in which stable cell lines were
produced and used, the Flp-In T-REx system (Life Technol-
ogies, Paisley, UK) was used to generate HEK293 cells with
tetracycline-inducible expression of the receptor of interest.
To generate these cell lines, Flp-In T-REx HEK293 cells were
cotransfected with the pOG44 vector and the receptor of
interest in pcDNA5/FRT/TO. Transfection with pOG44
drives expression of Flp recombinase, which, in turn, allows
for recombination between FRT sites in pcDNA5/FRT/TO
and in the genome of the Flp-In T-REx HEK293 cells, thus
allowing stable inducible cells for the receptor of interest to
be generated by appropriate antibiotic selection.
DNA constructs
Constructs for the human orthologs of FFA2 and FFA3 fused
at their C-terminal with enhanced yellow fluorescent protein
(eYFP) were as reported previously (19). To clone the bovine
orthologs, the coding sequences of bovine FFA2 and FFA3
(bFFA2 and bFFA3) were amplified without their stop codons
from commercially available bovine genomic DNA by PCR.
The PCR product was then ligated upstream and in-frame
with the eYFP sequence present in a pcDNA5/FRT/TO
expression vector (Life Technologies, Carlsbad, CA, USA).
Mutagenesis of human and bovine orthologs of FFA2 was
carried out according to the QuickChange method (Strat-
agene, Santa Clara, CA, USA).
Compounds
Formic acid (compound C1), acetic acid (compound C2),
propionic acid (compound C3), butyric acid (compound C4),
valeric acid (compound C5), caproic acid (compound C6),
heptanoic acid (compound C7), caprylic acid (compound C8),
pelargonic acid (compound C9), methylthioacetic acid (com-
pound 1), 3-methylbutyric acid (compound 2), pivalic acid
(compound 3), 2-methylbutyric acid (compound 4), cyclopro-
pylcarboxylic acid (compound 5), cyclobutylcarboxylic acid
(compound 6), 1-methylcyclopropanecarboxylic acid (com-
pound 7), vinylacetic acid (compound 9), 3-pentenoic acid
(compound 12), acrylic acid (compound 13), propiolic acid
(compound 14), 2-butynoic acid (compound 15), trans-crotonic
acid (compound 16), 2-methylacrylic acid (compound 18),
3-methylcrotonic acid (compound 19), trans-2-methylcrotonic
acid (compound 20), trans-2-pentenoic acid (compound 22),
trans-2-hexenoic acid (compound 23), 2,4-pentadienoic acid
(compound 24), sorbic acid (compound 25), 4,4,4-trifluoro-3-
methyl-2-butenoic acid (compound 26), 1-cyclopentenecarboxy-
lic acid (compound 27), trans-cinnamic acid (compound 28),
and 1-cyclohexene-1-carboxylic acid (compound 29) were all
purchased from Sigma-Aldrich (Dorset, UK). Angelic acid (com-
pound 21) was obtained from ABCR (Karlsruhe, Germany).
Cyclopropylacetic acid (compound 8) was purchased from
Alfa Aesar (Heysham, UK). 3-Butynoic acid (compound
10) was synthesized as described previously (20). The
identity and purity of all compounds were confirmed by 1H
and 13C NMR.
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-Arrestin-2 interaction assay
A bioluminescence resonance energy transfer (BRET)-based
approach was used to measure -arrestin-2 recruitment to
human and bovine forms of FFA2. Briefly, a plasmid encod-
ing an eYFP-tagged form of the receptor to be assayed was
cotransfected in a 4:1 ratio with a -arrestin-2 Renilla lu-
ciferase (Rluc) plasmid. Cells were transferred into white
96-well plates at 24 h post-transfection. Then, at 48 h post-
transfection, cells were washed, and the culture medium was
replaced with Hanks’ balanced salt solution (HBSS) immedi-
ately prior to conducting the assay. To measure -arrestin-2
recruitment, the Rluc substrate coelenterazine h was added to
a final concentration of 5 M; then, cells were incubated for
10 min at 37°C, test compounds were next added, and cells
were incubated for a further 5 min at 37°C. BRET, resulting
from FFA2 receptor--arrestin-2 interaction, was then as-
sessed by measuring the ratio of luminescence at 535 and 475
nm using a Pherastar FS fitted with the BRET1 optic module
(BMG Labtech, Aylesbury, UK).
Extracellular signal-regulated kinase (ERK) 1/2
phosphorylation assay
All ERK phosphorylation experiments were carried out using
Flp-In T-REx stable-inducible cell lines for the human or
bovine forms of FFA2 to be assayed. Briefly, 80,000 cells/well
were seeded in a 96-well plate and then allowed to attach for
3–6 h before the addition of doxycycline (100 ng/ml) to
induce expression of the receptor. After incubating over-
night, the culture medium was replaced with serum-free
DMEM-containing doxycycline (100 ng/ml), and cells were
then incubated for a further 5 or 6 h prior to the assay. For
the assay, test compounds were added to the cells and
incubated at 37°C for 5 min before the cells were lysed and
assayed for phospho-ERK using an Alphascreen-based detec-
tion kit (Perkin Elmer, Waltham, MA, USA), according to the
manufacturer’s protocol.
Ca2 mobilization assay
All Ca2 experiments were carried out using Flp-In T-REx
stable-inducible cell lines for the human or bovine forms of
FFA2 to be studied. Cells were plated at 80,000 cells/well in
black 96-well plates with clear bottoms and then allowed to
adhere for 3–6 h. Doxycycline was then added (100 ng/ml)
to induce expression of the receptor of interest, and cells
were maintained in culture overnight. Prior to the assay, cells
were labeled for 45 min with the calcium-sensitive dye Fura-2
AM; then they were washed and maintained in HBSS. Fura-2
fluorescent emission at 510 nm resulting from 340- or 380-nm
excitation was then monitored using a Flexstation plate
reader (Molecular Devices, Sunnyvale, CA, USA). Basal fluo-
rescence was measured for 16 s, test compounds were then
added, and fluorescence was measured for an additional 74 s.
The maximum difference in 340/380 ratios obtained before
and after compound addition was then used to plot concen-
tration-response data.
cAMP assay
All cAMP experiments were carried out using Flp-In T-REx
stable-inducible cell lines for the forms of FFA2 to be studied.
These experiments were carried out using a homogenous
time-resolved FRET-based detection kit (CisBio Bioassays;
CisBio, Codolet, France) according to the manufacturer’s
protocol. Cells were plated at 2000 cells/well in low-volume
384-well plates, and the inhibition of 1 M forskolin-stimu-
lated cAMP production was assessed following a 30-min
coincubation with test compounds.
[35S]GTPS incorporation assay
Total cell membranes were prepared from stable, doxycyline-
inducible Flp-In T-REx HEK293 cell lines. [35S]GTPS bind-
ing assays were then carried out in reactions with 5 g of cell
membrane protein preincubated for 15 min at 25°C in assay
buffer (50 mM Tris-HCl, pH 7.4; 10 mM MgCl2; 100 mM
NaCl; 1 mM EDTA; 1 M GDP; and 0.5% fatty acid-free BSA)
containing the indicated concentrations of ligands. The reac-
tion was initiated with the addition of 50 nCi of [35S]GTPS
to each tube, and the reaction was terminated after 1 h
incubation by rapid filtration through GF/C glass filters.
Unbound radioligand was washed from filters by 3 washes
with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, and 10
mM MgCl2), and [
35S]GTPS binding was determined by
liquid scintillation spectrometry.
Homology modeling
Modeling of hFFA2 was carried out using the 2-adrenergic
receptor structure as a template (20, 21). The bFFA2 homol-
ogy model was constructed on the basis of this hFFA2 model
using the Prime module of Schrödinger software with default
options (Schrödinger LLC, New York, NY, USA).
Dynamic mass redistribution (DMR) assays
DMR assays were performed on a beta version of the Corning
Epic biosensor (Corning Life Sciences, Corning, NY, USA), as
described previously in detail (22, 23). Briefly, stable induc-
ible cell lines expressing the hFFA2 or hFFA2-C4.57G/
H6.55Q mutant were grown to confluence for 20–24 h on
fibronectin-coated Epic biosensor 384-well microplates. Cells
were then washed twice with HBSS containing 20 mM HEPES
and kept for 1 h in the Epic reader at 28°C. DMR was
monitored before (baseline read) and after the addition of
compound solutions for6000 s. Concentration-effect curves
were generated from the real-time optical traces using the
area under the curve between 0 and 6000 s after ligand
addition.
Curve fitting and statistical analysis
All data presented represent means  se of 3 independent
experiments. Data analysis and curve fitting were carried out
using the GraphPad Prism 5.0b software package (GraphPad,
San Diego, CA, USA). Concentration-response data were fit to
3-parameter sigmoidal concentration-response curves. Statis-
tical analysis of curve fit parameters was carried out by
independently fitting the data from triplicate experiments
and comparing the resulting curve fit values by t test or 1-way
ANOVA, as appropriate.
RESULTS
Postactivation assays were established for both the
human and bovine orthologs of FFA2. In the first of
these, an ortholog of FFA2 to which eYFP had been
attached in-frame to the C terminus was cotransfected
into HEK 293 cells along with -arrestin-2 C-terminally
modified by the in-frame addition of Rluc. BRET
generated between Rluc and eYFP in response to an
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agonist ligand reflects induced interactions between
FFA2 and -arrestin-2. As anticipated from previous
studies using a number of different endpoints (19–21),
the SCFAs acetic acid (chain length C2) and propionic
acid (C3) displayed modest and similar potency at
hFFA2 in this assay (Fig. 1A). Although active at hFFA2,
n-butanoic acid (C4) displayed lower potency (Fig. 1A),
while both formic acid (C1) and valeric acid (C5) had
little effect at concentrations below 10 mM (Fig. 1A).
When equivalent studies were performed using bFFA2-
eYFP, a substantially different structure-activity relation-
ship (SAR) was observed. C1 was without effect, while
C2 was significantly (P0.05) less potent than com-
pound C3 (Fig. 1B). Furthermore, when exploring the
activity of fatty acids of longer chain length than C3,
potency significantly increased (P0.05), such that C3 
C4 C5 (Fig. 1B). Because of the increasing potency of
n-fatty acids with longer chain lengths observed at
bFFA2, we examined extended chain lengths from C6
to C9 at both the human and bovine forms of the
receptor. While none of the compounds C6–C9
showed appreciable activity at hFFA2 (Fig. 1C), all were
full agonists at bFFA2, although potency in this case
significantly decreased with each additional carbon
(P0.05), as chain length increased beyond C6 (Fig.
1D). Analysis of the potencies across the complete
series of n-fatty acids at hFFA2 and bFFA2 (Table 1)
reveals clearly distinct rank orders of potency, such that
for hFFA2, C3  C2  C1  C5, and all other
compounds were without effect, while for bFFA2, C6 
C5  C4  C7  C3  C8  C2  C9, and only C1 was
without effect.
To ensure that these differences were not limited to
measurement at only a -arrestin recruitment end-
Figure 1. bFFA2 is activated by longer-chain length n-fatty
acids than the human ortholog. A–H) The ability of fatty
acids of chain length C1–C5 or C6–C9 to activate hFFA2 (A,
C, E, G) or bFFA2 (B, D, F, H) was studied in either
receptor--arrestin-2 interaction assays (A–D) or phospho-
ERK 1/2 assays (E–H). Data are presented as a percentage
of the maximal effect of C3. I, J) Comparison of pEC50
values for each fatty acid at hFFA2 and bFFA2 in -arrestin-2
recruitment (I) and phospho-ERK 1/2 assays (J).
TABLE 1. Potency values for short-chain fatty acids in various assays at human and bovine orthologs of FFA2 and FFA3
Chain length
FFA2 -arrestin-2 BRET FFA2 pERK FFA3 [35S]GTPS
Human Bovine Selectivity Human Bovine Selectivity Human Bovine Selectivity
C1 2.60  0.40 2 0.6 2 2 2 2
C2 3.00  0.12 2.69  0.11 0.31 3.50  0.08 2.16  0.10 1.34 2.12  0.34 2.36  0.34 	0.24
C3 3.29  0.10 3.46  0.07 	0.17 3.64  0.06 3.26  0.07 0.38 3.70  0.13 3.81  0.18 	0.11
C4 2.83  0.26 4.16  0.06 	1.33 2.87  0.18 4.43  0.07 	1.56 3.60  0.21 3.58  0.14 0.02
C5 2.15  0.33 4.37  0.09 	2.22 2 4.30  0.10 	2.30 4.44  0.24 3.91  0.18 0.53
C6 2 4.68  0.09 	2.68 2 5.01  0.13 	3.01 3.69  0.33 3.90  0.21 	0.21
C7 2 3.81  0.09 	1.81 2 4.31  0.12 	2.31 4.16  0.56 3.80  0.61 0.36
C8 2 3.21  0.11 	1.21 2 3.12  0.13 	1.12 2 2
C9 2 2.47  0.22 	0.47 2 2 2 2
Selectivity is measured as human pEC50 	 bovine pEC50 for each assay.
4954 Vol. 26 December 2012 HUDSON ET AL.The FASEB Journal  www.fasebj.org
point, equivalent studies were performed by measuring
phosphorylation of ERK 1/2, and similar results were
obtained (Fig. 1E–H). In comparing the potencies for
the complete series of n-fatty acids in -arrestin-2
recruitment (Fig. 1I) and ERK 1/2 phosphorylation
(Fig. 1J), it is clear that consistently across assays, bFFA2
preferentially responded to longer chain lengths than
did hFFA2. By contrast, human and bovine orthologs of
the closely related GPCR FFA3 displayed very similar
patterns of responsiveness for each of the C1–C9 n-fatty
acids, as assessed in a [35S]GTPS assay (chosen be-
cause either bFFA3 or hFFA3 did not generate consis-
tent responses in the -arrestin-2 or ERK 1/2 assays).
Unlike bFFA2, bFFA3 displayed no preference for
longer chain lengths (Table 1).
We have recently shown that a series of small carbox-
ylic acids (SCAs) can also act as agonists at hFFA2 (20).
Considering the marked differences among the n-fatty
acids at hFFA2 and bFFA2, we next screened these
SCAs in the -arrestin-2 interaction assay to determine
whether there were also species differences within this
series (Fig. 2). A number of the SCAs, including
3-methylbutyric acid (compound 2), cyclopropylacetic
acid (compound 8), trans-crotonic acid (compound
16), and 3-methylcrotonic acid (compound 19), each
with modest potency and/or efficacy at hFFA2 in the
-arrestin-2 interaction assay were 
10- to 100-fold
more potent at bFFA2 (Fig. 3A–D). This was, however,
not a general reflection that all SCAs were more potent
at the bovine ortholog, as propiolic acid (compound
14) and angelic acid (compound 21), although display-
ing modest efficacy, were both more potent at hFFA2
than bFFA2 (Fig. 3E, F). SAR analyses of these results
with the SCAs suggest that in addition to its preference
for longer-chain fatty acids, bFFA2 also prefers com-
pounds with sp2 hybridization of the  carbon and
those with -carbon substituents.
On the basis of these SAR observations, we selected a
further set of SCAs predicted to have good selectivity
for bFFA2 because they contained longer chain lengths
(C5 or C6), sp2 hybridization of the -carbon, or bulky
substitutions at the -carbon (Table 2). Within this
series, all compounds were found to be full agonists at
bFFA2, while none possessed substantial activity at the
human receptor. In particular, it was the C5 and C6
compounds with conjugated double-bond systems that
displayed the highest potency at bFFA2. These com-
pounds included trans-2-pentenoic acid (compound 22;
Fig. 4A), trans-2-hexenoic acid (compound 23; Fig. 4B),
2,4-pentadienoic acid (compound 24; Fig. 4C), and
2,4-hexadienoic acid (sorbic acid; compound 25; Fig.
4D). Although some compounds in this series did
display weak activity at the human receptor (com-
pounds 22 and 24), all those tested that contained
larger -carbon substituents appeared to be essentially
inactive at hFFA2. These included 4,4,4-trifluoro-3-
methyl-2-butenoic acid (compound 26; Fig. 4E), 1-cy-
clopentenecarboxylic acid (compound 27; Fig. 4F),
trans-cinnamic acid (compound 28; Fig. 4G), and 1-cy-
clohexene-1-carboxylic acid (compound 29; Fig. 4H).
In addition, each of these bFFA2-selective ligands was
also inactive at the closely related hFFA3 receptor (data
not shown).
Having now identified several ligands with very good
selectivity for bFFA2 over hFFA2, we next set out to
define the molecular basis for this selectivity. In previ-
ous studies on hFFA2, sequence alignment with the
other members of the free fatty acid receptor family,
FFA1 and FFA3, identified 4 key positively charged
amino acids within the transmembrane domains. These
were arginine residues at positions 5.39 and 7.35 and
histidine residues at positions 4.56 and 6.55 (number-
ing according to the system introduced by Ballesteros
and Weinstein; ref. 24) and subsequent mutagenesis
demonstrated the importance of particularly R5.39,
R7.35, and H6.55 in coordination of the carboxylate
group of the SCFAs (19, 21). Alignment of hFFA2 and
bFFA2 indicated the presence of equivalent residues in
the bovine ortholog. However, in addition to R7.35, the
bovine ortholog has an additional arginine at position
7.36, (i.e., the next amino acid in the primary se-
quence). Each of these residues in bFFA2 was mutated
to alanine, and the resulting mutants were screened
using the -arrestin-2 interaction assay to determine
what role (if any) these residues had in the selectivity
among the identified bFFA2 ligands. The four com-
pounds that were selected for this screen were the most
prevalent SCFAs C2 and C3, and the bovine-selective
compounds C5 and 19, selected as being the most
potent bovine-selective ligands that still had apprecia-
ble activity at the human receptor (Fig. 5A; see Supple-
mental Table S1 for complete mutant screen data).
Mutation of R5.39 to alanine resulted in virtual com-
plete loss of function for all four compounds at both
the human and bovine forms of FFA2 (Fig. 5B). Inter-
estingly, although mutation to generate R7.35A in
hFFA2 resulted in complete loss of activity to each
ligand, the equivalent mutation in bFFA2 retained
some activity to the bovine-selective ligands C5 and 19,
although with 100-fold loss of potency (Fig. 5C).
Mutation of H4.56 to alanine in either hFFA2 or bFFA2
completely eliminated function (Fig. 5D), while the
H6.55 to alanine mutant retained some activity only in
bFFA2 to C5 and 19 (Fig. 5E). Mutation of the addi-
tional arginine residue present only in bFFA2 to gen-
erate R7.36A resulted in large reductions in both
efficacy and potency, although the rank-order of po-
tency of 19 C5 C3 C2 was preserved (Fig. 5F). To
assess the combined role of the two adjacent arginine
residues in bFFA2, a double R7.35A/R7.36A mutant
was generated, and this essentially failed to respond to
any ligand tested (Fig. 5G).
To identify residues in bFFA2 that may provide the
basis for its greater chain length acceptance and dis-
tinct SCA SAR, we aligned the sequence of human,
bovine, rat, and murine forms of FFA2 (Fig. 6A) and
generated a homology model of bFFA2 (Fig. 6B) based
on our previous models of the human receptor (20,
21). Nonconserved residues predicted to lie within 8 Å
of R5.39 and R7.35 of the orthosteric binding site were
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highlighted (Fig. 6B). Two of these, human S3.34/
bovine G3.34 and human C4.57/bovine G4.57, were
selected for mutational analysis. Alteration to generate
either human S3.34G or the reciprocal bovine G3.34S
forms of FFA2 had limited effects on ligand pharma-
cology, with each mutant exhibiting the same rank
order of potency for the four ligands tested as the
corresponding wild-type receptor (Fig. 6C). By contrast,
mutation to produce hFFA2-C4.57G produced a recep-
tor where although C2 and C3 remained equipotent,
the potency of C5 was increased markedly and became
significantly (P0.01) more potent than either C2 or
Figure 2. SCA concentration-response curve fit parameters in -arrestin-2 BRET at hFFA2 and bFFA2. Selectivity is expressed
as hFFA2 pEC50 	 bFFA2 pEC50. Emax values are reported as a percentage of C3 maximum response at the cognate receptor.
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C3 (Fig. 6D). Equally, compound 19 was also now
substantially more potent than C2 or C3 at this mutant
(P0.01) and, as at wild-type bFFA2, was also more
potent than C5. To confirm that this observation was
not restricted to only the -arrestin-2 interaction assay,
hFFA2-C4.57G was also assessed in ERK 1/2 phosphor-
ylation assays, and similar results were obtained (Fig.
6E). The reciprocal mutation G4.57C was also gener-
ated in bFFA2 (Fig. 6D), and although it did appear
that both C5 and 19 had reduced potency relative to C2
and C3, this was difficult to assess accurately, as this
variant receptor displayed substantially reduced effi-
cacy in the -arrestin-2 interaction assay. Therefore, to
confirm this observation, bFFA2-G4.57C was also tested
in the ERK 1/2 phosphorylation assay, which demon-
strated that it did, indeed, lose potency for the bovine-
selective compounds C5 and 19 relative to C2 and C3
(Fig. 6E).
On the basis of the gain in function we observed for
bovine-selective ligands C5 and 19 at hFFA2-C4.57G, we
next assessed whether the additional SCFAs and bovine-
selective SCAs would also activate this mutant receptor
using the -arrestin-2 interaction assay (Fig. 7 and
Table 3). Indeed, C6 and C7 were effective agonists at
this variant and now displayed potency akin to that at
the bovine ortholog (Fig. 7A, B). Among the SCAs,
particularly compounds with C6 chain lengths, such as
compounds 23 and 25, displayed dramatic gain of
function at this mutant (Fig. 7C, D), and indeed, these
compounds had equivalent activity at hFFA2-C4.57G, as
they do at the bovine receptor. In contrast, although
the series of -carbon-substituted carboxylic acids, in-
cluding, for example, compounds 26 and 29, also
gained function at the C4.57G mutant (Fig. 7E, F),
these compounds were substantially less potent at
hFFA2-C4.57G than at bFFA2, suggesting that addi-
tional residues besides 4.57 are likely to contribute to
this aspect of the bFFA2 ligand SAR.
Figure 3. A number of SCAs display marked selectivity for bFFA2. Ability of the noted compounds to promote -arrestin-2
recruitment at either hFFA2 or bFFA2 is displayed as a percentage of maximally effective concentration of C3 at each species
ortholog.
TABLE 2. Concentration-response curve-fit parameters for a refined set of SCAs predicted to have high potency and selectivity for
bovine FFA2
Compound
hFFA2 bFFA2
SelectivitypEC50 Emax pEC50 Emax
22 3 5.28  0.08 91  2 2.28
23 2 5.40  0.09 104  3 3.40
24 3.5 5.00  0.06 104  2 1.50
25 2 5.37  0.09 100  3 3.37
26 2 4.89  0.06 98  2 2.89
27 2 4.96  0.07 102  3 2.96
28 2 3.76  0.09 96  6 1.76
29 2 4.22  0.06 107  4 2.22
Selectivity is expressed as bFFA2 pEC50 	 hFFA2 pEC50. Values of pEC50  2 indicate that no measureable response was obtained. Emax
values are reported as a percentage of the C3 response at bFFA2.
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The substantial gain in function at hFFA2-C4.57G for
several ligands that are inactive at wild-type hFFA2 and
hFFA3 suggested that this mutant could form the basis
of a construct to selectively probe the function of FFA2.
However, to be useful in practice, a RASSL form of
FFA2 that not only gains function to one or more
nonendogenously generated ligands but also loses re-
sponse to the endogenous ligands is required. There-
fore, we used hFFA2-C4.57G as a lead in order to
generate a true RASSL form of hFFA2. For this, we
returned to the four positively charged residues, R5.39,
R7.35, H4.56, and H6.55, previously implicated in
SCFA binding to hFFA2 (19). Although our initial
studies on the bovine ortholog of FFA2 suggested that
mutation to alanine of either R5.39 or H4.56 resulted
in a complete loss of function (Fig. 5B, D), the alanine
mutations of both R7.35 or H6.55 each retained some
activity for the most potent bovine-selective ligands
(Fig. 5C, E). Because the retained function at R7.35
appeared to result from the presence of an additional
arginine at 7.36 in the bovine receptor that is not
present in hFFA2, we focused on H6.55. Initially, a
H6.55A mutation was incorporated into hFFA2-C4.57G
(Fig. 8A). Like bovine H6.55A, this form of hFFA2 also
retained some activity to the most potent ligand at the
human C4.57G receptor, compound 25, while losing
function for the endogenous SCFA C3. However, the
potency of compound 25 remained very low at this
mutant. Several less extreme mutations were, therefore,
also assessed. Replacement by lysine resulted in com-
plete loss of function (Fig. 8B). By contrast, introduc-
tion of asparagine, which is the residue present at this
position in the related long-chain fatty acid receptor
FFA1 (25, 26) to generate hFFA2-C4.57G/H6.55N
produced a receptor with reasonable potency for
compound 25 (Fig. 8C), while losing nearly all mea-
surable activity to the endogenous SCFA ligands
C1–C5 (Fig. 8D). To examine this further, we also
generated hFFA2-C4.57G/H6.55Q due to the similar-
ity between asparagine and glutamine. This form of
hFFA2 also retained potency for compound 25,
which was somewhat improved over hFFA2-C4.57G/
H6.55N (Fig. 8E) and also showed very little response
to each of C1–C5.
Considering the better potency observed for com-
pound 25, we further examined the potential of hFFA2-
C4.57G/H6.55Q as a true RASSL form of this receptor.
For this, it was tested across multiple functional end-
points, reflective of the range of known signaling path-
ways FFA2 is able to regulate (27). To assess Gi/o
coupling, we compared the effect of C3 at wild-type
hFFA2 on inhibition of forskolin-stimulated cAMP pro-
duction (Fig. 9A) with that of compound 25 at the mutant
receptor (Fig. 9B). While C3 and C2 were able to inhibit
forskolin-stimulated cAMP production via wild-type FFA2
(pEC504.280.19 and 4.600.30, respectively), they
both had 100-fold reduced effect on the mutant recep-
tor. Strikingly, compound 25, although completely inac-
Figure 4. Selected natural and syn-
thetic compounds display marked se-
lectivity for bovine FFA2. As in Fig. 3,
ability of the noted compounds to pro-
mote -arrestin-2 recruitment at either
hFFA2 or bFFA2 is displayed as a per-
centage of maximally effective concen-
tration of C3 at each species ortholog.
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tive at the wild-type hFFA2 receptor, strongly and potently
inhibited forskolin-stimulated cAMP production via the
mutant (pEC505.830.11). To assess coupling of
hFFA2-C4.57G/H6.55Q to Gq/11 pathways, the ability of
C3 and compound 25 to stimulate Ca2 mobilization was
examined in cells expressing wild-type hFFA2 (Fig. 9C) or
hFFA2-C4.57G/H6.55Q (Fig. 9D). Although C3 and C2
produced an increase in Ca2 via wild-type hFFA2
(pEC503.210.09 and 3.010.11, respectively), C3 had
no measurable effect at the C4.57G/H6.55Q mutant,
while C2 only produced a very small effect at 10 mM. By
contrast, compound 25 again had no effect on wild-type
hFFA2 but clearly increased Ca2 via the mutant receptor
(pEC504.630.05). Comparable experiments were con-
ducted measuring ERK 1/2 phosphorylation by C3 and
compound 25 via the wild-type (Fig. 9E) and C4.57G/
H6.55Q (Fig. 9F) forms of hFFA2. Again, similar results
were obtained: C3 and C2 effectively promoted ERK
1/2 phosphorylation via the wild-type receptor
(pEC504.130.09 and 3.940.08, respectively) but had
little effect on the mutant form, while compound 25 had
no effect at the wild type but was active and potent at the
mutant form of FFA2 (pEC505.610.06). Importantly,
not only did compound 25 activate hFFA2-C4.57G/
H6.55Q in each assay, the rank order of potency for
compound 25 at this RASSL form of hFFA2 across the
various assays was similar to that for C3 and C2 at the
wild-type receptor, such that cAMP pERK 1/2 Ca2 
-arrestin-2, suggesting that the active conformation(s) of
hFFA2-C4.57G/H6.55Q induced by compound 25 are
very similar to those of the wild-type receptor occupied by
C2 or C3. To more directly test this in an unbiased
manner, we employed a DMR assay, a method that has
been used in the past to broadly measure cellular re-
sponses to GPCR activation (20, 22, 23). As in the other
assays assessed, C3 and C2 produced DMR responses at
hFFA2 (pEC504.200.11 and 3.850.12, respectively),
and compound 25 was without effect (Fig. 9E), while at
hFFA2-C4.57G/H6.55Q, compound 25 produced a good
response (pEC505.350.06), and C3 and C2 had only
small effects at the highest concentrations tested (Fig. 9F).
Finally, DMR time-course experiments were conducted
using C3 on hFFA2 (Fig. 9G) or compound 25 on
hFFA2-C4.57G/H6.55Q (Fig. 9H). The resulting DMR
responses showed very similar profiles between the two
different forms of hFFA2, further supporting the conclu-
sion that the cellular responses of hFFA2-C4.57G/H6.55Q
to compound 25 are very similar to those of the wild-type
hFFA2 to its endogenous ligands.
In the past, generation of RASSL GPCRs has often re-
sulted in increased levels of ligand-independent constitutive
activity in the RASSL receptor (16). Therefore, in addition to
confirming that the cellular response to hFFA2-C4.57G/
H6.55Q is similar to wild-type hFFA2, it is also important to
demonstrate that hFFA2-C4.57G/H6.55Q does not display
altered levels of constitutive activity. The Flp-In T-REx cells
Figure 5. Mutational analysis of the orthosteric binding pocket of bFFA2: comparisons with the human ortholog. A–E) Wild-type
(A) and X-A mutants of residues 5.39 (B), 7.35 (C), 4.56 (D), and 6.55 (E) were assessed for -arrestin-2 recruitment at hFFA2
(Ai–Ei) and bFFA2 (Aii–Eii) in response to C2, C3, C5, and compound 19. F, G) Effects of mutating R7.36 that is present only
in bFFA2 to alanine (F) and of a double (R7.35A, R7.36A) mutant (G) were also assessed.
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provide an optimal experimental system to examine this, as
they allow direct comparison of basal signaling within the
same cell line, either with or without induced receptor
expression. However, the assays used to describe the signal-
ing properties of hFFA2-C4.57G/H6.55Q, including cAMP,
Ca2, pERK, and DMR, are not well suited to measuring
ligand-independent constitutive activity; therefore, we ex-
tended our studies to measure incorporation of [35S]GTPS,
an assay that has been widely used previously to study GPCR
constitutive activity (28–29). Initially, we demonstrated that
hFFA2 activity can be measured in this assay, as C3
(pEC504.160.11) but not compound 25 stimulated
[35S]GTPS incorporation in membranes induced to ex-
press wild-type hFFA2 (Fig. 10A). Similarly, in hFFA2-
C4.57G/H6.55Q-expressing membranes, compound 25 pro-
moted incorporation of [35S]GTPS (pEC505.460.15),
while C3 produced very little response and only at high
concentrations (Fig. 10B). To examine directly ligand-inde-
pendent activity, basal [35S]GTPS incorporation was mea-
sured in membranes isolated from either hFFA2 or hFFA2-
C4.57G/H6.55Q cells in the absence or presence of
doxycycline to induce receptor expression (Fig. 10C). In
both cases, doxycycline induction resulted in a statistically
significant (P0.001) increase in [35S]GTPS incorpora-
tion. Specifically, induced expression of hFFA2 resulted in a
157 7% increase in basal [35S]GTPS incorporation, while
induced expression of hFFA2-C4.57G/H6.55Q resulted in a
similar 156  4% (P0.05) increase. These findings dem-
onstrate that wild-type hFFA2 displays constitutive activity
and that this is unaltered by the alterations to generate
hFFA2-C4.57G/H6.55Q.
DISCUSSION
By exploring differences in pharmacology between the
human and bovine orthologs of FFA2, the most dissim-
ilar species variants of this receptor that have currently
been cloned, then generating homology models and
focusing on residues within 8 Å of the predicted
ligand-binding site for endogenously produced SCFAs,
we have been able to engineer the human ortholog to
respond to a novel group of ligands. By so doing, we
have provided new insights into the binding pocket of
the human ortholog that may allow the design of novel
and more potent ligands that target FFA2, a receptor
that is a potential therapeutic target in areas including
inflammation and metabolic diseases (4, 7, 8). More-
over, the hFFA2-C4.57G/H6.55Q mutant that we gen-
erated acts as a RASSL form of this receptor because it
Figure 6. Homology modeling and mutagenesis of
bFFA2 indicate a key role for residue G4.57 in fatty
acid chain length and compound selectivity. A, B)
Species orthologs of FFA2 were aligned (A), and
homology models of hFFA2 (Bi) and bFFA2 (Bii) were
generated. Key amino acids known to play roles in the
binding of SCFAs are boxed in red; those targeted for
mutagenesis are boxed in blue. C, D) Residues at
positions 3.34 (C) and 4.57 (D) were exchanged
between the orthologs, and the ability of C2, C3, C5,
and compound 19 to promote -arrestin-2 recruit-
ment to these variants was compared to wild type. E)
hFFA2 and bFFA2 mutants with exchanged residues at
4.57 were assessed in an ERK 1/2 phosphorylation
assay. To confirm responses were receptor mediated,
C3 concentration-response studies were also carried
out in the absence of doxycycline, to confirm it had no
effect when receptor expression was not induced.
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has also lost responsiveness to endogenously produced
activators. In this regard, the current studies have similar-
ity to the production of RASSL forms of the muscarinic
acetylcholine receptors, which no longer respond with
significant potency to acetylcholine but do so instead to
the synthetic ligand clozapine N-oxide (12, 13). However,
unlike the muscarinic receptor RASSLs, where the start-
ing point to evolve the variant forms was random mu-
tagenesis (13), herein, we have taken advantage of the
SAR differences in two species orthologs of the FFA2
receptor to the n-fatty acids and SCAs. In combination
with our previous analysis of the mode of binding and
selectivity of SCAs for FFA2 vs. the closely related receptor
FFA3 (19–21), this has allowed rational design of a RASSL
based on homology modeling and sequence alignments.
By contrast, rationalization of the basis of the selective
binding of clozapine N-oxide to a muscarinic RASSL (13)
was only possible post hoc (12).
A major challenge to understanding the physiologi-
cal roles of FFA2 is the similarity of the pharmacology
of the closely related receptor FFA3, a problem that is
compounded by the fact that these two receptors are
often coexpressed (30, 31). Although limited variation
in potency of C2 between human FFA2 and FFA3 has
resulted in its use as a selective FFA2 agonist (32),
because C2 does still have activity at FFA3 and has only
low potency at FFA2, this is far from ideal. Further-
more, apart from a series of SCAs described by Schmidt
et al. (20), which, because of their small size, also have
poor potency, the only FFA2-selective ligands currently
Figure 7. Substitution of C4.57G in hFFA2 generates responses similar to the bovine ortholog. Pharmacology of hFFA2-C4.57G
was assessed in -arrestin-2 recruitment assays with a number of ligands shown earlier to display marked selectivity for bFFA2:
C6 (A), C7 (B), compound 23 (C), compound 25 (D), compound 26 (E), and compound 29 (F).
TABLE 3. Concentration-response curve parameters for bovine selective SCFAs and SCAs at wild-type and C4.57G human FFA2
Compound
FFA2-wt FFA2-C4.57G
SelectivitypEC50 Emax pEC50 Emax vs. bFFA2
a
C6 2 4.62  0.14 112  4 NS 2.62
C7 2 3.98  0.10 119  5 NS 1.98
C8 2 2.97  0.13 109  13 NS 0.97
22 3 4.48  0.15 107  7 P  0.05 1.48
23 2 5.49  0.17 109  4 NS 3.49
24 3 4.64  0.14 113  7 P  0.01 1.64
25 2 5.34  0.21 113  6 NS 3.34
26 2 3.59  0.16 96  12 P  0.01 1.59
27 2 4.08  0.09 98  5 P  0.01 2.08
28 2 3.41  0.31 93  23 P  0.01 1.41
29 2 3.80  0.20 78  11 P  0.05 1.80
Selectivity is expressed as FFA2-C4.57G pEC50 	 FFA2-wt pEC50. Values of pEC50  2 indicate that no measureable response was obtained.
Values of pEC50  3 indicate that a response was observed; however, the data did not allow for the derivation of accurate curve-fit parameters.
Emax values are reported as a percentage of the C3 response at wild-type bFF2A.
aStatistical comparison of pEC50 curve-fit data between bFFA2
and hFFA2-C4.57G. NS, not significant.
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described derive from the phenylacetamide 4-CMTB
(21, 33). Although this compound has been used to
delineate effects of FFA2 (33, 34), it clearly binds to a
site distinct from the SCFAs and acts as a positive
allosteric modulator of the action of the SCFAs, as well
as a direct agonist (21, 33). With increasing apprecia-
tion of the ability of different ligands that bind to
overlapping sites on GPCRs to generate different sig-
naling profiles, a feature that is described as either
functional selectivity (35) or ligand bias (36, 37), there
must be the possibility that agonists that bind to differ-
ent sites of a GPCR will result in such bias. This issue,
although important, remains to be explored for the
actions of 4-CMTB and related allosteric ligands at
FFA2, and thus, we wished to modify the orthosteric
binding pocket of FFA2.
Figure 8. Alterations at residue 6.55 to hFFA2-C4.57G generate a RASSL form of hFFA2. hFFA2-C4.57G was modified further
by substitution of H6.55 to alanine (A), lysine (B), asparagine (C, D) or glutamine (E, F). Action of either C3 or compound 25
was then assessed in -arrestin-2 recruitment assays. D, F) C1–C5 n-fatty acids were tested for activity.
Figure 9. RASSL behavior of hFFA2-C4.57G/H6.55Q is ob-
served in a range of signal transduction endpoints. A–H)
Activity of C2, C3, and compound 25 was assessed at hFFA2
wild type (A, C, E, G) and hFFA2-C4.57G/H6.55Q (B, D, F, H)
for their ability to inhibit forskolin-stimulated cAMP produc-
tion (A, B), elevate intracellular Ca2 (C, D), increase phos-
pho-ERK 1/2 (E, F) and affect DMR (G, H). I, J) DMR time
course experiments are shown for hFFA2 with compound C3
(I) and for hFFA2-C4.57G/H6.55Q with compound 25 (J).
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An important secondary finding of this work is our
demonstration that the pharmacology of bFFA2 is
significantly different from that of hFFA2. Although
previous work had cloned the bovine SCFA receptors
FFA2 and FFA3 (38), little was known about their
pharmacology. Our demonstration that bFFA2 re-
sponds with a completely different rank order of po-
tency to the SCFAs than does hFFA2 suggests that this
receptor may serve different functions in bovines com-
pared with humans, and, clearly, future studies on
bFFA2 should take into account its unique ligand
selectivity. The bovine ortholog of FFA2 was chosen for
this study based on the hypothesis that species, includ-
ing ruminants, that rely heavily on nondigestible car-
bohydrates are exposed to significantly higher SCFA
concentrations (39) and, therefore, were most likely to
have SCFA receptors with distinct pharmacology. Al-
though our findings with bFFA2 appear to support this
conclusion, it is also important to consider whether this
pharmacology may be preserved in other species with
high dietary levels of nondigestible carbohydrates. An
alignment of species orthologs of FFA2 (Supplemental
Fig. S1) reveals that the only other species with glycine
at position 4.57, and, therefore, likely to display similar
pharmacology to bFFA2, is the goat, the only other
ruminant for which sequencing data are available.
Interestingly, the second unique residue that appears
to contribute to the pharmacology of bFFA2, R7.36, is
also conserved in goat FFA2, indicating that the phar-
macology of goat FFA2 is likely to be very similar to
bFFA2. Interestingly, the horse ortholog of FFA2 does
not appear likely to share pharmacology with bFFA2 on
the basis of this sequence alignment (Supplemental
Fig. S1), this despite the fact that the horse is also
heavily reliant on nondigestible carbohydrates, and, in
fact, shows SCFAs concentrations in the digestive tract
similar to those observed in ruminants (39). Therefore,
it appears that the unique pharmacology of bFFA2 is
likely restricted to ruminants and may be related to the
fact that FFA2 is expressed in the rumen of these
animals (38, 40). Indeed, it is conceivable that the two
primary changes that we describe in the pharmacology
of bFFA2, namely, a loss of potency to C2 and gain of
function to longer chain lengths, may be an evolution-
ary adaptation designed to maintain dynamic FFA2
function in the high-SCFA-concentration environment
of the rumen, where C2, as the predominant SCFA, is
present in very high concentrations, but lower levels of
longer-chain compounds are also observed (39).
Our initial studies, demonstrating the unique phar-
macology of bFFA2, precipitated efforts to understand
the molecular basis for this finding. Despite the avail-
ability of atomic level structure of a number of GPCRs
(41–43), homology modeling remains challenging.
This is particularly true for receptors with limited
sequence homology to GPCRs of known structure.
However, both because the binding sites for fatty acids
in FFA1 (25, 26, 44), FFA2 (19), and FFA3 (19) have
been explored by mutagenesis and our homology
model of FFA1 has been validated by its use in “virtual
screening” to identify novel ligands at FFA1 (26), we
have been able to model and compare hFFA2 and
bFFA2 with some confidence. The models indicated
two residues that differ between hFFA2 and bFFA2 that
are in proximity to arginine residues, two in the human
(5.39 and 7.35), and as we now show, three in the
bovine (5.39, 7.35, and 7.36) that coordinate the car-
boxylate group of the fatty acid ligands. These were,
therefore, potential candidates to underpin the species
chain-length selectivity. While alteration of position
3.34 in hFFA2 to the bovine sequence had little effect
on pharmacology, alteration of the cysteine at position
4.57 in hFFA2 to glycine, which is present in this
¹position of bFFA2, was sufficient to markedly en-
hance potency to the longer-chain SCFAs C5–C8, as
well as to a number of SCAs that we showed to be
markedly selective for bFFA2 over hFFA2. To gener-
ate a more useful RASSL form of hFFA2, it was also
important to develop a receptor that no longer
responded to its endogenous SCFA ligands. We
achieved this through the addition of a second
mutation H6.55Q, one of the positively charged
residues previously shown to play a role in SCFA
ligand binding (19). Overall, our development of this
RASSL form of hFFA2 represents a novel, more
rational, approach to chemically engineering ligand
Figure 10. Wild-type hFFA2 and hFFA2-C4.57G/H6.55Q display similar levels of ligand-independent constitutive activity. A, B)
Ability of C3 and compound 25 to stimulate [35S]GTPS incorporation was assessed in membranes expressing either hFFA2 (A)
or hFFA2-C4.57G/H6.55Q (B). C) Basal levels of [35S]GTPS incorporation were measured in membranes harvested from cells
that were either untreated or stimulated with doxycycline (Dox; 100 ng/ml) to induce expression of either hFFA2 or
hFFA2-C4.57G/H6.55Q.
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selectivity at a GPCR based on pharmacological dif-
ferences between species. This is in contrast to
approaches based on random mutagenesis and di-
rected molecular evolution used to develop RASSL
forms of the muscarinic receptors (13). However, a
combination of these two approaches, whereby spe-
cies differences could be used to rationally identify a
RASSL “lead,” followed by subsequent molecular
evolution to mature an ideal RASSL ligand binding
site, may well represent an approach to generate
RASSLs with even more favorable properties in the
future.
In addition to modifying the RASSL receptor to alter
its pharmacology, the selection of an ideal ligand to
activate the RASSL is also of critical importance. The
ligand chosen to activate the hFFA2-RASSL described
here, compound 25, is a natural compound that is
widely used as an antifungal preservative in various
foodstuffs (45). The compound is essentially nontoxic,
with a reported LD50 in rodents of 8–10 g/kg (46),
suggesting that it could be used in vivo without signifi-
cant side effects. At present, little is known about the
bioavailability or tissue distribution of compound 25,
and future work will need to address these issues.
Interestingly, the compound is approved for use as an
additive to cattle feed, and although at least one study
has suggested that its use does not affect cattle weight
gain (47), future work may well consider what biologi-
cal effects its use in this context might have, given its
ability to activate bFFA2.
Similar RASSLs of muscarinic acetylcholine receptor
subtypes have been used to produce transgenic ani-
mals to selectively study the functions of individual
muscarinic subtypes in a variety of both ex vivo and in
vivo assays (14, 15). Our demonstration that com-
pound 25 has similar signaling properties at the
hFFA2-RASSL to those of C3 at the wild receptor
across multiple assays indicates that this hFFA2-
RASSL would be ideal for these types of studies using
knock-in transgenesis. In addition to their use differ-
entiating the actions of closely related GPCRs,
RASSLs have also been used as a means to explore
selective activation of individual signaling pathways
in cells or tissues that have been engineered to
express the RASSL (16). Although there are RASSLs
described previously for each of the three primary
G signaling pathways (Gs, Gi, and Gq), the hFFA2-
RASSL described in the present work is the first
RASSL to selectively coactivate two of these pathways,
and thus may represent a novel means to explore
combined Gi/Gq activation after its expression in
vitro or in vivo. Furthermore, RASSLs have generated
recent interest for their potential use as molecular
switches in engineered tissues that could ultimately
be used therapeutically in humans (16). The FFA2
RASSL described in the current work may be of
particular interest in this respect, given that its ligand
is nontoxic and, indeed, already approved for human
consumption. Taken together, in the present work,
we have described a novel approach to developing
chemically engineered GPCRs based on the pharma-
cological variation between species orthologs, and in
doing so, have developed a valuable reagent for the
future study of FFA2 function.
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 Epilogue 
We presented an elegant way to generate a RASSL receptor based on variations between the human 
and the bovine FFA2 receptor. Instead of introducing random mutation, which is a common way to 
produce RASSL receptors, the interspecies differences were taken as a rational basis for receptor 
mutation. In a species-specific physiology-oriented approach, the differences in the composition of 
breakdown products of food constituents explained the variances in the FFA2 receptor structure 
between the two species1. Through the evolutionary process, the different species adapted to the 
range of diverse nutritive factors, which also function as signaling molecules for example at nutrition 
sensitive GPCRs2. Fatty acids are energy-generating nutrients and play important roles as signaling 
molecules3, hence it is not overly surprising that GPCRs targeted by FFAs show considerable adaptive 
changes in their structure from species to species. 
This RASSL form might eventually provide a valuable tool to dissect FFA3- from FFA2-mediated 
biological effects in vivo. However, this would require employing transgenic techniques, e.g. in a 
knock-in fashion. Another manifestation of the RASSL concept are designer receptors exclusively 
activated by designer drugs (DREADDs)4. These receptors were generated from a muscarinic 
Acetylcholine receptor that does not recognize the endogenous ligand Acetylcholine but the 
metabolically stable and physiologically inert substance Clozapine-N-oxide (CNO). Since then, 
DREADDs endowed with coupling specificity for the three main classes of G proteins (Gαs, Gαi and 
Gαq/11) were generated4. CNO is a drug-like small molecule that is extensively characterized and can 
be recognized as a selective DREADD ligand. Physiological properties of sorbic acid - the synthetic 
ligand for the FFA2-RASSL - although widely used as antifungal preservative in food, is less well 
described and off-target effects cannot be ruled out5–8.  
Regardless, the most striking downside of both approaches to designer receptors is the uncertainty 
about genuine receptor behavior of modified receptors compared to the wild-type receptor. 
Different ligands at one receptor can generate different signaling patterns or biological effects, since 
functional selectivity or signaling bias has shown that multiple receptor conformations can induce a 
plethora of different signal transduction pathways9,10. A RASSL or DREADD is per definition activated 
by another than the endogenous ligand, which implicates the possibility of - although it does not 
imperatively lead to - distinct biological effects between the synthetic designer drug and the 
endogenous ligand (i.e. ligand bias). Despite efforts to affirm the coupling behavior of a given 
receptor, an ample and bona fide characterization of the signaling repertoire is currently beyond the 
bounds of possibility. It can thus not be ruled out that RASSLs or DREADDs are a priori endowed with 
biased signal transduction capacities if compared to the wild type receptor in its native environment. 
Especially studies to explore the in vivo function of a given receptor are affected by this concern4,11. 
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Although a recent study compared the signaling properties of a muscarinic Acetylcholine receptor-
derived DREADD with its genuine wild-type receptor and did not find any signaling bias between the 
DREADD agonist CNO and the endogenous agonist Acetylcholine, this shortcoming cannot be 
brushed aside12. The more so as this study is entirely based on data from cells artificially engineered 
to express high levels of the DREADD/RASSL, a circumstance, which is known to confound the 
signaling fidelity and lower the transferability of conclusions drawn from such experiments13–16. 
However, in the here presented publication, we corroborated signaling fidelity of the FFA2-RASSL in 
comparison to the wild-type form using the holistic DMR readout. 
A next step could be to convert the downside of signaling bias into an advantage by using functional 
selectivity of distinct DREADDs or RASSLs. Generating designer receptors with specific signaling 
preferences could enable scientists to study the in vivo relevance of distinct signaling events. 
Nakajima et al. made a first attempt by constructing a DREADD that is β-arrestin biased17.  
Designer receptors embody a way to explore and modulate receptor biology in vivo in an 
unprecedented fashion. Similar to this, optogenetic methods are used to control and monitor the 
biological response by introduction of light-sensitive proteins into the cells. Recent developments in 
the field of optogenetics allow the generation of molecular switches pursuing that goal18. Light-
switchable receptors can be artificially expressed in living cells to track the consequence of their 
signaling19. There are, however, some differences between these two approaches that are briefly 
summarized. i) The pharmacosynthetic approach is non-invasive, if transgenic technologies were 
employed to introduce the designer receptor into the biological system. ii) Optogenetics induce 
polarization or depolarization in the target cell, whereas DREADDs engage G protein signaling. iii) 
There is considerable disparity in the signaling nature generated by these two methods. DREADD 
signaling is under control of physiological relevant parameters like receptor desensitization and 
internalization or diffusion, clearance and metabolism of the receptor ligand in the 
biopharmaceutically relevant compartments. On the other side, optogenetic methods directly affect 
the function of neurons or a neuronal circuit.  
Concisely, the difference between a pharmacosynthetic and an optogenetic measurement system is 
that in the first case the neuronal modulation is analyzed while in the latter case the actual effect on 
the neuron is measured. However, both technologies will allow to control and follow discrete 
signaling events and to gain insight into complexly regulated signaling networks. 
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 Section III 
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 Prologue 
As detailed in the introductory section, free fatty acids (FFAs) are lipids and play essential roles as 
metabolic energy carrier but they also act as components of biological structures such as 
membranes1,2. The physiological effects of FFAs were long reduced to their direct and indirect 
function in metabolic assembly and dismantling, however, this conception does not explain all effects 
of FFAs on the host organism. It was found that a group of G protein-coupled receptors is targeted by 
FFAs, from which the former orphan G protein-coupled receptor GPR40 is activated by medium to 
long chain fatty acids and was subsequently renamed to FFA13–5. FFA1 is part of the FFA receptor 
family that to date count four members (FFA1-4) and is abundantly expressed on pancreatic β-cells 
but was also found on enteroendocrine gut cells, in some brain regions and osteoclasts6–11. From 
these, presence of FFA1 on pancreatic β-cells attracted most interest and was rapidly associated with 
the previously recognized effect of enhanced glucose-stimulated insulin-secretion (GSIS) in the 
presence of fatty acids4. This resulted in the development of FFA1 receptor small molecule agonists, 
from which TAK-875/fasiglifam reached late stage clinical trials but was unexpectedly terminated in 
December 2013 because of unacceptable risk to benefit potential12–15. Beside the favorable effects of 
FFAs, also detrimental effects are frequently reported16. While acute elevation of free fatty acid 
blood levels enhances GSIS, long term elevation causes β-cell dysfunction and is referred to as 
(gluco)lipotoxicity6,16. Although (gluco)lipotoxicity is a well described phenomenon and the link to the 
presence of high plasma levels of fatty acids is well-established knowledge, the involvement of the 
FFA1 receptor was subject of intense debate16. Steinberg et al. proposed that detrimental effects of 
FFA on pancreatic function is mediated by the FFA1 receptor. By inducing FFA1-mediated insulin 
hypersecretion, the FFA1 receptor would be responsible for hyperinsulinemia-induced insulin 
resistance17. However, others could demonstrate that the damaging impact of FFA on the host 
metabolism is not mediated by the FFA1 receptor18–21.  
In the first publication of this chapter, we corroborate the beneficial FFA1-mediated effects of non-
esterified fatty acids (NEFA) and strengthen an FFA1-independent mechanism of β-cell death. 
Furthermore, we report that FFA1 activation counteracts the detrimental effects of NEFAs on β-cell 
survival. In addition, we explored genetic variations of FFA1 with regard to their influence on insulin 
secretion to NEFA stimulation. 
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The second paper focusses on a methodological aspect of FFA1-related research. A prerequisite of 
meaningful data on physiological function of distinct receptors is the knowledge about their tissue or 
cellular distribution and the determination of their expression level. Both are frequently studied 
using antibody-dependent western blotting detection techniques. Although much effort has been 
made to develop PCR-based methods, protein determination using antibody-relying techniques is still 
routinely used22. Conclusions based on results on defined localization of certain proteins must be 
correct in order to allow for the generation of accurate working hypotheses. Good-quality techniques 
and methods are essential prerequisites to drive and develop scientific ideas in general. Therefore, in 
drug research, more attention should be drawn to the correct evaluation of both the preliminary 
results (target localization) as well as target characterization such as the investigation of physiological 
roles of certain targets23. Both these factors are highlighted in the two following publications. 
While FFA1 expression in β-cells is well described and thoroughly associated with a specific 
physiological function4,18–21, the findings of FFA1 on other cell types and tissues must be questioned 
either because the results are contradictory or their evidential basis is low2,6. Some reports rely on 
the measurement of mRNA level (RT-PCR), which is a mediocre indicator of real expression levels 
since translation and functional expression is intricately regulated by a variety of cellular systems22. 
However, even the use of “specific” antibodies to detect receptor amounts on a protein level 
become controvert with the second publication in this chapter. Therein, we checked commonly used 
and commercially available antibodies against the FFA1 receptor protein for their suitability to detect 
and determine receptor level, compared the results with RT-PCR data, which is another frequently 
used method to determine expression, and question the significance of FFA1 receptor expression 
data derived from immunostaining techniques. 
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Reevaluation of Fatty Acid Receptor 1 as a Drug Target
for the Stimulation of Insulin Secretion in Humans
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Manuel Grundmann,3 Fausto Machicao,1,2 Andreas Peter,1,2 Evi Kostenis,3 Trond Ulven,4
Andreas Fritsche,1,2 Hans-Ulrich Häring,1,2 and Susanne Ullrich1,2
The role of free fatty acid receptor 1 (FFAR1/GPR40) in glucose
homeostasis is still incompletely understood. Small receptor
agonists stimulating insulin secretion are undergoing investiga-
tion for the treatment of type 2 diabetes. Surprisingly, genome-
wide association studies did not discover diabetes risk variants in
FFAR1. We reevaluated the role of FFAR1 in insulin secretion
using a specific agonist, FFAR1-knockout mice and human islets.
Nondiabetic individuals were metabolically phenotyped and gen-
otyped. In vitro experiments indicated that palmitate and a spe-
cific FFAR1 agonist, TUG-469, stimulate glucose-induced insulin
secretion through FFAR1. The proapoptotic effect of chronic
exposure of b-cells to palmitate was independent of FFAR1.
TUG-469 was protective, whereas inhibition of FFAR1 promoted
apoptosis. In accordance with the proapoptotic effect of palmi-
tate, in vivo cross-sectional observations demonstrated a negative
association between fasting free fatty acids (NEFAs) and insulin
secretion. Because NEFAs stimulate secretion through FFAR1,
we examined the interaction of genetic variation in FFAR1 with
NEFA and insulin secretion. The inverse association of NEFA
and secretion was modulated by rs1573611 and became steeper
for carriers of the minor allele. In conclusion, FFAR1 agonists
support b-cell function, but variation in FFAR1 influences NEFA
effects on insulin secretion and therefore could affect therapeutic
efficacy of FFAR1 agonists. Diabetes 62:2106–2111, 2013
Free fatty acids (also called nonesterified fattyacids [NEFAs]) regulate insulin secretion inb-cells. An acute increase in NEFA potentiatesglucose-induced insulin secretion, an effect me-
diated by free fatty acid receptor 1 (FFAR1; formerly
G-protein–coupled receptor 40 [GPR40]) (1–3). Targeting
FFAR1 with specific agonists is a promising way of en-
hancing insulin secretion in patients with type 2 diabetes
and results from clinical phase 2 trials have already
appeared (4).
Previously, we also described small compounds that
stimulate insulin secretion as selective FFAR1 agonists
(5,6). For this reason, and because of its exceptionally high
expression in b-cells, FFAR1 would be an ideal candidate
gene to associate with diabetes and insulin secretion.
Surprisingly, from the 53 glycemic trait–related genes
hitherto discovered in genome-wide association studies,
none is located in or near FFAR1 (7).
In contrast to the stimulatory effect of an acute increase
in NEFA, long-term exposure of insulin-secreting cells to
NEFA is believed to cause a reduction in b-cell mass at-
tributable to increased apoptosis (8–10). In humans, sev-
eral studies demonstrated reduced insulin secretion after
prolonged exposure to NEFAs (11,12), but these findings
were not unequivocal. The effect seemed to depend on the
metabolic status or the individual predisposition of tested
individuals (13,14). Animal studies suggested that the del-
eterious effect of prolonged NEFA elevation is inde-
pendent of FFAR1 activation, because mice deficient in
FFAR1 were not protected against high-fat diet–induced
glucose intolerance (15).
The current study uses a translational approach to ex-
amine the role of FFAR1 in the Janus-faced effect of
NEFAs on b-cell function. First, we analyzed effects of
a synthetic FFAR1 agonist (TUG-469) and an antagonist
(TUG-761) on insulin secretion and apoptosis. Second, we
analyzed a precisely phenotyped human study population
to answer the question of how NEFAs relate to insulin
secretion and whether it is influenced by common varia-
tion in the FFAR1 gene.
RESEARCH DESIGN AND METHODS
Culture and treatment of islets and insulin-secreting cells. Human islets
were cultured in CMRL1066 medium (Biochrom, Berlin, Germany) containing
5.5 mmol/L glucose supplemented with 2 mmol/L L-glutamine, 10 mmol/L
Hepes, and 10% FCS (Biochrom). Human islets were provided through the
Juvenile Diabetes Research Foundation award 31-2008-413 to the European
Consortium for Islet Transplantation (Basic Research program), and their use
was approved by the local Ethics Committee of the University Hospital,
Tübingen, Germany (533/2010BO2). Preparations of mouse islets from wild-
type (WT) and FFAR1 knockout (KO) littermates and preparations of single
cells are described in the Supplemental Materials (16). All animal experiments
were performed in accordance with the accepted standard of human care of
animals and were approved by the local Animal Care and Use Committee.
INS-1E cells were cultured as previously described (17).
Isolation of mouse islets and preparation of single islet cells. Islets were
isolated from WT and FFAR1 littermates by collagenase digestion (3 mg in 3
mL PBS) at 37°C for 9 min. The islets were collected under a dissecting
microscope and were sedimented twice through sterile culture medium and
cultured overnight in nonadhesive Petri dishes. Cells were prepared from
the islets by digestion with 0.001% trypsin in PBS for 3–6 min. After cen-
trifugation in culture medium, 20-mL drops of the cell suspension were
distributed onto culture dishes and, after 1 h of adhesion time, the dish was
filled with medium.
Measurement of insulin secretion. Isolated islets, after overnight culture,
were preincubated for 1 h in modified Krebs-Ringer bicarbonate buffer containing
the following (in mmol/L): 135 NaCl; 4.8 KCl; 1.2 MgSO4; 1.2 NaH2PO4; 4.8
Na2HPO4; 5 NaHCO3; 2.6 CaCl2; 10 Hepes; 2.8 glucose; and 0.05% (weight/volume)
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BSA (fatty acid–free; Sigma-Aldrich). Thereafter, batches of 10 islets/500 mL were
incubated for 1 h in Krebs-Ringer bicarbonate buffer supplemented with test
substances as indicated. INS-1E cells were cultured as previously described and
insulin secretion was measured using the same Krebs-Ringer bicarbonate buffer
as for islets (6). Insulin was measured by radioimmunoassay (Linco Research,
St. Charles, MO).
Because the stimulation of FFAR1 by the small receptor agonists and by
palmitate strongly depends on albumin, experiments with TUG-469 (19) and
TUG-761 (5) were performed in the presence of low concentrations of BSA
(0.05%) and serum (1.2%) (18). The palmitate concentration was adjusted
accordingly. Palmitate (100 mmol/L in DMSO) was merged with FCS at con-
centrations of 1 and 6 mmol/L when 10% FCS was used. The solutions were
further diluted when 1.2% FCS or 0.05% BSA were used.
Measurement of apoptotic cell death in mouse islet cells and INS-1E
cells. Apoptosis was quantified by TUNEL staining of isolated mouse and
human islet and INS-1E cells after 1–2 days of culture in the presence of test
substances using a commercial kit (Roche Diagnostics GmbH, Mannheim,
Germany). Nuclei were counterstained with 1 mmol/L TO-PRO3 (Invitrogen
GmbH, Karlsruhe, Germany).
Measurement of glycemic traits in humans. We studied 2,110 nondiabetic
subjects of European descent from the Tubingen Family Study. All participants
gave written informed consent. The study was approved by the local ethics
committee. This cross-sectional observational study enrolled individuals with
increased risk of type 2 diabetes (positive family history, glucose intolerance, or
overweight). All participants underwent an oral glucose tolerance test (OGTT).
After an overnight fast, 75 g glucose was ingested at 8:00 A.M.; plasma glucose,
insulin, C-peptide, and NEFA concentrations were determined after 0, 30, 60,
90, and 120 min.
Determination of blood parameters. Plasma glucose was determined using
a glucose analyzer (glucose oxidase method; Yellow Springs Instruments,
Yellow Springs, OH). NEFA concentrations were measured enzymatically
(WAKO Chemicals, Neuss, Germany) using the ADVIA 1800 analyzer (Siemens
Healthcare Diagnostics, Eschborn, Germany). Insulin and C-peptide were
analyzed using the ADVIA Centaur XP immunoassay system.
Selection of tagging single nucleotide polymorphisms in humans. Based
on publicly available data of the International HapMap Project derived from the
Central European population (release 24, phase II, NCBI B36 assembly), we
screened the FFAR1 gene, located on chromosome 19q13.12, and 5 kb of both
flanking regions in silico. Sixteen informative HapMap single nucleotide
polymorphisms (SNPs) were present in this range, but only 13 SNPs were
present with minor allele frequencies (MAFs) $0.05 (HapMap data). Nine
SNPs were selected as tagging SNPs covering all other common SNPs within
the locus, with r2 . 0.8 (100% coverage) based on Tagger analysis using
Haploview software.
Genotyping. DNA was extracted from peripheral blood after cell lysis, protein
precipitation, and purification steps. All SNPs were genotyped using the
MassARRAY platform from Sequenom (Sequenom, San Diego, CA). Genotype
calling was unsuccessful for rs12459138 and Hardy-Weinberg equilibrium was
rejected for rs10423648 (P , 0.05); therefore, seven SNPs went into analysis.
MAFs and P for Hardy-Weinberg equilibrium are provided in Supplementary
Table 1.
Calculations and statistics. Insulin sensitivity was assessed from glucose
and insulin values during the five-point OGTTwith theMatsuda index (19). Area
under the curve (AUC) was calculated with the trapezoid method. Insulin
secretion was estimated by AUC0–30Insulin/AUC0–30Glucose and AUC0–30
C-peptide/AUC0–30Glucose. These two parameters, based on independent
measurements and representing early insulin secretion, have been shown to
provide an excellent assessment of genetically determined b-cell function
from OGTT data (20).
To test genotype effects on b-cell function, linear regression models were
constructed with parameters of b-cell function as outcome variables. Geno-
types were coded as continuous variables with an additive model or with
a dominant model in which heterozygous and homozygous carriers of the
minor allele were pooled. Sex, age, BMI, and insulin sensitivity were used as
covariates. Interaction with NEFA was tested by adding fasting NEFA and the
interaction term fasting NEFA 3 SNP to the model. Variables with skewed
distribution were transformed to their natural logarithm before linear re-
gression analyses. To reduce the risk of type I error with multiple testing, the
Bonferroni method was used, accepting 0.05/7 = 0.007 as the significance level
for a, for which the null hypothesis is rejected. Effect sizes are displayed with
the regression coefficient b.
For the insulin-based outcome parameter, the study was sufficiently pow-
ered (sensitivity 80%) to detect an effect size of 3.3% in the lowest MAF variant.
The needed minimum effect size was 1.7% in the case of the highest MAF
variant.
Power analysis was performed with Quanto V1.2.4 (21). All other statistical
analyses were conducted with JMP10 (SAS).
RESULTS
A small synthetic agonist of FFAR1 mimics palmitate-
induced insulin secretion but antagonizes palmitate-
induced b-cell death. Effects of FFAR1 activation were
examined with a synthetic receptor agonist, TUG-469. This
small molecule concentration-dependently stimulated
hGPR40/hFFAR1 (22). TUG-469 maximally stimulated in-
sulin secretion of INS-1E cells at 3 and 10 mmol/L, whereas
1 mmol/L TUG-469 had no effect (Fig. 1A, B). That TUG-469
exerts insulinotropic effects through FFAR1 was corrob-
orated in islets from FFAR1-deficient mice (Fig. 1C, D).
Whereas glucose stimulated insulin secretion in FFAR1 KO
mouse islets as efficiently as in islets of WT mice, the
stimulatory effect of TUG-469 (10 mmol/L) was abrogated
and the effect of palmitate (50 mmol/L) was significantly
reduced in FFAR1-deficient islets compared with WT
islets. Finally, in three human islet preparations, TUG-469
(3 mmol/L) robustly augmented insulin secretion (Fig. 1E).
Next, we examined whether prolonged exposure to the
FFAR1 agonist affects cell survival. Although palmitate (50
mmol/L) for 1 day in culture medium containing 1.2% FCS
significantly increased the amount of TUNEL-stained nuclei,
TUG-469 (10 mmol/L) was without effect. Moreover, TUG-
469 efficiently antagonized palmitate-induced b-cell death
(Fig. 1F). The FFAR1 antagonist TUG-761 (10 mmol/L) sig-
nificantly increased the percentage of TUNEL-positive cells.
TUG-761, however, did not significantly augment palmitate-
induced cell death (Fig. 1G and Supplementary Fig. 1). The
role of FFAR1 for palmitate-induced b-cell death was fur-
ther analyzed using WT and FFAR1 KO mice (Fig. 1H, I). In
WT mouse islet cells, increased number of TUNEL-positive
nuclei was detected after 2 days of culture in the presence
of 10% FCS and 600 mmol/L, but not of 100 mmo/L, palmi-
tate. In islet cell cultures of FFAR1 KO mice, palmitate
already maximally induced cell death at 100 mmol/L, sup-
porting the prosurvival role of FFAR1. In accordance, TUG-
469 (3 mmol/L) abolished palmitate-induced apoptosis in
WT, but not in FFAR1 KO, islet cells (Supplementary Fig. 3).
Furthermore, the antagonist TUG-761 (10 mmol/L) in-
creased the percentage of TUNEL-positive cells from WT,
but not from FFAR1 KO, mice (Supplementary Fig. 3).
Pharmacological efficacy of TUG-761 applied alone can be
rationalized with the assumption that FFAR1 displays con-
stitutive activity in vivo, a notion that is corroborated in
FFAR1-HEK293 cells (Supplementary Fig. 1). These results
suggest that FFAR1 agonists are suitable insulinotropic
agents because they stimulate insulin secretion and counter
the adverse effects on b-cell survival.
Characteristics of the human cohort and association
of fasting NEFA with insulin secretion. Because physi-
ological stimulation of FFAR1 is mediated by NEFA, in-
cluding the major plasma fatty acids palmitate, stearate,
oleate, and linoleate, the correlation of glucose-induced
insulin secretion with plasma NEFA was evaluated in the
cross-sectional Tubingen Family Study cohort (for basic
cohort characteristics, see Table 1). Two independent
secretion parameters, AUC0–30Insulin/AUC0–30Glucose and
AUC0–30C-peptide/AUC0–30Glucose, associated negatively
with fasting NEFA after adjustment for sex, age, BMI, and
insulin sensitivity (b = 20.12, P , 0.0001, and b = 20.09,
P , 0.0001, respectively).
Genetic variation in FFAR1 and its association with
insulin secretion in humans. After adjusting for sex, age,
BMI, and insulin sensitivity, one of seven tagging SNPs of
FFAR1 was associated with either parameter of b-cell
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FIG. 1. FFAR1 contributes to palmitate-induced insulin secretion but not palmitate-induced b-cell death. INS-1E cells (A, B, F, G), mouse islets
(C, D, H, I), and human islets (E, J) were incubated with test substances as indicated and described in RESEARCH DESIGN AND METHODS. Results are
expressed as means6 SEM of n = 4 independent experiments. Statistical analysis was performed with ANOVA, followed by Newman-Keuls multiple
comparison test as post hoc test. *P < 0.05, **P< 0.01, and ***P< 0.001 are significant in controls (first bar of each chart). #P< 0.05, ##P< 0.01,
and ###P < 0.001 indicate significance in secretion at 12 mmol/L glucose. §§P < 0.05 indicates significance in secretion of WT mouse islets at the
same condition. & indicates significance in palmitate-induced apoptosis.
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function, insulin, or C-peptide (Table 2; P value for SNP
effects).
Given the physiological role of NEFA in the stimulation
of insulin secretion through FFAR1, we analyzed the in-
teraction of fasting NEFA and the investigated SNPs on
insulin secretion. Significant interactions were found for
both the insulin-based and C-peptide–based outcome pa-
rameter in rs1573611 (Table 2, first row). This implied that
the regression coefficients (b) of the model explaining
insulin secretion by NEFA levels were significantly differ-
ent for each genotype after adjustment for sex, age, BMI,
and insulin sensitivity. The negative slope of the regression
line between fasting NEFA and AUC0–30Insulin/AUC0–30Glu-
cose was more pronounced in carriers of the minor allele
(Fig. 2; CC: b = 20.061 6 0.03; CT: b = 20.19 6 0.04; TT:
b = 20.23 6 0.09). This has the consequence that carriers
of the major allele of rs1573611 are protected at least to
some extent from the negative effect of NEFAs on insulin
secretion.
DISCUSSION
The current study provides evidence that effective stimu-
lation of insulin secretion through FFAR1 in humans
requires specific genetic and metabolic predispositions.
Previously, a study analyzing two SNPs in FFAR1 found
clues for a possible association between genotypes and
insulin secretion (23). However, no association between
FFAR1 and insulin secretion could be shown in genome-
wide association studies for the SNPs rs387083, rs2301151,
rs12975589, rs12462800, rs417030, and rs1573611 in up to
46,186 individuals (24). In agreement with the genome-
wide association studies results, our analysis of seven
tagging SNPs in FFAR1 utilizing OGTT-based insulin se-
cretion parameters could not unravel significant effects on
insulin secretion either. Instead, we demonstrated that the
inverse association between NEFAs and reduced insulin
secretion is modulated by the genetic variation in
rs1573611. This interaction was robustly significant and
consistent for two independently measured secretion
parameters (AUC of insulin and C-peptide). The SNP
rs1573611 is located in the FFAR1 locus, 341 bases up-
stream from the exon, pointing to a possible effect of the
SNP on the modulation of FFAR1 transcription (Supple-
mentary Fig. 2).
Our findings strongly suggest that FFAR1 activation
does not mimic proapoptotic effects of palmitate, but that
it mediates a protective effect on b cells in addition to the
stimulation of insulin secretion. In line with our observa-
tion, it has been described previously that the protective
effect of oleate is lost in FFAR1-deficient cells (25).
Moreover, pharmacological inhibition of FFAR1 by TUG-
761 induced apoptosis.
Chronically elevated NEFAs deteriorate insulin secretion
in humans (14,26). This is a consequence of FFAR1-
independent reduction of b-cell function, which over-
whelms FFAR1-mediated stimulation of insulin secretion.
The FFAR1-dependent change in the NEFA–insulin secre-
tion regression slope could reflect different stimulatory
potentials for NEFA-induced insulin secretion and different
grades of b-cell protection against chronic noxious effects
of NEFA.
These data also clearly demonstrate that the therapeutic
efficacy of specific FFAR1 agonists could be subject to
TABLE 1
Basic demographic and metabolic characteristics of the study
cohort
N = 1,401/709 (F/M) Median (IQR)
Age (years) 38 (29–49)
BMI (kg/m2) 27.8 (23.6–34.5)
Fasting glucose (mmol/L) 5.1 (4.8–5.4)
Postload (2-h) glucose (mmol/L) 6.2 (5.2–7.3)
Insulin sensitivity, Matsuda index (AU) 12.4 (7.3–20.4)
AUC0–30Insulin/AUC0–30Glucose 36.6 (23.5–56.8)
AUC0–30C-peptide/AUC0–30Glucose 188.8 (149.2–244.5)
Fasting NEFA (mmol/L) 561.0 (423.0–723.0)
F, female; M, male; AU, arbitrary units.
TABLE 2
Association of common variants in FFAR1 with insulin secretion and their interaction with fasting NEFA
SNP Trait* n Mean 6 SE†
P
(SNP)‡
P
(SNP 3 NEFA)§
rs1573611 Insulin 1,061/785/132 45.5 6 1.02 46.3 6 1.18 47.5 6 3.11 0.921 0.001C-peptide 1,019/760/129 202.1 6 2.5 208. 6 2.83 202.1 6 7.61 0.378 0.001
rs387083 Insulin 956/826/215 46.4 6 1.1 46.2 6 1.25 43.7 6 2.07 0.431 0.247C-peptide 923/795/208 205.5 6 2.6 203.4 6 2.8 202.6 6 5.75 0.837 0.029
rs2301151 Insulin 1,288/614/91 45.9 6 0.99 46.7 6 1.32 42.9 6 2.83 0.757 0.678C-peptide 1,243/590/89 204.4 6 2.26 205.4 6 3.31 195.6 6 7.26 0.348 0.080
rs12975589 Insulin 567/997/428 44.7 6 1.32 46.3 6 1.09 47. 6 1.85 0.399 0.196C-peptide 553/958/410 201.9 6 3.3 205.9 6 2.65 203.8 6 3.75 0.709 0.546
rs12462800 Insulin 1,763/222/7 46.3 6 0.81 43. 6 2.49 67.2 6 14.84 0.409 0.597C-peptide 1,697/217/7 204.8 6 1.92 197.8 6 5.57 273.5 6 38.59 0.804 0.318
rs10422744 Insulin 690/957/348 47.4 6 1.44 45.4 6 1.07 44.9 6 1.65 0.198 0.708C-peptide 668/918/338 205.3 6 3.11 204.3 6 2.66 202.3 6 4.04 0.651 0.303
rs417030 Insulin 1,162/729/104 45.1 6 0.94 46.4 6 1.35 53.3 6 4.25 0.530 0.744
C-peptide 1,125/697/102 202.8 6 2.34 205.1 6 2.99 215.1 6 8.95 0.622 0.538
*For each gene variation (SNP), an insulin-based (AUC0–30Insulin/AUC0–30Glucose) and a C-peptide–based (AUC0–30C-peptide/AUC0–30Glucose)
secretion parameter was tested. †Mean of tested glycemic trait 6 SE for the genotype with homozygous major allele, heterozygous variant, and
homozygous minor allele, respectively. ‡Association of the SNP with insulin secretion. Adjusted for sex, age, BMI, and insulin sensitivity.
§Association of the SNP 3 fasting NEFA interaction term with insulin secretion. Adjusted for sex, age, BMI, insulin sensitivity, and fasting
NEFA. Bold values denote statistical significance.
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pharmacogenomic interactions. Genotype-dependent dose–
response analysis of FFAR1 agonists would provide in-
formation about the individual efficacy of FFAR1 agonists
in clinical trials.
The demonstration of an interaction between rs1573611
and NEFA shows for the first time that a frequent variant
of FFAR1 has a measurable effect on the biological func-
tion of the receptor in humans.
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Supplementary Table 1. Minor allele frequency (MAF) and p for Hardy-Weinberg equilibrium (HWE 
p) of genotyped SNPs. The SNP rs10423648 failed Hardy-Weinberg equilibrium, and therefore was not 
analyzed in the genotype-phenotype association study. 
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Supplementary Figure 1. Concentration-dependent effects of TUG-469 and TUG-761 in hFFAR1 
expressing HEK cells. HEK293 expressing the human FFAR1 receptor were stimulated with the 
indicated concentrations of FFAR1-agonist TUG-469 and FFAR1-antagonist TUG-761 and 
accumulation of IP1 (inositol-1-phosphate) as measure of G-protein coupled PLC activity was recorded 
(for method see ref. S1). Untransfected HEK cells and HEK cells transfected with FFAR2 or FFAR3 
respond neither to TUG-469 nor to TUG761 (data not shown). S1. Schmidt J, Smith NJ, Christiansen E, 
et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: Identification of the structural and 
chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011;286:10628-40. 
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Supplementary Figure 2. Localization of the SNP rs1573611 in the FFAR1 locus as downloaded from 
http://genome.ucsc.edu/index.html. ChIP-Seq analyses of transcription-factor binding and digital DNAse 
hypersensitivity cluster data indicate that rs1573611 is situated amidst an important cis-regulatory region 
(Encode project consortium, A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS 
Biol 2011; 9(4):e1001046). 
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Supplementary Figure 3. FFAR1 protects against palmitate-induced beta-cell death. WT (A) and 
FFAR1-KO (B) mouse islet cells were incubated with test substances as indicated and described under 
Research Design and Methods. Results are expressed as means ± SEM of n = 3 - 5 independent 
experiments. * (p<0.05) indicates significance to control culture condition in the presence of 1.2% FCS; 
§ (p<0.05) indicates significance to palmitate. 
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Abstract
Aims/hypothesis Adequate evaluation of protein expression is
a crucial prerequisite for functional studies. Commonly used
strategies comprise detection of proteins by specific antibod-
ies using western blotting and immunohistochemical staining,
or detection of mRNA by in situ hybridisation and RT-PCR.
We evaluated the tools for the detection of free fatty acid
receptor 1 (FFAR1) expression.
Methods Commercially available antibody preparations were
used to detect endogenous expression of the FFAR1 receptor
and this was compared with cell preparations deficient or
overexpressing the mouse or human receptor. Concentrations
of mRNAwere evaluated by RT-PCR.
Results All insulin-secreting cells, INS-1E, Min6 and mouse
islets showed specific expression of Ffar1 at the mRNA level.
However, none of the commercially available antibodies spe-
cifically detected rat, mouse or human FFAR1.
Conclusions/interpretation Proper positive and negative con-
trols are an important prerequisite for the evaluation of FFAR1
expression.
Keywords Antibodies . FFAR1/GPR40 . Ffar1expression .
RT-PCR .Western blotting
Abbreviations
DMR Dynamic mass redistribution
FFAR1 Free fatty acid receptor 1
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HEK Human embryonic kidney 293
HRP Horseradish peroxidase
IGF1R IGF-1 receptor
PKB Protein kinase B
TBS TRIS-buffered saline
TUG-488 3-(4-((2-(Cyanomethyl)phenyl)ethynyl)
phenyl)propanoic acid
YFP Yellow fluorescent protein
Introduction
Free fatty acid receptor 1 (FFAR1; also known as G-protein-
coupled receptor 40), encoded by Ffar1, is differentially
expressed in organs, with a particularly high level of expression
in the islets of Langerhans, where the receptor plays a stimula-
tory role in glucose-induced insulin secretion [1]. To understand
the role and function of FFAR1, especially during chronic
exposure of beta cells to fatty acids, as occurs in obesity,
detection of functional receptors at the plasma membrane is an
important requirement. Repetitive or continuous stimulation has
been found to result in receptor downregulation and
internalisation which may impair receptor function [2, 3].
Indeed, receptor desensitisation to agonists after initial
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stimulation has also been seen for FFAR1 [2]. Consequently, in
the case of excessive stimulation, receptor inactivation rather
than receptor activation may account for the observed cellular
effects. In a recent publication it was suggested that exendin-4
reduced FFAR1 levels using commercially available antibodies
against FFAR1 [4]. Previously, another study showed FFAR1
protein expression in mouse brain, although mRNA analysis
does not support the idea of Ffar1 expression in mouse brain
[5].
Here, we evaluated the expression of FFAR1 in insulin-
secreting cells by RT-PCR and western blotting using com-
mercially available antibodies. We found that all antibodies
tested so far are of limited use for FFAR1 protein detection,
and appropriate positive and negative controls should be used
for evaluation.
Methods
INS-1E cell culture and islet isolation INS-1E cells were
kindly provided by C. B. Wollheim (University of Geneva,
Geneva, Switzerland). INS-1E and Min6 cells were cultured
under standard culture conditions. Mouse islets were isolated
by collagenase digestion and cultured overnight under stan-
dard conditions [6].
Western blotting Cells and islets were lysed in buffer contain-
ing (in mmol/l): 125 NaCl, 10 EDTA, 10 Na4P2O7, 10 NaF, 1
Na2VO4, 2 phenylmethylsulfonyl fluoride, 25 HEPES, pH
7.3, supplemented with 0.1% SDS, 0.5% sodium
deoxycholate, 1% Triton X-100 and protease inhibitors. A
soluble and a crude membrane fraction of INS-1E cells were
prepared by ultrasonic homogenisation in buffer containing
(in mmol/l): 10 TRIS/HCl, pH 7.5, 5 EDTA and protease
inhibitors, and subsequent centrifugation (13,000 g for
30min) at 4°C [7]. Protein kinase B (PKB) and IGF-1 receptor
(IGF1R) were used as markers for soluble and transmembrane
proteins, respectively. Proteins were transferred onto nitrocel-
lulose membranes (Whatman, Dassel, Germany), and unspe-
cific binding was reduced by blocking the membranes for 1 h
at room temperature. Blocking solutions contained (in
mmol/l):137 NaCl, 20 TRIS and 1.5% Tween-20
supplemented with either 5% milk or 2.5% BSA; alternative-
ly: 150 NaCl, 50 TRIS, 5 EDTA, 0.05% Triton and 0.25%
gelatin. After blocking, the membranes were incubated with
the primary antibodies overnight at 4°C, and with the second-
ary antibody for 1 h at room temperature. FFAR1 antibodies
(diluted 1:500 and 1:1,000 with TRIS-buffered saline [TBS]–
Tween-20 buffer containing 5% BSA) were purchased from
Abcam (no. EP4632, Cambridge, UK), Aviva (no.
AVARP08008, London, UK) and Santa Cruz (no. 28416,
Dallas, TX, USA). Antibodies against PKB and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) were purchased
from Cell Signaling (Danvers, MA, USA), and IGF1R anti-
bodies were purchased from Santa Cruz. The horseradish
peroxidase (HRP)-conjugated secondary antibodies (diluted
1:2,000 with TBS–Tween-20 buffer containing 5%milk) were
purchased from Life Technologies (Carlsbad, CA, USA).
HRP activity was detected using a solution containing (in
Fig. 1 Detection of rat (r) and mouse (m) Ffar1 by RT-PCR. (a) PCR
products of Ffar1and β-actin as housekeeping control from mouse islets,
INS-1E (INS-1) andMin6 cells. (b) PCR products of Ffar1andβ-actin as
housekeeping control from wild-type (WT) and FFAR1-deficient (KO)
mice. (c–h) Amplification curves of semiquantitative RT-PCR of Ffar1
and Rps13 as housekeeping control, respectively, for (c and d) INS-1E,
(e and f) Min6, (g and h) WT (2 reactions) and KO (1 reaction) mouse
islets. (a, g and h) Reactions after RT are shown. (b–f) Reactions were
performed with (+) or without (−) RT. Shown are representative experi-
ments out of three
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mmol/l): 4.2 TRIS, 1.4 luminol and 6.7 p-hydroxycoumaric
acid.
RNA isolation and RT-PCR reactions INS-1E or Min6 cells
(5×106 cells/600 μl) or purified islets (100 islets/100 μl) were
lysed and cellular RNA was isolated using a commercial kit
(Qiagen, Hilden, Germany). After DNA digestion, 1 μg RNA
was transcribed into cDNA using oligo-dT primers and
Moloney murine leukaemia virus reverse transcriptase
(MMLV-RT), both purchased from Clontech (Mountain
View, CA, USA). PCR was performed with Taq polymerase
from peqLab (Erlangen, Germany) using primers from Life
Technologies (Carlsbad, CA, USA). Semiquantitative RT-
PCR was performed with the LightCycler 480 system
(Roche Diagnostics, Basel, Switzerland) using primers from
TIB Molbiol (Berlin, Germany). Sequences of all primers are
listed in electronic supplementary material [ESM] Table 1.
Functional dynamic mass redistribution measurements Human
embryonic kidney 293 (HEK) cells were stably transfected
with human or mouse orthologue of FFAR1 receptor using the
Flp-In T-REx system according to the manufacturer’s instruc-
tions (Life Technologies, Carlsbad, CA, USA). The FLAG-
tagged human FFAR1 receptor has an expected molecular
mass of 32 kDa; the mouse FFAR1 receptor is marked with
yellow fluorescent protein (YFP) and therefore has a
Fig. 2 Detection of rat, mouse
(m) and human (h) FFAR1
(FFA1) on western blots. (a) INS-
1E cell homogenate, a soluble
fraction (13,000 g supernatant
fraction) and a membrane fraction
(13,000 g pellet) were blotted as
indicated. PKB and GAPDH
were used as soluble markers and
IGF1R as a membrane marker.
(b–d) Homogenates of native
HEK cells and HEK cells
overexpressing mouse and human
FFAR1were probed against
FFAR1 antibodies as indicated.
Unless otherwise indicated, 20 μg
protein was loaded. GAPDH was
used as loading control. (c and d)
The red arrow indicates the
molecular mass of YFP-tagged
mouse FFAR1. (e–h) DMR
response of TUG-488 in (e) INS-
1E, (f) native HEK, (g) human
FFAR1 HEK, (h) mouse FFAR1
HEK cells. DMR response is
expressed as picometres (pm);
concentrations of TUG-488 are
presented in log10
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molecular mass of 58 kDa. Cell-based dynamic mass redistri-
bution (DMR) assays were performed, as described previous-
ly in detail [8, 9], using DMR readers, the Corning Epic
Biosensor (beta version, Corning Incorporated Life Sciences,
Tewksbury, MA, USA) or the EnSpire multimode reader
(PerkinElmer, Waltham, MA, USA). Cells were seeded at a
density of 18,000 cells/well (human FFAR1 HEK, mouse
FFAR1 HEK, and HEK) or 30,000 cells/well (INS-1E) on
fibronectin-coated biosensor plates and cultivated overnight
(37°C, 5% CO2) to obtain confluent monolayers. After wash-
ing the cells with HEPES-buffered salt solution the biosensor
plate was incubated for 1 h in the DMR reader. A baseline
optical signature was recorded, and compound solutions were
transferred onto the biosensor plate and DMR was monitored.
Shown are representative traces (+ SEM).
Results and discussion
Detection of Ffar1 expression by RT-PCR Using specific
primers, Ffar1 was detected in mouse islets, INS-1E and
Min6 cells (Fig. 1a). As the protein is encoded by a single
exon, up- and downstream primers bind to the same exon,
which makes it likely that amplicons of cellular DNA con-
taminate the PCR product. We therefore performed PCR
reactions with and without RT. A faint PCR product band
was detectable only from samples subjected to RT (Fig. 1b).
The reaction was specific, as no amplification product was
detected in islets from FFAR1-deficient mice. That RNAwas
correctly transcribed is suggested by the proper product accu-
mulation for β-actin. Real-time PCR was performed to quan-
tify Ffar1mRNA (Fig. 1c–h). Comparison of the results from
samples not subjected to RT confirmed a cDNA-dependent
amplification of Ffar1-specific products in insulin-secreting
INS-1E cells, Min6 cells and mouse islets (Fig. 1c, e, g,
respectively). Of note, a product accumulated also from
RNA without RT but at much later time points. Again, PCR
using RNA from islets of FFAR1-deficient mice did not result
in accumulation of a specific product, whereas accumulation
of the housekeeping gene product was comparable to that of
mouse islets expressing the receptor (Fig. 1g, h). The calcu-
lated relative mRNA amount, estimated fromΔCt, suggests a
four- to fivefold higher expression of Ffar1 in INS-1E cells
(0.024 AU) compared with Min6 cells (0.006 AU) and mouse
islets (0.005 AU). This analysis suggests that mouse islets,
INS-1E and Min6 cells express significant amounts of Ffar1.
Detection of FFAR1 by western blotting Three commercially
available antibody preparations (one monoclonal and two poly-
clonal) were used to detect FFAR1 protein in insulin-secreting
cells. As our INS-1E cell clone expressed the highest amount of
the receptor, it was used to optimise the detection procedure.
Using INS-1E cell homogenates, a single and prominent
protein band between 28 and 31 kDa was stained with one
antibody but not with the other two preparations (Fig. 2a; ESM
Fig. 1a–c). Exchanging milk for BSA or gelatin did not
improve specific staining (ESM Fig. 1d, e). High-speed centri-
fugation was applied after cell lysis in order to enrich the
membrane proteins and reduce background staining. Detection
of FFAR1 was performed in the resulting cytosolic and mem-
brane fractions, shown by PKB and IGF1R, respectively, as
marker proteins (Fig. 2a). Surprisingly, staining with the Abcam
antibody was enriched in the cytosolic fraction together with
PKB, while less FFAR1 protein was found in the membrane
fraction where IGF1R accumulated. Using the Santa Cruz or
Aviva antibody, minor protein bands at 28–31 kDa were detect-
ed in the membrane fraction. FFAR1 belongs to the transmem-
brane proteins and, consequently, its localisation should be
restricted to that particular fraction. Thus, the protein detected
by the Abcam antibody does not relate to FFAR1.
Finally, FFAR1 detection was performed with homoge-
nates of HEK cells which do not endogenously express the
receptor and with HEK cells overexpressing mouse or human
FFAR1 (Fig. 2b–d). The results confirm that the Abcam
antibody stains an unspecific protein, as the band in HEK cell
homogenates was even more pronounced than that detected in
INS-1E cells (Fig. 2b). None of the antibodies detected the
overexpression. That both mouse and human receptors
were functionally overexpressed in HEK cells is shown
by the DMR response to the specific full agonist,
3-(4-((2-(cyanomethyl)phenyl)ethynyl)phenyl)propanoic acid
(TUG-488) [10], which induced a four- to fivefold higher
response in human and mouse FFAR1 HEK cells than in
INS-1E cells (Fig. 2e–h). The absence of a DMR response
to agonist stimulation in native HEK cells confirms that these
cells do not express FFAR1 (Fig. 2f). Since mouse islets
expressed lower amounts of receptors than INS-1E cells, the
detection of FFAR1 in islet homogenates did not yield satis-
factory results (data not shown).
In conclusion, the analysis of FFAR1 protein expression
remains a challenge. More studies are needed to understand
whether the receptor is functionally expressed at the cell
surface, especially after chronic exposure of insulin-secreting
cells to fatty acids or agonists.
Acknowledgements We thank S. Haug (University of Tübingen and
IDM, Tübingen, Germany) for cell culture maintenance. TUG-488 was
kindly provided by T. Ulven (Southern University of Denmark, Odense
M, Denmark).
Funding This work was funded by the University of Tübingen,
Medical Facul ty, through a fel lowship to C-AT (IZKF-
Promotionskolleg 2012), and was supported by the following three
grants: the German Federal Ministry of Education and Research
(BMBF) to the German Center for Diabetes Research (DZD), the
German Research Foundation (UL140/7-2) and the Danish Council for
Independent Research, Technology and Production (grant 09-070364).
Diabetologia
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Contribution statement This study is part of the MD thesis of C-AT.
SU, H-UH and EKwere responsible for the study design and the concept.
C-AT, MP, MG and GK performed the experiments. C-AT, MP, GK, MG
and SU analysed the data. SU, MP, MG and EK drafted the manuscript.
GK, C-AT and H-UH critically revised the content. All authors approved
the final version.
References
1. Itoh Y, Kawamata Y, Harada M et al (2003) Free fatty acids regulate
insulin secretion from pancreatic beta cells through GPR40. Nature
422:173–176
2. Schmidt J, Liebscher K, Merten N et al (2011) Conjugated linoleic
acids mediate insulin release through islet G protein coupled receptor
FFAR1/GPR40. J Biol Chem 286:11890–11894
3. Millar RP, Newton CL (2010) The year in G protein-coupled receptor
research. Mol Endocrinol 24:261–274
4. Natalicchio A, Labarbuta R, Tortosa F et al (2013) Exendin-4 pro-
tects pancreatic beta cells from palmitate-induced apoptosis by
interfering with GPR40 and the MKK4/7 stress kinase signalling
pathway. Diabetologia 56:2456–2466
5. Nakamoto K, Nishinaka T, Matsumoto K et al (2012) Involvement of
the long-chain fatty acid receptor GPR40 as a novel pain regulatory
system. Brain Res 1432:74–83
6. Wagner R, Kaiser G, Gerst F et al (2013) Reevaluation of fatty acid
receptor 1 as a drug target for the stimulation of insulin secretion in
humans. Diabetes 62:2106–2111
7. Regazzi R, Ullrich S, Kahn RA, Wollheim CB (1991)
Redistribution of ADP-ribosylation factor during stimulation
of permeabilized cells with GTP analogues. Biochem J
275:639–644
8. Schröder R, Janssen N, Schmidt J et al (2010) Deconvolution of
complex G protein-coupled receptor signaling in live cells using
dynamic mass redistribution measurements. Nat Biotechnol 28:
943–949
9. Schröder R, Schmidt J, Blättermann S et al (2011) Applying label-
free dynamic mass redistribution technology to frame signaling of G
protein-coupled receptors noninvasively in living cells. Nat Protoc
6:1748–1760
10. Christiansen E, Due-Hansen ME, Urban C et al (2013)
Discovery of a potent and selective free fatty acid receptor
1 agonist with low lipophilicity and high oral bioavailability.
J Med Chem 56:982–992
Diabetologia
ed Milk
20µg    40µg
BSA
20µg    40µg
Gelatin
20µg   40µg
37 kDa
26 kDa
GAPDH
FFA1
Abcam
37 kDa
37 kDa
26 kDa
GAPDH
FFA1 
Aviva
37 kDa
Milk
20µg  40µg
BSA
20µg   40µg
Gelatin
20µg  40µg
INS-1E homogenate
10µg  20µg  40µg
INS-1E homogenate
10µg  20µg  40µg
INS-1E homogenate
10µg  20µg  40µg
a b c
37 kDa
26 kDa
37 kDa
26 kDa
37 kDa
26 kDa
ESM Fig. 1 INS-1E cell homogenates were prepared and subjected to western blotting as described
under Methods (a-c) Shown are the entire western blots of homogenates from Fig. 2a using (a) Abcam, 
(b) Aviva or (c) Santa Cruz antibody preparations. (d, e) Membranes with 20 or 40 µg/lane of INS-1E 
homogenates were blocked with three different blocking solutions as indicated. GAPDH was used as 
loading control.
ESM Table 1 List of Primers used for PCR and real time PCR (Roche Diagnostics, 
Basel, Switzerland) 
 
 
 
Gene 
Roche 
Probe 
no 
 
Upstream primer 
 
Downstream primer 
rat Ffar1 
 5-CCTTTGGATACCAAGCCATC-3 5-GAGCCATTCACGGGTATGTT-3 
rat -actin 
 5-TAGCCATCCAGGCTGTGTTG-3 5-GGAGCGCGTAACCCTCATAG-3 
mouse Ffar1 
 5-GGCGCAGTGTCCCACGCTAA-3 5-TCCGCCTGCGTAGAGGGGAG-3  
mouse -
Actin 
 5-CCAGCCTTCCTTCTTGGGTATGGA-3 5-ACGCAGCTCAGTAACAGTCCGC-3 
   
 
rat Ffar1 65 5-TCATAAACCCGGACTTAGAAGG-3 5-TCCAGGCTCCTGTGATGAG-3 
rat Rps13 12 5-CTGACGACGTGAAGGAACAA-3 5-TCACAAAACGGACCTGTGC-3 
mouse Ffar1 50 5-CATCACTCTGCCCCTGAAG-3 5-AAGGCAAAGACTGGGCAGA-3 
mouse 
Rps13 
110 5-TGCTCCCACCTAATTGGAAA-3 5-CTTGTGCACACAACAGCATTT-3 
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In the first paper, the role of the FFA1 receptor in the process of insulin secretion and β-cell survival 
was further elucidated. By using both small molecule ligands and endogenous agonists of the FFA1 
receptor, we corroborated the receptor-mediated enhancement of glucose-stimulated insulin 
secretion (GSIS) and provided further evidence against a role of the FFA1 receptor in mediating 
NEFA-induced β-cell death. In fact, we could demonstrate that FFA1 activation by both the small 
molecule TUG-469 and the endogenous ligand palmitate protected β-cells from fatty acid-induced 
detrimental effects, whereas antagonizing receptor activity with the inverse agonist TUG-761 
exacerbated β-cell death provoked by increased NEFA levels.  
Furthermore, this publication provides pharmacogenomic insight into the potential modulation of 
drug action since carrier of genetic receptor variants might react with different drug efficacies1. It 
turned out that people carrying the major allele of a single nucleotide polymorphism (SNP) 
(rs1573611) in the FFA1 receptor gene might be protected from high-fat diet-induced negative 
effects of increased NEFA blood levels. 
In summary, the role of FFA1 in the context of the metabolic syndrome was reevaluated. While 
providing further evidence to contradict a role for FFA1 in mediating (gluco)lipotoxicity of high NEFA 
blood levels, we posited the contrary by attesting that the FFA1 receptor protects against the 
deleterious effects of NEFAs. The physiological function of the receptor is moreover modulated by 
SNP genetic variations as shown by in vivo cross-sectional observations.  
As the results of the second paper indicate, insufficiency of antibody-derived expression data is a 
largely uncharted problem. Conclusions based on erroneous data mislead the scientific community 
and can hinder a fruitful research process resulting in the production of rather useless matter (also 
see chapter 6). Since the exact structure of commercially available antibodies often remain unknown 
or the characterization of key epitopes kept secret on purpose, a decent knowledge of the factors 
that account for antibody-dependent detection is problematic to obtain yet desirable. 
In the case of the FFA1 receptor, reports on certain tissue-specific expression patterns are argued by 
other researchers2,3. Flodgren et al. reported on the expression of FFA1 protein on glucagon 
producing α-cells in the pancreas4, whereas Hirsawa et al. could not confirm colocalization of FFA1 in 
glucagon-positive cells5. In addition, the potent FFA1 agonist TAK-875 did not reveal a glucagon-
modulating effect in studies with patients suffering from diabetes type 26. FFA1 expression in the 
brain was claimed, although no studies with FFA1-/- mice indicated a significant influence of FFA1 
expression in brain tissue, thus doubting the existence of FFA1 at least in mouse brain2,3,7,8. FFA1 was 
found in several diverse cell types, such as osteoblasts and osteoclasts, in mouse brain microvessels, 
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taste buds and also in a breast cancer cell line9. Studies on the functionality in some of these 
proposed tissues are rare and expression of the receptor itself has never even been unequivocally 
demonstrated2,3.  
We tested several commercially available antibodies against the FFA1 receptor and checked their 
capability to reliably detect the FFA1 protein. We therefore used endogenously expressing cell lines 
as well as artificially overexpressing cell lines in conjunction with RT-PCR methods and functional 
assays to confirm the cellular presence of the receptor. We demonstrated that all tested antibodies 
are of limited use to detect either the human or rodent forms of the FFA1 receptor. Some antibodies 
even detected an unspecific band in native HEK293 cells that do not endogenously express FFA1 
protein. Since efforts to study receptor biology such as receptor trafficking demand a reliable 
technique to determine the correct amount and localization of protein of a cell sample, we conclude 
that the available FFA1 antibodies do not meet these criteria and therefore raise the question on the 
significance of data obtained with those antibody-based detection methods. 
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 Prologue 
Targeting free fatty acid (FFA) receptors with endogenous ligands poses a challenge because free 
fatty acids as the natural agonists for these receptors are lipids and therefore substrates for a 
multitude of enzyme complexes and biological targets1–3. Moreover, since these “off-target” effects 
are relevant in metabolic homeostasis it is problematic to accurately define the biological role of the 
FFA receptors in an in vivo context4. Especially those targets are challenging to study with the 
endogenous ligands that show a significant overlap in the structural properties of their recognized 
ligands5–7. While this complication has been addressed for the FFA2/FFA3 receptor pair and already 
discussed in chapter 2 and chapter 3 with the discovery of a selective FFA2 modulator or the 
invention of a RASSL form of FFA2, this is also evident for the FFA1/FFA4 receptor pair, which are 
both activated by medium to long-chain fatty acids8.  
Both receptors are crucially involved in the regulation of host metabolism and both have been linked 
to glucose-stimulated insulin secretion and the pathology of diabetes type 2 and obesity8. Some of 
the beneficial effects of ω-3 fatty acids could be traced back to an interaction with the FFA4 
receptor9. On the other side conjugated linoleic acids (CLAs) act as agonists on the FFA1 receptor and 
have been associated with both ameliorating and deteriorating effects on the symptoms of metabolic 
diseases10–12. Thus, the biological effects of polyunsaturated fatty acids cannot be clearly attributed 
to either a FFA1- or a FFA4-dependent mechanism.  
As already mentioned above, FFA1 has attracted considerable interest as a possible target for the 
treatment of type 2 diabetes, since FFA1 is known to enhance glucose-stimulated insulin secretion 
(GSIS)13,14. To unambiguously put the effects down to an interaction with the FFA1 receptor, selective 
small molecule agonists for FFA1 are desirable and the search for suitable chemical compounds 
yielded in a substantial library of structures that show considerable activity with high selectivity for 
this receptor15–17. Since fatty acids were used as a the lead structure for the development of FFA1 
selective agonists, literally all found agonists show high lipophilicity, an unwanted compound 
property because these drug candidates also suffer from high attrition rates in clinical trials. High 
lipophilicity goes along with lower metabolic stability, less favorable pharmacokinetics, higher 
toxicity and higher promiscuity but also higher compound potency18–20. Consequently, increasing 
efforts were made to lower compound lipophilicity by largely maintaining ligand potency and 
efficacy21–23.  
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In this chapter, we report on the development of three FFA1 agonists. Inspired by already clinically 
investigated FFA1 compounds, the following structure-activity relationship (SAR) studies represent a 
possible way to rationally design and synthesize ligands with more favorable properties. 
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ABSTRACT: The free fatty acid receptor 1 (FFA1, also
known as GPR40) mediates enhancement of glucose-
stimulated insulin secretion and is emerging as a new target
for the treatment of type 2 diabetes. Several FFA1 agonists are
known, but the majority of these suffer from high lipophilicity.
We have previously reported the FFA1 agonist 3 (TUG-424).
We here describe the continued structure−activity exploration
and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low
lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on
glucose tolerance in mice.
■ INTRODUCTION
Type 2 diabetes (T2D) is characterized by insulin resistance
and insufficient insulin secretion by pancreatic β-cells, leading
to dysfunctional control of plasma glucose and numerous long-
term health consequences, such as increased risk of heart
disease and stroke, kidney failure, blindness, neuropathy, and
amputations. The global number of diabetics has now reached
350 million, of which 90% are type 2 diabetics.1,2 Besides a
healthy lifestyle, the most common treatments include insulin,
metformin, and sulfonylureas, all of which are associated with
problems such as weight gain, risk of hypoglycemia, and lack of
sustained efficacy, and there is an urgent need for improved
therapeutics.
The long-chain free fatty acid receptor 1 (FFA1, previously
known as GPR40) is highly expressed in pancreatic β-cells and
enhances glucose-stimulated insulin secretion (GSIS) but does
not affect insulin secretion at low glucose levels.3−6 This
mechanism provides the potential for boosting insulin levels of
type 2 diabetics without the risk of hypoglycemia associated
with sulfonylureas and insulin administration. FFA1 is also
expressed in enteroendocrine cells and has been implicated in
the secretion of the incretin hormones glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP).7 Thus, the receptor may potentially enhance insulin
secretion at high glucose levels through two independent
mechanisms.
A number of synthetic FFA1 agonists have been reported in
the literature (Chart 1),5,8−26 of which the compounds TAK-
875 and AMG-837 have reached clinical trials. A general
problem with the currently known FFA1 ligands is their
relatively high lipophilicity, which is associated with numerous
problems, such as poor pharmacokinetic properties, metabolic
instability, toxicity, and off-target effects, and correlates with
attrition in clinical trials.27−32 Studies have recommended that
ClogP values should not exceed 4−5,30,33 and ranking functions
such as ligand lipophilicity efficiency (LLE) have been
suggested to facilitate implementation of lipophilicity concerns
in the optimization process.27
We previously reported the discovery of the alkyne agonist
series with 3 (TUG-424, Chart 1) as the most potent
compound.13 The compound is, however, relatively lipophilic
and exhibited only moderate in vitro metabolic stability and is
thus not suitable as a drug candidate. We therefore aimed at
improving the lipophilicity and metabolic stability of the
compound by replacement of the terminal benzene ring by
nitrogen-containing heterocycles, which led to the identification
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of TUG-499 (Chart 1).19 Inspired by Takeda’s clinical
candidate TAK-875 (Chart 1), we recently explored the
attachment of a mesylpropoxy appendage on TUG-469
(Chart 1), the previously reported compound from another
series, and thereby identified TUG-905 (Chart 1), a compound
with significant reduction in lipophilicity.25 We have also
continued the further optimization and exploration of
structure−activity relationships (SAR) around 3 with focus
on lowering lipophilicity and improving metabolic stability by
the introduction of polar substituents. Herein, we report the
results from these studies, which led to the identification of 40,
a compound with improved potency, lower lipophilicity than
any previously reported FFA1 agonist, high selectivity, excellent
in vitro ADME properties, complete bioavailability, and
appreciable efficacy on glucose tolerance in mice.
■ RESULTS AND DISCUSSION
The majority of the alkyne ligands were synthesized directly by
Sonogashira cross-coupling between the alkyne intermediate 1
and aryl halides (Scheme 1).34 As the classical Sonogashira
protocol (method A) in most cases works unsatisfactorily with
1, we screened other methods and found that a method
reported by Beller and co-workers (method B) gave improved
results.35 This method however also often gave low yields,
especially with aryl iodides. We therefore optimized the method
further and found that addition of 10% water (method C)
resulted in suppression of Glaser−Hay dimerization of the
alkyne and very rapid cross-coupling in high yields with both
aryl bromides and iodides.34 Method C is more convenient and
has so far given significantly better results than other methods
in all cases where iodo- and bromobenzenes are used as
substrates.
The phenylacetic acid (6) and 4-phenylbutanoic acid (7)
analogues were synthesized from the corresponding aryl
bromides by Sonogashira coupling with phenylacetylene
(Scheme 2). Acrylic acid analogues 8 and 9 were synthesized
from 4-bromocinnamic acid via esterification and Sonogashira
cross-coupling reactions as for the propionic acids (Scheme 3).
Chart 1. Representative FFA1 Agonists
Scheme 1a
aReagents and conditions: (a) method A, Pd(PPh3)2Cl2, CuI, aryl
halide, Et3N, DMF, 50 °C; method B, Na2PdCl4, PIntB, CuI, aryl
halide, TMEDA, water, 80 °C; method C, Na2PdCl4, PIntB, CuI, aryl
halide, TMEDA, water, 80 °C. (b) LiOH, THF, water, room
temperature.
Scheme 2a
aReagents and conditions: (a) Na2PdCl4, PIntB, CuI, phenylacetylene,
TMEDA, water, 80 °C (78%). (b) LiOH, THF, water, room
temperature (95−99%).
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The β-methyl substituted analogue 10 was prepared by a
conjugated addition of methyl Gilman reagent to methyl 4-
bromocinnamate in the presence of chlorotrimethylsilane
(Scheme 4).36−38 All cyclopropyl analogues are racemic and
were prepared from methyl trans-2-(4-iodophenyl)-
cyclopropanoate (Scheme 5).19 The bicyclic alkyne 11 was
synthesized from 5-bromodihydroindanone by a Horner−
Wadsworth−Emmons reaction with triethyl phosphonoacetate,
reduction with triethylsilane and TFA, and Sonogashira
coupling with phenylacetylene followed by ester hydrolysis
(Scheme 6). Aryl halides used to prepare 27, 28, 42, and 43
were synthesized by alkylation of iodophenols. The methox-
ymethyl-substituted bromobenzene building blocks for 34 and
35 were synthesized following a FeSO4-promoted ether
synthesis of the corresponding bromobenzyl bromides.39 The
biphenylalkyne 21 was synthesized from the methyl ester 23a
by Suzuki cross-coupling (Scheme 7).
The mesylalkoxy-substituted alkynes were prepared from 26a
by a Williamson ether synthesis to form the bromoalkylated
intermediate, which was subsequently mesylated by gentle
heating with sodium methanesulfinate in PEG-400 (Scheme 8).
Compounds were screened on the human FFA1 in a calcium
mobilization assay. Besides overall activity, ligand efficiency
(LE)40 and calculated lipophilicity (ClogP), as well as LLE27
calculated as the difference between pEC50 and ClogP, were
taken advantage of in the evaluation of analogues. Since the
Scheme 3a
aReagents and conditions: (a) trimethylsilylacetylene, Na2PdCl4,
PIntB, CuI, TMEDA, water, 80 °C (77%). (b) K2CO3, MeOH,
room temperature (95%). (c) Na2PdCl4, PIntB, CuI, 2-bromotoluene
or phenylacetylene, TMEDA, water, 80 °C (68−84%). (d) LiOH,
THF, water, room temperature (85−91%).
Scheme 4a
aReagents and conditions: (a) MeMgCl, copper(I) thiophenolate,
TMSCl, THF, −78 °C → 0 °C (47%). (b) Na2PdCl4, PIntB, CuI,
phenylacetylene, TMEDA, water, 80 °C (57%). (c) LiOH, THF,
water, room temperature (64%).
Scheme 5a
aReagents and conditions: (a) trimethylsilylacetylene, Na2PdCl4,
PIntB, CuI, TMEDA, water, 80 °C. (b) K2CO3, MeOH, room
temperature (97% over two steps). (c) Na2PdCl4, PIntB, CuI, aryl
halide, TMEDA (or TMEDA with 10% water for R = 2-CH2CN), 80
°C (36−49%). (d) LiOH, THF, water, room temperature (97−99%).
(e) Pd(PPh3)2Cl2, CuI, phenylacetylene, Et3N, DMF, 50 °C (53%).
Scheme 6a
aReagents and conditions: (a) triethyl phosphonoacetate, 60% NaH,
toluene, 0 °C→ reflux (45%). (b) Et3SiH, TFA, room temperature→
50 °C (58%). (c) Na2PdCl4, PIntB, CuI, phenylacetylene, TMEDA,
water, 80 °C (57%). (d) LiOH, THF, water, room temperature (91%).
Scheme 7a
aReagents and conditions: (a) PhB(OH)2, Pd(OAc)2, SPhos, K3PO4,
toluene, 100 °C (74%). (b) LiOH, THF, water, room temperature
(94%).
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ClogP calculation method was used extensively in the
optimization, a validation and comparison of alternative
methods using related compounds with experimental log D7.4
values was performed, and log D7.4 values from representative
new alkynes were subsequently added to strengthen the
validation. Of 11 methods, the ClogP method showed the
best correlation with experimental values (R2 = 0.96; see the
Supporting Information).
We have previously reported the discovery of the potent and
selective FFA1 agonist 3 (Chart 1) by screening of a focused
library of constrained fatty acid analogues and optimization of a
4-(phenylethynyl)phenoxyacetic acid hit.13 The optimization
study revealed the phenylpropanoic acid analogue 2 (Table 1)
to be clearly favored over the phenoxyacetic acid of the initial
hit and that introduction of methyl substituents at the terminal
phenyl showed the 2-position (3) was preferred over the 3-
position (4), while a 4-methyl (5) did not result in increased
potency relative to the unsubstituted 2.25 Shortening or
elongating the propionic acid chain by one methylene group
(6 and 7) resulted in significant decrease in potency. The
planar acrylic acid 8 showed a further order of magnitude
reduced potency, which to some degree was regained by
introduction of the 2-methyl on the terminal phenyl ring (9).
The introduction of a β-methyl group (10) did not affect
potency, but is disfavored relative to 2 as it results in lower LE
and higher lipophilicity and introduces a chiral center that
complicates synthesis. Constraining the propionic acid by
connecting the methyl group of 10 back to the benzene ring via
a methylene group to form a dihydroindane system (11,
Scheme 6), in analogy to the structures reported by Takeda,21
yielded reduced potency. In contrast, connecting the β-methyl
to the α-carbon to form a cyclopropyl constraint of the
propionic acid chain (12) results in a moderate gain of activity.
Unfortunately, the gain was not maintained with the
introduction of methyl substituents at the terminal benzene
ring (13−15).
Although methyl substituents in both 2- and 3-position
resulted in increased potency, the initial studies showed that the
2,3-dimethyl as well as the 3,5-dimethyl pattern gave a
compound with lower potency than the corresponding
monomethyl analogues.13 To complete this study, we
synthesized the 2,5-dimethyl (16), 2,6-dimethyl (17), and 4-
chloro-2-methyl (18) analogues, all of which exhibited reduced
activity relative to 3 (Table 2).
We found that 3 had only moderate stability toward human
liver microsomes (HLM, see below) and suspected that the 2-
Scheme 8a
aReagents and conditions: (a) Br(CH2)n+1Br, K2CO3, acetone, reflux (79−93%). (b) MeSO2Na, PEG-400, 45 °C (38−51%). (c) LiOH, THF, water,
room temperature (58−80%).
Table 1. SAR Exploration of the Propionic Acid Chain
compd R1 R2 FFA1, calcium pEC50 (% efficacy)
a LEb ClogPc log D7.4
d LLEe
2f A H 6.70 ± 0.03 (106) 0.48 4.54 2.16
3f A 2-Me 7.34 ± 0.07 (103) 0.50 5.04 2.44 ± 0.01 2.86
4f A 3-Me 7.13 ± 0.05 (97) 0.49 5.04 2.75
5f A 4-Me 6.55 ± 0.04 (109) 0.45 5.04 2.13 ± 0.02 2.17
6 B H 6.01 ± 0.03 (93) 0.46 4.05 1.96
7 C H 6.00 ± 0.02 (99) 0.41 4.92 1.08
8g D H 5.03 ± 0.08 (83) 0.36 4.88 0.15
9 D 2-Me 5.64 ± 0.04 (104) 0.39 5.38 0.26
10 E H 6.70 ± 0.03 (103) 0.46 4.94 1.76
11 (Scheme 6) 6.46 ± 0.04 (99) 0.42 5.05 1.42
12 F H 6.84 ± 0.04 (107) 0.47 4.59 2.25
13 F 2-Me 6.86 ± 0.02 (99) 0.45 5.09 1.78
14 F 3-Me 7.03 ± 0.02 (102) 0.46 5.09 1.95
15 F 4-Me 6.51 ± 0.04 (107) 0.42 5.09 1.43
aEfficacy is given as percent response relative to 10 μM TUG-20.18 bLigand efficiencies (LE) were calculated by LE = RT lnKD, presuming that EC50
≈ KD. Values are given in kcal mol−1 per non-hydrogen atom.40 cCalculated by BioByte’s algorithm as implemented in ChemBioDraw Ultra 12.0 (the
“ClogP” option). dDetermined by the shake flask method.25 eLigand lipophilicity efficiencies (LLE) were calculated by the formula LLE = pEC50 −
ClogP.27 fPreviously reported.13 gTested with 0.05% bovine serum albumin (BSA).
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methyl group might be implicated. A 4-fluoro substituent on
the terminal phenyl ring (19) to stabilize the terminal phenyl
ring toward oxidation came with a penalty in terms of lower
potency. Increasing the steric bulk of the 2-methyl group of 3
by replacement with ethyl (20) or phenyl (21) resulted in
reduced potency. These analogues also had increased lip-
ophilicity and were unlikely to improve the HLM stability.
Replacement of the 2-methyl by metabolically stable chloro
(22), bromo (23), or trifluoromethyl (24) substituents did not
preserve potency, while lipophilicity was increased in all cases.
It is well-known that lipophilicity generally correlates with
poor metabolic stability, a consequence of the increased
tendency of more lipophilic molecules to seek out of the
aqueous phase and into the active sites of the metabolic
enzymes. We have previously described our efforts to optimize
3 by replacing the terminal phenyl group with hydrophilic
heterocycles,19 and we recently described the effects of
introducing a polar substituent on an FFA1 agonist, resulting
in reduced lipophilicity and higher HLM stability together with
preserved potency.25 Although initial attempts to introduce
polar substituents on the terminal phenyl ring of 3 had resulted
in compounds with low or no activity,13 we decided to continue
the exploration of this strategy. Introduction of a hydroxyl
group in the 2-position (25) resulted in a 2 orders of
magnitude erosion of activity. A 3-hydroxy substituent (26)
gave a moderate reduction in potency relative to 2, but a higher
LLE. It is thus clear that the positioning of a polar group is
critical. A rationale for this was provided by the modeling study
below. Methoxy groups in the 2- and 3-positions (27, 28)
improved the situation significantly compared to the hydroxyls.
In the case of the 3-MeO analogue 28, the reduction in
lipophilicity compensated for the lower potency and gave the
compound an LLE of 2.69 based on ClogP, compared to 2.86
for 3. As methoxy substituents imply a risk of metabolic
instability, the more stable trifluoromethoxy group was
explored in the same positions (29, 30). The activities of 29
and 30 paralleled those of methoxy analogues 27 and 28, but
the increased lipophilicity and decreased LE and LLE made the
compounds less attractive. Continuing the screen for more
polar substituents, the 2-acetyl (31) turned out equipotent with
the unsubstituted 2, but significantly less potent than 3. Fishing
for hydrogen-bond interactions further away from the scaffold,
Table 2. Exploration of Substitution on the Terminal Phenyl Ring
compd R FFA1, calcium pEC50 (efficacy, %)
a LEb ClogPc log D7.4
d LLEe
16 2-Me, 5-Me 6.91 ± 0.06 (102) 0.45 5.54 1.37
17 2-Me, 6-Me 6.38 ± 0.04 (103) 0.42 5.54 0.84
18 2-Me, 4-Cl 6.86 ± 0.02 (103) 0.45 5.75 1.11
19 4-F 6.28 ± 0.05 (96) 0.43 4.68 1.60
20 2-Et 7.05 ± 0.03 (101) 0.46 5.57 1.48
21 2-Ph 6.00 ± 0.02 (91) 0.33 6.43 −0.43
22 2-Cl 6.82 ± 0.04 (107) 0.47 5.25 1.57
23 2-Br 7.08 ± 0.06 (99) 0.49 5.40 1.68
24 2-CF3 6.47 ± 0.02 (98) 0.39 5.42 1.05
25 2-OH 4.79 ± 0.07 (83) 0.33 3.87 0.92
26 3-OH 6.35 ± 0.04 (103) 0.43 3.87 2.48
27 2-OMe 6.66 ± 0.03 (99) 0.44 4.46 2.20
28 3-OMe 7.15 ± 0.03 (101) 0.47 4.46 2.69
29 2-OCF3 6.65 ± 0.03 (106) 0.38 5.57 2.66 ± 0.01 1.08
30f 3-OCF3 7.02 ± 0.04 (103) 0.40 5.57 2.83 ± 0.01 1.45
31 2-COMe 6.73 ± 0.04 (101) 0.42 3.98 2.75
32 2-CH2OH 6.24 ± 0.02 (111) 0.41 3.50 2.74
33 2-C2H4OH 5.69 ± 0.02 (106) 0.35 3.73 1.96
34 2-CH2OMe 7.39 ± 0.03 (108) 0.46 4.34 1.29 ± 0.00 3.05
35 3-CH2OMe 7.42 ± 0.04 (99) 0.46 4.34 1.43 ± 0.01 3.08
36 3-O(CH2)3Ms 6.09 ± 0.03 (100) 0.31 3.55 2.55
37 3-O(CH2)4Ms 6.37 ± 0.03 (106) 0.31 3.33 0.88 ± 0.01 3.04
38 2-CN, 5-Me 6.33 ± 0.02 (103) 0.39 4.47 1.86
39 2-Me, 5-CN 7.40 ± 0.03 (105) 0.45 4.47 1.75 ± 0.01 2.93
40 2-CH2CN 7.70 ± 0.04 (103) 0.48 3.96 1.28 ± 0.01 3.76
41 3-CH2CN 6.72 ± 0.04 (98) 0.42 3.96 0.98 ± 0.01 2.76
42 2-OCH2CN 7.33 ± 0.03 (105) 0.44 3.45 3.89
43 3-OCH2CN 6.58 ± 0.03 (105) 0.39 3.45 3.14
44 (Scheme 5) 7.45 ± 0.03 (99) 0.45 4.01 3.44
aEfficacy is given as percent response relative to 10 μM TUG-20.18 bLigand efficiencies (LE) were calculated by LE = RT lnKD, presuming that EC50
≈ KD. Values are given in kcal mol−1 per non-hydrogen atom.40 cCalculated by ChemBioDraw Ultra 12.0 with the “ClogP” option. dDetermined by
the shake flask method.25 eCalculated by the formula LLE = pEC50 − ClogP.
27 fTested with 0.05% BSA.
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the 2-hydroxymethyl (32) and 2-hydroxyethyl (33) analogues
were investigated, but these did not display sufficient potency.
The methoxymethyl substituent in the 2- or 3-position (34,
35), however, brought the activity up to the same level as 3
while lower lipophilicity was maintained, thus increasing LLE.
Mesylalkoxy substituents, successfully applied on another
compound series,25 were investigated with various chain lengths
(36, 37). The 3-mesylbutoxy substituent (37) resulted in a
Figure 1. Complex of 3 (left) and 40 (right) with a homology model of the human FFA1. Residues situated close to the ligands are labeled with
sequence number, and Schwartz−Baldwin41 and Ballesteros−Weinstein42 notations are given as superscripts.
Figure 2. Activity of 40 on FFA1-transfected HEK-293 cells and in the rat β-cell line INS-1E that endogenously expresses FFA1. (A) Representative
traces from the dynamic mass redistribution (DMR) assay of 40 on HEK-FFA1 cells. (B) Concentration−response curves of 40 in FFA1-HEK cells
from the DMR assay (pEC50 = 7.4 ± 0.05, n = 3). (C) Traces from the DMR assay of 40 in INS-1E cells. (D) Concentration−response curve of 40
in INS-1E cells (pEC50 = 5.6 ± 0.16, n = 5) and inhibition of 40 (3 μM) by the FFA1 antagonist PPTQ (pIC50 = 5.3 ± 0.13, n = 3).
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small decrease in activity relative to 2 but more than an order of
magnitude reduced lipophilicity, and thereby a significantly
increased LLE relative to both 2 and 3. The concept of
introducing mesylalkoxy substituents to lower lipophilicity
while potency was maintained thus seems to work well,
although the potencies of these analogues were too low to place
them among the preferred compounds.
The introduction of a polar cyano substituent on the
terminal ring together with a methyl group (38, 39) resulted in
39 being equipotent with 3 with somewhat reduced lip-
ophilicity. Gratifyingly, combining the cyano and the methyl
into a 2-cyanomethyl substituent (40) produced a significant
increase in potency and a pronounced reduction in lipophilicity
relative to 3. The 3-cyanomethyl analogue (41) turned out an
order of magnitude less potent. Thus, the substituent position
is important, as for the hydroxyl analogues 25 and 26, but the
favored position is reversed. Extending the substituent to
cyanomethoxy (42, 43) led to reduced potency to the same
degree in both the 2- and 3-postion together with further
reduced lipophilicity. The preference for the 2-position is thus
in agreement with the methyl (3, 4) and cyanomethyl (40, 41)
analogues, but reversed in comparison to the other analogues
where oxygen is attached directly to the phenyl ring (25−29).
A combination of 2-cyanomethyl with the cyclopropyl
constraint of the propionic acid chain (44) resulted in a drop
in potency, as for the methyl substituents. Altogether, 40
remained the preferred compound, despite the slightly higher
LLE of 42.
A molecular modeling study was performed to explore the
basis for the interesting effects observed with the different
substituent positions. The complex of 3 and 40 with a
homology model of hFFA1 was generated as described
previously.19 The carboxylic acid of the compounds interacts
with the two arginine residues Arg183 and Arg258 and the
diphenylacetylene part extends toward TM2 (Figure 1). The
benzene rings are twisted with almost 90° between them, as
also observed in the crystal structure of 3,13 which favors
interaction between the central ring and Phe87 and places the
methyl group in a small hydrophobic cavity created by Leu262.
This hydrophobic cavity provides a rationale for the preference
of the 2-methyl substituent (3) over the 3-methyl (4) and the
unsubstituted compound (2), and for the highly disfavored
interaction with the 2-hydroxy-substituted 25 compared to the
3-hydroxy analogue 26. Likewise, the lower potency of the 2-
cyano-5-methyl-substituted 38 compared to the 5-cyano-2-
methyl-substituted 39 can be rationalized by the disfavored
polar ortho-substituent. The 2-cyanomethyl moiety of 40 fit
well into the hydrophobic cavity and, in addition, provides a
hydrogen bond acceptor that is perfectly situated to form a
hydrogen bond interaction with Lys259 (distance ∼ 2.0 Å) with
Lys62 as an alternative interaction point, thus providing a
rationale for the high potency of this compound.
The 2-cyanomethyl analogue 40 was the most potent agonist
by good margin and also had lower lipophilicity and was thus
chosen for further examination. The compound was evaluated
using a dynamic mass redistribution (DMR) assay, which
monitors real-time protein activity in the living cell without the
need of labeling.43 Potent activity in HEK293 cells transfected
with hFFA1 was confirmed [Figures 2 and S1 (Supporting
Information)]. Further testing of 40 with the insulin-secreting
rat β-cell line INS-1E endogenously expressing FFA1 showed a
concentration-dependent effect that was confirmed to be FFA1-
mediated by treatment with the FFA1 antagonist trans-1-oxo-3-
(4-phenoxyphenyl)-2-propyl-1,2,3,4-tetrahydroisoquinoline-4-
carboxylic acid (PPTQ).44
Counterscreens demonstrated >100-fold selectivity for FFA1
over FFA2 (GPR43, pEC50 < 5), FFA3 (GPR41, pEC50 < 5),
GPR120 (pEC50 = 5.32 ± 0.03), PPARγ (pEC50 < 5), and 55
other receptors, enzymes, and transporters (see the Supporting
Information). Physicochemical and in vitro ADME properties
of 40 were obtained for a full comparison with the lead
compound 3 (Table 3). Both 3 and 40 have good solubility and
demonstrated excellent chemical stability. The experimental
lipophilicity of 40 as measured by log D7.4 was reduced by an
order of magnitude relative to 3. Stability toward HLM was
drastically improved, supporting that the 2-methyl group was
involved in the insufficient stability observed with 3 and
demonstrating that reduction of lipophilicity is an efficient
means for mending unsatisfactory metabolic stability. No
significant cell toxicity or inhibition of the most important
CYP enzymes or P-glycoprotein (P-gp) was found. Both
compounds exhibited high permeability in Caco-2 cells. The
permeability of 40 was also examined on the mucus-secreting
cell-line HT29-MTX,45 an improved model system for the
intestinal epithelium, and was found to be significantly higher
[Papp = (2.54 ± 0.07) × 10
−5 cm/s, 78% recovered] than the
readily absorbed drug ketoprofen [Papp = (1.51 ± 0.05) × 10
−5
cm/s, 80% recovered].
Pharmacokinetic investigations of 3 and 40 in mice revealed
rapid and complete absorption of both compounds after oral
dosing (Table 4). The half-life in mice is as expected rather
short, but 40 showed a somewhat longer half-life than 3. The
exposure of 40 after oral dosing was 3.5-fold higher than for 3.
The relatively low volume of distribution for 40 can be
rationalized by the high plasma protein binding and contributes
to 40 having a half-life only moderately longer than 3 despite
higher metabolic stability. A low clearance was confirmed with
40 compared to a quite high clearance for 3, corresponding to
approximately 15% and 60% of the hepatic blood flow in mice,
respectively. Both compounds were well-tolerated by the mice
in acute exposures up to 250 mg/kg po. A satisfactory overall
pharmacokinetic profile was found for 40.
The effects of 3 and 40 on glucose tolerance in normal mice
after oral administration 30 min prior to glucose challenge were
Table 3. Physicochemical and in Vitro ADME Properties of
3 and 40
assay 3 40
aqueous solubility (PBS, pH 7.4)a 174 μM 188 μM
chemical stab. (PBS, 37 °C, 12 days) 99.9% 99.8%
log D (n-octanol/PBS, pH 7.4)b 2.44 (2.34) 1.28 (1.32)
plasma protein binding (human)c 97.7% >99.9%
metabolic stability (HLM)a 26% 81%
CYP inhibition (10 μM)a
CYP1A2 −8% −3%
CYP2C9 −25% 11%
CYP2C19 −1% −2%
CYP2D6 0% 5%
CYP3A4 −4% 8%
P-gp inhibition (% @ 30/100 μM)a 6.6/23.3 −4.0/−1.8
Caco-2 (A to B, TC7, pH 6.5/7.4)a 87 × 10−6 cm/s 91 × 10−6 cm/s
aDetermined at Cerep Inc. bDetermined by the shake-flask method.25
The values given in parentheses were determined at Cerep Inc.
cDetermined by equilibrium dialysis at Cerep Inc.
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studied. 3 showed a significant improvement in glucose
tolerance at a 50 mg/kg dose (Figure 3), similar to the effect
of the oral antihyperglycemic DPP-4 inhibitor sitagliptin (10
mg/kg), a compound on the market for treatment of T2D. 40
exhibited a dose-dependent response with a significant effect
similar to that of sitagliptin at 10 mg/kg and a maximal effect
reached at 50 mg/kg, sustained at 250 mg/kg (Figure 3).
Compound 40 is confirmed to be a full agonist also of the
murine FFA1, but with an order of magnitude lower potency
(pEC50 = 6.40 on mFFA1) than on the human orthologue. The
considerable difference in efficacy and to some degree potency
between the two compounds in the glucose tolerance test can
thus be ascribed mainly to the improved pharmacokinetic
properties of 40.
■ CONCLUSION
In the continued SAR exploration of the alkyne series of FFA1
agonists represented by 3, we focused especially on lowering
the lipophilicity of the compounds. Introduction of polar
substituents on the terminal phenyl ring led to the discovery of
40, a compound with significantly improved potency and
reduced lipophilicity relative to 3 (EC50 = 20 vs 46 nM, log D7.4
1.3 vs 2.4). Compound 40 exhibited high selectivity over a
panel of enzymes, receptors, and transporters, and in vitro
ADME-tox studies indicated high absorption, good metabolic
stability, and no inhibition of enzymes implicated in drug−drug
interactions. Pharmacokinetic evaluation in mice indicated
complete bioavailability and >3-fold higher exposure of 40
compared to 3. The effect of 40 in a glucose tolerance test in
mice indicated an effect comparable to sitagliptin at 10 mg/kg
after oral administration and maximal effect reached at 50 mg/
kg. Altogether, 40 appears as a promising candidate for more
advanced animal studies and further development of improved
therapeutics for T2D.
■ EXPERIMENTAL SECTION
All commercial starting materials and solvents were used without
further purification, unless otherwise stated. THF was freshly distilled
from sodium/benzophenone. Purification by flash chromatography
was carried out using silica gel 60 (0.040−0.063 mm, Merck). TLC
analysis was performed on silica gel 60 F254 plates.
1H and 13C NMR
spectra were calibrated relative to TMS internal standard or residual
solvent peak. High-resolution mass spectra (HRMS) were obtained on
Thermo Finnigan TSQ 700 using electrospray ionization (ESI) or
Table 4. Pharmacokinetic Profiles of 3 and 40 in Micea
3 40
Intravenous
Cmax (ng/mL) 2284 5071
tmax (min) 5 5
t1/2 (min) 10 17
AUC0‑∞ (μg/mL·min) 47 174
Vd (L/kg) 0.80 0.35
CLtotal (mL/min/kg) 53 14
Oral
Cmax (ng/mL) 2591 7757
tmax (min) 30 30
t1/2 (min) 48 50
AUC0‑∞ (μg/mL·min) 205 732
F (%) 109 105
aData are mean concentrations in mouse plasma (n = 3) following a
single 2.5 mg/kg intravenous dose or 10 mg/kg oral dose.
Figure 3. Effect of 3 and 40 on glucose tolerance in normal mice. Male C57Bl/6 mice were dosed po with test compound, vehicle, or positive
control (sitagliptin, 10 mg/kg) 30 min prior to a 2 g/kg glucose challenge. Top panels show plasma glucose concentration curves as a function of
time, and bottom panels show areas under the curves. Means ± standard errors (n = 6) are shown (*, p < 0.05; **, p < 0.01).
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Bruker micrOTOF-Q II (ESI). Purity was determined by HPLC and
confirmed by inspection of NMR spectra. HPLC analysis was
performed using a Dionex 120 C18 column (5 μm, 4.6 × 150 mm)
with 10% acetonitrile in water (0−1 min), 10−100% acetonitrile in
water (1−10 min), 100% acetonitrile (11−15 min), with both solvents
containing 0.05% TFA as modifier; a flow of 1 mL/min; and UV
detection at 230 and 254 nm. All test compounds were of ≥95% purity
unless otherwise stated.
General Procedure I: Sonogashira Coupling. A Schlenk flask
charged with Na2PdCl4 (1 mol %), 2-(di-tert-butylphosphino)-N-
phenylindole (PIntB, 2 mol %), CuI (2 mol %), alkyne (1 equiv), aryl
halide (1.1−1.5 equiv), H2O (0.2 mL/mmol), and TMEDA (1.8 mL/
mmol) was evacuated and back-filled with argon three times and then
heated to 80 °C. After consumption of the alkyne, the reaction was
cooled to room temperature, water was added, and the mixture was
extracted with EtOAc (×3). The organic phases were combined,
washed with brine, dried over MgSO4, and concentrated under
vacuum. The residue was purified by flash chromatography and dried
under vacuum to give the desired product.
General Procedure II: Ester Hydrolysis. A solution of
LiOH·H2O (2−3 equiv) in H2O (∼2 mL/mmol ester) was added
to the ester dissolved in THF (∼5 mL/mmol ester). The reaction was
stirred at room temperature until complete consumption of the
starting material as indicated by TLC, typically after 1−12 h. The
reaction had water added, was acidified with 3% HCl until pH <1, and
was extracted with EtOAc (×3). The combined extracts were washed
with brine, dried over MgSO4, and concentrated under vacuum.
3-(4-((3-(Methoxymethyl)phenyl)ethynyl)phenyl)propanoic Acid
(35). Step 1. 35a was prepared from 134 (93 mg, 0.49 mmol) and
1-bromo-3-(methoxymethyl)benzene (99 mg, 0.49 mmol) according
to the general procedure I to give 96 mg (64%) of a clear oily product
after purification by flash chromatography (SiO2, EtOAc:petroleum
ether, 1:10): Rf = 0.22 (EtOAc:petroleum ether, 1:4);
1H NMR
(CDCl3) δ 7.51 (s, 1H), 7.47−7.42 (m, 3H), 7.36−7.27 (m, 2H),
7.21−7.16 (m, 2H), 4.45 (s, 2H), 3.67 (s, 3H), 3.40 (s, 3H), 2.96 (t, J
= 7.7 Hz, 2H), 2.64 (t, J = 7.8 Hz, 2H); 13C NMR (CDCl3) δ 173.1,
140.9, 138.5, 131.8, 130.8, 128.44, 128.36, 127.5, 123.5, 121.2, 89.4,
89.0, 74.2, 58.2, 51.7, 35.4, 30.8.
Step 2. 35 was prepared from 35a (76 mg, 0.25 mmol) according to
the general procedure II to give 61 mg (84%) of a white solid (tR =
11.96, purity 98.7% by HPLC); 1H NMR (acetone-d6) δ 7.55−7.43
(m, 4H), 7.42−7.29 (m, 4H), 4.46 (s, 2H), 3.36 (s, 3H), 2.95 (t, J =
7.6 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H); 13C NMR (acetone-d6) δ 173.8,
142.9, 140.3, 132.4, 131.19, 131.15, 129.6, 129.4, 128.3, 124.1, 121.7,
90.0, 89.6, 74.3, 58.2, 35.5, 31.4; ESI-HRMS calcd for C19H18O3Na (M
+ Na+) 317.1148, found 317.1159.
3-(4-((5-Cyano-2-methylphenyl)ethynyl)phenyl)propanoic Acid
(39). Step 1. 39a was prepared from 134 (98 mg, 0.52 mmol) and
3-iodo-4-methylbenzonitrile (136 mg, 0.56 mmol) according to the
general procedure I to give 104 mg (68%) of a clear oily product after
purification by flash chromatography (SiO2, EtOAc:petroleum ether,
1:10): Rf = 0.20 (EtOAc:petroleum ether, 1:5);
1H NMR (CDCl3) δ
7.75 (d, J = 1.7 Hz, 1H), 7.49 (d, J = 1.7 Hz, 1H), 7.48−7.44 (m, 2H),
7.33 (d, J = 8.0 Hz, 1H), 7.24−7.18 (m, 2H), 3.68 (s, 3H), 2.98 (t, J =
7.7 Hz, 2H), 2.65 (t, J = 7.7 Hz, 2H), 2.56 (s, 3H); 13C NMR (CDCl3)
δ 173.0, 145.5, 141.7, 135.1, 131.8, 131.2, 130.3, 128.5, 124.8, 120.5,
118.4, 110.0, 95.6, 85.7, 51.7, 35.3, 30.9, 21.2; ESI-MS m/z 326.1 (M +
Na+).
Step 2. 39 was prepared from 39a (91 mg, 0.30 mmol) according to
the general procedure II to give 83 mg (96%) of a white solid (tR =
12.08, purity: 99% by HPLC); 1H NMR (CDCl3) δ 11.20 (s, 1H),
7.75 (d, J = 1.7 Hz, 1H), 7.52−7.44 (m, 3H), 7.33 (d, J = 8.0 Hz, 1H),
7.23 (d, J = 8.3 Hz, 2H), 2.99 (t, J = 7.6 Hz, 2H), 2.71 (t, J = 7.7 Hz,
2H), 2.56 (s, 3H); 13C NMR (CDCl3) δ 178.3, 145.5, 141.3, 135.1,
131.9, 131.2, 130.4, 128.5, 124.8, 120.6, 118.4, 110.0, 95.5, 85.8, 35.2,
30.5, 21.2; ESI-HRMS calcd for C19H15NO2Na (M + Na
+) 312.0996,
found 312.0983.
3-(4-((2-(Cyanomethyl)phenyl)ethynyl)phenyl)propanoic Acid
(40). Step 1. 40a was prepared from 134 (250 mg, 1.33 mmol) and
2-(2-iodophenyl)acetonitrile (354 mg, 1.45 mmol) according to the
general procedure I to give 312 mg (77%) of a white solid after
purification by flash chromatography (SiO2, EtOAc:petroleum ether,
1:4): Rf = 0.08 (EtOAc:petroleum ether, 1:4);
1H NMR (CDCl3) δ
7.55−7.46 (m, 4H), 7.37−7.34 (m, 2H), 7.21 (d, J = 8.4 Hz, 2H), 3.96
(s, 2H), 3.67 (s, 3H), 2.97 (t, J = 7.7 Hz, 2H), 2.64 (t, J = 7.5 Hz, 2H);
13C NMR (CDCl3) δ 173.0, 141.6, 132.3, 131.7, 131.6, 128.9, 128.5,
128.1, 122.9, 120.4, 117.4, 95.6, 85.7, 51.7, 35.3, 30.8, 22.7; ESI-MS m/
z 326.1 (M + Na+).
Step 2. 40 was prepared from 40a (292 mg, 0.96 mmol) according
to the general procedure II to give 216 mg (77%) of a white solid (tR =
11.44, purity: 99.9% by HPLC) after purification by flash
chromatography [SiO2, EtOAc (with 1% AcOH):petroleum ether,
1:2]; 1H NMR (DMSO-d6) δ 11.87 (br s, OH), 7.31−7.21 (m, 4H),
7.16−7.12 (m, 2H), 7.03−7.00 (m, 2H), 3.87 (s, 2H), 2.57 (t, J = 7.5
Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H); 13C NMR (DMSO-d6) δ 173.6,
142.3, 132.8, 132.0, 131.4, 129.3, 128.9, 128.7, 128.3, 122.2, 119.6,
118.4, 95.3, 85.9, 34.8, 30.3, 22.1; ESI-HRMS calcd for C19H15NO2Na
(M + Na+) 312.0996, found 312.1002.
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ABSTRACT: Free fatty acid receptor 1 (FFA1 or GPR40) enhances
glucose-stimulated insulin secretion from pancreatic β-cells and currently
attracts high interest as a new target for the treatment of type 2 diabetes.
We here report the discovery of a highly potent FFA1 agonist with
favorable physicochemical and pharmacokinetic properties. The com-
pound efficiently normalizes glucose tolerance in diet-induced obese mice,
an effect that is fully sustained after 29 days of chronic dosing.
KEYWORDS: Type 2 diabetes, free fatty acid receptor, TUG-770, insulin secretagogue, FFA1 agonist, GPR40 agonist
The free fatty acid receptor 1 (FFA1, previously known asGPR40) has, since its deorphanization in 2003, received
considerable attention as a new potential target for treatment
of type 2 diabetes (T2D).1−3 Activation of FFA1 increases
glucose-stimulated insulin secretion but does not affect insulin
secretion at low glucose levels, providing a potentially safe and
efficient strategy for enhancing insulin levels in patients
suffering from T2D. Accordingly, the interest in FFA1 as a
new drug target has been high, and several potent agonists for
the receptor have been disclosed.4−6 Of these, TAK-875 is most
advanced with highly encouraging results from phase II clinical
trials.7 Being a fatty acid receptor, FFA1 has a natural
preference for relatively lipophilic compounds. This property
has been reflected in the majority of the reported synthetic
agonists, which mostly have been at the high end of the
generally recommended lipophilicity range. We have previously
reported a series of alkyne FFA1 agonists8 and have
subsequently directed our efforts toward lowering the lip-
ophilicity of these compounds.9,10 Herein, we report the further
optimization of this compound series, leading to a highly potent
FFA1 agonist with excellent physicochemical and pharmacoki-
netic properties and sustained glucose lowering capability in
diet-induced obese (DIO) mice after acute and chronic dosing.
The alkyne ligands with either pyridine or fluoro-substituted
benzene as the central ring were synthesized from the
corresponding 4-bromoaldehydes (Scheme 1). Initially, a
Wittig reaction with the phosphonium ylide, formed in situ
from ethyl bromoacetate and triphenylphosphine, provided the
corresponding cinnamic esters. The double bond was reduced
by NaBH4 in the presence of catalytic CoCl2.
11 Subsequently,
Sonogashira coupling with phenylacetylene followed by a base
promoted hydrolysis provided the alkyne ligands.12
The 2-fluoro substituted ligands were synthesized from the
central intermediate 2, prepared from aryl bromide 1 by an initial
Sonogashira coupling with trimethylsilylacetylene and subsequent
removal of the TMS-group (Scheme 2). A second Sonogashira
coupling of 2 with various aryl halides followed by ester hydrolysis
gave the alkyne ligands in moderate to high yields.
We set out to investigate modifications in the central ring of
the alkyne ligands (Table 1). Compounds were tested on the
human FFA1 in a calcium mobilization assay and coun-
terscreened on the human FFA4 (previously GPR120)13
because of the selectivity issues frequently observed for these
receptors.14 The central benzene ring was replaced by pyridine
due to its marked lipophilicity lowering effect. The 2-pyridyl
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(4) and 3-pyridyl (5) analogues turned out to be twice as
potent as previously reported ligands with pyridines as the
terminal ring9 but, nevertheless, resulted in >20-fold decrease in
potency compared to 3. Aromatic fluoro-substituents often
result in higher metabolic stability and have been applied with
success in the corresponding ring of other compound
series.15,16 Thus, we selected three mono- and difluoro-
substituted analogues for synthesis and testing. The 3-fluoro
analogue (6) showed maintained potency and only a small
increase in ClogP compared to 3. The 2-fluoro analogue (7)
resulted in a 5-fold increased potency and the highest ligand
efficiency (LE)17 and ligand lipophilicity efficiency (LLE)18
values and, moreover, the highest selectivity over FFA4 (>200-
fold). Introduction of a second ortho-fluoro substituent (8) led
to a reduction of potency back to the level of 6 and 3.
With 7 showing high potency and LE, we decided to focus
on the 2-fluoro scaffold in the exploration of the terminal ring
in analogy with our previous studies (Table 2). Introduction of
a corresponding 2-fluoro substituent in the lead structure
TUG-424 (9) to give 10 resulted in increased potency but
less so than for the terminally unsubstituted pair 3 and 7
(ΔpEC50 = 0.14 vs 0.78). Moving the methyl of the terminal
ring to the meta-position (11) gave a further increase in
potency. The order of potency is thus reversed relative to the
analogues lacking the 2-fluoro substituent,8 implying that
previous SAR information is not directly transferrable to the
2-fluoro series.
Introduction of a cyano-substituent on 10 to give the
2-methyl-5-cyano analogue (12) resulted in reduced ClogP
together with doubled potency and increased selectivity over
FFA4. The difluoromethyl analogue (13) was found to be more
potent than 10 but only equipotent with 12, despite its higher
lipophilicity. The 3,5-dichloro analogue (14) was synthesized to
mimic the previously published chloro-substituted pyridine
alkyne TUG-4999 but turned out only equipotent with TUG-
499, despite its high lipophilicity.
Extension of the ortho- and meta-methyl with the hydrophilic
mesyl group was explored (15 and 16) and resulted in
significantly reduced ClogP values and improved LLE but
unfortunately also markedly reduced potency. Methoxymethyl
substituents on the terminal ring have previously shown good
potency and significantly reduced lipophilicity in the alkyne
series.10 When adding larger substituents on the terminal
ring of the alkyne ligands, the meta-substituted compounds
(18 and 20) were found to be favored over the ortho analogues
(17 and 19). Although all four analogues exhibited high
selectivity over FFA4, the potency was found to be rather low
(EC50 = 0.3−0.7 μM).
We then directed our attention to the cyanomethyl alkyne
TUG-488 (21).10 The corresponding 2-fluoro analogue 22
(TUG-770) showed a pronounced increase in potency on
FFA1 (ΔpEC50 = 0.51) with EC50 = 6 nM and 150-fold selec-
tivity over FFA4. Moving the cyanomethyl to the meta-position
(23), which had been beneficial for the methyl analogue (11),
led to 12-fold erosion of potency. Finally, homologation to the
Scheme 1a
aReagents and conditions: (a) ethyl bromoacetate, PPh3, NaHCO3,
water, EtOAc, room temp, 18 h, 87−96%; (b) CoCl2·6H2O, NaBH4,
MeOH, 0 °C→ room temp, 3 h, 59−87%; (c) PhCCH, Na2PdCl4, 2-
(di-tert-butylphosphino)-1-phenylindole (PIntB), CuI, TMEDA,
water, 70 → 80 °C, 0.5−4.5 h, 56−86%; (d) LiOH, THF, water,
room temp, 12 h, 79−97%.
Scheme 2a
aReagents and conditions: (a) trimethylsilylacetylene, Na2PdCl4,
PIntB, CuI, TMEDA, water, 70 → 80 °C, 10 min; (b) K2CO3,
MeOH, room temp, 2 h, 74% over two steps; (c) aryl halide,
Na2PdCl4, PIntB, CuI, TMEDA, water, 80 °C, 1−4 h, 52−70%; (d)
LiOH, THF, water, room temp, 12 h, 69−100%.
Table 1. SAR Investigations of the Central Ring
aEfficacy is given as % response relative to 10 μM TUG-20.19 bEfficacy
is given as % response relative to 9; n.a. = no activity (pEC50 < 4).
14
cCalculated by BioByte’s algorithm as implemented in ChemBioDraw
Ultra 12.0 (ClogP option). dLE = RTln KD, presuming that EC50 ≈
KD. Values are given in kcal mol
−1 per non-hydrogen atom.17 LLE =
pEC50 − ClogP.18
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corresponding cyanoethyl (24) resulted in good potency but
the compound could not compete with 22.
With 22 being the clearly superior agonist in terms of
potency and LLE, as well as displaying significantly higher
potency (EC50 = 6 vs 14 nM), lower lipophilicity (log D7.4 =
1.41 vs 2.24) and higher ligand efficiency (LE = 0.49 vs 0.29)
compared to the most advanced compound in the field TAK-
875,20 we set out to evaluate the compound further using our
previously preferred compound 21 as reference (Table 3).
Compound 22 displayed excellent physicochemical and in vitro
ADME properties, with good aqueous solubility, good chemical
stability, low lipophilicity, and decreased plasma protein
binding (PPB). In support of the lower PPB, 21 showed
significantly decreased activity on hFFA1 in a BRET assay in
the presence of 0.1% BSA (from 7.16 ± 0.09 to 6.62 ± 0.05, p =
0.0024), whereas the corresponding reduction of activity for 22
was insignificant (from 7.64 ± 0.09 to 7.58 ± 0.06, p = 0.5635).
Compound 22 furthermore showed excellent stability toward
human liver microsomes (HLM), no inhibition of selected
CYP-enzymes implicated in drug−drug interactions, no
P-glycoprotein (P-gp) inhibition, and good permeability in
the Caco-2 cell assay. Pharmacokinetic studies in mice showed
a fast oral absorption, higher plasma concentration, a longer
half-life, lower clearance, and increased bioavailability, overall
giving a markedly improved pharmacokinetic profile compared
to 21. No cytotoxicity was observed in vitro in up to 100 μM
concentration (see the Supporting Information), and no adverse
effects were seen in mice after four weeks of daily oral treatment
of 20 mg/kg and acute treatment in doses up to 250 mg/kg.
In addition to the counterscreen on FFA4, 22 showed a high
selectivity over FFA2, FFA3, PPARγ, and 54 diverse receptors,
transporters, and enzymes (see the Supporting Information).
The compound exhibited lower potency on the rodent orthologs
(mFFA1, pEC50 = 6.83 ± 0.07 (n = 3); rFFA1, pEC50 = 6.49 ±
0.05 (n = 2)). The effect of 22 was initially evaluated in vitro in
Table 2. Structure−Activity Investigations of the 2-Fluoro Alkyne Agonists
pEC50 (efficacy, %)
compd R1 X hFFA1, calciuma hFFA4, BRETb ClogPc LEd LLEe
9 2-Me H 7.34 ± 0.07 (103) 5.84 ± 0.01 (103) 5.04 0.50 2.30
10 2-Me F 7.48 ± 0.03 (107) 5.80 ± 0.03 (98) 5.18 0.49 2.30
11 3-Me F 7.65 ± 0.03 (100) 5.41 ± 0.07 (124) 5.18 0.50 2.47
12 2-Me, 5-CN F 7.77 ± 0.03 (104) 5.02 ± 0.04 (123) 4.62 0.46 3.15
13 2-CF2H, 5-F F 7.74 ± 0.04 (97) 5.93 ± 0.04 (117) 5.02 0.44 2.72
14 3,5-Cl F 7.42 ± 0.07 (99) 5.50 ± 0.25 (90) 6.11 0.46 1.31
15 2-CH2Ms F 5.84 ± 0.02 (97) n.a. 2.67 0.33 3.17
16 3-CH2Ms F 5.71 ± 0.02 (104) 4.19 ± 0.06 (26) 2.67 0.33 3.04
17 2-CH2O(CH2)2Ms F 6.21 ± 0.03 (94) n.a. 3.33 0.31 2.88
18 3-CH2O(CH2)2Ms F 6.44 ± 0.03 (93) n.a. 3.33 0.33 3.11
19 2-CH2O(CH2)3Ms F 6.14 ± 0.04 (92) n.a. 3.59 0.30 2.55
20 3-CH2O(CH2)3Ms F 6.43 ± 0.04 (83) n.a. 3.59 0.31 2.84
21 2-CH2CN H 7.70 ± 0.04 (103) 6.11 ± 0.06 (99) 3.96 0.48 3.76
22 2-CH2CN F 8.21 ± 0.03 (102) 6.03 ± 0.06 (98) 4.11 0.49 4.10
23 3-CH2CN F 7.13 ± 0.03 (104) 5.41 ± 0.07 (115) 4.11 0.42 3.02
24 2-CH2CH2CN F 7.74 ± 0.04 (97) 5.86 ± 0.00 (114) 4.25 0.44 3.50
aEfficacy is given as % response relative to 10 μM TUG-20.19 bEfficacy is given as % response relative to 9; n.a. = no activity (pEC50 < 4).
14
cCalculated by BioByte’s algorithm as implemented in ChemBioDraw Ultra 12.0 (ClogP option). dLE = RTln KD, presuming that EC50 ≈ KD. Values
are given in kcal mol−1 per non-hydrogen atom.17 eLLE = pEC50 − ClogP.
18
Table 3. Physicochemical Properties, in Vitro ADME, and
Pharmacokinetics of 21 and 22
physicochemical properties 21 22
aqueous solubility (PBS, pH 7.4)a 196 μM 197 μM
chemical stab. (PBS, 37 °C, 12 days) 99.8% 99.1%
log D (n-octanol/PBS, pH 7.4)b 1.28 (1.32) 1.35 (1.44)
in vitro ADME propertiesc
PPB (human) >99.9% 97.3%
metabolic stability (HLM) 81% 87%
CYP inhibition (10 μM)
CYP1A2 −3% −10%
CYP2C9 11% −33%
CYP2C19 −2% −5%
CYP2D6 5% −1%
CYP3A4 8% −1%
P-gp inhibition (% @ 30/100 μM) −4.0/−1.8 −4.4/−3.6
Caco-2 (A to B, TC7, pH 6.5/7.4) 91 × 10−6 cm/s 72 × 10−6 cm/s
pharmacokinetic propertiesd 21 22
Intravenous
Cmax (ng/mL) 5071 7811
tmax (min) 5 5
t1/2 (min) 17 119
AUC0‑∞ (μg/mL·min) 174 809
Vd (L/kg) 0.35 0.53
CLtotal (mL/min/kg) 14 3.1
Oral
Cmax(ng/mL) 7757 12340
tmax (min) 30 15
t1/2 (min) 50 355
AUC0‑∞ (μg/mL·min) 732 4388
F (%) 105 136
aThe maximum concentration of the assay is 200 μM. bDetermined by
shake-flask method.16 The values given in parentheses were
determined at Cerep Inc. cDetermined at Cerep Inc. dData are
mean concentrations in mouse plasma (n = 3) following a single
2.5 mg/kg intravenous dose or 10 mg/kg oral dose.
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the rat INS-1E cell line, performed as previously reported,9
where the compound caused significantly increased insulin
secretion (10.75 ± 0.74% of total content with 10 μM 22 vs
8.74 ± 0.54 with vehicle, p < 0.05) at high glucose concen-
tration (12.4 mM) and, as expected, no effect (4.14 ± 0.15% of
total content with 10 μM 22 vs 4.02 ± 0.08 with vehicle) at low
glucose concentration (2.8 mM).
In vivo examination of 22 in an acute intraperitoneal glucose
tolerance test (IPGTT) in normal mice revealed a good dose
dependent response with maximal reduction in glucose level
reached at 50 mg/kg (Figure 1). The study was followed up by
a chronic oral glucose tolerance test (OGTT) study in DIO
mice, which showed that 22 was more effective than 21 (see the
Supporting Information) and that the effect of 22 was fully
sustained after 29 days of daily oral treatment. Additional
evaluation of 22 in rats confirmed a significant glucose lowering
effect for the high doses already after 10 min and for all doses
after 30 min (Figure 2). This was in agreement with an
observed increase in plasma insulin concentration, with
maximum concentration 15 min after glucose challenge. With
an approximately 30-fold higher potency on human than on
rodent receptors, it appears reasonable to expect that the
effective dose would be correspondingly lower in humans.
In conclusion, optimization of the FFA1 alkyne agonists has
resulted in the discovery of 22, a highly potent FFA1 agonist
with excellent physicochemical and pharmacokinetic properties.
The compound demonstrated a potent effect on glucose
tolerance in DIO mice, a situation that was sustained after 29
days of chronic dosing. The compound all together appears as a
promising candidate for development of improved T2D
therapeutics.
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■ ABBREVIATIONS
BRET, bioluminescence resonance transfer; FFA1, free fatty
acid receptor 1 (GPR40); IPGTT, intraperetoneal glucose
Figure 1. In vivo evaluation of 22 in mice on glucose tolerance. (A)
Effect of 22 on acute IPGTT in normal mice. Mice were dosed ip with
22, vehicle, or control (sitagliptin, 10 mg/kg). (B) Effect of 22 on
OGTT in a chronic study in DIO mice: acute (4 weeks vehicle prior to
treatment with 22), chronic (4 weeks treatment with 22), and control
(vehicle). Means ± standard errors (n = 6) are shown (*, p < 0.05;
**, p < 0.01; ***, p < 0.001).
Figure 2. In vivo evaluation of 22 in Sprague−Dawley rats on glucose
tolerance after oral dosing. (A) Effect on plasma glucose levels. (B)
Effect on plasma insulin levels. Means ± standard errors (n = 6) are
shown (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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tolerance test; LE, ligand efficiency; LLE, ligand lipophilicity
efficiency; OGTT, oral glucose tolerance test
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ABSTRACT: FFA1 (GPR40) is a new target for treatment of type 2 diabetes. We recently identified the potent FFA1 agonist
TUG-469 (5). Inspired by the structurally related TAK-875, we explored the effects of a mesylpropoxy appendage on 5. The
appendage significantly lowers lipophilicity and improves metabolic stability while preserving potency, resulting in discovery of
the potent FFA1 agonist 13.
■ INTRODUCTION
Current methods used for design, synthesis, screening, and
optimization in drug discovery tend to produce compounds
with higher than ideal lipophilicity, a property that recently has
been repeatedly pointed at as a critical factor for the success of
new potential drugs in the development stages because high
lipophilicity is associated with poor absorption, metabolic
instability, high promiscuity, toxic effects, and consequently a
higher risk of attrition in clinical trials.1−7 To counteract this,
concepts such as ligand efficiency (LE, free energy binding
divided by the number of non-hydrogen atoms),8 ligand
lipophilicity efficiency (LLE, logarithmic potency subtracted by
log P or log D)1 and ligand efficiency-dependent lipophilicity
(LELP, log P divided by LE)7 have been introduced and are
increasingly being implemented in drug discovery programs
and useful in directing optimization away from oversized and
highly lipophilic compounds.
The free fatty acid receptor 1 (FFA1, also known as GPR40)
is activated by medium- and long-chain free fatty acids (FFAs),
is highly expressed on pancreatic β-cells, and enhances glucose-
stimulated insulin secretion.9−11 This observation has attracted
considerable attention to the receptor as a new potential target
for improved therapeutics for treatment of type 2 diabetes, and
several potent and selective FFA1 agonists are now known
(Chart 1).12−26 Many of these ligands have relatively high
lipophilicity, most likely resulting from fatty acids being used as
initial leads and from the lipophilic nature of the FFA1 binding
site. We recently addressed this issue in our alkyne series, where
we were able to lower the lipophilicity of the compounds by
replacing the terminal benzene ring by aromatic nitrogen
containing heterocycles (cf. TUG-499 in Chart 1).22
In our program aimed at discovery of potent and selective
FFA1 (GPR40) agonists, we identified 4-benzyloxydihydrocin-
namic acid (TUG-20) in screening of a focused library of
constrained FFA analogues.19 Inspired by the subsequent
publication of the related potent FFA1 agonist GW9508,12 we
explored the structure−activity relationships (SAR) around
these compounds and found that whereas the central ether is
favored for small compounds, a central amine is preferred when
the structures are more extended such as for GW9508 and
TUG-469.19 The central amine has the additional advantage
that it provides less lipophilic compounds. Takeda recently
published their clinical candidate TAK-875, corresponding to a
conformationally constrained analogue of TUG-469 with an
Received: February 14, 2012
Published: June 25, 2012
Chart 1. Representative FFA1 Agonistsa
aClogP is calculated by ChemBioDraw.
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additional ortho-methyl and a para-mesylpropoxy chain on the
biphenyl system and furthermore contains a central ether linker
rather than the amine linker predicted by our SAR studies
(Chart 1).18 Calculations indicated that the mesylpropoxy
appendage decrease lipophilicity by an order of magnitude. As
the ClogP of 5 is in the uppermost part of the generally
acceptable range, we were interested in exploring the effects of
introducing a mesylpropoxy chain on this compound.
■ RESULTS AND DISCUSSION
Compounds 5, 6, and 9 were synthesized as described
previously.18−20 The mesylpropoxy-appended analogues 7 and
8 were synthesized as described for 519 using the
mesylpropoxy-substituted biphenyl building blocks 4b and
4c18 (Scheme 1). The 2-fluoro substituted intermediate 3a was
prepared by a Heck coupling of 1 with ethyl acrylate followed
by ester hydrolysis. Reductive amination of 2 with 2′-
methylbiphenyl-3-carboxaldehyde followed by hydrogenation
of the double bond over palladium provided 10 but in very
poor yield (see Supporting Information (SI)). By swapping the
first two steps and reducing 2 to 3a followed by reductive
coupling with 4d, 4e, and 4b, compounds 11−13 were
obtained, respectively, in moderate to good overall yields
(Scheme 1).
In our assay, 5 is somewhat more potent than 6 (racemic
TAK-875) but also more lipophilic, giving 6 a slightly higher
LLE (Table 1). The potency of EC50 = 26 nM found for 6 is in
excellent agreement with the activity reported by Takeda for
TAK-875 (EC50 = 14 nM), given that this enantiomer is
primarily responsible for the activity.18 Takeda has also
reported the racemic analogue of TAK-875 lacking the
mesylpropoxy substituent to have pEC50 = 7.66, i.e., equipotent
with TAK-875 when it is taken into account that one
enantiomer is mainly responsible for the activity.18 Thus, the
mesylpropoxy tail appears to improve ADME properties by
lowering lipophilicity rather than to increase potency.
We proceeded by attaching a corresponding mesylpropoxy
tail to 5. The resulting 7 indeed turned out equipotent with 5
but had lipophilicity reduced by one log unit and thereby
obtained a significant advantage in terms of LLE. Introducing
the second ortho-methyl group in the biphenyl system (8)
resulted in a barely significant increase in potency and a drop in
LLE due to increased lipophilicity.
The values for 6−8 in Table 1 are in the presence of 0.05%
BSA. In the absence of BSA, the values were significantly lower
(pEC50 6.85 ± 0.04 for 6, 7.46 ± 0.06 for 7, and 7.52 ± 0.04 for
8). BSA often reduces the observed potency by competitive
binding of the ligand but can also increase potency by
increasing solubility, presumably the explanation of the effects
observed here.27
The precursor in the development of TAK-875 is the highly
potent and lipophilic 9 (Cmp 4p in Chart 1), which differs
from 5 in having a second ortho-methyl substituent on the
biphenyl system, a central ether linker, and a 2-fluoro
Scheme 1a
aReagents, conditions and yields: (a) ethyl acrylate, Pd(OAc)2, P(o-
tolyl)3, DIPEA, DMF, 80 °C, 4 h, 86%; (b) LiOH, THF, MeOH, H2O,
rt, 3 d, 99%; (c) Pd/C, MeOH, H2, rt, 2 h, 73%; (d) NaBH(OAc)3,
CH2Cl2, AcOH (cat.), rt, 3−21 h, 38−67%.
Table 1. Effects of para-Mesylpropoxy Chain and Substituents on FFA1 Agonist Activity and Lipophilicity
R1 R2 R3 R4 X
FFA1 pEC50
(% efficacy)a
GPR120 pEC50
(% efficacy) LogD7.4 (ClogP)
b LEc LLEd HLMe (%)
5 Me H H H NH 7.73 ± 0.04 (114) 5.20 ± 0.02 (53) 2.49 ± 0.01 (4.9) 0.41 5.2 (2.8) 87
6f Me Me MsC3H6O O 7.59 ± 0.04 (91)
g n.t.h 2.24 ± 0.03 (4.7) 0.28 5.4 (2.9) 101
7 Me H MsC3H6O H NH 7.76 ± 0.03 (98)
g 4.96 ± 0.07 (90) 1.43 ± 0.01 (3.9) 0.31 6.3 (3.8) 106
8 Me Me MsC3H6O H NH 7.83 ± 0.04 (92)
g n.t.h 1.77 ± 0.02 (4.4) 0.31 6.1 (3.7)
9i Me Me H F O 7.46 ± 0.04 (92) 5.08 ± 0.08 (82) 3.82 ± 0.13 (6.2) 0.37 3.6 (1.3) 42
10 Me H H F NH 8.03 ± 0.04 (102) 5.07 ± 0.04 (92) 2.86 ± 0.03 (5.4) 0.41 5.2 (2.7)
11 Et H H F NH 7.63 ± 0.02 (101) 5.37 ± 0.08 (91) 2.88 ± 0.01 (5.9) 0.37 4.8 (1.7)
12 Me Me H F NH 7.75 ± 0.02 (104) 4.03 ± 0.08 (78) 3.03 ± 0.04 (5.6) 0.38 4.7 (2.2)
13 Me H MsC3H6O F NH 8.04 ± 0.02 (102) 4.36 ± 0.09 (66) 1.87 ± 0.01 (4.4) 0.32 6.2 (3.7) 100
aEfficacy is given as percentage of the full agonist TUG-20.19 bLogD7.4 values were determined by shake-flask procedure. ClogP values were
calculated by the BioByte’s algorithm as implemented in ChemBioDraw Ultra 12.0 (the “ClogP” option). cLE values were calculated by −Δg = RT ln
KD, presuming EC50 ≈ KD.8 dLLE values were calculated by the formula pEC50 − LogD7.4 (values in parentheses were calculated by pEC50 − ClogP).
eStability toward human liver microsomes (HLM) was evaluated at Cerep Inc. (see the SI) fRacemic TAK-875 (structure in Chart 1). The pure (S)-
enantiomer is previously reported by Takeda as with EC50 = 14 nM (pEC50 = 7.85) in a FLIPR assay with 0.1% BSA.
gTested with 0.05% BSA. hNot
tested. iPreviously reported by Takeda as an FFA1 agonist with EC50 = 5.7 nM (pEC50 = 8.22) in a FLIPR assay with 0.1% BSA.
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substituent on the central benzene ring.20 The compound
surprisingly appeared significantly less potent in our assay than
reported by Takeda. It is possible that the difference is related
to Takeda using 0.1% BSA in the assay. We wished to explore
the ortho-fluoro substituent, which was introduced by the
Takeda group to resolve metabolic issues with preceding
compounds but which also was found to slightly increase
potency. Introducing the 2-fluoro substituent on 5 to give 10
indeed boosted potency to the single-digit nanomolar range but
also increased lipophilicity correspondingly, leading to virtually
unchanged or slightly decreased LE and LLE. Substituting the
ortho-methyl for ethyl (11) gave a significant decrease in
potency and a similar increase in lipophilicity. Surprisingly, a
second ortho-methyl substituent (12) also resulted in decreased
potency.
In an attempt to reach an optimal combination of high
potency and moderate lipophilicity, the 2-fluoro substituent and
the mesylpropoxy chain were introduced to 10 to give 13.
Again, whereas the two compounds exhibited identical potency,
lipophilicity (ClogP and logD7.4) was lowered by an order of
magnitude. Despite the LE of 13 being significantly lower than
5 and 10 and that the compound exhibits an LLE value similar
to 7 and 8, we believe that 13 represents the optimal
combination of high potency and acceptable lipophilicity in this
series. In contrast to the other compounds with mesylpropoxy
appendages, the potency of 13 was not affected by 0.05% BSA.
Lipophilicity is known to influence the metabolic stability by
increasing interaction with enzymes. We found that 6 (racemic
TAK-875), 7, and 13 all were completely stable toward human
liver microsomes, whereas the somewhat more lipophilic
compound 5 had slightly reduced stability (Table 1). The
significantly reduced stability of 9 (Chart 1) is in agreement
with the higher lipophilicity of the compound.24
Compound 13 was examined further using a dynamic mass
redistribution (DMR) assay, enabling real-time label-free
detection of intracellular events.28 Concentration dependent
activation of hFFA1 transfected HEK293 cells was confirmed,
with no detectable activity on native HEK293 cells (Figure 1).
Likewise, 13 induced a concentration dependent response in
insulin secreting rat β-cell line INS-1E endogenously expressing
FFA1. Pretreatment with the FFA1 antagonist TUG-76122
resulted in a right-shifted curve, and pretreatment with the
selective FFA1 agonist TUG-499 (Chart 1 and ref 22)
prevented activation by 13 (Figure S1, SI), demonstrating
that the activity is mediated through FFA1. 13 was devoid of
activity on the related receptors FFA2 and FFA3 (Figure S2,
SI) and on nontransfected HEK293 cells in the DMR assays
(Figure 1) and exhibited 4800-fold selectivity over GPR120, an
order of magnitude higher than 5 (Table 1).
The pharmacokinetic properties of compounds 5 and 13
were investigated in mice. Both compounds were rapidly
absorbed, and compound 13 exhibited twice as high exposure
as 5 (Table 2). This effect can be rationalized by reduced first-
pass metabolism due to the lower lipophilicity of 13.
■ CONCLUSION
By combining features of the previously published compounds
5, 6, and 9, we identified 13 as a compound with higher
potency and lower lipophilicity than any previous FFA1
agonist. The 2-fluoro substituent increases both potency and
lipophilicity by approximately the same degree and is therefore
only an advantage as long as the compound is not already too
lipophilic. The mesylpropoxy chain decreased lipophilicity by
one log unit without affecting potency on FFA1. A
consequence of the reduced lipophilicity was increased stability
toward human liver microsomes. It seems possible that
attachment of mesylalkoxy or similar groups can represent a
general strategy for lowering the lipophilicity and thereby
Figure 1. Activity of 13 on FFA1 transfected HEK293 cells and on the rat β-cell line INS-1E. (A) Representative traces (mean + SEM) from the
dynamic mass redistribution (DMR) assay of HEK293 cells stably expressing the human FFA1 receptor (FFA1-HEK) and stimulated with the
indicated concentrations of 13. (B) Receptor activation in FFA1-HEK cells is concentration-dependent (pEC50: 7.34 ± 0.06, n = 3); no activation is
detectable in native HEK293 cells. (C) Representative traces from the DMR assay of INS-1E cells endogenously expressing FFA1. (D)
Concentration-effect-curve of 13 on INS-1E cells (pEC50 = 6.74 ± 0.14, n = 6). Preincubation with the FFA1 antagonist TUG-761
22 (30 μM)
resulted in a right-shifted curve (pEC50 = 5.71 ± 0.21, n = 3), confirming FFA1-dependent DMR responses.
Table 2. Pharmacokinetic Parameters after Oral Dosinga
Cmax (ng/mL) Tmax (min) AUCpo (ng·h/mL)
5 2360 15 2740
13 8748 15 5202
aCompounds were dosed p.o. at 10 mg/kg in mice (n = 3).
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“rescuing” otherwise problematic compound series. The
viability of this strategy is currently being explored on other
compound series.
■ EXPERIMENTAL SECTION
All commercial starting materials and solvents were used without
further purification unless otherwise stated. THF was freshly distilled
from sodium/benzophenone. DIPEA was dried over 4 Å sieves, and
anhydrous DMF was purchased from Sigma-Aldrich. Purification by
flash chromatography was carried out using silica gel 60 (0.040−0.063
mm, Merck). 1H and 13C NMR spectra were recorded at 400 MHz
and 101 MHz, respectively, and calibrated relative to TMS internal
standard or residual solvent peak. High-resolution mass spectra
(HRMS) were obtained on a Bruker micrOTOF-Q II (ESI). HPLC
analysis was performed using a Dionex 120 C18 column (5 μ, 4.6 ×
150 mm2); flow, 1 mL/min; 10% acetonitrile in water (0−1 min), 10−
100% acetonitrile in water (1−10 min), 100% acetonitrile (11−15
min), with both solvents containing 0.05% TFA as modifier; UV
detection at 254 nm. Purity was determined by HPLC analysis and
confirmed by inspection of NMR spectra. All target compounds have
>95% purity.
(E)-3-(4-Amino-2-fluorophenyl)acrylic Acid (2). Step 1: A dry
Schlenk flask was charged with 4-bromo-3-fluoroaniline (1140 mg,
6.01 mmol), Pd(OAc)2 (67 mg, 0.30 mmol), tris(2-methylphenyl)-
phosphine (182 mg, 0.60 mmol), DMF (4.2 mL), and DIPEA (4.2
mL) under N2-flow. The flask was evacuated and backfilled with argon
before addition of ethyl acrylate (0.8 mL, 7.36 mmol) and heated to 80
°C for 4 h. The reaction was cooled to room temperature, added
water, and extracted with EtOAc. The organic phase was washed with
water and brine, dried (MgSO4), and concentrated. The residue was
purified by flash chromatography (SiO2, EtOAc:petroleum ether, 1:2)
to give ethyl 4-amino-2-fluorocinnamate (1079 mg, 86%) as a yellow
solid; Rf = 0.19 (EtOAc:petroleum ether, 1:2).
1H NMR (CDCl3) δ
7.71 (d, J = 16.1 Hz, 1H), 7.31 (t, J = 8.3 Hz, 1H), 6.42 (dd, J = 8.4
Hz, 2.3 Hz, 1H), 6.35 (dd, J = 12.6 Hz, 2.1 Hz, 1H), 6.32 (d, J = 16.1
Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 4.08 (s, 2H), 1.32 (t, J = 7.1 Hz,
3H). 13C NMR (CDCl3) δ 167.6, 162.8 (d, J = 253.5 Hz), 150.2 (d, J
= 12.1 Hz), 137.7 (d, J = 2.4 Hz), 130.4 (d, J = 5.1 Hz), 116.0 (d, J =
7.1 Hz), 112.5 (d, J = 13.1 Hz), 110.9 (d, J = 2.0 Hz), 101.6 (d, J =
26.3 Hz), 60.3, 14.3. Step 2: A solution of ethyl 4-amino-2-
fluorocinnamate (1002 mg, 4.79 mmol) in THF (32 mL) was added
to a solution of LiOH·H2O (567 mg, 20.0 mmol) in H2O (16 mL),
and MeOH (5 mL) was added to give a homogeneous solution. The
reaction was stirred at room temperature until complete hydrolysis,
then added aqueous HCl (1 M) until pH <2 and extracted with EtOAc
(×3). The combined organic phases were washed with brine, dried
(MgSO4), and concentrated to give 858 mg (99%) of 2 as an orange
solid; tR = 8.03 min (HPLC).
1H NMR (MeOH-d4) δ 7.70 (d, J = 16.0
Hz, 1H), 7.36 (t, J = 8.5 Hz, 1H), 6.48 (dd, J = 8.5 Hz, 2.2 Hz, 1H),
6.38 (dd, J = 13.5 Hz, 2.2 Hz, 1H), 6.26 (d, J = 16.0 Hz, 1H), 4.91 (s,
2H). 13C NMR (MeOH-d4) δ 171.4, 164.5 (d, J = 250.5 Hz), 154.5 (d,
J = 13.3 Hz), 139.9 (d, J = 3.0 Hz), 131.3 (d, J = 5.1 Hz), 115.1 (d, J =
7.1 Hz), 111.8 (d, J = 1.8 Hz), 111.5 (d, J = 12.1 Hz), 101.3 (d, J =
26.3 Hz).
3-(4-Amino-2-fluorophenyl)propanoic Acid (3a). To a sol-
ution of 2 (388 mg, 2.14 mmol) in MeOH (15 mL) was added 10%
Pd/C (35 mg). The reaction mixture was placed under argon, the
argon was replaced with H2, and the reaction mixture was stirred under
ambient pressure. After 2 h, the reaction mixture was filtered through
Celite, concentrated, and purified by flash chromatography (SiO2,
EtOAc) to give 3a (285 mg, 73%) as a pale-brown solid; tR = 4.88 min
(HPLC). 1H NMR (DMSO-d6) δ 12.09 (s, 1H), 6.89 (t, J = 8.7 Hz,
1H), 6.39−6.23 (m, 2H), 5.19 (s, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.40
(t, J = 7.7 Hz, 2H). 13C NMR (DMSO-d6) δ 173.7, 161.2 (d, J = 240.7
Hz), 149.0 (d, J = 11.5 Hz), 130.5 (d, J = 7.1 Hz), 113.3 (d, J = 16.5
Hz), 109.8 (d, J = 2.1 Hz), 100.2 (d, J = 25.0 Hz), 34.5, 23.2 (d, J = 2.1
Hz).
3-(2-Fluoro-4-(((2′-methyl-4′-(3-(methylsulfonyl)propoxy)-
[1,1′-biphenyl]-3-yl)methyl)amino)-phenyl)propanoic Acid
(13). A dry flask charged with 2′-methyl-4′-(3-(methylsulfonyl)-
propoxy)-[1,1′-biphenyl]-3-carbaldehyde (4b, 35 mg, 0.11 mmol), 3-
(4-amino-2-fluorophenyl)propanoic acid (3a, 19 mg, 0.11 mmol),
CH2Cl2 (1 mL) and AcOH (1 drop) under argon was added
NaBH(OAc)3 (34 mg, 0.16 mmol) and stirred at room temperature
until consumption of the starting material. The reaction mixture was
quenched with water and aqueous HCl (1 M), and extracted with
CH2Cl2. The combined organic phases were washed with brine, dried
over (MgSO4), and concentrated. The residue was purified by flash
chromatography (SiO2, EtOAc:petroleum ether, 1:2) to give 30 mg
(58%) of 13 as a light-brown foam; Rf = 0.54 (EtOAc) (purity 98.1%
by HPLC). 1H NMR (acetone-d6) δ 7.40−7.29 (m, 3H), 7.22−7.07
(m, 2H), 7.05−6.94 (m, 1H), 6.90−6.78 (m, 2H), 6.48−6.32 (m, 2H),
4.40 (s, 2H), 4.18 (t, J = 6.1 Hz, 2H), 3.35−3.26 (m, 2H), 2.99 (s,
3H), 2.77 (t, J = 7.7 Hz, 2H), 2.49 (t, J = 7.7 Hz, 2H), 2.34−2.19 (m,
2H), 2.18 (s, 3H). 13C NMR (acetone-d6) δ 174.3, 163.8 (d, J = 241.4
Hz), 158.9, 150.1 (d, J = 11.1 Hz), 142.6, 140.7, 137.4, 135.5, 131.7 (d,
J = 8.1 Hz), 131.5, 129.1, 128.6, 126.4, 117.3, 115.5 (d, J = 16.2 Hz),
112.7, 109.7 (d, J = 2.0 Hz), 100.0 (d, J = 26.3 Hz), 66.6, 52.0, 48.0,
40.8, 30.1, 24.5 (d, J = 2.0 Hz), 24.5, 23.5, 20.8. ESI-MS calcd for
C27H30FNO5SNa (M + Na
+), 500.1901; found, 500.1916.
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 Epilogue 
The discovery of selective and potent FFA1 agonists provides a valuable means not only as tool 
compounds to study receptor biology in a controlled in vitro environment but also as potential 
structures for the development of drug like molecules with the aim to be employed in vivo, even in 
the treatment of type 2 diabetes in the long run. Because of this perspective the compounds were 
not only tested with traditional endpoint assays such as the detection of intracellular calcium flux 
and inositolmonophosphate (IP) production but also with a label-free technology that is capable to 
display compound behavior as an integrated cell response, thereby allowing for the disclosure of 
receptor-independent (“off-target”) effects. This additional information is helpful to evaluate the 
compounds more accurately, particularly with regard to a possible use of the FFA1-targeted ligands 
as drug compounds. By the same token, we also reported on in vivo relevant parameters, such as 
ADME (administration, distribution, metabolism and elimination) properties, compound toxicity and 
the ability to modulate insulin-secretion.  
In this chapter, we demonstrated a way to stepwise evolve small molecule compounds to more 
favorable FFA1-targeted ligands. Structure-activity relationship investigations lead to insights into the 
incremental construction of FFA1 ligands.  
Starting point for this optimization process was the compound TUG-424, an already potent but 
lipophilic FFA1 selective agonist1. By introducing polar substituents in the terminal benzene ring, a 
series of derivatives were synthesized and analyzed for their potency and physicochemical 
properties. In TUG-488 (compound 40) the methyl group at the terminal benzene ring of TUG-424 
was replaced by a cyanomethyl substituent, which significantly lowered the lipophilicity and 
enhanced potency as described in the first publication. In the second paper of this chapter, we 
presented TUG-770 as an optimized TUG-488 derivative. By introducing a fluorine substituent in the 
middle benzene ring the potency could be further enhanced at the expense of a slightly increased 
lipophilicity. However, the fluoro-substituted structure significantly improved the compound’s 
metabolic stability. In the third paper, a previously published compound TUG-4692 was finally 
evolved inspired by the clinically exploited drug TAK-875/fasiglifam3. A mesylpropoxy appendage on 
the precursor compound resulted in a higher potent but less lipophilic FFA1 prevalent agonist TUG-
905 (compound 13). 
The discovery and optimization of selective receptor ligands is an important task since the prevailing 
concepts of pharmacological treatments are built on selective and potent compounds. Further in-
depth biological studies are highly reliant to good quality and potent FFA1 agonists. The high potency 
of these ligands allows for a detailed exploration and gives greater headroom for pharmacological 
 
Chapter 5: Small molecule FFA1 agonists  168 
characterization in a variety of experimental settings and cellular backgrounds. As shown in the 
aforementioned chapter (see chapter 4), selective small molecule FFA1 ligands (activators and 
inhibitors) prove very useful to elucidate the biology of the FFA1 receptor. 
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 Section IV 
 Chapter 6: Non-canonical cNMPs 
 Prologue 
As in most biomedical research areas, technological advances are a driving force in the discovery 
process and are in the center of new scientific findings. The history of research on cyclic nucleotide 
monophosphates (cNMPs) has not been straightforward from the first hints in the discovery of the 
non-canonical cyclic nucleotides cCMP and cUMP to their biological function as second messengers1. 
The acknowledgement of non-canonical cNMPs as true second messenger has been compromised by 
erroneous findings and methodological issues. Claims of a selective cCMP generating enzyme could 
not be backed by further investigations2,3. In analogy to chapter 4, immunostaining data likewise in 
the field of cNMP research are questionable due to antibody cross-reactivity4. Furthermore, due to 
technical limitations initial attempts to quantify cNMP levels were doomed to failure5,6, whereas 
standard methods such as high performance liquid chromatography (HPLC) suffer from low 
sensitivity7 and radiometric analyses are only applicable to cell-free systems8. Hence, methodological 
issues emerge as a crux of preceding cNMP research. Beyond the cNMP research field, a critical 
examination of the strengths and weaknesses of the techniques employed in a particular research 
question should generally be addressed as already discussed in chapter 1 and 4. The above 
mentioned methodological setbacks led to a negative perception of cCMP and cUMP research in the 
scientific community and might explain why non-canonical cNMPs were long ignored or overlooked 
as second messenger molecules.  
A molecule to be considered as second messenger must fulfill several criteria9–11. In essence, this is 
the quest for (i) a generating system upon stimulation with a first messenger, (ii) a cellular effector 
system that controls (iii) a biological function in cells, organs or tissues. To control the effect a (iv) 
signal terminating system must be present.  
Finally, a recent revival of research activities in the field of non-canonical cNMPs using state-of-the-
art experimental techniques (HPLC-MS/MS, HPLC-MS/TOF and DMR) and key experimental tools 
(cNMP-AMs and bacterial toxins such as ExoY) gave the field of non-canonical cNMP research a 
strong boost, thereby providing evidence for a true second messenger role of cCMP and cUMP1.  
As a method that displays compound behavior as an integrated cell response, the DMR technology in 
particular (also see Chapter 1) provides priceless insights into uncharted biological effects. The label-
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free  measurement  principle  allows  the  recording  of  cellular  activity  in  a  pathway‐unbiased  yet 
pathway‐specific fashion12.  
On the part of molecular tools recently introduced, acetoxymethyl ester of cNMPs (cNMP‐AM) allow 
detailed  insight  into  the biological  effects of  cNMPs13.  They  represent  a  novel  class of  chemically 
modified substances that can cross the cell membrane and release the actual active cNMP part of the 
molecule in the cytosol. This in situ triggering of signaling transduction is an elegant way to overcome 
previous  issues with modulators of the  intracellular cNMP  level that were either natural (toxins) or 
synthetic (cNMP‐derivatives) in nature. Nevertheless, we also took advantage of bacterial toxins such 
as ExoY and CyaA. The first toxin derives from the bacterium Pseudomonas aeruginosa and increases 
intracellular levels of cGMP and cUMP causing τ‐phosphorylation and microtubule breakdown14,15. In 
turn, endothelial cells produce gaps that cannot be repaired by the host for a prolonged time. Thus, 
ExoY represents a bacterial edema factor, assumedly playing a role in the pathological process of P. 
aeruginosa‐induced lung injury15. CyaA on the other side is an endotoxin of the bacterium Bordetella 
pertussis, which is mainly responsible for the whooping cough disease. This protein induces massive 
generation  of  cAMP  and  also  cCMP  contributing  to  the  clinical  pathology  of  pertussis  (whooping 
cough)7,16,17. CyaA paralyzes  immune cell  function and  facilitates bacterial  survival. Although  the  in 
vivo relevance of the specific cNMP elevation remains unclear, the two bacterial toxins together with 
the chemically modified cNMP analogues proved exquisitely useful to dissect the biological function 
of cCMP and cUMP. 
In  this chapter, as well as  in Chapter 1, 2 and 3,  the advent of novel  technologies or experimental 
methods paved the way for a fruitful scientific  journey.  In the following paper we further elucidate 
the biological  functions of  cCMP  and  cUMP  taking  advantage of novel  yet  validated  experimental 
techniques and  tool compounds,  thereby contributing  to  the conclusion  that cCMP and cUMP can 
unequivocally be considered as true second messenger molecules1. 
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In addition to the well-known second messengers cAMP and cGMP, mammalian cells contain the cyclic
pyrimidine nucleotides cCMP and cUMP. The Pseudomonas aeruginosa toxin ExoY massively increases
cGMP and cUMP in cells, whereas the Bordetella pertussis toxin CyaA increases cAMP and, to a lesser
extent, cCMP. To mimic and dissect toxin effects, we synthesized cNMP-acetoxymethylesters as prodrugs.
cNMP-AMs rapidly and effectively released the corresponding cNMP in cells. The combination of cGMP-
AM plus cUMP-AMmimicked cytotoxicity of ExoY. cUMP-AM and cGMP-AM differentially activated gene
expression. Certain cCMP and cUMP effects were independent of the known cNMP effectors protein
kinases A and G and guanine nucleotide exchange factor Epac. In conclusion, cNMP-AMs are useful tools
to mimic and dissect bacterial nucleotidyl cyclase toxin effects.
 2014 Elsevier Inc. All rights reserved.1. Introduction cNMP concentrations in mammalian cells [4]. The PseudomonascAMP and cGMP are well-established second messengers [1,2].
In addition to these cyclic purine nucleotides, mammalian cells
contain the cyclic pyrimidine nucleotides cCMP and cUMP [3,4].
Soluble adenylyl cyclase plays a key role in maintaining basalaeruginosa nucleotidyl cyclase toxin ExoY induces massive
increases in cGMP and cUMP in mammalian cells and smaller
increases in cAMP and cCMP [5]. In contrast, the Bordetella pertussis
nucleotidyl cyclase toxin CyaA massively increases cAMP and, to a
lesser extent, cCMP [5]. ExoY induces lung damage and necrosis of
cells [5,6]. However, given the fact that ExoY increases the levels of
all four cNMPs, it is impossible to answer the question what the
contribution of any given cNMP to the biological toxin effect is.
In order to address this problem, we studied the set of four
cNMP-AMs shown in Fig. 1. In cNMP-AMs, the hydrophilic phos-
phate group is protected by an acetoxymethylester so that the
compounds can penetrate the plasma membrane [7]. Within the
cells, the cNMP moiety is released and induces biological effects.
As control compound, we used PO4-AM3. Here, we show that
cNMP-AMs are useful experimental tools to mimic and dissect bac-
terial nucleotidyl cyclase toxin effects.2. Materials and methods
2.1. Materials
Rp-cAMPS, Rp-8-Br-cAMPS, Rp-8-Br-PET-cGMPS, Rp-8-pCPT-
cGMPS, 8-pCPT-20-O-Me-cAMP, cNMPs and PO4-AM3 were
obtained from Biolog LSI (Bremen, Germany).
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Fig. 1. Structures of cNMP-AMs and PO4-AM3. The AM group neutralizes the
negative charge of the cNMP phosphate group. Accordingly, AM compounds can
penetrate the plasma membrane. In the cytosol, esterases cleave the AM
compounds, releasing the free cNMP and phosphate, respectively. Please note that
PO4-AM3 contains three AM groups. Accordingly, in experiments, PO4-AM3 is used
at threefold lower concentrations than cNMP-AMs. In order to avoid cleavage of AM
compounds by extracellular esterases, experiments should be performed in the
absence of serum supplementation.
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All chromatographic experiments were performed at ambient
temperature. The analytical HPLC-system consisted of a L 6200
pump, a L 4250 variable wavelength UV/Vis-detector, and a D
7500 chromato-integrator (all Merck-Hitachi, Darmstadt, Ger-
many). The stationary phases were YMC ODS-A 12 nm, S-11 lm
(YMC, Dinslaken, Germany) or Kromasil 100-10, RP-8 (Eka Nobel,
Bohus, Sweden) in 250  4.6 mm stainless steel columns with
Gemini C18, 4  3 mm Security guard columns (Phenomenex,
Aschaffenburg, Germany). Semipreparative HPLC was performed
with a LC-8A preparative liquid chromatograph (Shimadzu,
Duisburg, Germany), a preparative K 2001 UV-detector (Knauer,
Berlin, Germany), a L200E analog recorder (Linseis, Selb, Germany),
and either YMC ODS-A 12 nm, S-11 lm (YMC) as stationary phase
in a 250  20 mm stainless steel column (CS-Chromatography
Service, Düren, Germany). Mass spectra were recorded with an
Esquire LC 6000 spectrometer (Bruker Daltonics, Bremen,
Germany) in the ESI-MS mode with 50/49.9/0.1 (v/v/v) propanol-
2/water/formic acid as matrix. UV-spectra for preparation of
aliquots were recorded with a Helios b-spectrometer (Spectronic
Unicam, Leeds, UK) in aqueous phosphate buffer, pH 7. All reagents
were of analytical grade or the best grade available from commer-
cial suppliers.2.2.1. cCMP-AM
220 lmol cCMP (diisopropylethylammonium salt) were care-
fully dried and suspended in 10 mL acetonitrile. After addition of
1100 lmol (110 lL; 5 equivalents) acetoxymethyl bromide and
1320 lmol (305 mg; 6 equivalents) Ag2O, the reaction mixturewas stirred vigorously at ambient temperature for 35 min. Progress
of AM-ester formation was monitored by analytical HPLC with 16%
(v/v) acetonitrile, 20 mM triethylammonium formate (pH 6.80) as
eluent. After reaction was completed, solid Ag2O was removed by
filtration through a 0.2 lm PTFE membrane, and 2 mL aliquots of
the raw mixture were evaporated under reduced pressure with
oil pump vacuum. The residue was redissolved in DMF
(2–3 mL) and purified by semipreparative HPLC using 15% (v/v)
acetonitrile as eluent. Product fractions were evaporated under
reduced pressure to produce 84.5 lmol cCMP-AM as mixture of
axial and equatorial isomers with a purity of >99.5% (yield:
38.4%). Formula: C12H16N3O9P (MW: 377.2); ESI-MS pos. mode:
m/z 378 (M + H)+, m/z 479 (M + H + TEA)+; neg. mode: m/z 376
(M  H), m/z 304 (M  AM  H); UV–VIS (pH 7.0) kmax 270 nm
(e = 9000).
2.2.2. cUMP-AM
Synthesis and work-up of cUMP-AM was performed in parallel
reactions with 3  500 lmol cUMP (silver salt) and 2500 lmol
(250 lL; 5 eq.) acetoxymethyl bromide in 30 mL acetonitrile as
described for cCMP-AM. The reaction was monitored by analytical
HPLC (Kromasil) with 15% (v/v) acetonitrile, pH 5 (0.25 lL acetic
acid per 1 L), and the raw product was purified by semipreparative
HPLC (Kromasil) with 5–10% (v/v) acetonitrile. Product-containing
fractions were evaporated in vacuo and 110.7 lmol cUMP-AM
were obtained as a mixture of isomers with a purity of 98.78%
(yield: 7.4%). Formula: C12H15N2O10P (MW: 378.2); ESI-MS pos.
mode: m/z 401 (M + H + Na)+, m/z 379 (M + H)+; neg. mode: m/z
305 (M  AM  H), m/z 377 (M  H); UV–VIS (pH 7.0) kmax
260 nm (e = 10000).
2.3. DMR measurements
For DMR measurements a beta version of the Corning Epic bio-
sensor (Corning, Corning, NY, USA) or the Enspire multimode
reader (Perkin Elmer, Hamburg, Germany) that contains an inte-
grated DMR module was used. Each well of the DMR biosensor
microplate contains a grating biosensor that guides polarized
broadband light through the bottom of the plate generating an
electromagnetic field that extends 150 nm into the cell layer. As
a result of cellular response, relocation of intracellular constituents
leads to a local change of refraction index that is translated into a
wavelength shift (in pm) of the reflected light. The magnitude of
this wavelength shift is proportional to the amount of DMR.
Increase of mass contributes positively and decreases negatively
to the overall response. The resulting optical signatures reflect cel-
lular processes such as shape change, cytoskeletal reorganization
or cellular adhesion as a consequence of engagement of intracellu-
lar signaling cascades.
DMR measurements were performed as described [8]. In brief,
HEK293 and B103 cells were seeded into 384-well fibronectin
coated DMR biosensor microplates with a density of 15,000 cells
per well and grown overnight (at 37 C and 5% (v/v) CO2) to conflu-
ent monolayers. Esterases present in the serum supplements of the
cell culture medium can degrade the test compounds by hydrolysis
of esters and, therefore, strongly reduce cell-loading efficiency.
Hence, after removal of medium cells were washed at least twice
with HBSS containing 20 mM HEPES (DMR buffer) to ensure
absence of serum supplements, and a residual volume of 30 lL of
DMR buffer was left in each well. Immediately before DMR regis-
tration test compounds were prepared at 4 final concentration
in pre-warmed DMR buffer and placed into the compound source
plate. Then, the sensor plate was scanned and a baseline optical
reading was recorded. Finally, 10 lL of compound solutions were
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least 9000 s.
2.4. Other methods
cNMP quantitation in cells was performed via HPLC–MS/MS as
described using a QTrap5500 triple quadrupole mass spectrometer
(ABSCIEX, Foster City, CA, USA) [9,10]. Cell culture and B103 cell
transfection with ExoY plasmid was performed as described
[3–5]. Cell viability was assessed using light microscopy and EABO
staining [11]. FACS analysis of cell viability was performed as
described [5]. Guanine nucleotide exchange factor activity of Epac1
on Rap1B was determined with the fluorescent GDP analog 20,30-O-
(N-methylanthraniloyl)-GDP as described [12]. Gene expression in
B103 cells was performed using the ‘‘Whole Rat Genome Oligo
Microarray 4  44 Kv200 (Agilent, Böblingen, Germany) containing
45,220 oligonucleotide probes. For RT-PCR studies, HEK293 cells
were incubated with different compounds for 1 h, followed by
TaqMan probe analysis for c-fos using the DDCt method [11].
2.5. Statistics
Data are presented as means ± SD, and are based on 4–8 inde-
pendent experiments.3. Results
In B103 neuroblastoma cells, ExoY induces massive increases in
cGMP and cUMP and necrosis [5]. cGMP-AM (200 lM for 4 h)
increased cGMP levels in B103 cells to a similar extent as did a
4-h treatment of cells with P. aeruginosa expressing ExoY (Fig. 2)
[5]. By analogy, cUMP-AM (200 lM for 4 h) was similarly effective
at increasing cUMP as a 4-h treatment of cells with P. aeruginosa
expressing ExoY (Fig. 2) [5]. The combination of cGMP-AM and
cUMP-AM yielded similar levels of the cognate cNMPs as treatment
with the single cNMP-AM. cGMP-AM and cUMP-AM exhibited no
effect on cAMP and cCMP levels. cUMP-AM induced a small cGMP
increase which may be due to blockade of a cGMP-degrading phos-
hopdiesterase by cUMP. The control compound PO4-AM3 had no
effect on cNMP levels. The uptake of cNMP-AMs into cells was very
rapid, i.e. already after 5 min significant levels of the free cognate
cNMP were reached, and levels remained elevated at least for 6 h
(later time points were not studied) (Fig. S1). In contrast, non-
cognate cNMP levels remained low.Me
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Fig. 2. cGMP- and cUMP-uptake of B103 cells after cGMP-AM and cUMP-AM incubation.
with 200 lM cGMP-AM and cUMP-AM alone or with a 1:1 mixture of both (each 200
Subsequently, cells were processed for HPLC–MS/MS quantitation of cNMPs. nd: not deUnder control conditions B103 cells grew as monolayer with
neurite extensions (Fig. 3A–C) [11]. Green color in the EBAO stain-
ing is indicative for cell viability. cGMP-AM had little effect on cell
morphology and viability (Fig. 3D–F). In contrast, cUMP-AM
induced marked cell clustering but no marked decrease in cell via-
bility (Fig. 3G–I). The combination of cGMP-AM and cUMP-AM
resulted in detachment of the cells from the surface and a massive
decrease in viability as evident by change in cell staining from
green to red (Fig. 3J–L). Analysis of cell viability by FACS [5]
revealed an increase in the percentage of necrosis from 2–3% in
control cells or cells treated with either cGMP-AM or cUMP-AM
alone to 54% in cells treated with the combination of cGMP-AM
plus cUMP-AM (data not shown). Transfection of B103 cells with
ExoY induced similar morphological changes as treatment with
cGMP-AM plus cUMP-AM. Specifically, we observed cell rounding
and cell clustering and an increase in increase in the percentage
of necrotic and apoptotic cells (Fig. S2D–F). These data fit to the
recently reported FACS analysis data [5]. In contrast, transfection
of B103 cells with the catalytically inactive ExoY mutant K81M
did not result in cell rounding, cell clustering, apoptosis and necro-
sis (Fig. S2A–C).
Morphological and viability changes in B103 cells following
exposure to cGMP-AM and cUMP-AM were accompanied by
changes in gene expression after a 2 h incubation (Fig. S3). We
conducted a microarray analysis encompassing P45,000 genes.
Somewhat unexpectedly, we found that expression of only few
genes changed significantly. Specifically, cGMP-AM significantly
increased expression of the cyclic-dependent kinase inhibitor 1
(cdkn1a, regulator of cell cycle progression), early response gene
1 (egr1, promoting neuronal differentiation and neurite growth),
egr2 and inducible heme oxigenase 1 (hmox1, a redox gene usually
elevated by heavy metals, endotoxin and oxidizing compounds).
cUMP-AM increased expression of cdkn1a, egr1, egr2, growth dif-
ferentiation factor 15 (gdf15, a neuroprotective and neurotrophic
factor) and small GTPase inhibitor of RhoA (rnd1, promoting neu-
ronal differentiation and neurite growth). cUMP-AM was more
effective at inducing expression of cdkn1a, egr1 and rnd1 than
cGMP-AM, whereas the opposite was true for hmox1. Collectively,
these data show that cGMP-AM and cUMP-AM alter expression of
few genes associated with cell cycle, cell differentiation and cell
stress. The selective effects of cGMP-AM and cUMP-AM on the
expression of only few genes argues against non-specific effects
of the cNMPs.
We also addressed the question whether cNMP-AMs are feasi-
ble for dissecting the mechanisms underlying the biological effectsM 
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Fig. 3. ExoY mimicry by cGMP-AM and cUMP-AM in B103 cells. B103 cells were incubated with 200 lM of cGMP-AM, cUMP-AM and a 1:1 mixture of cGMP-AM/cUMP-AM,
respectively. PO4-AM3 in a concentration of 132 lM served as control. C, F, I and L represent EBAO stained cells. All other panels represent unstained cells. White arrows
indicate representative apoptotic/necrotic cells. The experiment was conducted at least three times. Green = viable cells, red = apoptotic/necrotic cells. Magnification, 200-
fold. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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assay that has already been very successfully applied with regard
to the dissection of signaling pathways activated by G protein-
coupled receptors [8]. The DMR assay is very sensitive in terms
of picking up cell signals, and therefore, we hoped that we could
use cNMP-AMs at lower concentrations than for mimicry of ExoY
effects (Figs. 2, 3, S2 and S3) [5]. Such a procedure would facilitate
studies with inhibitors of known cNMP targets, i.e. PKA and PKG
because such inhibitors compete with intracellular cNMPs for
binding to kinases [13]. cAMP-AM up to 100 lM had no effect on
DMR in HEK cells (Fig. 4A). cGMP-AM exhibited only a small and
delayed signal (Fig. 4B). In marked contrast, cCMP-AM induced
large and sluggish DMR signals, reaching saturation between 50
and 100 lM (Fig. 4C). cUMP-AM (100 lM) induced substantial lar-
ger DMR signals than cCMP-AM (Fig. 4D). In contrast to cCMP-AM,
cUMP-AM also exhibited a pronounced rapid DMR response phase.
In addition, the cUMP-AM response was not yet saturated at
100 lM. Control experiments revealed that PO4-AM3, the non-
esterified cNMPs themselves and the membrane-permeable Epac
activator 8-pCPT-20-O-Me-cAMP (up to 300 lM) had no effect on
DMR responses (data not shown). A combination of PKG inhibitors
suppressed the responses of cUMP-AM more effectively than a
combination of PKA inhibitors (Fig. 4E). The addition of PKA inhib-
itors on top of PKG inhibitors exhibited no additional inhibitory
effect. Whereas PKA inhibitors strongly inhibited the DMR
response of cCMP-AM, PKG inhibitors potentiated the cCMPresponse and unmasked a rapid signature (Fig. 4F). Addition of
PKA inhibitors on top of PKG inhibitors had no additional effect.
Similar to the observations made for HEK293 cells, cCMP-AM
induced a delayed DMR response in B103 cells (Fig. S4). Again,
PKA inhibitors strongly reduced the cCMP-AM signal, whereas
PKG inhibitors unmasked a rapid cCMP-AM response. PKA inhibi-
tors had no effect in the presence of PKG inhibitors. In HEK293
cells, cCMP-AM slightly increased c-Fos expression (Fig. S5). The
effect of cCMP-AM on c-Fos expression was strongly potentiated
by a PKA or PKG inhibitor and a combination of both inhibitors.
Finally, we assessed the effects of cCMP and cUMP on the activity
of purified Epac. cCMP up to 100 lM, in contrast to cAMP, had vir-
tually no stimulatory effect on Epac, and even an increase of cCMP
of up to 1 mM resulted only in a minimal response (Fig. S6). cUMP
was ineffective at activating Epac.
4. Discussion
cNMP-AMs enter cells and release the cNMP into the cytosol
following cleavage of the ester. Sustained and high cNMP levels
result, with no marked evidence for cross-regulation of other
cNMPs by a given cNMP-AM. The control compound PO4-AM3 is
also inert with respect to cNMP increases. The combination of
cGMP-AM and cUMP-AM mimics the effects of the P. aeruginosa
nucleotidyl cyclase toxin ExoY with respect to intracellular cGMP
and cUMP levels and cytotoxicity [5]. The combination of both
0 20 40 60 80
0
25
50
75
100
100 µM
30 µM
buffer
50 µM
10 µM
cAMP-AM
time [min]
re
sp
on
se
 (p
m
)
0 20 40 60 80
0
25
50
75
100 100 µM
30 µM
buffer
50 µM
10 µM
cGMP-AM
time [min]
re
sp
on
se
 (p
m
)
0 20 40 60 80
0
25
50
75
100 100 µM
30 µM
buffer
50 µM
10 µM
cCMP-AM
time [min]
re
sp
on
se
 (p
m
)
0
100
200 100µM
50µM
30µM
10µM
buffer
cUMP-AM
0 20 40 60 80 100 140 160120
time [min]
re
sp
on
se
 (p
m
)
0 20 40 60 80
0
20
40
60
cCMP-AM + PKA-combi
cCMP-AM + PKG-combi
cCMP-AM
buffer
Effects of PK-inhibitors on cCMP-AM
cCMP-AM + PKA- + PKG-combi
time [min]
re
sp
on
se
 (p
m
)
Effects of PK-inhibitors on cUMP-AM
0
100
200
300
400
500 cUMP-AM
cUMP-AM + PKA-combi
cUMP-AM + PKG-combi
buffer
cUMP-AM +PKA- +PKG-combi
0 20 40 60 80 100 120
time [min]
re
sp
on
se
 (p
m
)
A B C
D E F
Fig. 4. DMR responses in HEK293 cells treated with cNMP-AMs. DMR tracings of HEK293 cells treated with cAMP-AM (A), cGMP-AM (B), cCMP-AM (C), and cUMP-AM (AM)
(D) for 80 min. (E) HEK293 cells treated with 50 lM cUMP-AM in the presence or absence of PKA inhibitors (500 lM Rp-8-Br-cAMPS and 500 lM Rp-cAMPS) and/or PKG
inhibitors (300 lM Rp-8-Br-PET-cGMPS and 500 lMRp-8-pCPT-cGMPS). (F) HEK293 cells treated with 10 lM cCMP-AM in the presence or absence of PKA inhibitors (500 lM
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inhibitors alone in the absence of cNMP-AMs.
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functionally not equivalent because only cUMP-AM induced mor-
phological changes alone and moreover, cGMP-AM and cUMP-
AM exhibited differential effects on gene expression.
cCMP-AM and cUMP-AM induce pronounced DMR responses.
The responses were observed at low compound concentrations
(10–100 lM) and were not mimicked by cAMP-AM, cGMP-AM,
PO4-AM3 or non-esterified cNMPs. All these data indicate the
DMR responses by cCMP-AM and cUMP-AM are specific for the
intracellularly released cNMP. Dissection between effects of cCMP
and cUMP versus cAMP and cGMP is critical for postulating a sec-
ond messenger role of the former cNMPs. Both, the effects of cCMP
and cUMP are partially mediated by PKA as revealed by the partial
inhibitory effects of PKA inhibitors. The EC50 values of cCMP and
cUMP for PKA and PKG activation [14] fit well to the concentra-
tions required for induction of DMR responses by cNMP-AMs.
cCMP and cUMP are also partial activators of purified PKG [14],
and modulation of DMR responses of cCMP-AM and cUMP-AM
by PKG inhibitors is consistent with a role of PKG in cell responses.
However, while in the case of cUMP, PKG plays a stimulatory role,
in case of cCMP, PKG exerts a tonic inhibition that is released by
PKG inhibition and dominates the PKA regulation. These data also
indicate that cCMP and cUMP act via different mechanisms. This
interpretation is supported by the different cCMP and cUMP kinet-
ics. An implication of these data is that ExoY from P. aeruginosa
(predominantly increasing cUMP) and CyaA from B. pertussis
(predominantly increasing cCMP) [5] manipulate mammalian
signal transduction pathways in different manners and address
distinct intracellular targets. Furthermore, there is no evidence
for a role of Epac in DMR responses. Most importantly, the persis-
tence of cCMP-AM DMR and gene expression responses in the
presence of PKA and PKG inhibitors and the inefficiency of cCMP
and cUMP at activating Epac indicate that additional effector
proteins for these cNMPs exist.In conclusion, the present study has made an important contri-
bution towards elucidation of the pathophysiological effects of
ExoY and different second messenger functions of cCMP and cUMP.
cGMP and cUMP, can be clearly dissociated from each other, and
cCMP and cUMP induce distinct cellular responses that cannot be
explained by the known cNMP effector proteins PKA, PKG and
Epac. The next two steps in the elucidation of the second messen-
ger functions of cCMP and cUMP are straightforward. First, we
need to identify the specific binding proteins of cCMP and cUMP.
The appropriate methodologies are already in place [15]. Second,
the research community is invited to follow the paradigm outlined
in this study and examine the biological effects of cNMP-AMs alone
and in combination in multiple systems to understand the
(patho)physiological roles of cUMP and cCMP. A recent study
revealed that cCMP and cUMP are present in numerous mamma-
lian cell culture lines and primary mammalian cells and that any
given cell type possesses a unique cNMP pattern [16]. Based on
these data it can be assumed that cCMP and cUMP play important
biological roles in many systems. These cNMP roles can be
unmasked with cNMP-AMs. Lastly, it should be kept in mind that
it is not only important to add a single cNMP-AM to cells. Rather,
cNMP-AM combinations are critical, mimicking intracellular cNMP
patterns.
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 Epilogue 
In  comparison  to  other  domains  of  life,  cUMP  and  cCMP  are mainly  present  in mammalian  cells 
suggesting  that,  from  an  evolutionary  perspective,  cUMP  and  cCMP  represent  a  relatively  young 
group of substances1. This might indicate that these molecules undertake a more specialized task in 
the signaling network of mammalian cells. Due to the organization of signaling networks by so‐called 
signaling hubs,  it  is not surprising that canonical and non‐canonical cNMPs show overlapping target 
specificity.  In  this  chapter, we  have  shown  that  both  cCMP  and  cUMP  signal  via  interaction with 
protein  kinase  A  (PKA)  and  protein  kinase G  (PKG),  targets  that  are  frequently  associated  to  the 
signaling axis of cAMP and cGMP. These protein kinases are key regulators  in the wide spectrum of 
biological  functions of canonical cyclic nucleotide second messenger. However, we  found that non‐
canonical  cNMPs do not  target exchange proteins directly activated by  cAMP  (epac), which act as 
guanine nucleotide exchange factors (GEF) for small GTPases such as Rap2. Furthermore, the holistic 
DMR  readout  could  clearly  distinguish  between  the  signal  composition  of  cAMP/cGMP  and 
cCMP/cUMP. The unbiased real‐time methodological approach even allowed distinguishing between 
cCMP and cUMP mediated cell response, since the non‐canonical cNMPs are differently modulated 
by PKG. While PKG plays a stimulatory role  for cUMP‐signaling,  it acts as an  inhibitory regulator of 
cCMP‐signaling. Moreover, the non‐canonical cNMPs,  in contrast to cAMP and cGMP, show overall 
different kinetics  in the process of cell activation, another  indicator of different biological  function. 
This  notion  is  substantiated  by  distinct  pathophysiological  consequences  of  infection with  either 
bacterial  toxin  ExoY  or  CyaA, which  can  clearly  distinguish  in  the  activation  of  cUMP  and  cCMP 
production, and  the  infection with edema  factor  (EF) derived  from Bacillus anthracis  that primarily 
increases cAMP  levels.  In synopsis with data  from other publications  regarding  the generation and 
termination of cCMP and cUMP, these molecules can now be classified as true second messengers3. 
This  study demonstrated  the  importance of powerful and well‐characterized  tool  compounds  that 
interrogate the label‐free readout to decode signal transduction. As described in chapter 1 and 2 and 
several other publications4–6,  the explanatory power of  label‐free  readouts  inevitably  relies on  the 
availability of and the combination with tool compounds. 
As  already  mentioned  in  the  introductory  section,  signal  transduction  pathways  are  better  be 
conceived as signaling networks rather than  linear pathways because they are  inevitably associated 
with high structural texture and complexity that will continue to challenge researchers to thoroughly 
investigate  signal  transduction  processes7.  Tending  to  oversimplification  or  reductionism  in  the 
overall  approach  in  drug  research  is  sometimes  indispensable  with  regard  to  the  challenge  of 
studying  complex  biological  processes.  Indeed,  this  approach  results  in  considerable  short‐term 
success, although long‐term achievements are with regard to high attrition rates of drug candidates 
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in all stages of the development process questionable8–10. Label-free techniques, such as dynamic 
mass redistribution assays, provide an important means to display biological processes authentically 
and thus broaden the view to a more translational biology-orientated approach. The perception of 
these innovative methods indicates a general reorientation to holistic readouts, such as whole organ 
experiments, which were at the forefront of drug discovery in former times11,12. Intriguingly, in these 
same times, many medically highly valuable drugs were discovered. With regard to the shift in 
mindset, the return of holistic label-free methods is sometimes described as a “back to the future-
approach”13.  
Label-free assays were used in every previous chapter of this thesis. However, unlike in the 
aforementioned chapters, where we focused on the investigation of signaling mediated by surface 
receptors, we here used the DMR technique to study signal transduction at a post-receptor level, 
which is – to our knowledge – the first report on the attempt to decipher cell signaling beyond 
membrane receptor generated cell responses using this methodological approach. 
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 Prologue 
Studying signal transduction at both the receptor and the post-receptor level indispensably demands 
for well-suited methods to selectively inhibit distinct components in signaling networks. For instance, 
this can be achieved genetically by knock-down or knock-out, or pharmacologically using molecular 
inhibitors as tools. Since defects or dysfunction of signal transduction is the crux of the matter in 
almost all diseases, discovering inhibitors of certain signaling events represents an attractive goal for 
future treatment options1. The understanding of their mode-of-action is essential to gain mechanistic 
insights into signaling networks. Compounds that activate (agonists) or inhibit (antagonists) signaling 
at the receptor level have been widely used with great success to decipher signal transduction. If 
selective perturbation of distinct receptors is amenable, inhibitors attract much attention. However, 
although equally relevant, pharmacological inhibition at the post-receptor level is largely 
underexploited2 and thus mechanistic studies on the inhibition of signaling partners at this level are 
often lacking.  
As already detailed in the introduction, G protein-coupled receptors (GPCRs) represent cellular 
signaling hubs that regulate the signal generation from outside the cell into the intracellular 
compartments. These receptors are extremely variable and can produce a plethora of different 
cellular signaling events3–5. Therefore, they are ideal targets to study the regulation of signaling 
networks. G proteins belong to the group of GTPases and are molecular switches that play a crucial 
role in the transmission of cell signaling6,7. These proteins can occur in an inactive, GDP-bound, and 
an active, GTP-bound, state that are regulated by interaction with other proteins such as guanine-
nucleotide exchange factors (GEFs) or GTPase-activating proteins (GAPs). Heterotrimeric G proteins 
consist of three subunits (α, β and γ), of which the α subunit is a target for specific G protein 
inhibition. The bacterial product pertussis toxin (PTX) from Bordetella pertussis selectively inhibits 
Gαi subunits by ADP-ribosylation and thereby prevents Gαi signaling through uncoupling of the G 
protein from the receptor. The natural product YM-254890 from Chromobacterium sp. was 
characterized as selective Gαq inhibitor8,9. YM-254890 restricts GDP exit from the guanine nucleotide-
binding pocket within the αq subunits by impairing the linker flexibility between the GTPase and the 
helical domain and is therefore dubbed guanine nucleotide dissociation inhibitor (GDI). However, no 
cell membrane-permeable compound to date can inhibit Gαs or Gα12/13.  
BIM-46174 (= BIM) and its dimer BIM-46187 were initially published as pan-G protein inhibitor and 
thus could represent attractive compounds to distinguish between G protein-dependent and G 
protein-independent GPCR-mediated signaling10,11. In this chapter, BIM is characterized in detail and 
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is redefined as a G protein inhibitor that does not act as a pan G protein inhibitor in all cells, but as a 
selective Gαq-inhibitor in a cell-type dependent manner. As the aforementioned chapter clearly 
stated, tool compounds that selectively modulate distinct signaling events proof valuable as 
“signaling decoders”. G protein inhibitors that function as such “signaling decoders” will help 
understanding signaling networks in both physiological and pathological contexts. 
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In spite of the crucial role of heterotrimeric G proteins
as molecular switches transmitting signals from
G protein-coupled receptors, their selective manipu-
lation with small molecule, cell-permeable inhibitors
still remains an unmet challenge. Here, we report
that the small molecule BIM-46187, previously clas-
sified as pan-G protein inhibitor, preferentially si-
lences Gaq signaling in a cellular context-dependent
manner. Investigations into its mode of action reveal
that BIM traps Gaq in the empty pocket conformation
by permitting GDP exit but interdicting GTP entry, a
molecular mechanism not yet assigned to any other
small molecule Ga inhibitor to date. Our data show
that Ga proteins may be ‘‘frozen’’ pharmacologically
in an intermediate conformation along their acti-
vation pathway and propose a pharmacological
strategy to specifically silence Ga subclasses with
cell-permeable inhibitors.
INTRODUCTION
Heterotrimeric abg guanine-nucleotide-binding proteins (G
proteins) are molecular switches that relay signals from activated
G protein-coupled receptors (GPCRs) to (intra)-cellular effector
systems such as ion channels or enzymes that, in turn, control890 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Lproduction, release, or degradation of second messengers
(Wall et al., 1998; Neves et al., 2002; Milligan and Kostenis,
2006; Johnston and Siderovski, 2007; Oldham and Hamm,
2008). These G proteins function by adopting two principal
conformational states: an ‘‘off state’’ in which guanosine diphos-
phate (GDP)-bound Ga is in complex with the Gbg heterodimer,
and an ‘‘on state’’ in which guanosine triphosphate (GTP)-bound
Ga is liberated from its Gbg binding partner. Ligand-activated
GPCRs act as guanine nucleotide exchange factors (GEFs) for
G proteins that stimulate exchange of GDP for GTP on the Ga
subunit (Wall et al., 1998; Johnston and Siderovski, 2007; Old-
ham and Hamm, 2008; Kimple et al., 2011). Crystal structures
have been resolved for both GDP-bound inactive and GTP-
bound active conformations and have shed light on the discrete
differences of these nucleotide-dependent conformational
states (Oldham and Hamm, 2008). Consequently, efforts have
been undertaken to develop nucleotide-state-selective inhibitors
for both inactive GDP-bound heterotrimers and active GTP-
bound Ga or Gbg dimers (Johnston et al., 2008; Bonacci et al.,
2006). Despite enormous advances in understanding structure
and function of Ga proteins at a mechanistic level since their
discovery, very few small molecule Ga subunit inhibitors with ac-
tivity in whole cells have been reported to date (Smrcka, 2013). In
fact, of the four families of Ga proteins (Gai/o, Gas, Gaq/11, and
Ga12/13) only Gai/o proteins can be specifically inhibited with
pertussis toxin (PTX), which has served as an invaluable probe
toanalyzeGPCRsignalingmechanismsandGai-mediated cell re-
sponses (Mangmool and Kurose, 2011; Saulie`re et al., 2012;
Ashkenazi et al., 1989; Wong et al., 1991; Itoh et al., 2003). PTX,
however, cannot be considered a small molecule but representstd All rights reserved
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Trapping Gaq in the Empty Pocket Conformationa typical A-B toxin using its A protomer to ADP-ribosylate Gai/o
protein family members and thereby uncouple receptors from
their cognate G proteins (Mangmool and Kurose, 2011; West
et al., 1985). YM-254890, a cyclic depsipeptide isolated from
the fermentation broth of Chromobacterium sp. QS3666, has
recently been shown to specifically silence function of Gaq/11 pro-
teins, includingGa14 (Takasaki et al., 2004;Nishimura et al., 2010).
YM-254890 is the only inhibitor for which high-resolution
structural information is available to provide the framework for
understanding its mechanism of action at the molecular level.
A major shortcoming of YM-254890 is that it is not commercially
available and, therefore, is only accessible for very few research
laboratories worldwide.
In spite of their diverse structures, all inhibitors of Ga function
apparently share a common mechanism of action, i.e., bind to
Ga subunits to prevent receptor-mediated or intrinsic nucleotide
exchange (Smrcka, 2013). This mechanism of action also was
proposed for two small molecules, BIM-46174 and BIM-46187,
suggested as experimental anticancer drugs (Pre´vost et al.,
2006; Ayoub et al., 2009). BIM-46174 was identified in a differen-
tial screening approach as a molecule that inhibits cyclic AMP
(cAMP) production in MCF7 cancer cells that were pretreated
with the irreversible Gas activator choleratoxin but not in those
pretreated with the direct adenylyl cyclase activator forskolin
(Pre´vost et al., 2006). Such a screening strategy allows identifi-
cation of compounds that target Gas proteins but not Gas-sensi-
tive receptors or adenylyl cyclases. Additional mechanistic
investigations revealed that both BIM molecules display an
intriguing pharmacological phenotype in that they do not only
target heterotrimeric G proteins of the Gas family but also target
Gaq/11, Gai/o, andGa12/13 proteins, a feature referred to as pan-G
protein inhibition (Pre´vost et al., 2006; Ayoub et al., 2009).
An initial goal of the present studywas to take advantage of the
pan-G protein inhibitory nature of BIM-46187 to specifically
investigate G protein-independent signaling. However, we found
that BIM-46187 does not abolish signaling of all Ga subfamilies
equally but instead acts in a cellular context-dependent manner,
ranging from pan-G protein inhibition to selective Gaq silencing.
We identified mammalian human embryonic kidney 293
(HEK293) and Chinese hamster ovary (CHO) cells, two cell lines
frequently used to examine signaling of recombinant or endoge-
nous GPCRs, as hosts in which BIM-46187 specifically silences
Gaq over Gas, Gai, and Ga13 proteins. Based on the Gaq-specific
inhibition, we investigated the molecular mechanism underlying
BIM-46187 action. Our results are consistent with the idea that
BIM-46187 targets Ga proteins and show that it interferes with
agonist function, but not agonist binding to Gaq-sensitive
GPCRs, by exhibiting amechanism not yet assigned to any other
small molecule Ga inhibitor to date.
RESULTS
BIM-46174 and themore stable derivative BIM-46187 (Figure 1A,
also referred to as BIM-monomer and BIM-dimer, respectively)
are two small molecules that interdict signaling of GPCRs by
direct binding to and inhibition of a subunits of heterotrimeric
G proteins (Pre´vost et al., 2006; Ayoub et al., 2009). Both mole-
cules are thought to inhibit all Ga subfamilies equally and there-
fore serve to silence receptor signaling in complex pathologiesChemistry & Biology 21,that involve multiple GPCRs (Smrcka, 2013; Pre´vost et al.,
2006). We wanted to take advantage of the pan-G protein inhib-
itors to specifically dissect G-protein-dependent versus G-pro-
tein-independent signaling events mediated by cell surface
GPCRs. We hypothesized that the free thiol group-containing
monomeric BIM should be intrinsically sensitive to oxidation;
therefore, we initially investigated stability in aqueous solution
(D2O) over time by nuclear magnetic resonance (NMR) spectros-
copy (Figure 1B). NMR spectra are clearly indicative of BIM-
monomer oxidation in a time-dependent manner: After 48 hr,
BIM-monomer is virtually undetectable (Figure 1C). Since the
integration area of the signals correlates with the concentration
of BIM-monomer, we were able to deduce a half-life of 11.4 hr
for this first-order reaction (Figure 1D and Table S1 available
online). We reasoned that oxidation of BIM-monomer should
depend on the presence of reducing agents and therefore
examined stability by NMR in D2O containing reactive thiols
(L-cysteine, glutathione [GSH]), and mercaptoethanol. Indeed,
under these conditions, quantitative formation of covalent
complexes with selected thiols was observed: BIM-cysteine,
BIM-mercaptoethanol, and BIM-dimer (Figure S1). Additionally,
we investigated the stability of both BIM-monomer and -dimer
during cellular assays by analyzing the cell culture supernatant
with liquid chromatography-mass spectrometry. We identified
BIM-cysteine, BIM-mercaptoethanol, BIM-dimer, or BIM-mono-
mer, respectively, after 24 hr at 37C (Figure S2). These data
suggest that (1) assessment of biological activity of BIM-
monomer should take into account that extracellular BIM-mono-
mer might be entirely converted to BIM-dimer during the assay
period, and (2) that both BIM molecules are prone to formation
of redox-reversible adducts when thiol-containing components
are present. This notion might be particularly relevant when anti-
proliferative activity of BIM is assessed, because such assays
typically range from many hours to days.
Despite the short duration of assays that assess GPCR activity
by quantifying intracellular secondmessengers and the absence
of reducing agents in these assays, we chose the chemically
more stable BIM-dimer for further studies. In agreement with
the inability of BIM to affect cAMP production in the breast can-
cer MCF7 and COS7 cell background upon stimulation with the
direct adenylyl cyclase mimetic forskolin (Pre´vost et al., 2006;
Ayoub et al., 2009), it did not blunt cAMP synthesis in forsko-
lin-stimulated HEK293 cells (Figure 2A). It is surprising, however,
that BIM also was largely ineffective when cAMP production was
triggered with prostaglandin E1 (PGE1), a bona fide stimulus of
the Gas-linked E prostanoid EP2 and EP4 receptors that are
endogenously expressed in this cell system (Figure 2B). Proper
functionality of our cAMP assay was ascertained by preincuba-
tion of cells in the presence of an EP2/EP4 antagonist, which
completely blunted PGE1-mediated cAMP synthesis (Figure S3).
Lack of BIM inhibition of Gas-coupled receptor signaling is not
due to BIM decomposition during the assay period, because
BIM significantly dampened EP2/EP4 receptor signaling in a
COS7 cell background (Figure 2C). We therefore reasoned that
BIM interferes with G protein signaling in a cell-type-specific
manner. Such a pharmacological phenotype would be of rele-
vance for an anticancer agent, particularly if it is applied under
the assumption that the entire set of G protein pathways is
silenced simultaneously in any cell type.890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 891
Figure 1. Structures of BIM-Monomer and BIM-Dimer and Stability in Aqueous Solution, D2O, as Determined by NMR Spectroscopy
(A) Chemical structures of the BIM-monomer and the BIM-dimer.
(B) 1HNMRof the BIM-monomer at t = 0 hr. The signals at d = 7.4–7.8 ppmbelong to the protons of the aromaticmoiety and the imidazole ring. The signal at d = 6.0
ppm corresponds to the proton in position 2 and the area from d = 4.0 to 5.0 ppm comprises the protons of position 12, 13 and 15 partially overlayed by the
residual solvent (DOH) signal. At about d = 3 ppm, the diastereotopic methylene protons next to the thiol group resonate (position 16), followed by the DMSO
signal and the high-field shifted protons of the cyclohexylmethyl group.
(C) Oxidation of the BIM-monomer over time. The oxidation process can be observed using the protons in position 2 and 16. At t = 0 hr, only the proton signals of
the monomer were observed. Within 48 hr, the integration areas of the signals of the monomer protons decrease, while the dimer signals increase until 100%
dimer was observed at t = 48 hr. h, hours. R-SH denotes BIM-monomer, and R-S-S-R denotes BIM-dimer.
(D) A diagram of the natural logarithm of the concentration (ln c) of BIM-monomer versus time. Since the integration area of the signals in (C) correlates with the
concentration of the BIM-monomer, a half-life of 11.4 hr is calculated for this first-order reaction.
See also Figures S1 and S2 and Table S1.
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Trapping Gaq in the Empty Pocket ConformationTo explore the consequences of BIM exposure for function-
ality of the remaining G protein pathways, HEK293 cells were
treated with a set of different stimuli for Gai-, Gaq-, and Ga13-
linked receptors that are natively or were exogenously ex-
pressed in this cell system. It is interesting that preincubation
of cells with BIM completely abolished signaling of Gaq-sensitive
receptors (Figures 3A–3C) but hardly affected signaling of those
that are functionally coupled to Gai proteins (Figures 3D–3F).
Even when cells were preincubated with 100 mM of BIM—the
highest applicable concentration—robust Gai activation was still
detected. A similar lack of BIM inhibition was observed when
GPCR engagement of Ga13 signaling was recorded using
lysophosphatidylinositol and its target receptor GPR55 in
bioluminescence resonance energy transfer (BRET) assays.892 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier LWe recorded a substantial agonist-promoted decrease in
BRET in cells coexpressing GPR55 along with the energy donor
Ga13-106RLuc8, the energy acceptor Gg2-GFP
10, and unlabeled
Gb1. This BRET decrease reflects the separation of the Ga-heli-
cal domain from the N terminus of Gg thereby creating the route
for GDP exit and GTP entry (Gale´s et al., 2006; Saulie`re et al.,
2012). Pretreatment of transfected cells with BIM did not alter
GPR55-Ga13 activation (Figure 3G) but significantly blunted acti-
vation-dependent rearrangement of the Gaq-b1g2 heterotrimer
triggered with carbachol via muscarinic M3 receptors (Fig-
ure 3H). These results suggest that the BRET partners used
are suitable for examining inhibition of G protein signaling by
BIM and that BIM is competent to interdict Gaq but not Ga13
signaling.td All rights reserved
Figure 2. Effects of BIM on Cellular cAMP Levels in an HEK293 and
COS7 Cell Background
(A) Increasing concentrations of BIM do not lower forskolin-mediated cAMP
production in HEK293 cells.
(B) BIM slightly diminishes cAMP signaling of the Gas-sensitive EP2/EP4 re-
ceptors in HEK293 cells. Negative logarithm of EC50 (pEC50) for PGE1 (without
[w/o] BIM) = 8.91 ± 0.07; pEC50 for PGE1 (100 mM BIM) = 8.29 ± 0.06.
(C) BIM largely suppresses prostaglandin E1-mediated cAMP production in
COS7 cells. Data shown in (A) through (C) are mean values ± SEM of three to
ten independent experiments, each performed in triplicate.
See also Figure S3.
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Chemistry & Biology 21,So far, BIM has been applied to a number of different cancer
cell lines, such as breast cancer MCF7 and human colorectal
cancer HCT8/S11 and HT29, among many others (Ayoub
et al., 2009; Pre´vost et al., 2006). Nonetheless, its utility to silence
all G protein signaling pathways in immortalized cell lines that are
frequently used for recombinant expression such as HEK293 or
CHO is undefined. So far, only COS7 cells have been used as an
immortalized host in elegant studies to examine the mechanism
of BIM action in great detail (Ayoub et al., 2009). We therefore
investigated the influence of BIM on second messenger path-
ways using CHO cells as an expression system. Again, BIM
did not exert pan-G protein inhibitory activity but rather targeted
Gaq proteins as evidenced by the clear preference to interdict
signaling of the Gaq-sensitive muscarinic M1 receptor over
Gas-linked prostanoid and Gai-linked serotonin receptors (Fig-
ures 4A–4C). A similar preference for inhibition of Gaq-signaling
was observed when monomeric BIM was applied in analogous
second messenger assays, both in CHO (Figures 4D–4F) and
HEK cell backgrounds (Figures 4G–4I). From these data, we infer
that (1) cellular context-dependent inhibition of Gaq signaling is
not related to the inability of the cells to convert dimeric BIM
into its reduced counterpart, and hence to different reductive ca-
pacities of cells; and (2) dimeric BIM is superior to monomeric
BIM for silencing of Gaq signaling, at least in the CHO and HEK
cell backgrounds.
We next addressed whether the absence of pan-G protein
inhibition may be related to the export of BIM via multidrug
transporters. If BIMwas a substrate for active outward transport,
inhibition of BIM efflux by coadministration of a transport inhibi-
tor should improve its capacity to interdict Gaq signaling. To test
this assumption, we pretreated HEK cells, which endogenously
express multidrug transporters, with MK571 or elacridar to block
efflux protein activity. MK571 inhibits MRP1 and MRP2, two
transporters that export hydrophilic molecules and GSH conju-
gates (Wortelboer et al., 2003; Leyers et al., 2008). Elacridar in-
hibits P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP), the former preferring hydrophobic and the latter trans-
porting rather diverse and nonconjugated compounds (Ahmed-
Belkacem et al., 2005). None of the applied inhibitors rendered
Gaq signaling more sensitive toward BIM inhibition (Figure S4).
Thus, we conclude that export of BIM via multidrug transporters
does not account for cell-type-specific differences in G protein
inhibition profiles.
It is interesting to note that BIM displays antiproliferative ef-
fects in HEK cells (Pre´vost et al., 2006) yet only silences Gaq
signaling in this cellular background. Furthermore, the effective
concentration of BIM to inhibit cellular proliferation is much lower
as compared with the concentration required to achieve full
silencing of Gaq signaling (compare Pre´vost et al., 2006 with Fig-
ure 3). Such data imply that inhibition of Gaq signaling may be
sufficient for blockade of cellular proliferation or that the antipro-
liferative effects of BIM are unrelated to pan-G protein inhibition.
To explore a mechanistic link between G protein inhibition and
abrogation of cell growth, we chose to directly compare these
parameters in the patient-derived human skin cancer cell line
MZ7. BIM exhibited concentration-dependent inhibition of cell
growth in MZ7 cells as evidenced by crystal violet staining
and determination of cell viability in parallel treatment groups
(Figure 5A). A similar reduction of cell growth was obtained on890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 893
Figure 3. BIM Interdicts Gaq Signaling but Not Gai or Ga13 Signaling in HEK293 Cells
(A–C) BIM (100 mM) silences Gaq activation induced by stimulation of three Gaq-sensitive receptors (muscarinic M3, P2Y, and FFA2) with their cognate agonists
carbachol, ATP, and propionic acid, respectively. w/o, without.
(D–F) BIM (100 mM) hardly affects productive Gai interaction of FFA2 and FFA3, as well as OXE-R.
(G and H) BIM does not block molecular rearrangement of activated Ga13 (G) but efficiently dampens activation of the Gaq-BRET biosensor (H). Opening of the
nucleotide binding pocket is detected as BRET decrease after receptor activation in HEK293 cells transfected to express Ga13-106RLuc8 + Gg2-GFP
10 +
unlabeled Gb1 (G) or Gaq-97RLuc8 + Gg2-GFP
10 + unlabeled Gb1 (H). ***p < 0.001; n.s., not significant.
The means ± SEM in (A) through (F) or + SEM in (G) and (H) of three to six independent experiments, each conducted in triplicate, are shown.
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Trapping Gaq in the Empty Pocket Conformationtreatment with the DNA-replication inhibitor aphidicolin, which
inhibits cell cycle progression at the G1/S phase (Figure 5A).
However, aphidicolin-arrested cells resumed cell growth on in-
hibitor removal as opposed to BIM-treated cells, indicating that
BIM likely induces cell death. It is interesting that inhibition of
cell growth by BIM was maximal at 10 mM, yet an even greater
10-fold increase of BIM concentration was required to dampen
cellular signaling via Gai, Gas, and Gaq pathways (Figures 5B–
5D). BIM inhibition of second messenger pathways appears to894 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Loccur specifically at the level of the G proteins, even at these
high concentrations, because prior addition of 100 mM BIM
completely blocked endothelin-1, but not thapsigargin-induced
Ca2+ mobilization (Figure 5B), and because BIM did not lower
cAMP production triggered with forskolin (Figure S5) but
completely prevented cAMP formation in response to adreno-
corticotropic hormone (ACTH), a stimulus for the Gas-sensitive
melanocortin 1 (MC1) receptor (Figure 5C). Together, these
data indicate that BIM does indeed silence all three secondtd All rights reserved
Figure 4. Monomeric and Dimeric BIM Preferentially Silence Gaq Signaling in a CHO and HEK293 Cell Background
(A–C) Dimeric BIM almost completely blunts Gaq signaling over Gas and Gai signaling in CHO cells transfected to express the muscarinic M1 receptor (A) or
endogenously expressing Gas-linked EP2/EP4 receptors (B) and the Gai-sensitive serotonin 5-HT receptors (C).
(D–F) Monomeric BIM resembles dimeric BIM in its ability to preferentially silence Gaq signaling of the muscarinic M1 receptor (D) over Gas signaling of EP2/EP4
receptors (E) or Gai signaling of serotonin 5-HT receptors (F) in a CHO cell background yet displays reduced potency and efficacy.
(G–I) Monomeric BIM partially diminishes Gaq activation of the muscarinic M3 receptor in HEK293 cells (G) but does not dampen signaling mediated via
Gas-sensitive EP2/EP4 receptors (H) or Gai-sensitive CRTH2 receptors (I). Means ± SEM of at least three experiments, each conducted in triplicate, are shown.
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Trapping Gaq in the Empty Pocket Conformationmessenger pathways in the cancer MZ7 cell background but at
concentrations clearly exceeding those required to inhibit cell
growth. This discrepancy may be explained by (1) short (second
messenger assays) versus long (cell growth assays) BIM prein-
cubation times; (2) cumulative/cooperative effects of BIM in
cell growth assays, where multiple signaling pathways are
silenced simultaneously; and/or (3) abrogation of ligand-stimu-
lated signaling (second messenger assays) versus endogenous
receptor signaling (cell growth assays).
Context-dependent pharmacology of GPCR ligands is a well-
known phenomenon that is widely appreciated. Often, cell-type-
specific differences in the relative amount or stoichiometry of
signaling components may account for functionally differentChemistry & Biology 21,effects of ligands across cell lines (Kenakin and Christopoulos,
2013). We therefore investigated whether the extent of BIM inhi-
bition may be related to the level of expression of its protein
target. To this end, HEK293 cells were enriched with increasing
amounts of Gaq proteins using a gene dosing approach (Figures
6A and 6B), and sensitivity of Gaq proteins toward BIM inhibition
was examined in assays monitoring inositol monophosphate
(IP1) production upon stimulation of endogenous muscarinic
M3 receptors with carbachol. Indeed, a clear correlation be-
tween BIM inhibition and Gaq expression could be detected:
BIM inhibition gradually declined when cellular abundance of
Gaq proteins was raised (Figure 6C). These data imply a link be-
tween the expression level of BIM target proteins and the extent890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 895
Figure 5. BIM Inhibits Cell Growth and Second Messenger Production in the Patient-Derived MZ7 Cancer Cell Background
(A) MZ7 cancer cells were exposed to the indicated concentrations of BIM or the cell cycle inhibitor aphidicolin for 72 hr and cell proliferation was assessed by
crystal violet staining (green bars). In parallel treatment groups cell viability wasmeasured using the XTT-based cell viability kit (orange bars), means + SEM, n = 3.
(B) In (i), untreated MZ7 cells respond to both the Gaq–stimulus endothelin-1 (ET-1) and thapsigargin (Thaps). (ii) BIM completely blunts Ca
2+ mobilization
triggeredwith ET-1 but does not impair thapsigargin-induced release of Ca2+ from the endoplasmic reticulum. (iii) Quantification of Ca2+ traces in the absence and
presence of BIM in single cells. Data in (i) and (ii) show representative traces; data in (iii) are means + SEM of n = 159 cells. sec, seconds. ***p < 0.001.
(C) At a concentration of 100 mM, BIM silences Gas-mediated cAMP production induced via ACTH and its cognate Gas-linked MC1 receptor.
(D) BIM diminishes Gai coupling of endogenous ET-1 receptors. Data shown in (C) and (D) are means ± SEM of three to ten independent experiments, each
conducted in triplicate.
See also Figure S5.
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Trapping Gaq in the Empty Pocket Conformationof BIM inhibition. We reasoned that the disparate G protein inhi-
bition profiles observed in MZ7 versus HEK293 cells might also
be related to cellular Ga abundance and quantified expression
of Gaq, Gas, and Gai proteins by immunoblotting in both cell896 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Llines. Figures 6D–6F reveal equal expression of Gaq but sig-
nificantly lower abundance of Gas in theMZ7 background. These
data lend further support to the notion that Ga subunit ex-
pression and BIM inhibition might be mechanistically linked.td All rights reserved
Figure 6. Mechanistic Link between Sensitivity toward BIM Inhibition and Cellular Abundance of BIM Target Proteins
(A) Immunoblot detection of HEK293 lysates prepared after transfection with the indicated amounts of Gaq plasmid complementary DNA harboring an
internal HA-epitope tag. Membranes were reprobed for tubulin to ensure equal sample loading and transfer. Shown is one representative of four independent
experiments.
(B) Densitometric analysis of the immunoblot experiments depicted in (A). Means ± SEM of four individual experiments are shown.
(C) Enrichment of HEK293 cells with the indicated amounts of Gaq proteins is inversely related to BIM inhibition of Gaq signaling (means ± SEM, n = 4).
(D) Immunoblot detection of lysates prepared from native HEK293 and MZ7 cells. Membranes were initially probed for Gaq, Gai, and Gas proteins and then
reprobed for tubulin to ensure equal sample loading and transfer. Shown is one representative of three independent experiments.
(E and F) Densitometric analysis of the immunoblot experiments depicted in (D); means + SEM, n = 3.
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incongruent with our hypothesis. Together, these data may
help explain the absence of pan-G protein inhibition across
diverse cell lines yet also indicate that variation in Ga expression
does not exclusively account for cell-type-dependent pharma-
cology of BIM. Clearly, the mechanistic basis underlying cellular
context-dependent inhibition must be ascribed to additional
reasonswhy this apparent paradox exists betweenGaq selective
inhibition in some cells and pan-G protein inhibition in others.
We were intrigued by the finding that BIM might serve to spe-
cifically abrogate Gaq signaling in defined cellular environments
and wanted to ascertain that perturbation of Gaq-sensitive re-
ceptor function is not due to disruption of agonist binding. We
chose the carbachol-ligated muscarinic M1 receptor as a model
system using radioligand competition assays. Our binding as-
says in whole CHO-M1 cells clearly revealed that BIM did notChemistry & Biology 21,impair but rather enhanced carbachol displacement of the
radio-antagonist [3H]N-methylscopolamine ([3H]NMS) from M1
receptors (Figure 7A). Hence, inhibition of Gaq signaling by
BIM in CHO-M1 cells is due to BIM interference with agonist
function but not agonist binding.
BIM has been reported to completely prevent G protein
activation in [35S]GTPgS binding assays, regardless of whether
activation is achieved with a ligand-occupied GPCR, the direct
G protein activators mastoparan or AlF4
, or the Gai mimetic
FUB132 (Pre´vost et al., 2006; Ayoub et al., 2009). While all of
these studies support a direct action of BIM on the Ga protein
itself, it has not yet been clarified whether BIM impairs GDP
exit or GTP entry. To discriminate between these possibilities,
we performed radioligand binding assays on membranes iso-
lated from CHO-M1 cells using the radio-antagonist [3H]NMS.
Initial homologous competition experiments indicated that BIM890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 897
Figure 7. Effect of BIMonCarbachol Recognition of theM1Muscarinic Receptor in RadioligandCompetition Binding Assays and on [3H]GDP
Dissociation from Purified Gaq
(A) BIM (100 mM) enhances carbachol affinity to muscarinic M1 receptors labeled with the radio-antagonist [3H]NMS in whole CHO-M1 cells: pKI(control) = 3.61 ±
0.08, (n = 6); pKI(BIM) = 4.09 ± 0.09, n = 3, p < 0.05. w/o, without.
(B) In membrane preparations from CHO-M1 cells, carbachol competes for [3H]NMS sites with high and low affinity. In the presence of 1 mM GTP, 51% of the
high-affinity sites were converted to low-affinity sites.
(C) BIM (100 mM) does not impair formation of high-affinity agonist complexes in CHO-M1 membranes.
(D) BIM (100 mM) does not impair [3H]GDPdissociation frompurified recombinant Gaq. [
3H]GDPwas preloaded onGaq for 18 hr before dissociation was visualized
in the presence of 750 mM (NH4)2SO4.
(E) BIM counteracts the effect of GTP on high-affinity agonist binding in membrane preparations from CHO-M1 cells. In the absence of GTP, 20% of receptors
resumed the high-affinity state that was reversed entirely in the presence of GTP, the effect of whichwas counteracted by BIM. Data in (A) through (E) aremeans ±
SEM of three to four independent experiments, each conducted at least in duplicate.
(legend continued on next page)
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(Figure S6). If BIM acted as guanine-nucleotide dissociation in-
hibitor (GDI), i.e., precluded GDP exit from the nucleotide binding
pocket, it would be evident as inhibition of high-affinity agonist
binding, a conformational receptor state that is stabilized by the
nucleotide-free, empty-pocket G protein (De Lean et al., 1980;
Oldham and Hamm, 2008; Rodbell et al., 1971). Note that high-
affinity ternary complexes can only be visualized when guanine
nucleotides are absent but are short-lived intermediates in intact
cells where guanine nucleotides are abundant (Rodbell et al.,
1971; Oldham and Hamm, 2008; Seifert et al., 1999; De Lean
et al., 1980). We also detected high affinity-binding of carbachol
to G-protein-coupled and low-affinity binding to G-protein-
uncoupled M1 receptors in [3H]NMS competition binding assays
(Figure 7B and Table S2). GTP (1 mM) almost completely con-
verted the high-affinity sites to a low-affinity population because,
under these conditions, GDP is rapidly exchanged for GTP and
the short-lived empty pocket conformation is no longer detect-
able (Figure 7B and Table S2). In contrast, high-affinity agonist
binding was indistinguishable in the absence and presence of
BIM, suggesting that it does not uncouple receptors from their
cognate G proteins (Figure 7C and Table S2). Thus, despite the
presence of BIM, stable active-state complexes do form, indi-
cating that BIM uncouples high-affinity agonist binding from
agonist function. This mode of action can only be rationalized if
BIM permitted GDP exit but precluded GTP entry. To further
substantiate the proposed mechanism of action, we measured
[3H]GDP dissociation from purified recombinant Gaq. Since
Gaq-bound GDP dissociates very slowly (Chidiac et al., 1999),
we took advantage of (NH4)2SO4 to accelerate and, therefore,
visualize its dissociation. GDP dissociation in the presence of
750mM (NH4)2SO4was completewithin 120min but, notably, un-
affected by the presence of BIM (Figure 7D). These data strongly
suggest that BIM does not act as a GDI but permits egress of
GDP from the nucleotide binding pocket. BIM, however, does
counteract the effect of GTP on high-affinity agonist binding (Fig-
ure 7E). Therefore, our results are entirely consistentwith the view
that BIM inhibits Gaq function by permittingGDPexit but preclud-
ing GTP entry, i.e., ‘‘freezes’’ Gaq in the empty pocket conforma-
tional intermediate along the activation pathway.
To rationalize this mode of inhibitor action, we conducted
docking experiments and all-atom molecular dynamics (MD)
simulations to assess the effect of BIM on motions required for
nucleotide exchange. Given the absence of mutagenic mapping
or structural data, two scenarios were taken into consideration.
The first scenario was covalent attachment to cysteine residues
that are conserved among all Ga proteins but are not part of the
Ga/Gbg interface (C144 and C330 within Gaq). This assumption
is based on the notion that BIM, in principle, inhibits all Ga sub-
families but does not impair formation of Ga-Gbg heterotrimers
in vitro (Ayoub et al., 2009). The second scenario was noncova-
lent binding to an epitopewithin Ga, as determined through inde-
pendent molecular docking experiments. Docking results reveal(F and G) Root-mean-square-fluctuations (RMSF) as a function of their residue
BIM covalently bound to GDP-Gaq (red trace). (G) Simulation of GDP-Gaq (black t
BIM-dimer binding site encompassing residues 292–311 (aG-a4 loop and a4 he
(H) BIM-dimer complex conformation I after 10 ns of MD simulation.
See also Figures S6–S8 and Table S2.
Chemistry & Biology 21,high binding energies and a large overlap in the binding sites for
BIM-monomer and -dimer, respectively, at least for the best
scoring cluster conformations (Figure S7 and Table S3).
We then subjected the individual Ga-BIM complexes to all-
atom MD simulations. We calculated average protein structures
and used fluctuations of Ca residues relative to the average
structure as a measure of dynamic motion, which is often linked
to intrinsic domain motion (Jones et al., 2012). As shown in Fig-
ure 7F, fluctuations in GDP-Gaq (indicated by black trace) are
greatest in the three switch regions of the Ras-like domain and
in the aB-aC loop of the helical domain (please note that the
energy donor RLuc of our Gaq BRET sensor is inserted into the
aB-aC loop). When BIM is covalently bound to Cys330 within
Gaq (Figure 7F, red trace), the magnitude of local fluctuations
in switch regions II and III and in the aB-aC loop is clearly dimin-
ished. This reduction in local mobility aligns well with the
impaired helical domain motion that is detected in our BRET ex-
periments (compare with Figure 3H). In contrast, when BIM is
linked to Cys144, only switch region II and the aB-aC loop
display reduced mobility (Figure S8, blue trace). It is intriguing
that we observed even higher reduction in local fluctuations,
particularly in switch region III for the best scoring complex
conformation of BIM-dimer (Figure 7G, magenta trace, and Fig-
ure 7H). No changes in the local fluctuations were recorded for
the other complex conformations analyzed with all-atom MD
simulations (Figures S8B–S8D). Together, we propose three po-
tential binding sites for BIM. All of these sites are compatible with
the notion that BIM impairs intradomain motion within Ga by
compromising local mobility, most likely the conformational
changes required for GTP binding in the switch regions, and
additionally, the large motion of the helical domain away from
the Ras-like domain, a prerequisite for GDP/GTP exchange.
DISCUSSION
Great therapeutic interest exists for modulation of GPCR-pro-
moted signal transduction. Although most current therapies uti-
lize receptor agonists or antagonists (Rask-Andersen et al.,
2011), manipulation of GPCR signaling at steps distal to recep-
tors, such as on the level of heterotrimeric G proteins, is an
attractive alternative, particularly for diseases with complex pa-
thologies, involving multiple receptors and signaling pathways
(Smrcka, 2013). One example for small molecules interfering
with GPCR signaling at the postreceptor level are the imidazo-
pyrazine derivatives BIM-46174 and its more stable derivative
BIM-46187 (Figure 1A), each reported to dampen cellular
signaling of all four families of heterotrimeric G proteins equally,
a property coined pan-G protein inhibition (Pre´vost et al., 2006;
Ayoub et al., 2009). The pan-G protein inhibition may represent
an innovative molecular intervention to target oncogenic sig-
naling pathways.
We wanted to take advantage of the pan-G protein inhibitory
nature of BIM to study G-protein-independent signaling butnumber for the indicated simulation. (F) Simulation of GDP-Gaq (black trace),
race), BIM-dimer complex conformation I (BIM-GDP-Gaq, magenta trace). The
lix) is boxed in light blue.
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G protein subfamilies equally but rather interferes with G protein
signaling in a cellular context-dependent manner; (2) BIM may
even serve to specifically silence Gaq signaling in defined cellular
backgrounds; and (3) BIM inhibits Gabg heterotrimer function via
interference with nucleotide cycling, using a unique molecular
mechanism: precluding GTP entry into rather than GDP exit
from the nucleotide binding pocket.
Inhibition of heterotrimeric G proteins may be achieved on the
level of the abg heterotrimer or on the level of the dissociated
subunits. Of the few existing inhibitors for G protein signaling,
mechanistic details at the structural level are only available for
theGaq-selective YM-254890 (Nishimura et al., 2010). Its binding
mode, as elucidated by means of mutagenesis and structural
data, provides a plausible mechanism for inhibition of GDP
release. A similar mechanism of action has been proposed for
suramin, a polysulphonatedmolecule with a preference for inhib-
iting Gas proteins, but this molecule is of limited utility in cell-
based assays because it does not cross cell membranes due
to its strong negative charge (Smrcka, 2013; Hohenegger
et al., 1998). BIM has also been proposed to interfere with the
GDP/GTP exchange reaction, but it has not been clarified
whether BIM resembles suramin and YM in that it prevents re-
ceptor-stimulated GDP release. To address this question, we
performed radioligand binding studies under conditions that
allow assessment of nucleotide-sensitive binding states of
GPCRs. Agonist docking to GPCRs promotes an active receptor
state that engages heterotrimeric G proteins and initially triggers
GDP release from the Ga subunit (Oldham and Hamm, 2008).
Nucleotide-free G proteins, in turn, stabilize the agonist-bound
active state of GPCRs. These active-state ternary complexes
can only be observed when guanine nucleotides are absent
but are transient conformational intermediates in intact cells
where GTP and GDP are abundant (Rodbell et al., 1971; De
Lean et al., 1980; Seifert et al., 1999). Herein, we took advantage
of the formation of such active-state ternary complexes as indi-
cators for the mechanism of interference of BIM with the nucle-
otide-bound state of Ga. It is well accepted that high-affinity
agonist binding can be disrupted with high concentrations of
guanine nucleotides such as GTP because, under these condi-
tions, GDP is rapidly exchanged for GTP and the short-lived
empty pocket conformation is no longer detectable. Therefore,
agents that act like GTP, i.e., promote the uncoupling of the
activated G protein from the receptor, can be identified in radio-
ligand binding assays. Similarly, such assays are ideal for identi-
fyingmolecules that stabilize GDP-boundGa, i.e., act as guanine
nucleotide dissociation inhibitors (GDIs). Both GDIs and G-pro-
tein-uncoupling agents share the capacity to convert high-affin-
ity agonist sites into low-affinity agonist sites. BIM has been
reported to interdict function of Gabg heterotrimers (Pre´vost
et al., 2006; Ayoub et al., 2009). Inhibition of heterotrimer
signaling can only be achieved with molecules that preclude
nucleotide exchange. Because BIM does not compromise
high-affinity agonist binding, it must, consequently, permit
GDP exit and occurrence of the nucleotide-free, empty pocket
transition state of the G protein. Therefore, lack of perturbance
of high-affinity agonist binding by BIM can only be rationalized
if BIM interfered with GTP entry. Such a mechanism would be
entirely consistent with the ability of BIM to permit [3H]GDP900 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Ldissociation from purified Gaq proteins (Figure 7D). It also ex-
plains why BIM enhances carbachol binding to muscarinic M1
receptors in intact cells (Figure 7A), because a GTP entry
inhibitor likely prolongs the lifetime of active-state complexes.
This mechanism also rationalizes why BIM is incompetent to
completely prevent opening of the nucleotide binding pocket
of activated Gaq-bg proteins (Figure 3H) in our BRET assay. In
this experimental setup, Gaq-RLuc is coexpressed with Gg2-
GFP10 and responds with negative BRET on agonist stimulation
of a Gaq-sensitive GPCR. This BRET decrease is indicative of the
separation of the Ga-helical domain from the N terminus of Gg
and reliably reflects opening of the nucleotide binding pocket,
thereby creating the route for GDP exit and GTP entry (Gale´s
et al., 2006; Saulie`re et al., 2012). In the presence of receptor
antagonists, agonist-mediated BRET decrease can be entirely
prevented (Gale´s et al., 2006; Saulie`re et al., 2012). Inhibitors
of G protein function that act as GDIs, such as pertussis toxin,
also completely abolish agonist-mediated BRET in this experi-
mental setting (Gale´s et al., 2006). BIM, in contrast, significantly
diminishes negative BRET in response to agonist stimulation but
does not completely abolish opening of the nucleotide binding
pocket of Gaq. We infer from these BRET data (Figure 3H)—in
conjunction with our radioligand binding, docking, and MD sim-
ulations, as well as in vitro GDP dissociation studies (Figure 7)—
that BIM interdicts Gabg heterotrimer function by permitting
GDP escape but preventing GTP entry. Thus, BIM can be classi-
fied as a Gaq-specific GTP entry inhibitor that traps Gaq in the
empty pocket conformation, thereby blocking receptor-cata-
lyzed activation of the Gabg heterotrimer, a mechanism of action
not yet assigned to any other small molecule Ga inhibitor to date.
SIGNIFICANCE
Exchange of GDP for GTP on the Ga subunit is the key step
toward G protein activation and initiation of downstream
signaling. Structural, biochemical, and biophysical studies
on active and inactive conformations of heterotrimeric
G proteins have led to the recognition that Ga subunits are
endowedwith numerous clefts amenable for small molecule
targeting. However, few Ga inhibitors with activities in
cellular systems are available to date. Our study is signifi-
cant for two reasons: first, we show that two small mole-
cules, BIM-46174 and BIM-46187, previously classified as
pan-G protein inhibitors, preferably silence Gaq signaling
depending on the cellular background. Although themecha-
nistic basis underlying these disparate, cell-type-dependent
G protein inhibition profiles are not clear, BIM molecules
may be exploited as lead structures for generation of Ga
protein subfamily selective probes, which would be highly
desired to understand the contribution of G protein signaling
in physiology and disease. Our study also provides a ratio-
nale for the development of small molecule probes interro-
gating Gaq’s molecular and physiological functions and its
potential as a therapeutic target.
Second, andmore significantly, this study proves that cell-
permeable inhibitors for Ga proteins may be developed that
‘‘freeze’’ Ga in its empty pocket conformation, an intermedi-
ate conformation along the activation pathway. Such inhibi-
tors enrich the mechanistic portfolio of Ga modulators andtd All rights reserved
Chemistry & Biology
Trapping Gaq in the Empty Pocket Conformationmay constitute important molecules for cocrystallization
with Ga to provide deeper insight into the nucleotide-free
conformation of Ga proteins. This knowledge will help to
refine our picture on the complex series of conformational
transitions from agonist binding to G protein activation—
events that underlie a host of cellular responses in hormone
and neurotransmitter signaling and, therefore, rank among
the most fundamental issues in signal transduction.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293 and COS7 cells were maintained in high glucose Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and
1% penicillin/streptomycin mixture at 37C and 5% CO2 in a humidified atmo-
sphere. For culture of human CRTH2-HEK cells, 0.4 mg/ml G418 (InvivoGen)
was added to the medium. Stable human free fatty acid receptor 3 (FFA3)
Flp-In T-REx and human free fatty acid receptor 2 (FFA2) Flp-In T-REx cells
were cultured in DMEM supplemented with 10% fetal calf serum (FCS), 1%
penicillin/streptomycin mixture, 15 mg/ml blasticidin, and 100 mg/ml hygromy-
cin B. Expression from the Flp-In locus was induced by treatment with 1 mg/ml
doxycycline for 16–18 hr. HEK293 cells stably coexpressing the human 5-oxo-
eicosatetraenoic acid receptor (OXE-R) and the promiscuous Ga16 protein
(HEK-OXER-Ga16 cells) were maintained in DMEM supplemented with 10%
FCS, 1% penicillin/streptomycin mixture, 0.25 mg/ml hygromycin B, and
0.4 mg/ml G418.
CHO-K1 cells were cultured in Ham’s nutrient mixture F-12 GlutaMAX
supplemented with 10% (v/v) FCS and 1% penicillin/streptomycin mixture.
CHO-M1 cells were maintained in the same medium additionally supple-
mented with 0.2 mg/ml G418.
The autologous humanmelanoma cell lineMZ7-MELwas established from a
splenic melanoma metastasis in 1988. Cells were cultured in complete RPMI
1640 medium supplemented with 10% FCS (Biochrome), 2 mM L-glutamine
(GIBCO), 10 mM nonessential amino acids (GIBCO), 1 mM HEPES (GIBCO),
20 mM 2-mercaptoethanol, 100 IU/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen).
Transfection
For gene dosing experiments, the calcium phosphate DNA precipitation
method was used as described elsewhere (Kostenis et al., 2005). Assays
were performed 48 hr after transfection.
Second Messenger cAMP and IP1 Accumulation Assays
Changes of the intracellular second messengers cAMP and IP1 were quanti-
fied with the HTRF-cAMP dynamic kit and the HTRF-IP1 kit, respectively
(CisBio International), on a Mithras LB 940 reader (Berthold Technologies)
according to the manufacturer’s instructions and as described elsewhere in
detail (Schro¨der et al., 2009; Schmidt et al., 2011). If BIM or its solvent were
present during the assay, it was preincubated for 2 hr at 37C.
Crystal Violet Staining
Human melanoma cell line MZ7-MEL was seeded into 96-well plates (2 3
104 per well) in complete RPMI medium. BIM was added to the cells in
various concentrations (0.1, 0.3, 1, 3. and 10 mM) along with its vehicle.
After 72 hr, cells were washed with PBS and fixed with 4% paraformalde-
hyde for 5 min. Afterward, cells were stained with 0.05% crystal violet
dye for 30 min, rinsed twice with tap water, and thoroughly dried. Staining
intensity was measured using the Li-Cor Odysee SA imaging system.
Values are expressed as percentage staining intensity ± SEM relative to
control.
Colorimetric XTT Assay
Human melanoma cell line MZ7-MEL was seeded into 96-well plates (2 3 104
per well). Solvent control, BIM (0.1, 1, 10 and 100 mM), or the cell cycle inhibitor
aphidicolin (1 mg/ml) were added in various concentrations to the cells. After
72 hr, cell viability was measured using the XTT-based Cell Proliferation Kit IIChemistry & Biology 21,(Roche) according to the manufacturer’s protocols. Absorption wasmeasured
at 405 nm using an ELISA-Reader. Results are expressed as percentagemeta-
bolic activity ± SEM relative to control.
Western Blot
Protein lysates were prepared from native HEK293 andMZ7-MEL cells as well
as HEK293 cells transfected with different amounts of hemagglutinin (HA)-
tagged Gaq protein. Samples (10 or 20 mg of protein) were dissolved in
SDS-PAGE sample buffer, heated at 70C for 10 min, fractionated on 10%
acrylamide gels, and electrically transferred to nitrocellulose membranes.
Membranes were blocked with Roti Block (Carl Roth) and then incubated in
primary antibody solution: anti-HA (#11583816001, Roche); anti-b-tubulin
(#3708-100, BioVision); anti-Gaq/11 (sc-392), anti-Gas (sc-823), and anti-Gai3
(sc-262, all from Santa Cruz Biotechnology). Bound antibodies were detected
with an anti-rabbit horseradish-peroxidase-conjugated secondary antibody
(ABIN 102010, antibodies-online), visualized by ECL Prime Western blotting
reagent (RPN2232, Amersham), and quantified by densitometry (GelScan
V6.0 Software).
Single Cell [Ca2+]i Imaging
MZ7-MEL tumor cells were incubated for 2 hr with BIM (100 mM) or its solvent
DMSO (1:500) in RPMI medium (20% FCS) at 37C, and mobilization of [Ca2+]i
was monitored as outlined in detail in Supplemental Experimental Procedures.
BRET
G protein activation was quantified in HEK293 cells transiently transfected to
express GPR55, Ga13-106RLuc8 (human muscarinic receptor M3 and Gaq-
97RLuc8 for Gaq pathway), Gg2-GFP
10, and unlabeled Gb1. Assays were per-
formed 48 hr after transfection. Cells were detached and resuspended in
Hank’s balanced salt solution with 20 mM HEPES at a density of 1.06 3 106
cells per ml. A volume of 170 ml cell suspension was seeded in 96-well micro-
plates and incubated with BIM or buffer for 2 hr. After agonist addition, cells
were incubated for 2 min (1 min for carbachol). G protein activation was
measured after the addition of RLuc substrate DeepBlueC coelenterazine
(Gold Biotechnology). To detect BRET, light emission at 400 and 515 nm
was measured sequentially using a Mithras LB 940 instrument. The BRET
signal (milliBRET ratio) was determined by calculating the ratio of the light
emitted by the fluorescence acceptor GFP10 (515 nm) and the light emitted
by Rluc (400 nm).
Other Methods
For synthesis of BIM-monomer and -dimer, remaining experimental proce-
dures, and a more detailed description of the aforementioned procedures,
see the Supplemental Information.
Data Analysis
Results are expressed asmean values ± SEM andwere analyzed usingGraph-
Pad Prism 5.04 (Graph Pad). Half maximal effective concentration (EC50)
values were determined by nonlinear regression, and comparison between
two experimental groups was based on a two-tailed Student t test. The
p values were considered as significant (*p < 0.05), very significant (**p <
0.01), and extremely significant (***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.06.003.
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 Epilogue 
In this publication, BIM was characterized and suggested to reconsider the mode-of-action from a 
pan G protein inhibitor to a cell background-dependent Gαq-selective inhibitor. We could further 
reveal a to-date unprecedented mechanism of G protein inhibition. Thus, BIM-46174 is the first 
member of the new class of GTP entry inhibitors. It stabilizes the empty pocket conformation of the 
G protein that occurs when GDP exits its binding site and the G protein changes shape into an 
intermediary state before GTP enters the protein1. In contrast to the selective Gαq-inhibitor YM-
254890 or the selective Gαs-inhibitor suramin, which function as guanine nucleotide dissociation 
inhibitors (GDI)2–4, BIM-46174 does not exclude GDP exit, nor does it preclude coupling between the 
G protein and its GPCR as PTX does5,6. BIM-46174 freezes the state between GDP exit and GTP entry, 
thus allowing for the occurrence of high affinity states between the GPCR and its cognate G protein. 
The exact mechanism how BIM-46174 interacts with the G protein remains concealed, although two 
cysteine residues within the Gα subunit for a covalent modification by the inhibitor were identified 
but the possibility for a noncovalent interaction could not be ruled out. 
As GPCRs play a role in virtually every process in humans it is not an unexpected finding that GPCRs 
are also involved in many cancer types7,8. Likewise G proteins are involved in many cancers, 
especially mutated forms of Gα subunits are reported to be associated with certain forms of 
cancer9,10. Importantly, some mutations lead to constitutive G protein activity by preventing GTP 
hydrolysis whereas others show high basal levels of GDP/GTP exchange11,12. Cancer cells 
overexpressing those latter types of mutated G proteins would be sensitive to treatment with GDP 
exit inhibitors or GTP entry inhibitors, such as BIM-46174. GTPase deficient mutants of G proteins, 
however, would be resistant to pharmacological intervention with either type of G protein inhibitor 
once the G protein is in the active state (i.e. the GTP-bound state).  
There are also concerns about a pharmacological anti-cancer strategy that targets ubiquitously 
expressed proteins, which are moreover involved in a huge amount of biological processes. 
Considerable fear exists about severe side effects of such treatments but those might be outweighed 
by the beneficial anti-cancer effects and would not be a backward step in synopsis with the majority 
of currently used anti-cancer medicines that share these disadvantages3. Another effort to 
circumvent systemic side effects would be a locally limited use, which is a priori restricted to 
stationary types of cancer. While there has already been promising results from personalized 
treatments of cancer types, which are characterized by specific mutations in certain key signaling 
regulators, there is indubitably hope to be able to inhibit disease-relevant mutant forms of G 
proteins. In turn, this implies a feasible way to selectively target those proteins while simultaneously 
ignoring proper G protein function. Beside the here discussed Gα subunit inhibition, selective βγ 
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subunit inhibition could be a suitable practice, since signaling of the Gα subunit, which is 
independent of the βγ subunit, would be preserved3.  
In this publication, a new mechanism of G protein inhibition was presented. BIM-46174 expands the 
repertoire of signal transduction modulating tool compounds. In the future this toolbox could help to 
further investigate G protein inhibition for Gαs and Gα12/13 mediated pathways, which to date cannot 
be inhibited in a biologically relevant way. Together with true pan G protein inhibitors these tools 
would provide an important means to study G protein-independent signaling, which is frequently 
discussed and associated with β-arrestin signaling, although it has never been corroborated because 
to date no pan G protein inhibitor exists. Workarounds such as overstimulation of all G proteins with 
aluminiumfluoride or mastoparan are not suited to authentically reflect inhibited G protein signaling. 
In conclusion, the discovery of true G protein inhibitors with potentially new mechanisms is highly 
desirable. 
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 Conclusion 
Knowledge about the function and dysfunction of cellular signal transduction is at the very heart of 
biomedical research since every physiological and pathophysiological process is intimately associated 
with functional or defective signaling, respectively. The advent of innovative methodological 
techniques paved the way for major breakthroughs in deciphering cell signaling in the life sciences. 
Granting this, it is not technology per se but proactive adjustment and attentive implementation of 
the various methodological approaches that lay the foundation for rewarding research efforts. It is 
becoming increasingly clear that data obtained from a single assay readout are generally insufficient 
to mirror the multidimensionality of biological signaling networks. Thus, it was an aim of this thesis 
by synopsis of different technological, biochemical and pharmacological approaches to provide new 
insights into the anatomy of signaling events.  
G protein-coupled receptors (GPCRs) do not only represent the largest group of drug targets but are 
also prototype microprocessing units in the cellular signaling machinery and therefore ideally suited 
to study the biology of signal transduction. This class of receptors represents a cornucopia of 
signaling diversity since a plethora of signal transduction concepts are mirrored herein. Hence, GPCRs 
are supremely favored research objects and examined in the majority of the publications 
communicated in this thesis. 
Section I explained the principle of dynamic mass redistribution (DMR). The optical biosensor-based 
technique allows the detection of cellular events as an integrated whole-cell readout and its label-
free nature is capable to reflect signaling events in a non-invasive fashion without using any 
interfering labels. A set of different cellular backgrounds was used to demonstrate the versatility and 
applicability of the assay. The integration of recombinant, native and primary cells highlighted the 
potential of this technique to glean in vivo relevant biological information about investigated 
substances already in early stages of the drug discovery process. Since DMR provides unbiased 
insights into cell activation, the testimony of multiple concurrent pathways triggered by a stimulus is 
accessible and helps to understand the underlying biology. The first chapter described the possibility 
to untangle the GPCR signaling repertoire by means of selective pathway modulators and explained 
why the real time measuring mode allows the exploration of kinetic aspects in the cell response. 
Chapter 2 opens section II of this thesis, in which the biology of the G protein-coupled free fatty acid 
receptor FFA2 is detailed. With a multifaceted approach exploiting the advantages of holistic label-
free readouts, it was possible to uncover an unprecedented mode-of-action of a GPCR modulating 
ligand. 4-CMTB previously classified as positive allosteric modulator and allosteric agonist (ago-PAM) 
at the FFA2 receptor was disclosed as the first sequentially activating ligand (SEAL) reported so far. 
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This ligand binds and activates a first recognition site of the receptor before it is also recognized by a 
further  receptor  site,  where  a  second  signaling  impulse  is  generated.  Thus,  the  association  of 
multiple binding events with multiple signaling events therein is a key difference between SEALs and 
classical bitopic ligands that simultaneously bind the receptor. In the concept of SEALs, GPCRs could 
function as transceivers that de‐ and encode the  information  in an adjustable manner by extending 
the possibility to encrypt biological information by a temporal dimension.  
Correlating  certain  signaling  events  and  the  resulting  phenotype  rationally  within  a  complex 
biological environment remains a prime challenge  in signal transduction research. The  invention of 
designer receptors bettered the prospects to approach this question. By isolating a certain receptor 
signaling behavior and introduce this signaling machinery into an in vivo context, scientists might be 
able to assess the relevance of a certain activation pattern for the  individual phenotype. Chapter 3 
reports on a  strategy how  to design and generate a designer FFA2  receptor on a  rational basis. A 
receptor form activated solely by a synthetic  ligand (RASSL) of FFA2 was designed based on species 
differences in agonist selectivity between the human and bovine FFA2 receptor and consequently did 
not respond to the endogenous short‐chain fatty acid ligands anymore but was selectively activated 
by stimulation with sorbic acid. Future studies  involving designer receptors can help elucidating the 
in  vivo  role  of  the  FFA2  receptor,  since  the  ubiquitous  availability  of  fatty  acids  in  the  body  and 
overlap  in  ligand  recognition as well as  in  the expression patterns of FFA2 and FFA3  challenged a 
clear definition of FFA2‐mediated phenotypes so far. 
Section  III deals with  the human G protein‐coupled  free  fatty  acid  receptor  FFA1 and begins with 
Chapter 4 that presents a study that investigated the interplay between FFA1 and non‐esterified fatty 
acids  (NEFAs)  in  a  diabetes  type  2  (TD2)  disease  context.  The  deleterious  effects  of  NEFAs  on 
pancreatic β‐cell function and survival were claimed to be dependent of FFA1 activation by previous 
reports. In the present study, however, the activation of FFA1 with a selective small molecule agonist 
proved  even  beneficial,  while  antagonists  deteriorated  β‐cell  health,  a  finding  that  is  also 
corroborated by other studies. Furthermore, a single nuclear polymorphisms (SNP) in the gene of the 
FFA1 was  identified  to modulate  the  sensitivity  against  (gluco)lipotoxic  effects of  fasting  levels of 
non‐esterified  fatty  acids  (NEFA)  in  humans  confirming  a  modulatory  role  of  FFA1  in  the 
pathophysiology of TD2. The second publication in chapter 4 focused on a methodological issue and 
notes the importance to diligently validate the experimental tools used to determine localization and 
amount  of  protein  expression,  a  prerequisite  of  reliable  data  acquisition.  In  doing  so,  several 
inconsistent results in the literature of FFA1 receptor biology must be questioned. 
In Chapter 5, the chemistry and optimization of synthetic FFA1  ligands  is presented. Because of the 
aim to develop highly selective and potent FFA1 agonists, the unbiased DMR assay proved valuable 
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to interrogate potential off-target effects of the investigated compounds, as well as confirmed their 
competence to activate the receptor with appropriate potency and efficacy. The three publications 
within this chapter present different chemical strategies to tailor the structures for their employment 
as pharmacologically validated substances. The availability of those ligands is indispensable to study 
receptor biology and was thus a prerequisite to conduct biological research as depicted in the other 
chapters.  
In the last part of the thesis, section IV, two chapters describe the analysis of signal transduction at a 
post-receptor level. Chapter 6 provides further evidence for a bona fide second messenger role of the 
non-canonical cyclic nucleotides cCMP and cUMP by delineating the biological effectors. The label-
free DMR assay disclosed cNMP target proteins and shed light into the signal transduction network 
of cNMPs in human cells, thereby emphasizing the applicability of this technique that is not restricted 
to the analysis of signal transduction generated from cell surface receptors but also at the post-
receptor level. Chapter 7, finally, characterized and defined the mode-of-action of a previously 
published pan-G protein inhibitor (BIM-46187). By stabilizing the empty-pocket conformation of Gα 
subunits BIM46187 is the first reported GTP entry inhibitor and was furthermore redefined as a 
compound that selectively targets Gαq proteins in a cell-type dependent manner.  
In conclusion, this thesis comprises several studies covering multiple aspects of cellular signal 
transduction providing a range from biological-pharmacological, technological and chemical 
perspectives on the subject. The bulk of the publications deals with the analysis of GPCR biology, 
especially the exploration of the free fatty acid receptors FFA1 and FFA2. A technology-centered, 
conceptual section and a section analyzing signal transduction at the post-receptor level complement 
the overall focus on receptor biology. 
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